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The CYP450 superfamily of enzymes metabolise ~90% of all therapeutic drugs. CYP3A5 is 
involved in the metabolism of multiple drugs and endogenous compounds. Enzyme 
expression is highly variable and associated with differential efficacy of therapeutic drugs and 
risk of adverse drug reactions (ADRs). 
 
Four functionally important CYP3A5 variants: CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7, 
have been identified in broad human population surveys. CYP3A5*1 produces a functional 
protein while CYP3A5*3, CYP3A5*6 and CYP3A5*7 define variants which reduce enzyme 
expression. Reduced CYP3A5 expression is associated with ADRs. Conversely elevated 
CYP3A5*3 frequencies are observed in non-equatorial populations and have been reported to 
protect against the onset of salt-sensitive hypertension. 
 
Little is known about CYP3A5 variability in Africa; a region that has more genetic diversity 
than the rest of the world combined. The main objectives of this thesis were to characterise 
intra-African variation in the CYP3A5 gene; identify likely implications of CYP3A5 variability 
on African healthcare; and examine evidence of selection on the gene. Appreciable African 
frequencies of CYP3A5*6 (12-33%) and CYP3A5*7 (3-22%) were identified and are likely to 
contribute to variable CYP3A5 expression across the continent. CYP3A5*6 was observed in 
every genotyped African population; CYP3A5*7 was observed almost exclusively in Niger-
Congo speaking populations. Evidence of positive selection acting on CYP3A5 was found and 
coalescent dates of low/non-expresser CYP3A5 variants indicate that CYP3A5*3 is likely to 
have undergone a recent, rapid, increase in frequency in non-African populations.  
 
Re-sequencing of a ~12kb CYP3A5 region in five Ethiopian populations; and a ~4.5kb region 
in eight additional African populations, identified additional variants which may cause 
low/non-expression of CYP3A5. 
 
Considerable intra-African differences in CYP3A5 allele frequencies and haplotype structure 
were identified. Intra-African CYP3A5 variability suggests that there is likely to be differential 
efficacy of CYP3A5 metabolised drugs, and associated susceptibility to ADRs between 
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 This thesis is concerned with the molecular and population genetics of variation in the 
gene encoding the human drug metabolising enzyme Cytochrome P450 3A5 (CYP3A5) in sub-
Saharan Africa; with a special emphasis on Ethiopian populations. CYP3A5 plays an important 
role in the metabolism of many endogenous and exogenous substrates (Patki et al. 2003) 
including a wide spectrum of drugs in clinical use (Frohlich et al. 2004; Wong et al. 2004; 
Mirghani et al. 2006). It is also of particular interest in medical research due to its role in 
predicting disease pathology and risk (Givens et al. 2003; Zhenhua et al. 2005). Despite its 
importance, enzyme expression is polymorphic; individuals can express the protein at high 
concentrations or have low/undetectable levels of enzyme (Kuehl et al. 2001). A number of 
factors, such as demography and drift, can cause inter-population differences in allele 
frequencies, however it is becoming increasingly clear that for the CYP3A5 locus, selection has 
played an important role (Thompson et al. 2004; Chen et al. 2009). 
 This introduction reviews the current literature on the impact of human genetic 
variation on healthcare. The importance of understanding the role of ancestry in healthcare is 
also addressed; with reference to sub-Saharan African populations. The background on the 
CYP3A5 gene is then described in detail along with a review of the evidence for its role in drug 
metabolism and in predicting disease risk and pathology. Finally an overview of methods used 
to evaluate selection, and a review of the evidence for selection on the CYP3A5 gene, is 
discussed. The specific aims and outline of this thesis are described in detail thereafter. 
 
1.1 Part I: Human genetic variation and healthcare implications 
1.1.1 Human genetic variation 
 The human genome exhibits considerable inter-individual sequence variation 
between and within population groups. This variation may be influenced by a number of 
demographic factors including fluctuations in population size, and random mutation. 
Selection and genetic drift within and between populations can lead to differentiation of sub-
sections of individuals from a wider population.  
Genomic variation can be both significant and non-significant; depending upon any 
consequent effect on transcription and translation of particular proteins, and any associated 
phenotypic effect of these changes. Variation in the genome can range from single base 
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changes (single nucleotide polymorphisms: SNPs) to large regions of genomic sequence(s) 
being inserted, deleted (INDELs) or copied (copy-number variants: CNV). 
Since the publication of the human genome sequence in 2000 (Venter et al. 2001), 
millions of SNPs have been identified. Humans have been reported to differ at the single 
nucleotide level at approximately 1 in every 1000 base pairs (Sachidanandam et al. 2001; 
Rotimi and Jorde 2010). A principal challenge of the genomics era is to identify functionally 
important variation within the human genome in order to reconstruct human evolutionary 
history and to understand the genetic basis of human diseases. Improved understanding of 
the genetic determinants of human diseases will inevitably aid efforts to treat endemic and 
emerging global infections (Tishkoff and Verrelli 2003). Much research has focused on 
identifying medically important genetic variants. Many studies have mapped disease causing 
genes and variants using methods which exploit the existence of linkage disequilibrium 
(Goldstein and Weale 2001) where a set of markers have been observed to be associated with 
a particular phenotype and then mapped to specific chromosomes.  
 Recently there has been a move towards examining structural variation in the human 
genome. Structural variation defines genomic alterations that affect DNA structure and 
arrangement of the genome (Scherer et al. 2007). Structural variation commonly includes 
INDELs and CNV which have been the focus of recent studies attempting to identify medically 
important variation (Patrinos and Petersen 2009; Wain et al. 2009), in addition to SNP based 
analysis (Giacomini et al. 2007). 
Genetic variability does not only influence disease phenotype and pathology, it can 
also influence the efficacy of drug treatment. These studies are now increasingly frequent and 




Pharmacogenetics is the combination of pharmacological and molecular genetics 
based fields to determine how genetic factors may affect the efficacy and safety of drug 
treatment (Weinshilboum 2003; Wilke et al. 2007; Johnson 2008). The clinical vision for 
pharmacogenetics is that genetic information might be used to identify drugs and dosages 
that have the most beneficial treatment outcome for an individual patient.  
The results of drug therapy can vary within and between populations. Whilst many 
patients respond well to drug treatment, there are individuals who have minimal or no 
therapeutic response, additionally some patients experience severe adverse drug reactions 
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which are major contributors to global morbidity and mortality (Weinshilboum 2003; Wilke 
et al. 2007). 
A number of different factors may affect the ability of a patient to respond effectively 
to drug treatment including sex, age, underlying co-morbidities, stage of disease and 
concurrent medications. Aside from environmental factors which may influence drug efficacy 
and safety, genetic factors are also important.  
Variation in drug metabolising enzymes has been shown to have conflicting effects on 
the ability of an individual to metabolise a variety of drugs including warfarin, HIV-1 protease 
inhibitors and antidepressant medication (Lin et al. 2002; Givens et al. 2003; Pirmohamed and 
Park 2003; Weinshilboum 2003; Frohlich et al. 2004; Mouly et al. 2005; Lynch and Price 2007; 
Wilke et al. 2007; Kohlrausch et al. 2008). Once a drug is administered, it is absorbed and 
distributed to the site of action, where it interacts with targets such as receptors and/or 
enzymes. Most drugs undergo metabolism before being excreted. Genetic variation may affect 
absorption, enzyme activity, cellular uptake, and metabolism, resulting in altered drug activity 
or half-life (Weinshilboum 2003). When compared to the effect of complex and potentially 
interacting environmental influences, genetic factors that alter the pharmacodynamics of a 
particular drug may be easier to detect. 
The implementation of genotypic guided medicine for individuals is not in widespread 
clinical use. Although physicians are becoming increasingly aware of clinically relevant 
genetic polymorphisms; a 2006 study by the Federal Drug Administration reported that 
~25% of all prescriptions written in the USA contained pharmacogenetics labelling (Gardiner 
and Begg 2006). The paucity of affordable and efficient testing methods; and the continuous 
identification of clinically important genetic variants are factors which have delayed the 
translation of human genetic information into clinical practice and healthcare administration 
(Weinshilboum 2003; Constable et al. 2006). 
 Population-based studies have been invaluable in filling this gap. Individuals of a given 
population may have underlying genetic similarities which could potentially distinguish them 
from other populations. The focus on identifying important variants within populations 
instead of individuals has identified common, medically important, variation (Wojnowski et 
al. 2004; Dandara et al. 2005; Mirghani et al. 2006; Gebeyehu et al. 2011).  
 
1.1.3 Ancestry and human health 
 Many genetic studies have identified common variation, i.e. that which is observed at a 
frequency greater than 5% in all human populations (Rotimi and Jorde 2010). However it is 
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important to mention that perceptions of population differences are strongly influenced by 
which human populations have been sampled. 
 Although common genetic variation has been identified between populations, there 
are well-established inter-ethnic and inter-population differences in disease prevalence. 
Examples include higher frequencies of Tay-Sachs disease in Ashkenazi Jewish populations 
(Myerowitz 2001; Frisch et al. 2004) and high frequencies of blood disorders in populations 
within malaria endemic regions, such as glucose-6-phosphate dehydrogenase deficiency 
(Tishkoff et al. 2001) and sickle cell disorder (Mabayoje 1956; Trowell et al. 1957). 
 However, there are disparities in population-based healthcare which are due to 
sampling bias. Approximately 90% of genome wide association studies, aiming to identify 
genetic variation important in disease susceptibility, have been performed in populations 
with recent European ancestry (hereafter called European populations). Only one major 
genome wide study on disease causing variants has been performed in individuals with recent 
African ancestry which examined variants important in malaria causation and phenotype 
(Rotimi and Jorde 2010). 
 Large sample and ascertainment biases in studies on human genetic variation do not 
account for considerable diversity within African populations (Reed and Tishkoff 2006). Many 
disease-related SNP microarrays are biased towards European populations and so overlook 




1.1.4 Sub-Saharan Africans in evolutionary and medical-based research 
 The importance of including sub-Saharan Africans as study populations within 
evolutionary and medical based research should not be underestimated. From an 
evolutionary research perspective, sub-Saharan Africa is essential for reconstructing human 
evolutionary history and in understanding how demographic factors, such as changes in 
population size, and long range migration, have influenced diversity within human 
populations, as has selection (Campbell and Tishkoff 2008). 
Sub-Saharan Africa is a region which extends from just below the Sahara desert to 
South Africa, Figure 1.1. The region has extensive genetic, cultural, linguistic and phenotypic 
diversity; only a fraction of which has been observed outside of the sub-continent (Tishkoff 
and Verrelli 2003; Manica et al. 2007; Campbell and Tishkoff 2008). Approximately 30.5% 
(over 2000) of the world’s languages, representing multiple language families, are spoken in 
the region (http://www.ethnologue.com), see Figure 1.2. Populations on the continent inhabit 
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diverse environments (Reed and Tishkoff 2006), which have been susceptible to change over 
thousands of years, simultaneously with human evolution (Scholz et al. 2007) and are likely to 
have influenced diversity within the region. 
 Genetic variation within sub-Saharan Africa has been influenced by demographic 
events over 200,000 years: including short and long range migration, population admixture 
and fluctuations in population size (Tishkoff and Verrelli 2003; Manica et al. 2007; Campbell 
and Tishkoff 2008; Campbell and Tishkoff 2010). 
 





Figure 1.2: A map showing the distribution of major language families in Africa. Image has been taken 





One of the most significant events is the migration of Niger-Congo Bantu speaking 
agricultural populations from the region that is known as Cameroon today initially into the 
rainforests of equatorial Africa, followed by separate phases of expansion into eastern and 
southern Africa; known as the Expansion of the Bantu Speaking Peoples (Tishkoff and Verrelli 
2003; Beleza et al. 2005; Campbell and Tishkoff 2010). Genetic data also suggest that Bantu 
speakers migrated from east and west Africa into the southern region, see Figure 1.3. As these 
populations migrated they displaced many of the regional, indigenous populations and 
patterns of migration can be traced using mitochondrial DNA and Y chromosome markers 
(Quintana-Murci et al. 1999; Tishkoff and Verrelli 2003; Beleza et al. 2005; Berniell-Lee et al. 
2009). The wide distributions of Niger-Congo A and Bantu languages within sub-Saharan 
Africa (Figure 1.2) are attributed to these migration events. 
 Sub-Saharan African populations also practise a wide range of subsistence methods 
(Campbell and Tishkoff 2008; Campbell and Tishkoff 2010). Previous studies have observed 
multiple mutations, at high frequencies, that have evolved to aid dietary adaptation in 
populations from the sub-continent (Hollox et al. 2001; Ingram et al. 2007; Perry et al. 2007; 
Tishkoff et al. 2007; Ingram et al. 2009; Ingram et al. 2009). 
 From a medical perspective, over 90% of the global burden of disease is found in 
developing countries (Sgaier et al. 2007; Oliveira et al. 2009) and a substantial number of 
developing countries are within sub-Saharan Africa. In addition to common infectious 
diseases such as influenza and bacterial meningitis, sub-Saharan Africa has an added burden 
of high rates of transmission of infectious diseases such as malaria, HIV and tuberculosis as 
well as so called “neglected diseases” including Leishmaniasis, Human African 
Trypanosomiasis and Leprosy. Approximately 800 million people reside in sub-Saharan Africa 
and are at risk from common and neglected diseases (Aspray et al. 1998; Hotez and Kamath 
2009). Therefore it is important to understand not only how socio-economic factors may 
impact disease burden within the sub-continent; but also identify genetic influences that may 
impact disease progression, transmission and treatment. 
  
 21 
Figure 1.3.: A map showing the phases of expansion of the Bantu Speaking People. 





There are marked differences that have been identified between sub-Saharan African 
populations and European populations in the response to treatment that is administered for 
specific diseases (Fellay et al. 2005; Mouly et al. 2005). However over 95% of drug 
development and clinical trials are carried out in populations with recent European ancestry 
from Europe and North America. Many developing countries, including many in sub-Saharan 
Africa, rely on FDA and European guidelines for safety levels and optimal therapeutic dosages 
(Li et al. 2011). Given the substantial burden of disease within sub-Saharan Africa, coupled 
with high levels of genetic diversity in the sub-continent, it is necessary to examine how 
variation in response to treatment impacts clinical outcomes within populations from the 
region. This has become particularly important in recent years given the new emphasis on the 
use of mass drug administration (MDA) by organisations such as the World Health 
Organisation (WHO) and Médecins Sans Frontières (MSF) in the treatment of many endemic 
diseases (Hotez 2009; Smits 2009; Solomon et al. 2009). It is necessary to examine the extent 
of variation in the response to specific treatments and whether alternative dosages or drugs 
are required than those administered in different parts of the continent.  
Despite these convincing reasons for including sub-Saharan Africans, they have been 
largely underrepresented in human evolutionary and medical studies (Campbell and Tishkoff 
2008). There has been a tendency within the literature to extrapolate data obtained for 
African-American individuals to sub-Saharan African populations. This is problematic given 
the extent of European admixture within African-American populations (Reed 1969; Parra et 
al. 1998; Destro-Bisol et al. 1999). Additionally this method of extrapolation does not 
acknowledge the high level of genetic diversity between different sub-Saharan African 
populations, for example the high levels of Semitic admixture within East African populations 
(Hammer et al. 2000; Tishkoff and Verrelli 2003; Lovell et al. 2005) have not been observed in 
populations from western and southern Africa. Clearly there is a need for focused studies in 
sub-Saharan African populations to guide the effective global prescription of drugs. 
 
1.1.5 Sub-Saharan Africa and modern human origins 
The majority of archaeological and genetic data support a recent African origin model 
of the evolution of anatomically modern humans. This model postulates that anatomically 
modern humans (Homo sapiens) evolved in Africa from archaic humans ~150,000-200,000 
years ago. Anatomically modern humans then migrated from Africa and inhabited other parts 
of the world replacing archaic humans with little or no genetic mixing (Quintana-Murci et al. 
1999; Tishkoff and Williams 2002; Relethford 2008). 
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The discovery of fossil remains with early human morphological traits within sub-
Saharan Africa provides support for this model of human evolution (Campbell and Tishkoff 
2008; Relethford 2008). Fossil remains, with morphological features of anatomically modern 
humans, dated to 160,000 (White et al. 2003) and 195,000 years ago (McDougall et al. 2005) 
have been found in the sub-continent. These dates precede those estimated for fossils 
discovered in the Middle East (~92,000 years ago), Australia (~60,000-40,000 years ago) and 
Europe (~40,000-30,000 years ago) (Relethford 2008). 
Genetic data are also consistent with a recent African origin model of human evolution 
(Campbell and Tishkoff 2008; Relethford 2008). Coalescent models have been used to 
estimate the time and location of the most recent common ancestor of modern humans. The 
models assume that in any sample of DNA markers, there is a point backwards in time in 
which they will coalesce to a common ancestor. Analyses of mitochondrial DNA, inherited 
solely maternally, have dated a most recent common ancestor to ~200,000 years within 
Africa (Relethford 2008). 
High levels of genetic diversity observed within sub-Saharan Africa comparative to 
other global regions also supports evidence for a recent African origin of modern humans 
(Watkins et al. 2001; Manica et al. 2007; Campbell and Tishkoff 2008). Sub-Saharan African 
populations have higher levels of structural variation in the genome (Relethford 2008; 
Campbell and Tishkoff 2010). Additionally, sub-Saharan African populations have been 
reported to have more “private” alleles comparative to other global populations. 
 Modern humans in Africa would have a longer period of time to accumulate mutations 
than those who were dispersing out of the continent. The number of modern humans leaving 
Africa would be a small percentage of the total population; and represent a fraction of all 
African genetic diversity. In other words, non-African populations have been subject to a 
population bottleneck and so have less variation than the founding African population from 
which they have separated (Manica et al. 2007; Relethford 2008; DeGiorgio et al. 2009). 
 
1.1.6 Ethiopia and human evolutionary history 
East Africa is an important region in human evolutionary history. It is widely believed 
to be the region from which anatomically modern humans left Africa to expand across the 
world. Evidence for an East African migratory route, via Ethiopia, out of sub-Saharan Africa is 
supported by fossil evidence for anatomically modern humans dated to ~150,000-160,000 
years ago (White et al. 2003; Kivisild et al. 2004). 
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Archaeological data support the presence of anatomically modern humans within 
Ethiopia (White et al. 2003; McDougall et al. 2005). Additionally, fossils supporting the 
presence of early hominids within the country have also been uncovered, an example is the 
famous “Lucy”: a well preserved skeleton which was found in Ethiopia and dated to 3.2 
million years ago (Shreeve 1994).  
Data from studies on mitochondrial and Y chromosome DNA have successfully tracked 
human migration out of Africa via Ethiopia (Quintana-Murci et al. 1999; Tishkoff and Verrelli 
2003; Lovell et al. 2005; Campbell and Tishkoff 2008). Additionally, global analyses of 
microsatellite variation (Ramachandran et al. 2005) have shown that genetic diversity is 
negatively correlated with distance from Ethiopia (Prugnolle et al. 2005; Li et al. 2008). In 
other words, the further the distance a population is geographically located from Ethiopia, the 
less genetic diversity it contains. 
 East Africa is a particularly diverse region of sub-Saharan Africa (Tishkoff et al. 2009). 
Genetic diversity within the region has been shaped by multiple demographic events. One of 
the most significant is admixture with individuals of Semitic origin who migrated into Africa 
via East Africa and mixed with the indigenous populations ~5000 years ago (Hammer et al. 
2000; Tishkoff and Verrelli 2003; Lovell et al. 2005). This is reflected at the cultural, genetic 
and linguistic levels with the presence of  Semitic speaking East African groups that claim 
Jewish ancestry, a feature that distinguishes them from other sub-Saharan African 
populations (Lovell et al. 2005). 
 
1.1.7 The rationale for studying human genetic variation in Ethiopian populations 
 Given the high levels of genetic diversity observed in Ethiopia (Prugnolle et al. 2005; 
Li et al. 2008), it is anticipated that populations from this region will have higher levels of 
variation in medically important genes, comparative to that which has already been reported 
for other global populations. 
 A recent study on human genetic variation in the gene encoding the drug metabolising 
enzyme CYP1A2 in Ethiopian populations, significantly increased existing knowledge of 
variability in this gene (Browning et al. 2010). In addition, the authors ascertained that 
uncharacterised variation in medically important genes is likely to put individuals with recent 
Ethiopian ancestry, both within Ethiopia and overseas, at increased risk of adverse drug 
reactions. 
 Through studying variation in medically important genes, in the diverse populations 
of Ethiopia, and combining the results with those previously reported for other global 
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populations, a more complete picture of global variation in particular genes will be obtained. 
Additionally improved understanding of medically important variation will aid in tailoring 
healthcare to particular populations, and reduce the likelihood of adverse treatment 
outcomes; which are major contributors to annual global morbidity and mortality 
(Weinshilboum 2003; Wilke et al. 2007). 
 
1.2 Part II: CYP3A5, population genetics and human adaptation 
1.2.1 The Cytochrome P450 super-family of drug metabolising enzymes 
Cytochromes P450 (CYP450) are a super-family of haem-containing mono-oxygenases 
which are widely conserved across species (Nebert and Russell 2002). There are 116 
identified human CYP450 genes: 57 encode active CYP450 enzymes; the remaining 59 are 
pseudogenes (http://drnelson.utmem.edu/human.P450.table.html). Human CYP450 are 
predominantly membrane-bound proteins, located in the inner membrane of the 
mitochondria or in the endoplasmic reticulum of cells (Nelson 2009). CYP450 are mainly 
found in the liver, although extra-hepatic isoforms exist (Nelson 2009), and are involved in 
the metabolism of multiple endogenous and exogenous compounds (Porter and Coon 1991). 
CYP450 mediate oxidation, reduction, and hydrolysis reactions which expose or add 
functional groups to substrates to produce polar molecules (Li et al. 2011). It is thought that 
the ability of CYP450 enzymes to metabolise exogenous compounds evolved 400-500 million 
years ago to enable animals to digest chemicals in plants, creating water-soluble compounds 
which are easier to excrete (Gonzalez and Gelboin 1994). 
CYP450 are also important in the first phase metabolism of many therapeutic drugs 
used to treat a wide spectrum of diseases (Brockmoller et al. 2000; Pirmohamed and Park 
2003; Kirchheiner and Seeringer 2007; Lynch and Price 2007). Of the 57 active CYP450 
enzymes, six are together involved in the metabolism of more than 90% of clinically used 
drugs (Pirmohamed and Park 2003; Lynch and Price 2007). Not unexpectedly, 
polymorphisms in genes encoding CYP enzymes are associated with many adverse drug 
reactions (Ingelman-Sundberg 2004). 
 
1.2.2 The Cytochrome P450 3A sub-family 
The CYP450 super-family of genes are grouped into families and sub-families; CYP 
families, such as CYP3, are defined by at least 40% amino acid sequence similarity; and sub-
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families by 55% (Nelson et al. 2004; Qiu et al. 2008). Of the various sub-families that comprise 
the CYP450 super-family, the Cytochrome P450 3A sub-family (CYP3A) have a central role in 
drug metabolism; CYP3A proteins metabolise many therapeutic drugs and are the most 
abundant sub-family expressed in the liver, comprising up to 50% of hepatic CYP content 
(Kuehl et al. 2001; Lamba et al. 2002; Xie et al. 2004). The two most important drug 
metabolising enzymes within this sub-family are CYP3A4 and CYP3A5 (Kuehl et al. 2001; 
Lamba et al. 2002; Wojnowski 2004; Xie et al. 2004). Given the wide substrate range of 
CYP3A, functionally significant variation in the genes encoding CYP3A enzymes can have 
important medical implications due to the large number of substrates metabolised solely or 
predominantly by this sub-family. 
The CYP3A sub-family is mapped to a ~231kb region on chromosome 7 (Figure 1.4). 
There are six CYP3A genes; mRNA sequences corresponding to each of four CYP3A genes; 
CYP3A4, CYP3A5, CYP3A7 and CYP3A43 have been isolated (Lamba et al. 2002). There are also 
two pseudogenes: CYP3A5P1 and CYP3A5P2 which have sequence homology to CYP3A5 
(Lamba et al. 2002). Each of CYP3A7 and CYP3A4 encode proteins consisting of 503 amino 
acids, CYP3A43 encodes a 504 amino acid protein and CYP3A5 a 502 amino acid protein 
(http://www.ncbi.nlm.nih.gov/). There is high sequence homology at the CYP3A cluster, and it 
has been suggested that multiple CYP3A genes arose as a result of duplication of an ancient 
CYP3A sequence, estimated to be approximately 40-50kb in size (Finta and Zaphiropoulos 
2000). 
 
Figure 1.4: A schematic of the organisation of the human CYP3A locus on chromosome 7. Arrows 
indicate the orientation of each gene in the CYP3A cluster. 
 
 The CYP3A locus is highly conserved across mammals: CYP3A orthologues have been 
identified in primates (Williams et al. 2004; Williams et al. 2007), horses (Schmitz et al. 2010) 
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and in rodents (Zaphiropoulos 2003). Allelic variation and subsequent CYP3A haplotype 
diversity are high within and between species (Thompson et al. 2006; Chen et al. 2009). 
 For the human CYP3A locus, multiple CYP3A alleles, both functionally important and 
unimportant, have been identified (http://www.cypalleles.ki.se/index.htm). Different studies 
have reported evidence of selection on CYP3A genes. A paper by (Thompson et al. 2004) 
reported that high frequencies of a low/non-expresser CYP3A5 variant, CYP3A5*3, in non-
African populations were evidence of positive selection acting to increase frequencies of this 
derived allele outside of the African continent. However, a paper in 2006 argued that selection 
was acting on the functionally ambiguous CYP3A4*1B allele in non-African populations. As this 
allele has been reported to be in high linkage disequilibrium with CYP3A5*3, the authors 
argued that CYP3A4 is a more important gene of the CYP3A sub-family, and was likely to be 
under stronger selective pressure than CYP3A5 (Schirmer et al. 2006).  
 A more recent study of the CYP3A locus reported evidence of purifying selection on 
CYP3A4 and CYP3A7. The authors reported low levels of nucleotide diversity, i.e. high levels of 
sequence conservation in the coding regions of these two genes. In contrast, the authors 
reported a significant departure from neutrality in the coding regions of CYP3A5 and CYP3A43 
in Caucasian individuals, consistent with a selective sweep and positive selection. The authors 
reported higher frequencies of derived, non-functional CYP3A5 and CYP3A43 alleles in 
Caucasian individuals comparative to Africans (Chen et al. 2009). Recently, an examination of 
functionally important SNPs in multiple genes involved in drug metabolism provided further, 
strong evidence of a selective sweep/positive selection, on the low/non-expresser CYP3A5*3 
mutation in populations from the Middle East, Europe and Central South Asia (Li et al. 2011). 
 Given the substantial overlap in CYP3A drug and environmental substrates, it is 
difficult to ascertain exactly what may be the underlying causes of different selective patterns 
on individual CYP3A genes. Inter-population variability in haplotype structure at the CYP3A 
locus is likely to contribute to population differences in drug disposition and metabolism 
(Thompson et al. 2006; Chen et al. 2009). 
 This thesis focuses on characterising human genetic variation in the CYP3A5 gene. 
Whilst many previous studies have argued that the CYP3A4 enzyme has the most significant 
role, of all CYP3A enzymes, in therapeutic drug metabolism (Boobis et al. 1996) reports 
indicate that CYP3A5 has a greater role in populations with recent African ancestry (Roy et al. 
2005; Mirghani et al. 2006; Quaranta et al. 2006). Additionally the high frequencies of 
low/non-expresser variants in populations outside of Africa suggest that there has been 




1.2.3    Cytochrome P450 3A5 (CYP3A5) 
Human CYP3A5 has been mapped to the negative strand of the long arm of 
chromosome 7 at 7q21.1 at chromosomal location 7:99245928-99277519 (Build 132, NCBI: 
http://www.ncbi.nlm.nih.gov/). The gene is ~33kb long and has thirteen exons and twelve 
introns (Figure 1.5). One hundred nucleotides of exon 1 and the downstream sequence of 
exon 13 are untranslated regions. 87 nucleotides of exon 1 and 114 nucleotides downstream 
of exon 13 are untranslated from the mature mRNA. Multiple CYP3A5 transcripts have been 
identified (NCBI: http://www.ncbi.nlm.nih.gov/), a transcript of 1509 nucleotides is 
translated into a protein of 502 amino acid residues (Aoyama et al. 1989). The crystallised 
structure of CYP3A5 has not been elucidated, unlike for its paralogue CYP3A4 (Williams et al. 
2004). CYP3A5 is the major extra-hepatic CYP3A isoform; protein is also expressed in the 
kidneys, small intestine, prostate and lungs (Anttila et al. 1997; Lamba et al. 2002; Hukkanen 
et al. 2003; Moilanen et al. 2007). Additional transcripts have been identified, from cancer cell 
lines, although they do not encode functional nor alternative enzyme forms (NCBI: 
http://www.ncbi.nlm.nih.gov/). 
 
1.2.3.1 The genetic basis of variable CYP3A5 protein expression 
Human hepatic CYP3A5 was first detected by Aoyama and Schuetz in 1989 who 
observed that cDNA, corresponding to functional CYP3A5, could not be isolated from every 
individual and therefore enzyme expression was polymorphic; individuals tend to either 
express high quantities of CYP3A5 or have significantly reduced, often undetectable, protein 
levels (Aoyama et al. 1989; Schuetz et al. 1989).  
 CYP3A5 is polymorphically expressed between and within ethnic groups. 
Approximately 10-25% of Europeans, 30-50% of Asian and South Americans and 55-95% of 
African Americans (Kuehl et al. 2001; Quaranta et al. 2006) have detectable levels of hepatic 
CYP3A5 protein. Multiple variants have been reported to affect CYP3A5 expression (Xie et al. 
2004). Four CYP3A5 alleles; CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7, are the most 
common determinants of interethnic variability in protein expression (Hustert et al. 2001; 
Kuehl et al. 2001; Lee et al. 2003). 
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Figure 1.5: A representation of the CYP3A5 locus.  
Pink boxes represent exons; Xn indicates the exon number in the sequence. The red box at the 5´ of the sequence represents the proximal promoter. The green 
box is the 3´ untranslated region (UTR). The arrow indicates the direction of transcription. Black lines flanking the boxes are intronic sequences. Spacing 
between the exons is proportional to the distance between them on the chromosome. The largest CYP3A5 introns are annotated on the Figure.  









CYP3A5*1 is the CYP3A5 “expresser” allele and is genotyped at the same locus as 
CYP3A5*3 (rs776746). Genotyping of an A allele at the CYP3A5*1/*3 locus defines CYP3A5*1 
and a G allele defines CYP3A5*3. High frequencies of CYP3A5*1 have been observed in all, 
genotyped, populations with recent African ancestry (Hustert et al. 2001; Kuehl et al. 2001; 
Wojnowski et al. 2004; Xie et al. 2004; Roy et al. 2005; Mirghani et al. 2006; Quaranta et al. 
2006). Individuals homozygous for CYP3A5*1 have been found to have levels of CYP3A5 
mRNA that make up at least 50% of total hepatic CYP3A content (Kuehl et al. 2001).  
CYP3A5*3 (rs776746; 6980A>G)1 defines a splice variant in which an A>G transition in 
the third intron of CYP3A5 causes 132 nucleotides of intron three, which would normally be 
spliced out, to be retained in the mature mRNA, causing a frameshift, protein truncation and a 
reduction in protein expression to undetectable levels, see Figure 1.6 (Kuehl et al. 2001). The 
original 2001 study, which identified this variant, found a significant reduction in the 
concentration of CYP3A5 protein in liver specimens of CYP3A5*3 homozygotes (>21pmol/mg) 
than in individuals with at least one CYP3A5*1 allele (21-202pmol/mg). CYP3A5*3 
homozygotes also had a 2.5-fold reduced ability to metabolise midazolam (a known CYP3A 
substrate) to its primary metabolites (Kuehl et al. 2001).  
An independent study established that CYP3A5*3 mRNA transcripts are degraded by 
nonsense mediated decay (Busi and Cresteil 2005). Transcripts which contain the aberrant 
insertion (SV1-CYP3A5-mRNA) are only observed in the tissues of CYP3A5*3 carriers. 
CYP3A5*3 homozygotes have high levels of SV1-CYP3A5-mRNA, comparative to normally 
spliced CYP3A5 mRNA (Lin et al. 2002; Busi and Cresteil 2005). SV1-CYP3A5-mRNA levels vary 
between CYP3A5*1/CYP3A5*3 heterozygotes, and this may explain inter-individual 
differences in CYP3A5 protein expression levels observed in CYP3A5*3 heterozygotes (Lin et 
al. 2002). 
 
                                                             
1
 6980 refers to the position, in base pairs, of the CYP3A5*3 allele relative to the ATG start codon; consistent 
with all previous studies on this CYP3A5 variant. 
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Figure 1.6: A diagrammatic representation of the alternative splicing pathway created by the 
CYP3A5*3 mutation. An A>G transition (alleles are shown in brackets) causes 132 nucleotides of intron 
3 (labelled 3B and annotated on the right hand image) to be retained in the mature mRNA transcript; 
known as SV1-CYP3A5-mRNA. This causes a frameshift and premature termination of the reading frame. 
Normally spliced mRNA is detected in the tissues of CYP3A5*3 homozygotes but at very 




CYP3A5*6 (rs10264272; 14684G>A) defines a G>A transition associated with exon 7 
“skipping”. The exonic G>A transition is a synonymous change, reported to lead to the 
creation of a cryptic splice site within exon 7; resulting in its excision from the mature mRNA. 
The exonic excision leads to a frameshift and the creation of a premature termination codon, 
leading to degradation of the mRNA transcript and a reduction in CYP3A5 expression levels 
(Kuehl et al. 2001). It was hypothesised that the CYP3A5*6 defining G>A transition in exon 7 
could disrupt an exonic splicing silencer or activate an exonic splicing enhancer, leading to an 
aberrant splicing pathway (Kuehl et al. 2001), although this is yet to be confirmed 
experimentally.  
It is important to note that the effect of CYP3A5*6 on mRNA splicing has only been 
established once; mRNA was extracted from three CYP3A5*1/CYP3A5*6 heterozygotes, 
reverse transcribed to cDNA and the products analysed by gel electrophoresis, see Figure 1.7. 
For CYP3A5*1/CYP3A5*6 heterozygotes, two cDNA products were isolated; one of which was 
smaller than the normal mRNA length and did not contain the sequence for exon 7 (Kuehl et 
al. 2001). An examination of the gel reported in the original paper (Figure 1.7) suggests that 
an alternative mRNA transcript is produced in CYP3A5*6 carriers, however the results from 
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this paper have never been independently replicated and therefore alone are not entirely 
conclusive. The paucity of data on mRNA splicing and composition in CYP3A5*6 homozygotes 
means that the exact effect of CYP3A5*6 on CYP3A5 splicing is not fully understood. 
 
Figure 1.7: The Figure from the original paper reporting that the CYP3A5*6 allele causes aberrant 
splicing of CYP3A5 mRNA transcripts. mRNA from human livers was reverse transcribed and analysed 
by gel electrophoresis (shown below). The authors reported that the CYP3A5*6 mRNA transcript did 
not have the sequence for exon 7 of the gene but did not show the sequence. The Figure has been 
adapted from (Kuehl et al. 2001). The circled band is the CYP3A5*6 aberrant splice variant identified in 
the 2001 study. Wt refers to normally spliced mRNA, SV refers to splice variants. Data for CYP3A5*3 
heterozygotes and homozygotes are also shown on the right hand side of the image; and correspond to 




CYP3A5*7 (rs41303343; 27125_27126insT) defines a T nucleotide insertion into exon 
11. CYP3A5*7 is associated with a reduction in CYP3A5 expression levels. The T nucleotide 
insertion causes a frameshift, the creation of a premature stop codon and early termination of 
the open reading frame (Chou et al. 2001; Hustert et al. 2001).  
Normally spliced mature mRNA, as well as abnormally spliced mRNA, is detected in all 
tissues in individuals heterozygous and homozygous for CYP3A5*3 (although normally spliced 
mRNA levels are significantly lower, and often undetectable, in CYP3A5*3 homozygotes) and 
individuals heterozygous for CYP3A5*6. It is important to note that unlike CYP3A5*3 and 
CYP3A5*6, no experimental work has examined CYP3A5 mRNA levels, or composition, in 
CYP3A5*7 carriers. However, as the mutation leads to the creation of a premature stop codon, 
it is highly likely that these individuals do not produce any normally spliced CYP3A5 mature 
mRNA unless they are CYP3A5*1/CYP3A5*7 heterozygotes. 
 Many previous studies have described CYP3A5*3, CYP3A5*6 and CYP3A5*7 as “knock-
out”, or null, CYP3A5 alleles. However the effects of CYP3A5*3 and CYP3A5*6 on in vivo splicing 
have been shown to be “leaky” given the identification of normally spliced mRNA in the 
tissues of CYP3A5*3 and CYP3A5*6 carriers. (Kuehl et al. 2001; Lin et al. 2002). Many previous 
studies have also tended to group CYP3A5*3, CYP3A5*6 and CYP3A5*7 to infer population 
frequencies of non-expressers of CYP3A5. However the, independent, comparative effects of 
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these CYP3A5 variants on CYP3A5 splicing and protein expression have not been 
experimentally established. Therefore, it is preferable to group the CYP3A5*3, CYP3A5*6 and 
CYP3A5*7 alleles as variants which can contribute to polymorphic CYP3A5 expression. The 
extensive interethnic variability in CYP3A5 expression has highlighted the need for careful 
sampling of individuals when evaluating the importance of this enzyme in drug metabolism 
(Foti and Fisher 2004; Quaranta et al. 2006).  
CYP3A5 had previously been thought of as less important in the metabolism of CYP3A 
substrates due to its polymorphic expression and the predominance of CYP3A4 expression in 
the liver (Boobis et al. 1996). However, recent work has not only challenged this view but 
found that CYP3A5 represents at least 50% of the total hepatic and intestinal CYP3A content 
in individuals who express the protein at high concentrations (Lin et al. 2002). This has lead 
to various studies concluding that variation in the DNA sequence of CYP3A5 may be the most 
important genetic contributor to interethnic and interpopulation differences in CYP3A 
dependent drug clearance (Kuehl et al. 2001; Lamba et al. 2002; Givens et al. 2003; Zheng et 
al. 2003; Foti and Fisher 2004; Frohlich et al. 2004; Xie et al. 2004; Mouly et al. 2005). 
 
1.2.3.2 Regulation of CYP3A5 transcription 
 CYP3A5 transcription is regulated by a promoter situated upstream of exon 1, from -
800 to +50 (Lamba et al. 2002; Burk et al. 2004). A diagrammatic representation of the 
proximal promoter region, including all known transcription factor binding sites, is presented 
in Figure 1.8. The 5´-proximal promoter region of CYP3A5 has 89.6% homology to the 
equivalent region of the pseudogene CYP3AP1 (Finta and Zaphiropoulos 2000). High levels of 
homology between CYP3A5 and CYP3AP1 lead to the initial characterisation of the CYP3A5 
promoter region being incorrect (Jounaidi et al. 1994). Given the differences in CYP3A5 
expression levels between different populations, it was hypothesised that promoter variants 
were responsible for the variability observed in enzyme activity. A study in 2000 identified 
two variants, believed to be in the 5´ promoter of CYP3A5, as being responsible for the 
variable activity (Paulussen et al. 2000). However, subsequent reports found that these 
variants actually occurred in the 5´ upstream region of CYP3AP1 and so could not be 
responsible for polymorphic CYP3A5 expression (Lamba et al. 2002). A later study did find 
that linkage disequilibrium (LD) between these variants and the CYP3A5*1 allele is high 
(Kuehl et al. 2001) although this is likely to be due to high levels of LD across the entire CYP3A 
cluster (see chapter 5) (Thompson et al. 2006). 
 To date, few variants have been identified in the CYP3A5 proximal promoter 
(Nakamura et al. 2001); none occur in known transcription factor binding sites of the gene; 
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and none of the variants have been reported to be associated with low or altered CYP3A5 
enzyme activity (Lamba et al. 2002; Xie et al. 2004). Due to high levels of LD across the gene, 
these variants are often found on the same haplotype background as the CYP3A5*3 allele (Xie 
et al. 2004). 
 CYP3A5 is not as inducible by nuclear hormones/genes as CYP3A4 (Lamba et al. 2002; 
Lin et al. 2002) and transcription is not known to be regulated by a distant enhancer located 
~7000 base pairs upstream of the CYP3A cluster, as is the case for CYP3A4 (Matsumura et al. 
2004; Martinez-Jimenez et al. 2005). However, CYP3A5 is the major extra-hepatic CYP3A 
enzyme (Lamba et al. 2002; Wojnowski 2004) and a previous study reported that CYP3A5 
accounts for at least 50% of the CYP3A hepatic content in individuals who are homozygous for 
CYP3A5*1 (Kuehl et al. 2001). CYP3A5 transcription can be induced by a number of 
transcription factors including specificity proteins (Sp) and nuclear factor-Y proteins (Iwano 
et al. 2001); both classes of these transcription factors are ubiquitous in human tissues (Roder 
et al. 1999; Suske 1999; Kolell and Crawford 2002) and this may explain the large tissue range 
in which the CYP3A5 gene is transcribed and CYP3A5 enzyme is expressed. 
 
1.2.3.3 The 3´ downstream region of CYP3A5 
 The 3´ region of a gene is a critical regulator of protein expression. The 3´ region 
encodes a series of signals which can affect translation termination, the export from the 
nucleus and stability of an mRNA transcript (Neilson and Sandberg 2010). Polymorphisms 
which occur in the 3´ untranslated region can significantly affect protein expression and 
cellular localisation (Alt et al. 1980). Additionally, a number of mutations which occur in the 3´ 
region of specific genes have been associated with several disease pathologies, including 
numerous cancers (Chatterjee and Pal 2009). Several CYP3A5 mRNA transcripts, with 
alternate 3´ ends, have been isolated from cancer cell lines (http://www.ncbi.nlm.nih.gov/). 
Despite the importance of the 3´ region, studies have estimated that over half of all human 
genes have multiple mRNA 3´ ends (Tian et al. 2005; Hughes 2006) suggesting that eukaryotic 
gene regulation is much more complex than by the 5´ region alone. 
 The 3´ region of the full CYP3A5 transcript, known to encode a 502 amino acid protein, 
is 114 base pairs in length. To date three variants have been identified in the 3´ UTR of 
CYP3A5 (http://www.ncbi.nlm.nih.gov/) and of these two occur at global frequencies of over 
1%. One of these variants, rs15524, is tightly linked to the CYP3A5*3 allele; although 
experimental work has found that this variant alone does not influence CYP3A5 mRNA 
processing, nor does it impact protein expression in any other way (Busi and Cresteil 2005). 
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Figure 1.8: The known proximal promoter region of CYP3A5. Known regulatory motifs are in red text and underlined. The diagram has been adapted 
from (Lin et al. 2002). Positions are numbered according to the ATG start codon where base A is +1.  
Abbreviations: NFSE, Nifedipine specific element; PRE/GRE, pregnane/glucocorticoid receptor element; ERE, oestrogen response element; HNF-5, human 




1.2.4 Drugs metabolised by CYP3A5  
 Variability in CYP3A5 expression has a significant effect on drug treatment-related 
adverse clinical outcomes and disease susceptibility. A significant proportion of CYP3A 
substrates are metabolised by both CYP3A4 and CYP3A5. These enzymes overlap in their 
substrate specificity, however studies have shown that overlapping substrates are 
metabolised much more efficiently in individuals who express both CYP3A5 and CYP3A4 than 
in individuals who solely express CYP3A4 (Lin et al. 2002; Zheng et al. 2003; Mouly et al. 
2005; Mirghani et al. 2006). It should be noted that it is unclear whether an increase in 
metabolism is due to the specificity of CYP3A5 for certain CYP3A substrates, or due to the 
presence of two CYP3A enzymes that are equally efficient at metabolising CYP3A substrates 
and hence enable much more efficient metabolism. However studies have found a significant 
contribution of CYP3A5 in the metabolism of HIV-1 protease inhibitors, drugs used in the 
treatment of severe malarial infection, kidney diseases and mental illness. In each of these 
examples, the contribution of CYP3A5 to drug metabolism was greater than CYP3A4 (Kuehl et 
al. 2001; Lin et al. 2002; Givens et al. 2003; Zheng et al. 2003; Frohlich et al. 2004; Wojnowski 
et al. 2004; Mouly et al. 2005; Mirghani et al. 2006; Kohlrausch et al. 2008).  
 
1.2.4.1  HIV-1 protease inhibitors 
 One of the most important classes of drugs that are metabolised by CYP3A5 are 
protease inhibitors used in the treatment of HIV-1 infections (Haas et al. 2006; Josephson et 
al. 2007); one of the best studied examples in pharmacogenetics is saquinavir (Frohlich et al. 
2004; Mouly et al. 2005; Josephson et al. 2007).  
 Saquinavir is a HIV-1 protease inhibitor and has been reported as having low 
bioavailability (the proportion of a drug that is available to the target body tissue after 
administration) due to extensive first phase metabolism by Cytochromes P450 (Frohlich et al. 
2004; Mouly et al. 2005). Clinical studies have also found that saquinavir bioavailability has 
interethnic and interpopulation variability; a feature that is consistent with CYP3A substrates.  
 Recent studies have found that saquinavir bioavailability is influenced by hepatic 
CYP3A5 content (Frohlich et al. 2004; Mouly et al. 2005; Josephson et al. 2007). In one study, 
urine samples were tested for parent/metabolite ratio. Increased bioavailability would result 
in a higher proportion of metabolite than parent compound. The study found that the ratio 
was independent of CYP3A4 activity, however in individuals genotyped with at least one 
CYP3A5*1 allele; hepatic expression of CYP3A5 correlated positively with a higher proportion 
of metabolite in the urine samples and furthermore the proportion was twice as high as that 
for individuals heterozygous or homozygous for CYP3A5*3, i.e. low/non-expressers (Mouly et 
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al. 2005). Significantly, intestinal CYP3A5 content was not correlated with increased ratio of 
metabolite to parent compound; indicating a significant role for hepatic CYP3A5 in saquinavir 
metabolism.  
 An additional study found that patients who were homozygous for two low/non-
expresser CYP3A5*3 alleles had a 34% increased likelihood of treatment failure; individuals 
who were heterozygous for CYP3A5*1/CYP3A5*3 had increased time to clear the drug from 
the system compared to CYP3A5*1 homozygotes. Thus patients who were CYP3A5*3 
homozygotes were exposed to the toxic compound saquinavir for a longer period of time than 
patients who were CYP3A5 expressers; and so at increased risk of adverse clinical effects 
(Josephson et al. 2007).  
 Aside from saquinavir, researchers are now assessing the role of CYP3A5 in the 
metabolism of other drugs used in the control of HIV-1 infections, and for new anti-retroviral 
agents such as Maraviroc which targets the chemokine receptor CCR5 on the host cell with the 
aim of blocking viral entry. A recent study found that CYP3A5 appeared to have a role in the 
bioavailability of this drug but concluded that further work was required to determine the 
exact nature of the interaction (MacArthur and Novak 2008).  
 These studies highlight a significant role for CYP3A5 in the metabolism of drugs used 
in the control of HIV-1 infections. They have also provided evidence for the importance of 
hepatic CYP3A5 in the metabolism of CYP3A, and CYP450, specific substrates. 
 
1.2.4.2  Drugs used in the treatment of severe malarial infections 
 CYP3A are involved in the first phase metabolism of drugs used in the treatment of 
malaria infections (Mirghani et al. 2006; Diczfalusy et al. 2008; Ferreira et al. 2008). In 
malaria endemic regions, the recommended first line of treatment for uncomplicated malaria 
is artemisinin-combination therapy (ACT) in which an artemisinin containing drug (e.g. 
artemether) is paired with another anti-malarial agent (Cook et al. 2009). Artemisinin has 
been shown to be a substrate for CYP3A4 in vitro and in vivo (Ferreira et al. 2008; Piedade and 
Gil 2011); few studies have examined the ability of CYP3A5 to metabolise this compound. 
However studies have reported a role for CYP3A5 in the metabolism of quinine; an agent used 
in the treatment of severe malarial infections (Mirghani et al. 2006; Diczfalusy et al. 2008; 
Ferreira et al. 2008).  
 In 2006 (Mirghani et al. 2006) explored the relationship between CYP3A5 variation 
and quinine metabolism in Tanzanian and Swedish individuals. Healthy participants were 
given one 250mg oral dose of quinine hydrochloride and a blood sample was taken from each 
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participant sixteen hours post drug administration. The investigators measured the metabolic 
ratio of quinine hydrochloride (the parent compound) to 3-hydroxyquinine (the primary 
metabolite with anti-malarial properties). Individuals who were found to have high levels of 
3-hydroxyquinine in their blood compared to quinine hydrochloride (i.e. had a low metabolic 
ratio) were considered to be efficient metabolisers of the oral drug. Each participant was 
genotyped for the CYP3A5*1/CYP3A5*3, CYP3A5*6 and CYP3A5*7 alleles and inferred CYP3A5 
expression phenotypes were compared to the metabolic ratio of parent compound to 
metabolite to examine the association. 
 Tanzanians had a significantly lower mean quinine metabolic ratio when compared to 
Swedes i.e. Tanzanians on the whole metabolised quinine hydrochloride much more 
effectively than Swedish participants were able to. The study also found that Tanzanians were 
more likely to express CYP3A5 at detectable levels, due to higher frequencies of the CYP3A5*1 
allele than observed in the Swedish group; consistent with independent reports (Hustert et al. 
2001; Kuehl et al. 2001; Roy et al. 2005; Quaranta et al. 2006). Inferred low/non-expressers of 
CYP3A5 from both populations had high quinine metabolic ratios, i.e. low concentrations of 
the primary metabolite 3-hydroxyquinine but high concentrations of the parent compound 
quinine hydrochloride in the blood, indicating that the bioavailability of the active compound 
was low. Conversely, individuals who were CYP3A5 expressers had low quinine metabolic 
ratios, i.e. high concentrations of the primary metabolite 3-hydroxyquinine and low 
concentrations of the parent compound quinine hydrochloride in the blood. This suggests a 
role for CYP3A5 in the metabolism of this drug substrate. Interestingly the study also found 
that Tanzanians who did not express CYP3A5 (i.e. only CYP3A4 was expressed) were 
significantly less able to metabolise quinine than Swedes who only expressed CYP3A4. Since 
malaria is endemic in Tanzania and not Sweden, this is an important example of how 
population-specific expression of CYP3A5 could have significant clinical implications. 
 
1.2.4.3  Drugs used in the treatment of mental illness 
 Previous research has identified a role for CYP3A enzymes in the metabolism of 
various drugs used in the treatment of depression and other mental illnesses (Lin et al. 2002; 
Floyd et al. 2003; Eap et al. 2004; Wong et al. 2004; Yu et al. 2004; Fromm et al. 2007; Kang et 
al. 2009). A recent paper found a significant role for CYP3A5 in the metabolism of certain 
drugs used to manage schizophrenia in European-Brazilian patients (Kohlrausch et al. 2008).  
 This study examined the influence of SNPs in five genes on the ability to respond to 
treatment with haloperidol and chlorpromazine in 186 European-Brazilian patients with 
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schizophrenia; both drugs need to be metabolised for bioavailability of active compounds. 
Patients were identified as non-responders to treatment if they were unable to metabolise 
either or both of these drugs and if they did not demonstrate appropriate behavioural control 
within two years of starting therapy.  
 A total of 40 known SNPs in five genes (two dopamine receptors; DRD2 and DRD3 and 
three Cytochrome P450 genes; CYP2D6, CYP3A4 and CYP3A5) were genotyped based on 
evidence of their effect on protein function; a single SNP was genotyped in DRD2, five in DRD3, 
24 polymorphisms in CYP2D6, nine in CYP3A4 and one in CYP3A5.  
 Multiple logistic regression analysis found that individuals who had at least one copy 
of a haplotype of mutations at all five loci of the dopamine receptor DRD3 and who had one 
copy of the CYP3A5*3 allele had a significant reduction in the ability to respond to treatment. 
Individuals homozygous for the CYP3A5*3 allele but did not have mutations in the dopamine 
receptor DRD3 had a resistance to treatment, although resistance to treatment was not as 
severe in these patients as in those who had mutations in both of these genes.  
 This study was one of many that have examined the effect of variation in CYP450 on 
the ability to metabolise drugs used in the treatment of mental illness (Lin et al. 2002; Floyd et 
al. 2003; Eap et al. 2004; Wong et al. 2004; Yu et al. 2004; Fromm et al. 2007; Kang et al. 
2009). However it should be noted that it is unclear as to whether CYP3A5 variation affects 
the ability of an individual to absorb these drugs, into the site of action, or on the ability to 
excrete drugs effectively from the system. Further research will need to establish the 
molecular interactions between the enzyme and substrate in order to determine the exact role 
of CYP3A5 in the metabolism of these drugs.  
 
 1.2.4.4  Drugs used in the management of patients post solid organ transplantation 
 One of the best studied examples of CYP3A substrates are therapeutic drugs used in 
the management of patients following solid organ transplantation. When individuals undergo 
solid organ transplantation there is a high chance that the transplanted organ will be rejected 
by the patient’s immune system. Following surgery it is necessary to prescribe 
immunosuppressive drugs to manage this immune response. Aside from problems that exist 
due to compliance of patients with taking these medications, there is a high degree of 
variability in treatment outcome following surgery; of which a significant proportion can be 
attributed to variation in response to immunosuppressive therapy.  
 One of the most commonly used drugs following solid organ transplantation is 
tacrolimus (Iwasaki 2007; Cattaneo et al. 2008). Tacrolimus can be administered both orally 
and intravenously. High rates of interethnic variability in drug treatment have been reported 
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for orally administered tacrolimus; a feature that is consistent with CYP3A substrates 
(Iwasaki 2007). Intravenously administered tacrolimus displays minimal interethnic 
variability and improves clinical outcome (personal communication with Dr Ian MacPhee)2. 
However intravenous administration of the drug is a lengthy and difficult process due to the 
need for repeated injections every four hours within hospital and after discharge of the 
patient; it is for this reason that oral administration of this compound is favoured over 
intravenous administration and studies have attempted to adjust oral concentrations of 
tacrolimus to improve clinical outcome. Tacrolimus is a substrate for multiple drug 
metabolising enzymes, including those outside of the CYP450 superfamily, however there is a 
significant association between the effective metabolism of the drug and CYP3A5 expression 
(Hesselink et al. 2003; Zheng et al. 2003; Goto et al. 2004; Zhao et al. 2005; Quteineh et al. 
2008).  
Tacrolimus needs to be metabolised in order to become active and enable 
immunosuppression. Tacrolimus has a narrow therapeutic index; i.e. there is a narrow 
window between concentrations of the drug that are effective and concentrations that are 
toxic to patients. Therefore the interethnic variability in drug response is problematic as 
standardised dosing of this drug following surgery has biased against groups of individuals 
who are much more likely to express CYP3A5 than groups who do not. Individuals who 
express CYP3A5 tend to metabolise tacrolimus at a much faster rate than low/non expressers, 
therefore they have an insufficient dosage to ensure immunosuppression and higher rates of 
organ rejection. Conversely, low/non expressers of CYP3A5 tend to metabolise tacrolimus at 
slower rates than CYP3A5 expressers which is problematic as they are exposed to a toxic 
compound for longer periods of time and have increased levels of liver toxicity (Hesselink et 
al. 2003; Zheng et al. 2003; Goto et al. 2004; Zhao et al. 2005; Iwasaki 2007; Cattaneo et al. 
2008; Quteineh et al. 2008).  
Therefore it has become necessary to examine how best to tailor tacrolimus treatment 
to an individual patient based on their CYP3A5 genotypic profile. However this will require 
further studies on other factors that can affect tacrolimus metabolism as it is not understood 
how multiple proteins involved in tacrolimus metabolism may interact at the molecular level 
and whether this influences tacrolimus bioavailability (Cattaneo et al. 2008). 
 
 
                                                             
2 Dr Ian MacPhee is an academic consultant nephrologist at St George’s Hospital in London with a 
specific interest in kidney transplantation. He has published numerous papers on the 
pharmacogenetics of tacrolimus. 
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1.2.5 CYP3A5 and disease risk 
Variability in CYP3A5 expression is also attributed to inter-ethnic differences in the 
risk of developing certain diseases, including hypertension (Fromm et al. 2005) and kidney 
diseases (Givens et al. 2003; Zheng et al. 2003; Quaranta et al. 2006). Controversial and 
contested reports have identified associations between CYP3A5 alleles and increased risk for 
the development of different cancers (Dandara et al. 2005; Zhenhua et al. 2005).  Elevated 
disease risks may be associated with the role of CYP3A5 in the metabolism of endogenous 
substrates including oestrogens, testosterone, androgens and steroid hormones (Lamba et al. 
2002). Of all identified disease risks, the best studied example is the association between salt-
sensitive hypertension and CYP3A5 genotypes. 
 
1.2.5.1 CYP3A5 variability and hypertension risk 
Hypertension is a leading cause of global morbidity, affecting approximately 37-55% 
of the adult population in Europe (Wolf-Maier et al. 2003) and an even higher proportion of 
adults in Asia and Africa (Brown 2006). Hypertension is diagnosed based on readings of the 
pressure at which blood is pumped from (systolic blood pressure) and to the heart (diastolic 
blood pressure). Hypertension is categorised into three major categories: pre-hypertension, 
stage one hypertension and stage two hypertension (National Institute for Clinical Excellence 
[NICE], United Kingdom: 
http://www.nice.org.uk/newsroom/pressreleases/NewGuidelineForDiagnosingAndTreating
HighBloodPressure.jsp). A diagnosis of hypertension is made when readings of systolic and 
diastolic blood pressure, for an individual patient, are consistently in the range for classifying 
stage one hypertension. 
A number of dietary and environmental factors are associated with hypertension, 
however more recently genetic associations have also been identified (Bochud et al. 2009). 
Associations between high CYP3A5 protein expression levels and hypertension have been 
reported (Givens et al. 2003; Fromm et al. 2005).  CYP3A5 is involved in the metabolism of the 
endogenous substrate cortisol to 6β-hydroxycortisol, a key regulator of renal sodium 
transport (Wrighton et al. 1990). Selective inhibitors of CYP3A5 have been found to decrease 
the level of 6β-hydroxycortisol and decrease blood pressure (Watlington et al. 1992). It has 
been proposed that CYP3A5*1 carriers have enhanced sodium reabsorption and, given the 
high frequencies of CYP3A5*1 in populations with recent African ancestry, it has been 
proposed that high frequencies of this CYP3A5 allele are advantageous in equatorial 
populations in times of water shortage (Kuehl et al. 2001; Thompson et al. 2004). However, 
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there are conflicting data on whether CYP3A5*1 is associated with hypertension, and where 
associations have been observed, there are conflicting data on whether the association is to 
increase or decrease blood pressure (Bochud et al. 2009). The associations between CYP3A5*1 
and hypertension appear to be more pronounced in populations with recent African ancestry 
(Thompson et al. 2004). However there may be a possibility of ascertainment bias in studies 
which only sample African or African-American populations as they are known to have high 
frequencies of  CYP3A5*1. Comparisons of populations with recent African ancestry and other 
global populations will provide a better indication of how important CYP3A5*1 is in 
hypertension physiology. 
 
1.3 Part III: Population genetic theory and selection 
 Population genetics examines variation in haplotype and allele frequencies to 
determine which evolutionary processes have occurred, or are occurring within and between 
populations. Mutation is the main source of genetic variation. The three main processes which 
can influence allele and haplotype frequencies are gene flow, drift and selection (Hedrick 
2007). Population genetics models need to account for, and differentiate between, each of 
these processes to explain observed patterns of diversity. Of particular relevance to this thesis 
are methods used to detect selection. 
 
1.3.1 The different trajectories of neutral and selected mutations  
 Selection may influence allele and haplotype frequencies, we can compare the 
trajectories of neutral and selected mutations (Figure 1.9a). The two graphs compare changes 
in the frequencies of selected and neutral mutations over time. The frequency of a neutral 
mutation is entirely dependent upon genetic drift. A neutral mutation can rise to high 
frequencies/fixation, but this process is much slower than for a selected allele; as seen in the 
top graph.  
 In contrast, the time taken for an allele that confers a selective advantage to increase 
in frequency is much lower than for neutral alleles. In either graph, new alleles are being 
continuously introduced into the population by mutation, but alterations in their frequencies 
are entirely dependent upon genetic drift; consequently many mutations remain at low 




1.3.2 Signatures of positive selection within the human genome 
 The majority of new mutations are lost as a result of random genetic drift. The neutral 
theory of evolution proposes that the majority of inter- and intra-population differences in 
allele frequencies are a result of random fluctuations in the frequencies of neutral mutations 
(Kimura 1979; Kimura 1991). Population genetics models have been developed to identify 
marks, or “signatures”, of selection within the human genome (Sabeti et al. 2007). An 
overview of models for detecting positive selection, which are relevant to work presented in 
this thesis, is presented below. 
 
Figure 1.9a: The different trajectories of neutral and selected mutations. Image has been taken from Di 
Rienzo, A. (2007), "The Signature of Local Adaptations in Human Polymorphism Data": a talk from the 




1.3.2.1 Comparing non-synonymous and synonymous mutations 
 Population genetics has focused on examining how variation within gene coding 
regions may be a result of selection. Exonic variants tend to fall into two categories: those 
which are predicted to alter protein structure/function (often non-synonymous/harmful 
mutations) and benign (synonymous) mutations.  
 Deleterious mutations are unlikely to reach high frequencies within a population; 
therefore if a non-synonymous mutation is neutral it will increase in frequency at the same 
rate as synonymous mutations. This can be measured by comparing the ratio of non-
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synonymous (dN) to synonymous (dS) changes. If a non-synonymous change is neutral then 
the ratio dN/dS will be equal to 1; if the change is deleterious then it will not reach high 
frequencies/fixation and dN/dS will be equal to less than 1; if a non-synonymous change is 
advantageous then dN/dS will be equal to greater than 1. If an excess of high frequency 
function-altering variants are observed in the data, which can be tested using a McDonald-
Kreitman test (McDonald and Kreitman 1991), then it may indicate an adaptive 
change/positive selection for a particular mutation.  
 Whilst this method has been useful in identifying changes which can affect the 
expression and function of particular genes; it overlooks the role of non-coding and regulatory 
genomic regions which can also affect gene function and expression. An additional limitation 
of this test is that it relies heavily on the assumption that non-synonymous variation is 
function altering when this is not universally the case. However this test is useful for 
evaluating coding region selection. 
 
1.3.2.2 Allele frequency spectrums 
 As seen in Figure 1.9a, an adaptive allele will rise to high frequency along with 
additional neutral variation to which it is tightly linked; this is known as a selective sweep, see 
Figure 1.9b. Here an adaptive allele arises in the population, is selected for and therefore 
increases in frequency; eventually defining all haplotypes within a population (Figure 1.9b-c).  
 
Figure 1.9b: The mechanism of a selective sweep whereby an adaptive allele (shown in blue) increases 
in frequency along with all tightly linked neutral variation (shown in red), and eventually goes to 
fixation, as a result of a selective sweep. The image has been taken from (Kelley and Swanson 2008). 
 
  A reduction in polymorphism levels is often seen following a selective sweep (until 
new mutations or recombination events increase variation in and around the selected region). 
The overall mutation rate in the human genome is estimated to be 10-8 (Jobling et al. 2004) for 
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each nucleotide per generation. Given the rapid increase in frequency of an adaptive allele, 
along with all tightly linked variation, new mutations often do not accumulate on these 
haplotypes and those that do are rare and so observed at low frequencies (Figure 1.9). 
Therefore an excess of rare alleles, which can be measured by the Tajima’s D statistic (Tajima 
1989), and a reduction in polymorphism levels, which can be measured by the HKA test 
(Wright and Charlesworth 2004), in a genomic region may indicate a past selective event. 
 
1.3.2.3 High frequency derived alleles 
 Mutation can introduce new alleles into a population. Neutral mutations can rise to 
high frequency as a result of genetic drift (Figure 1.8); but this process takes much longer than 
for selected alleles. During a selective sweep, derived alleles which are tightly linked to an 
adaptive allele can rise, or effectively “hitch-hike” to high frequency. Some neutral variants 
may not increase in frequency as a result of an incomplete sweep, or recombination of the 
selected region during a selective sweep. Therefore a region containing many derived alleles 
at high frequencies can indicate a past selective event. A significant number of high frequency 
derived alleles can be measured by Fay and Wu’s H test (Fay and Wu 2000). 
 
1.3.2.4 Population differentiation 
 Population specific differences in allele frequencies may indicate differential positive 
selection in one population over another. One of the most common methods for identifying 
population differentiation is the FST statistic (Wright 1950). FST measures the significance of 
population differences in allele frequencies; the statistic ranges from 0 to 1; where 1 indicates 
that inter-population allele frequencies are different. 
 However there are problems associated with forming conclusions about differential 
selection based on use of the FST statistic alone. Large differences in allele frequencies are 
estimated to occur at over 30% of all polymorphic loci identified in the human genome. 
Furthermore, demographic factors; in particular population bottlenecks where substantial 
genetic diversity is lost (Manica et al. 2007), can mimic a signature of positive selection and 
lead to significant inter-population differences in allele frequencies and in FST values (Hofer et 
al. 2009). Additionally the FST statistic will identify inter-population differences for both 
neutral and adaptive alleles. Therefore the test should be used in conjunction with those 
which examine functional implications of particular loci in order to identify adaptive alleles. 
Inferences about positive selection in the human genome should also use additional tests, in 




1.3.2.5 Haplotype based methods for detecting selection 
 In addition to allele frequency tests of selection; there are also those which examine 
haplotype diversity and structure. As mentioned previously, a single allele can be a target of 
selection but it will often rise to high frequency along with a tightly linked genomic region; 
known as a haplotype (or large linkage disequilibrium block). Selective sweeps can be both 
hard and soft; and each with different signatures on haplotypes surrounding the adaptive 
allele.  
 A long region of extended haplotype homozygosity (EHH) surrounding the adaptive 
allele is often seen after a hard sweep. This is seen as additional mutations would not have 
had time to accumulate on a region tightly linked to an adaptive allele, and recombination will 
not have been able to rearrange genomic regions to increase diversity (Kim and Nielsen 
2004). Many scans for signatures of hard selective sweeps have identified multiple regions 
believed to have undergone positive selection (Sabeti et al. 2002; Sabeti et al. 2006; Sabeti et 
al. 2007) and through the use of a long range haplotype (LRH) test identified regions of low 
diversity tightly linked to adaptive mutations (Sabeti et al. 2002). 
 However there are instances where a previously neutral allele may become 
advantageous, perhaps due to new environmental conditions, and so becomes adaptive and 
selected for. This allele may increase in frequency to fixation rapidly due to a selective sweep 
on standing neutral variation. Given the previous neutrality of the now selected allele, there is 
likely to be substantial diversity in the haplotype classes which have now risen to high 
frequency. This is due to recombination and mutation events during the neutral phase of the 
allele; additionally tightly linked regions may be smaller and so unsuitable for examination 
with the LRH test. A review of selective sweeps (Pritchard et al. 2010) proposed that soft 
selective sweeps would enable necessary adaptation and were perhaps much more prominent 
in our evolutionary history than hard selective sweeps alone. 
 
1.3.3 CYP3A5 and the salt-retention hypothesis 
 Some previously published studies have attempted to explain the significant inter-
population differences observed in the frequencies of low/non-expresser CYP3A5 alleles. A 
paper by (Thompson et al. 2004) found a strong positive correlation between high 
frequencies of a low/non-expresser CYP3A5 allele; CYP3A5*3 and distance from the equator.  
 The authors speculated that the CYP3A5 expresser allele; CYP3A5*1, may be 
advantageous in populations close to the equator due to the role of CYP3A5 in sodium 
reabsorption and water retention. CYP3A5 is responsible for the conversion of cortisol into 
6β-hydroxycortisol in the kidney. 6β-hydroxycortisol is important in maintaining immune 
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responses that cause inflammation, and is a key regulator of renal sodium transport 
(Wrighton et al. 1990). A side effect of 6β-hydroxycortisol is increased sodium and water 
retention which is responsible for the clinical phenotype of salt-sensitive hypertension. For 
equatorial human populations, retention of salt and water was proposed to be advantageous; 
particularly during periods of water shortage. However the retention of salt in populations 
residing in non-humid climates is disadvantageous and so it was proposed that the correlation 
between high frequencies of CYP3A5*3 and increased latitude was due to a selective 
advantage in non-equatorial populations to not readily retain salt as much as populations 
from humid climates. 
 In fact a strong positive correlation is observed between increased latitude and 
functionally important variants of genes implicated in salt-sensitive hypertension (Young et 
al. 2005). Given the substantial diversity observed in sub-Saharan Africa, it will be interesting 
to see whether there is any evidence of longitudinal differences in low/non-expresser CYP3A5 
allele frequencies between populations from the sub-continent. 
  
 48 
1.4 Aims and overview of thesis 
The overall objective of this thesis is to examine whether there are significant inter-
population differences in, and evidence of positive selection on, the gene encoding the drug 
metabolising enzyme Cytochrome P450 3A5 (CYP3A5) in sub-Saharan Africa; with a specific 
emphasis on Ethiopian populations.  
 
The specific aims addressed within each of the results chapters are as follows: 
1. To determine and compare the frequencies of the three main low/non-expresser 
CYP3A5 alleles: CYP3A5*3, CYP3A5*6 and CYP3A5*7 and the expresser allele: CYP3A5*1 
in 36 geographically and ethnically distinct populations from in and around sub-
Saharan Africa. 
2. To examine intra-African diversity within a ~4.5kb region of CYP3A5. To compare sub-
Saharan African diversity in the CYP3A5 gene with data previously reported for global 
populations. 
3. To identify novel variants, from sub-Saharan African re-sequencing data, that may 
affect CYP3A5 transcription, translation or CYP3A5 expression. 
4. To compare diversity within a ~12.3kb region of CYP3A5 in five ethnically distinct 
Ethiopian populations. To then compare diversity within an overlapping re-
sequencing data for an 8063 base pair region of CYP3A5, between Ethiopians and 
other global populations. 
5. To characterise the evolutionary relationships between expresser and low/non-
expresser CYP3A5 haplotypes and to date low/non-expresser variants.
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2. Materials and Methods 
2.1 DNA samples and population histories 
All samples re-sequenced and genotyped for this thesis are part of a large DNA 
collection at University College London, UK. The samples were collected anonymously and 
with informed consent (verbal in Africa) from specified locations in and around Africa [ethical 
approval: UCLH 99/0196]. Additional ethical approval was obtained from the Ethiopian 
Science and Technology Commission in Addis Ababa for Ethiopian collections. The samples 
were collected from males aged 18 years and over, and unrelated at the parental and paternal 
grandparental level. Sociological data including age, current residence, birthplace, primary 
language spoken, self-declared ethnic identity and religion of the individual, the individual’s 
father and paternal grandfather were also collected. Individuals were grouped, either by the 
location from which they were collected or by ethnicity, into “sample sets” for analysis. The 
criterion for inclusion of individual samples was that they could be grouped with at least 19 
other individual samples by either ethnicity and/or a shared language family within a 
particular location. Individuals who could not be grouped by ethnicity and/or shared 
language family were excluded from the studies. Samples were not grouped according to 
country; the partitioning of the African continent by colonial powers was recent and largely 
irrespective of ethnic identities (Pakenham 1991). Analysis of sub-Saharan African diversity 
by ethnicity, language or specified location within Africa is an appropriate method.  
 
2.1.1 DNA samples used for re-sequencing of CYP3A5 
 Thirteen sub-Saharan African sample sets were chosen for re-sequencing of CYP3A5. 
The entire CYP3A5 coding region, exon-flanking introns, proximal promoter and 5´ and 3´ 
gene flanking sequence, were re-sequenced in five Ethiopian populations. 
 
 
2.1.1.1 Ethiopian samples 
 The five populations re-sequenced for this thesis overlap completely with those used 
to characterise genetic variation at the CYP1A2 locus (Browning et al. 2010). The five 
Ethiopian groups represent a rough northeast to southwest transect across Ethiopia (Figure 
4.7). Pairwise FST estimates, based on Ethiopian Y chromosome and mitochondrial DNA 
hypervariable region 1 data (unpublished), suggest that the majority of Ethiopian genetic 




 The Afar are a pastoralist population located primarily in the Afar region, located in 
the northeast, of Ethiopia (Lewis 1994). The 2008 census reported that the total population 
size of the Afar as 1,276,372 (http://www.ethnologue.com/web.asp). The Afar language is a 
member of the Cushitic branch of the Afro-Asiatic language family (Lewis 1994). Given the 
harsh environmental conditions of the Afar region the population are nomadic pastoralists, 
who raise goats, sheep, camels and cattle in the desert (Getachew 1998; Getachew 2002). The 
pastoral and nomadic practises of the Afar are similar to Arabs (Murdock 1959) and it is likely 
that genetic diversity within the Afar has also been shaped by Arab migrations in and out of 
the region (Henze 2000; Kivisild et al. 2004; Lovell et al. 2005). 
 
2.1.1.1.2 Amhara 
 The Amhara are one of the most politically influential and powerful groups within 
Ethiopia. The Amharic language is one of four national languages; used in government, 
education and commerce. Amharic is a Semitic language from the Afro-Asiatic language 
family. The Amhara are found all over the country but mainly reside in the Amhara region in 
central Ethiopia and in Addis Ababa (http://www.ethnologue.com/web.asp). The 2008 
census reported that the Amhara population is approximately ~20,000,000. The Amhara are 
culturally, linguistically and genetically similar to Arab populations (De Stefano et al. 2002). 
 
2.1.1.1.3 Anuak 
 The Anuak are one of the smallest ethnic groups; the 2007 census estimated that the 
total population size is ~86,000 (http://www.ethnologue.com/web.asp). The Anuak live in 
small communities of ≤500 in the Gambela region of Ethiopia, which extends into southern 
Sudan (Lewis and SIL International 2009). They are culturally, linguistically and historically 
different from the dominant ethnic groups within Ethiopia. The Anuak language is part of the 
Eastern Sudanic branch of the Nilo-Saharan language family.  
 
2.1.1.1.4 Maale 
 The Maale are also a small ethnic group (98,114 individuals according to the 2007 
census) who reside in the southwest of Ethiopia in the Omo region, southeast of Jinka 
(http://www.ethnologue.com/web.asp). The Maale language is from the Omotic region of the 





 The Oromo are one of the largest ethnic groups within Ethiopia; the total number of 
Oromo individuals was reported as 25,448,344 in 2008. The Oromo reside predominantly in 
the Oromo region, west and central Ethiopia; although they are also found in Kenya (Henze 
2000). The Oromo language is part of the Cushitic branch of the Afro-Asiatic language family 
and is widely spoken in Ethiopia. 
 
2.1.1.2 Non-Ethiopian sub-Saharan African populations 
 Seven CYP3A5 exons, and their flanking introns, were re-sequenced in eight additional 
sample sets from sub-Saharan Africa. The entire gene could not be re-sequenced in these 
individuals due to time and funding constraints. 
 
2.1.1.2.1 Asante 
 The Asante are a population who reside in the Ashanti province in the south central 
region of Ghana (http://www.ethnologue.com/web.asp). The Asante speak three dialects of 
the Akan language family (Twi, Asanti and Achanti) which are all from the Atlantic-Congo 
branch of the Niger-Congo A language family (Lewis and SIL International 2009). The Asante 
re-sequenced for work presented in this thesis are all Twi speakers; of which there are 




 The Bulsa are a population found in the Sandema District in north central Ghana 
(http://www.ethnologue.com/web.asp). Like the Asante, the Bulsa speak languages from the 
Atlantic-Congo branches of the Niger-Congo A language family (Lewis and SIL International 
2009) and the 2003 Ghanaian census estimated the total population to be ~150,000. 
 
2.1.1.2.3 Shewa Arabs 
 The Shewa Arabs re-sequenced in this thesis were collected from a number of 
locations in the Lake Chad region of Cameroon. Shewa Arabs are spread over multiple 
countries including Chad, Niger and Cameroon. The first records of Shewa Arabs date back to 
the 14th century and Shewa Arab ancestors are believed to have migrated from Sudan to Chad 
(http://www.prayway.com/unreached/peoplegroups2/1752.html). The total number of 
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Shewa Arabs is estimated at 1,1,39,000 (http://www.ethnologue.com/web.asp) and they all 
speak a form of Arabic (Lewis and SIL International 2009).  
 
2.1.1.2.4 Mambila from Somie 
 The Mambila were collected from the village of Somie, Adamawa Province on the 
Nigerian/Cameroonian border. There are estimated to be 30,000 Mambila, the Mambila 
language is a Bantoid language (Lewis and SIL International 2009). 
 
2.1.1.2.5 Congolese from Brazzaville 
 The Congolese samples represent a mixture of ethnic groups from Brazzaville in the 
Republic of Congo; hereafter called “Brazzaville”. Every individual speaks a Bantu language 
(Niger-Congo B).  
 
2.1.1.2.6 Chewa 
 The Chewa are an ethnic group who reside in west-central and south-western Malawi 
(Lewis and SIL International 2009); the Chewa re-sequenced for this thesis were collected 
from Lilongwe. The Chewa speak Chichewa, which is a Niger-Congo B (Bantu) language 
(http://www.ethnologue.com/web.asp) and ~7,000,000 were estimated to reside in Malawi 
in the 2001 census.  
 
2.1.1.2.7 Sena from Mozambique 
 The Mozambican samples represent a mixture of ethnic groups collected from Sena, 
Mozambique; hereafter called “Sena”. Every individual speaks a Bantu language (Niger-Congo 
B).  
 
2.1.1.2.8 Sudanese from Kordofan 
 Sudanese individuals collected from Kordofan also represent a mixture of ethnic 
groups collected from the Kordofan Mountains, just north of Khartoum. Each of the 






2.1.2 Additional populations genotyped for the CYP3A5 geographic survey 
 An additional 23 populations were genotyped as part of a geographic survey, 
presented in chapter 3. The groups were chosen to represent as much African genetic 
diversity, as possible.  
 
2.1.2.1 Armenians 
 The Armenians were collected from the South of Armenia; every individual speaks 
Armenian (an Indo-European language) as their first language. 
 
2.1.2.2 Anatolian Turks 
 The Turks were collected across East and West Anatolia; every individual speaks 
Turkish (an Altaic language) as their first language. 
 
2.1.2.3 Algerians 
 The Algerians were collected from Port Say in the North of Algeria; every individual 
speaks Arabic (an Afro-Asiatic language) as their first language. 
 
2.1.2.4 Moroccan Berbers 
 The Moroccan individuals were collected from Ifrane and are all from the Berber 
ethnic group. The Berber language is an Afro-Asiatic language. 
 
2.1.2.5 Northern Sudanese 
 Sudanese individuals collected from Khartoum; hereafter referred to as Northern 
Sudanese individuals, are a mixture of ethnic groups. Every Northern Sudanese individual 
speaks an Afro-Asiatic language. 
 
2.1.2.6 Wolof 
 The Wolof individuals were all collected from Dakar in Senegal. A 2007 Senegalese 
census reported that there are 3,976,500 Wolof speakers across the world (3,930,000 in 
Senegal (http://www.ethnologue.com/web.asp). The Wolof language is from the Atlantic-





 The Manjak individuals were all collected from the Southern region of Senegal. A 2006 
Senegalese census reported that there are over 300,000 Manjak speakers across the world 
(105,000 in the southwest of Senegal) (http://www.ethnologue.com/web.asp). The Manjak 
language is from the Atlantic-Congo branch of the Niger-Congo A language family. 
2.1.2.8 Kasena 
 The Kasena individuals were collected from the Navrongo district in the north central 
region of Ghana. The Kasena all speak Kasem which is from the Atlantic-Congo branch of the 
Niger-Congo A language family. A 2004 Ghanaian census reported that there are 130,000 
Kasem speakers in Ghana. 
 
2.1.2.9 Igbo 
 The Igbo were collected from the Calabar region of Nigeria. The Igbo are one of the 
largest groups within Nigeria itself; a 1999 Nigerian census reported that there were 
18,000,000 within Nigeria itself and they are spread all over the country. The Igbo language is 
Igbo and is from the Atlantic-Congo region of the Niger-Congo A language family. 
 
2.1.2.10  Kotoko 
 The Kotoko were all collected from a number of locations in the Lake Chad region of 
Cameroon. The Kotoko language is from the Chadic branch of the Afro-Asiatic language family. 
 
2.2.2.11  Mayo Darle 
 Cameroonians from Mayo Darle; hereafter called “Mayo Darle”, are a mixture of 
Cameroonian ethnic groups all collected from the Mayo Darle region of Cameroon. Every 
individual speaks a Niger-Congo A language. 
 
2.1.2.12  Southern Sudanese 
 Sudanese individuals collected south of Khartoum; hereafter referred to as Southern 
Sudanese individuals, are a mixture of ethnic groups. Every individual speaks a Nilo-Saharan 
language. 
2.1.2.13  Bantu speakers from Uganda 
 Ugandan individuals collected from the Ssese Islands were a mixture of ethnic groups 




2.1.2.14  Chagga 
 The Chagga are an ethnic group who are found in Tanzania. Chagga individuals were 
collected from the area immediately surrounding Mount Kilimanjaro. The Chagga speak a 
Niger-Congo B (Bantu) language (Lewis and SIL International 2009).  
 
2.1.2.15  Yemeni from Hadramaut 
 The Yemeni individuals collected from the Hadramaut region are a mixture of ethnic 
groups; all of whom speak an Afro-Asiatic language as their first language. 
 
2.1.2.16  Yemeni from Sena 
 The Yemeni individuals collected from the Sena region are a mixture of ethnic groups; 
all of whom speak an Afro-Asiatic language as their first language. 
 
2.1.2.17  Ngoni 
 The Ngoni are an ethnic group from Malawi. The Ngoni were all collected from 
Lilongwe. Ngoni speak Nyanja which is related to the Chichewa language of the Chewa from 
Malawi (Lewis and SIL International 2009); most of the Ngoni speak the Chewa dialect. 
 
2.1.2.18  Tumbuka 
 The Tumbuka are an ethnic group found predominantly in the north of Malawi and 
around the west shore of Lake Malawi, but a small number of Tumbuka reside in Zambia 
(http://www.ethnologue.com/web.asp). The Tumbuka individuals genotyped for this thesis 
were collected from Lilongwe. A 2001 Malawian census reported that the total number of 
Tumbuka individuals is 1,142,000; and approximately 1,000,000 reside in Malawi. The 
Tumbuka language is from the Atlantic-Congo branch of the Niger-Congo B (Bantu) language 
family. 
 
2.1.2.19  Yao 
 The Yao are also an ethnic group found predominantly in the southeast region 
surrounding Lake Malawi and bordering Mozambique, but individuals also reside in 
Mozambique, Tanzania and Zambia (http://www.ethnologue.com/web.asp). The Yao 
individuals genotyped for this thesis were collected from Lilongwe. The global Yao population 
is estimated to be 1,916,000 (1,000,000 within Malawi). The Yao language is from the 




2.1.2.20  Lomwe 
 The Lomwe are a Malawian ethnic group found in the southeast of the country. The 
numbers are estimated at 250,000 and the language is a mixed language with the Lomwe 
dialect of Mozambique, although it is a Niger-Congo B (Bantu) language (Lewis and SIL 
International 2009). 
 
2.1.2.21  Zimbabweans from Mposi 
 The Zimbabwean individuals genotyped in this thesis were collected from Mposi, a 
village near Mberwengwa, in Zimbabwe. The Zimbabweans were a mixture of ethnic groups, 
although all were Niger-Congo B (Bantu) speakers. 
 
2.1.2.22  Lemba 
 The Lemba are a southern African, Niger-Congo B (Bantu) speaking, tribe located in 
Southern Africa who claim Jewish ancestry and observed many Semitic traditions including 
Kosher-like dietary restrictions (http://www.freemaninstitute.com/Gallery/lemba.htm). The 
Lemba genotyped for this thesis were all collected from Zimbabwe. 
 
2.1.2.23  Bantu speakers from Pretoria 
 South African Bantu (Niger-Congo B) speakers collected from Pretoria consisted of 
mixed ethnic groups including the Tswana, Zulus and Sotho. 
 
2.1.3 Samples used for integrative analyses 
 The African samples were analysed in a global context by performing comparative 
analyses with CYP3A5 re-sequencing and genotyping data that are available from online 
resources and the literature. Some individuals have been genotyped or re-sequenced as part 
of multiple human DNA panels and care was taken to ensure that individuals were only 
analysed once. 
 
2.1.3.1 Coriell DNA samples 
 The bulk of integrative analyses were performed using CYP3A5 data which have 
previously been published (Thompson et al. 2004; Thompson et al. 2006), and were kindly 
provided by Dr Emma Thompson and Professor Anna Di Rienzo from the University of 
Chicago. The CYP3A5 study was performed using samples from three Human Variation panels 
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of the Coriell Cell Repositories (24 individuals of recent European ancestry, 23 African-
Americans and 23 Han Chinese from Los Angeles). The Coriell Institute have set up a number 
of projects in order to examine the effect of human genetic variation, in multiple populations, 
on healthcare outcomes including neurological diseases and cancer risk 
(http://www.cogforlife.org/imr90CoriellFullReport.pdf). Coriell DNA samples are all derived 
from cell cultures, and since the publication of the CYP3A5 surveys by Thompson et al, the 
number of populations in the repositories has increased (http://ccr.coriell.org/). The 
Europeans, Han Chinese and African-American individuals are all unrelated and healthy 
individuals. Unlike for the UCL collection, the Coriell samples are a mixture of male and female 
samples. 
 
2.1.3.2 Human Genome Diversity Panel-Centre d’Etude du Polymorphisme Humain 
 Genotype data generated for the geographic survey (presented in chapter 3) were 
analysed in a global context using CYP3A5*1/CYP3A5*3 genotyping data for the Human 
Genome Diversity Panel-Centre d’Etude Polymorphisme Humain (HGDP-CEPH), previously 
published (Thompson et al. 2004), and kindly provided by Dr Emma Thompson and Professor 
Anna Di Rienzo from the University of Chicago. The HGDP-CEPH panel is a large, and widely 
used, collection of DNA samples from around the world. A total of 1063 individuals from 52 
global populations are available from the HGDP-CEPH collection, the populations were 
collected with the aim of aiding studies of sequence diversity and human migratory and 
population history (http://www.cephb.fr/en/hgdp/diversity.php/) and like the Coriell cell 
repositories, the DNA is derived from lymphoblastoid cell lines. 1028 HGDP-CEPH individuals 
from 51 global populations were analysed alongside the African genotyping data in chapter 3. 
Geographic co-ordinates were also available for all samples genotyped from the panel to 
enable comparisons of latitude with frequencies of low/non-expresser CYP3A5 alleles. 
 
2.1.3.3 NIEHS populations 
 The National Institute of Environmental and Health Sciences (NIEHS) have set up a 
project to examine the effect of environmental factors and inter-individual sequence variation 
on disease risk in human populations (primarily from the USA) 
(http://egp.gs.washington.edu/). The NIEHS SNPs programme is one part of the project in 
which identified candidate genes were re-sequenced to identify common and rare 
polymorphisms for functional analysis and population-based studies. To date CYP3A5 has 
been re-sequenced in 95 individuals from five ethnic groups (12 Yoruba, 15 African-
Americans, 22 Europeans, 22 Hispanics and 24 East Asians [12 Japanese and 12 Chinese]) at 
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25X coverage. Although NIEHS have a large re-sequencing survey, the data available online do 
not currently allow for the extent of missing data, per individual, to be accurately deduced and 
so integrative analyses were limited to genotype data alone. 
2.1.3.4 HapMap samples 
 The International HapMap project is a collaborative initiative which aims to determine 
the common patterns of human genetic variation to aid researchers examine genetic variants 
which affect healthcare outcomes; such as the response to pharmaceutical drugs 
(http://hapmap.ncbi.nlm.nih.gov/). Although common haplotypes occur within all human 
populations, there are population specific differences in frequency, and in haplotype 
structure, between global populations. The HapMap project comprises a total of 1184 samples 
from 11 global populations (see Table 3.8) (Altshuler et al. 2010). Genotype data from the 
International HapMap consortium were used for integrative analyses with the data generated 
from the CYP3A5 geographic survey in chapter 3. Genotype data for the CYP3A5*1/CYP3A5*3 
locus were available for each of the 11 populations; CYP3A5*6 data were available for some of 
the populations; CYP3A5*7 data are not currently available from the HapMap project.  
 
2.1.3.5 1000 Genomes data 
 The 1000 Genomes project was launched in 2008 and aims to be the most detailed 
survey of human genetic variation in over 1000 study participants from 29 populations using 
next generation sequencing technologies (http://www.1000genomes.org/about). The project 
aims to characterise the most common genetic variants (those with a global frequency of 
≥1%). The 1000 Genomes data promise to be invaluable in evolutionary and medical based 
studies (Kuehn 2008; McGuire 2008; Gamazon et al. 2009; Patterson 2011). However there 
are limitations; currently the data available for the majority of individuals re-sequenced 
(~1200) are low coverage (X2) (Pennisi 2010). For each individual, the genome needs to be 
re-sequenced in segments; which requires deep sequence coverage (estimated at X28 by the 
1000 Genomes consortium) to ensure that the entire genomic sequence is covered. The 
project aims to complete re-sequencing for the full set of samples at 4X coverage 
(http://www.1000genomes.org/about). While this will not provide the complete genotype of 
each sample, 4X coverage is expected to allow for the majority of common variants (at a 
frequency of ≥1%) to be identified (http://www.1000genomes.org/about). For work 
presented in this thesis, 1000 Genomes re-sequenced data were not included for analysis as it 
is possible that a substantial amount of genetic variation would be missed in integrative 
analyses with the African datasets. Given that the 4X coverage re-sequencing data are due to 
be released by June 2012, it was not possible to incorporate higher coverage re-sequencing 
  
 59 
data into the analysis due to time constraints. However, genotyping data for the most common 
functionally important CYP3A5 variants were extracted from the website and analysed as part 
of the geographic survey (see chapter 3). 
 
2.2 Experimental Methods 
2.2.1 DNA extraction 
 DNA extraction from buccal swabs had been, previously performed, using a phenol 
chloroform method (Freeman et al. 2003). Briefly, 800μl of 2μg/ml proteinase K solution was 
added to the sample tubes; which were left to incubate at a minimum of 2 hours at 60°C. 
Following incubation, 800μl of sample solution was transferred to new 1.5ml eppendorf tubes 
containing 600μl of a 1:1 ratio of phenol/chloroform. The tubes were inverted to mix and then 
centrifuged at 16,000xg for 10 minutes. Following centrifugation the supernatant/aqueous 
phase was removed and transferred to clean 1.5ml eppendorf tubes containing 600μl of a 1:1 
ratio of phenol/chloroform and 30μl of 5M sodium chloride. The samples were mixed and 
centrifuged again at 16,000xg for 10 minutes and the supernatant/aqueous phase again 
transferred into a clean 1.5ml eppendorf tube containing 700μl chloroform and centrifuged 
again. Following the third centrifugation the supernatant/aqueous phase was transferred to a 
clean 1.5ml eppendorf tube containing 700μl of 100% isopropanol solution. The tubes were 
inverted to mix and left to cool at -20°C for a minimum of 2 hours. Following incubation the 
samples were centrifuged at 16,000xg for 12 minutes after which the supernatant was poured 
away and the tubes inverted at an angle for one minute to allow the final remnants of 
supernatant to drain away. 800μl of 70% ethanol was then added to each tube followed by a 
centrifugation step of 16,000xg for 10 minutes. The supernatant was discarded and the tubes 
left to drain (by inverting at an angle) for 20 minutes. The DNA pellet was resuspended in 
300μl of 1x T.E. buffer and the tubes incubated at 56°C for 10 minutes with occasional mixing. 
Samples were pulse centrifuged and stored at -20°C.  
2.2.2 Primer design 
 Primers were designed by hand using a reference sequence obtained from NCBI 
(http://www.ncbi.nlm.nih.gov/). The CYP3A5 reference was aligned with homologous CYP3A 
sequences: CYP3A4, CYP3A7 and CYP3A43, to ensure primer specificity. The primers were 
then checked using the BLAT resource on UCSC Genome Browser (http://genome.ucsc.edu/) 
and using NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to check specificity. Primers 
were provided by MWG Biotech®. 
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2.2.3 Polymerase chain reaction (PCR) 
 DNA was amplified, by polymerase chain reactions (PCR), in 10µl-reaction volumes 
containing 50pmol of each primer, 0.2 units Taq DNA polymerase (HT Biotech, Cambridge, 
UK), 0.2µM dNTPs, 0.1µM of 10x Buffer IV [750mM Tris-HCl, pH 8.8; 200mM (NH4)2SO4; 0.1% 
(v/v) Tween® 20 and 25mM MgCl2] (Thermo Scientific®), and between 10-20ng genomic 
DNA. Cycling conditions were individually optimised for each PCR reaction; each assay 
included an initial denaturisation followed by a minimum of 38 cycles of denaturisation, 
primer annealing and elongation. Details of oligonucleotides used to amplify specific genomic 
regions are provided in Table 2.1. PCR cycles were performed with the following conditions: 
95°C for 5 minutes, followed by 38 cycles of 95°C for 40 seconds, (optimum annealing 
temperature, see Table 2.1)°C for 40 seconds and 72°C for 40 seconds. 
 Approximately half of the CYP3A5 region re-sequenced in Ethiopian populations was 
performed externally by Macrogen USA (http://www.macrogenusa.com/). Re-sequencing of 
the 4448 base pair region in non-Ethiopian populations, and half of the CYP3A5 gene region in 
Ethiopian populations, were performed by me. 
 
2.2.4 Gel electrophoresis 
 Prior to sequencing and following PCR, 2μl of the PCR reaction mixture (mixed with 
2μl of loading buffer) was loaded on a 2% agarose gel (containing 80ml 1x TBE buffer, 1.6 
grams of agarose and 2μl ethidium bromide), and photographed under ultraviolet light. 
 
2.2.5 PCR clean-up 
 Prior to re-sequencing the amplified PCR product was “cleaned up” in order to remove 
excess nucleotide primers and salts. PCR clean-up was performed using a polyethylene glycol 
precipitation method; 30μl of Microclean (i.e. 3x the volume of the PCR reaction mixture) was 
added to each well and mixed thoroughly before centrifuging at 3870rpm for 60 minutes. 
Following centrifugation the supernatant, which contains excess nucleotides, primers and 
salts, was removed by removing the plate lids and inverting the plate onto a piece of tissue 
and centrifuging gently at 300rpm for 30 seconds. A 150μl ethanol wash (70%) was then 
added to each well to remove any excess nucleotides or contaminants; this time the plate was 
not mixed. The plate was then centrifuged again at 3870rpm for 10 minutes and the wash 
discarded by inversion and centrifugation as described above. The purified DNA pellets were 
air dried at room temperature, to allow for any excess alcohol to evaporate, and re-suspended 
in 10μl of distilled water. 
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Table 2.1: A list of the primers used for PCR amplification and sequencing of CYP3A5. Rows shaded in light blue show the regions of CYP3A5 which were only re-
sequenced in Ethiopians, boxes shaded in white show regions of CYP3A5 which were re-sequenced in Ethiopian and North, West, West Central and South East African populations. 
Region of CYP3A5 Fragment 
name 
Primer sequences Fragment size 
(base pairs) 
Position from the 
ATG start codon 
Position on chromosome 7 





5’ upstream U5 F: 5´-CACTTTGTTGATTGCTTTCTTTGTG-3´ 
R: 5´-CTGGGGGAAAAGACAGTCTCTTC-3´ 
631 -2500 › -1870 99280019 - 99279389 60 40 
 U4 F: 5´-CATTTGTGAATAGTGGCTATTGTG-3´ 
R: 5´-TGAAGAACTACCCCACAAGCA-3´ 
632 -1973 › -1342 99279492 - 99278861 60 40 
 U3 F: 5´-ACTCAAATGCAGCCACACTGTGT-3´ 
R: 5´-CACAATATCCAGAAATCCCCATGC-3´ 
633 -1449 › -817 99278968 – 99278336 55 40 
Proximal promoter U2 F: 5´-ACACATCTTTACCCACGAAATTC-3´ 
R: 5´-TTATGAGGAATTAAGTGGCAGAA-3´ 
520 -914 › -395 99278433 – 99277914 55 40 
Proximal promoter U1 F: 5´-CGCCACTTTCCTTCTTCAACTG-3´ 
R: 5´-TAAGGAAAAATTTTAGCAGAAGGGG-3´ 
511 -511 › -22 99278030 – 99277541 55 40 
Exon 1  F: 5´-GAACCCAGAACCCTTGGACT-3´ 
R: 5´-TCCCACTACCAAATGCTGTCCCT-3´ 
598 -277 › 320 99277796 – 99277199 59 38 
Exon 2  F: 5´-AGACTTCAGCTGCTTTCAGC-3´ 
R: 5´-TGGGCTACCATATCATGCACAGG-3´ 
595 3462 › 4056 99274057 – 99273463 61 38 
Exon 3  F: 5´-AGCTTCCTTCAACTGCCAGTGAA-3´ 
R: 5´-ACCACAACTTTGCACAAAGGCT-3´ 
594 5180 › 5773 99272339 – 99271746 63 38 
Exon 4  F: 5´-ATGGGCCCCACACCAACTGC-3´ 
R: 5´-TACCACTGGGCGGGACAGGAT-3´ 
715 6747 › 7461 99270772 – 99270058 64 38 
Exons 5 and 6*  F: 5´-TACACTCAGAAGAGGCTAGGCA-3´ 
R: 5´-CATCTTACCCAATGCAAGGCAA-3´ 
1226 12444 › 13670 99265075 – 99263849 58 40 
Exon 7  F: 5´-TATGACTGGGCTCCTTGACCT-3´ 
R: 5´-TTTGTGGTGGGGTGTTGACAGCT-3´ 
618 14324 › 14941 99263195 – 99262578 61 38 
Exon 8  F: 5´-GTCGCCGGCCTGAAAGAAGGGC-3´ 
R: 5´-ATTCTTTACCAATCTGTGATATGA-3´ 
651 15641 › 16291 99261878 – 99261228 58 40 
Exon 9  F: 5´-AGATGGAACCGGCAACTCTTT-3´ 
R: 5´-CCAAGTAGAGGTTCTCACTTGGTG-3´ 
691 16708 › 17398 99260811 – 99260121 58 40 
Exon 10  F: 5´-TGGGAAAAAGCCTACCCCAT-3´ 
R: 5´-TCTCCTCAGAGGCTTCCTAC-3´ 
678 18861 › 19538 99258658 – 99257981 55 40 
Exon 11  F: 5´-CCCTGGGGTGAGGATGGTCT-3´ 
R: 5´-TGTCTTGTGCTGGGACTGTGGATG-3´ 
671 26880 › 27550 99250639 – 99249969 61 38 
Exon 12  F: 5´-TCTCATCTCAAGAAACGCTCCT-3´ 
R: 5´-CATGTCATGCTAATCTGTGTGGAC-3´ 
607 29434 › 30040 99248085 – 99247479 55 40 
Exon 13  F: 5´-ACGATGGATGGTGAGTGCTT-3´ 
R: 5´-TCTGATGAGAGCTCAGGAGGAGTT-3´ 
600 31297 › 31876 99246222 – 99245643 58 40 
3’ downstream D1 F: 5´-TTGCTGGTTTTCAGTCATTCAGT-3´ 
R: 5´-GTTATTCTAAGGATTTCTACTT-3´ 
522 31592 › 32113 99245927 – 99245406 55 40 
 D2 F: 5´-TCTTGTCCACCTTAATGTGTGGCT-3´ 
R: 5´-ATTAAGCGAAGTGATAAAATCCC-3´ 
571 32014 › 32584 99245505 – 99244935 55 40 
 D3 F: 5´-GTCTATCTATCCATCTATCTATCT-3´ 
R: 5´-CGTCAGTTGATTGGGCAGCATGT-3´ 
537 32447 › 32983 99245072 – 99244536 55 40 
 D4 F: 5´-AAGTGCTACCAATTTTGTACGT-3´ 
R: 5´-AAGTATACTGGAAGCTAGGTGTG-3´ 
652 32822 › 33483 99244697 – 99244036 60 40 
 D5 F: 5´-TATACTTTGAAGTCAGGTAAAT-3´ 
R: 5´-TGATTTCTAAATGATATTTCCAT-3´ 
531 33343 › 33873 99244176 – 99243646 55 40 




 Sequencing was performed in 10μl reaction volumes; 2μl of cleaned up DNA was 
transferred to a new plate and heated to 95°C for 5 minutes to evaporate the excess distilled 
water. Following this, 2.15μl of 5x sequencing buffer (ABI Biosystems), 0.35μl BigDye v3.1 (AB 
Biosystems) 0.32μl of 5μM sequencing primer (see Table 2.1) and 7.18μl distilled water were 
added to each well. Sequencing cycling conditions were as follows: 96°C for 1 minute followed 
by 25 cycles of 96°C for 10 seconds, 55°C for 5 seconds and 60°C for 4 minutes.  
 As for PCR reactions, the sequencing assays needed to be cleaned up following the 
sequencing reaction to remove any contaminants. 2.5μl of 125mM EDTA was added to each 
well followed by a 30μl ethanol wash (100%), the plate was then mixed and centrifuged at 
3870rpm for 60 minutes. Following centrifugation the plate lids were removed and the 
supernatant removed by inverting the plate onto a piece of tissue and centrifuging at 300rpm 
for 30 seconds. A final 30μl ethanol wash (70%) was then added to each well and the plate 
centrifuged, without mixing, at 3870rpm for 10 minutes. The supernatant was again removed 
by inverting the plate and centrifuging at 300rpm for 30 seconds. The plate was then left to air 
dry for 15 minutes at room temperature. 
 
2.2.6.1 Sequencing strategy 
 All regions involved in transcription and translation of the gene were re-sequenced to 
identify variants which could affect protein expression. Appendix A shows the regions of the 
entire CYP3A5 gene region which were re-sequenced. 2500 base pairs of genomic sequence 
located upstream of the ATG start codon, including the proximal promoter of CYP3A5, were 
re-sequenced. Re-sequencing of this region would identify all variants that can influence 
CYP3A5 transcription, including its initiation; no enhancer is known to initiate transcription of 
the gene. 2500 base pairs of genomic sequence located downstream of exon 13, including the 
3´ untranslated region, were also re-sequenced. Re-sequencing of this region would identify 
all variants which can affect CYP3A5 mRNA stability and processing; thus influencing protein 
translation. A -GT microsatellite repeat was also genotyped in this region, located ~1400 base 
pairs downstream of exon 13; microsatellite repeat data were used as one method of dating 
identified variants (chapter 7). 
 The entire CYP3A5 coding region; all 13 exons plus the flanking intronic sequences, 
were re-sequenced. Variants which occur in coding regions can potentially affect CYP3A5 
transcription, mRNA processing and protein translation. Few deleterious mutations are likely 
to occur, at high frequencies, in the coding regions of important genes. However, this is not 
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always observed in genes which are not widely expressed in certain populations (Nachman 
and Crowell 2000). For CYP3A5, a known low/non-expresser allele (CYP3A5*3) has risen to 
high frequencies in populations outside of sub-Saharan Africa (discussed in chapter 3). In 
these populations, the accumulation of additional null/low expresser alleles would not 
essentially matter and selection for removing these alleles would be weak. However if, as it is 
believed, CYP3A5*3 was driven to high frequency by selection; a paucity of variation in the 
coding region of the gene would be seen. An examination of the structure and distribution of 
variation over the CYP3A5 coding region will indicate whether selection has acted on the gene 
and whether the CYP3A5*3 allele is likely to have rapidly risen to high frequency. 
 As indicated in Table 2.1, not all regions of CYP3A5 were re-sequenced in each of the 
thirteen sample sets. The entire gene was re-sequenced in Ethiopian populations, however 
only exons 1, 2, 3, 4, 6, 7 and 11, plus the flanking introns, were re-sequenced in the remaining 
sample sets. Given time and funding constraints it was not possible to re-sequence the entire 
CYP3A5 gene in individuals from North, West, West Central and South East Africa. However, 
the regions encompassing the CYP3A5*1/CYP3A5*3, CYP3A5*6 and CYP3A5*7 loci were re-
sequenced, as well as part of the proximal promoter. Table 2.2 shows the CYP3A5 regions re-
sequenced in each population and provides information on the total amount of re-sequencing 
data obtained for each group. 
 
2.2.7 Sequencing analysis 
10μl of HiDi formamide (ABI Biosystems) was then added to the plates and denatured 
at 95°C for five minutes. Sequencing was performed in an ABI 96-capillary 3730xl DNA 
Analyser. Sequencing chromatograms were read using Sequencher version 4.7. 
Chromatograms were analysed, a minimum of 4x, using Sequencher version 4.7 and were 
aligned with a reference sequence downloaded from UCSC genome browser (hg18). 
For samples re-sequenced in-house, sequencing was performed in both directions, to 
duplicate the genotype calls at each locus. For samples re-sequenced by Macrogen USA, all 
dubious and novel identified polymorphisms were checked in-house by re-sequencing. 
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Table 2.2: Information on the regions of CYP3A5 re-sequenced in this study, and the total amount of sequencing data generated for each sample 
set. Sample sizes are listed in chapters 3-5. 
 







































Ethiopia Afar                  12,237 
 Amhara                  12,237 
 Anuak                  12,237 
 Maale                  12,237 
 Oromo                  12,237 
Sudan Kordofan                  4448 
Ghana Asante                  4448 
 Bulsa                  4448 
Cameroon Shewa Arabs                  4448 
 Mambila                  4448 
Congo Brazzaville                  4448 
Malawi Chewa                  4448 




2.2.8.1  TaqMAN allelic discrimination 
TaqMAN allelic discrimination is dependent upon the 5’-3’ nuclease activity of 
AmpliTaq Gold DNA polymerase (Lyamichev et al. 1993), during each successive round of PCR 
(Figure 2.3). In addition to primers, minor groove binding probes, containing one of two 
possible fluorescence dyes (VIC or FAM) and a quencher (NFQ) are also used in the PCR. 
Separation of a reporter dye from its quencher, due to cleavage by AmpliTaq Gold DNA 
Polymerase, results in an increase in fluorescence which is measured. Both primer and probe 
must bind to their target DNA in order for amplification and cleavage to occur. Fluorescence 
signals are only generated if the target sequences have been amplified during PCR (McGuigan 
and Ralston 2002; Shen et al. 2009). 
TaqMAN genotyping technology was used to genotypes samples at the 
CYP3A5*1/CYP3A5*3 and CYP3A5*6 loci. 244 samples from the Senegalese Manjak and Wolof 
ethnic groups, and Cameroonian samples from Mayo Darle, were genotyped at the 
CYP3A5*1/CYP3A5*3 locus. 1017 samples from across the dataset were genotyped at the 
CYP3A5*6 locus. Samples genotyped using TaqMAN were also re-sequenced to confirm the 
genotyping results. 
TaqMAN probes were previously designed by Applied Biosystems 
(CYP3A5*1/CYP3A5*3 locus; ABiosystems, product code: C_26201809_30 and CYP3A5*6 locus; 
ABiosystems, product code: C_30203959_10). The samples were diluted prior to genotyping; 
2μl of 1ng/μl DNA was then dried down prior to PCR amplification. DNA was amplified in 384-
well plates in 4µl-reaction volumes containing 2μl of TaqMAN Genotyping Master Mix 
(Applied Biosystems), 0.2μl of 20X assay mix (containing the primers and probes supplied by 
ABiosystems) and 1.8μl of sterile water. Polymerase chain reactions were performed with the 
following conditions: 95°C for 10 minutes, followed by 40 cycles of 92°C for 15 seconds and 
60°C for 1 minute. Fluorescence was measured using an ABI Prism 7000 sequence detection 
system and genotypes were assigned with 95% confidence using ABI Prism 7000 SDS 
software version 2.1. No samples were genotyped at the CYP3A5*7 locus using TaqMAN 
genotyping technology. 
 
2.2.8.2  KASPar genotyping 
The remaining samples were genotyped externally by KBiosciences®, UK using the 
KASPar method; results were viewed using SNPviewer2®. 1738 samples were genotyped at 
the CYP3A5*1/CYP3A5*3 locus, 965 samples were genotyped at the CYP3A5*6 locus, and 1982 
samples were genotyped at the CYP3A5*7 locus.  
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Figure 2.3: A diagram outlining the steps involved in TaqMAN allelic discrimination: taken from the 







2.2.9 Microsatellite analysis 
 A GT microsatellite, located ~1500 base pairs downstream of the 3´ end of CYP3A5, 
was genotyped in 379 Ethiopian individuals. Microsatellite genotyping was performed using a 
high-throughput method adapted from (Thomas et al. 1999). 
 Briefly, a 456 base pair region, which has sequence overlap with the 652 base pair D4 
region (see Table 2.1), was amplified using the forward primer 5´-
AATATATGTGTTTGTATGTGTG-3´ and a fluorescently labelled (with FAM dye (Thomas et al. 




Figure 2.4: A 452 base pair region amplified for fragment analysis. The primers are highlighted in blue 











 PCR amplification was performed in 10μl reaction volumes containing 0.5μM of 
primers, 0.2 units Taq DNA polymerase (HT Biotech, Cambridge, UK), 0.2µmol dNTPs, 0.1µmol 
reaction buffer and 0.28μl of magnesium chloride (concentration 25mM). DNA was amplified 
in 38 cycles, as outlined in section 2.2.2 with an optimum primer annealing temperature of 
55°C (as determined during the PCR amplification stage). 
 Fragment analysis was performed using GS-500 ROX size standard markers (Applied 
Biosystems). Following PCR amplification a 10μl aliquot of a 1:90 ratio of ROX size markers: 
HiDi Formamide (Applied Biosystems) was added to 1.1μl of amplified PCR product. The 
samples were then centrifuged at 1000rpm for 1 minute and sent to Mari-Wyn Burley who 
performed the fragment analysis using an ABI 3730xl DNA Analyser (Applied Biosystems). 
Fragments were visualised using GeneMapper software (version 4.0; Applied Biosystems). 
 
2.3 Statistical methods 
 Allele frequencies were calculated from genotype frequency data using the formula 
frequency(A)=f(AA)+½f(Aa), where AA and Aa are genotypes and A and a are independent 
alleles at the same locus.  
 
2.3.1 Deviations from Hardy-Weinberg equilibrium 
 Hardy-Weinberg Equilibrium (HWE) refers to the proportions of genotypes expected, 
in a randomly mating population, given allele frequency data. The expected proportion of 
genotypes within a randomly mating population is given by the formula: 
p2 +2pq + q2 = 1 
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Where p is the major allele frequency and q=1-p. Deviations from HWE can be due to 
population stratification, selection or non-random mating. HWE also provides a data quality 
check, particularly for small sample sizes (Balding 2006). Each of the three CYP3A5 loci were 
tested for deviations from HWE using Arlequin version 3.5 software (Excoffier et al. 2005).  
 Arlequin employs an analogue of the Fisher’s Exact test when evaluating deviations 
from HWE (Guo and Thompson 1992). Arlequin initially generates a contingency table with 
the proportions of genotypes observed for each defined population in the cohort. A Markov-
chain random walk algorithm is then employed to generate contingency tables, containing all 
possible genotype frequencies within each population, based on the allele frequency data. The 
p value of the test reflects the number of generated tables which contain genotype 
proportions that differ from the observed genotype frequencies. If a significance threshold of 
5% is used and p≤0.05; this indicates that the observed genotypes will differ from those 
expected under a hypothesis of neutrality 95% of the time. 
 
2.3.2 Chi-squared and Fisher’s exact tests 
 Pearson’s chi-squared ( 2) tests were used to calculate inter-population heterogeneity 
between populations grouped by geographic region and language family in chapter 3. 
Pearson’s 2 is used to compare the frequencies of one nominal variable with those obtained 
for another nominal variable(s) in the same population. At first a test, or 2, statistic is 
calculated using the formula: 
 
Where O is the observed value for a class and E is the expected value for the population. 2 is 
the sum of the iteration of all classes. The 2 test measures the probability of drawing the test 
statistic from the 2 distribution based on predefined degrees of freedom (total number of 
classes used to calculate the 2 statistic minus one). The probability of drawing the value can 
then be compared against a pre-defined significance threshold (often 0.05): values below the 
threshold can be accepted as being significantly different from those expected given the 
values for the class. 
 Fisher’s exact tests also compare the values for two nominal values for a given 
population but are more accurate than the 2 test when the expected values are small and are 
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restricted to analysing 2x2 contingency tables and two nominal variables. Both Pearson’s 2 
and Fisher’s exact tests were performed using GraphPad software available freely online at 
http://www.graphpad.com/quickcalcs/index.cfm.  
 
2.3.3 Haplotype inference 
 A haplotype is the combination of allelic states at a set of polymorphic markers on a 
single chromosome (Jobling et al. 2004). Haplotypes are useful in the analysis of population 
genetic data as they provide information on how polymorphic data in a genomic region are 
organised. 
There are multiple methods to reconstruct haplotypes, such as pedigree analysis, 
physical separation of one allele from the other using laboratory techniques or by statistical 
algorithms for haplotype reconstruction (Jobling et al. 2004). For work presented in this 
thesis, pedigree information is unavailable as all individuals analysed are unrelated. 
Additionally, experimental methods to separate alleles on different chromosomes are 
expensive and laborious. All haplotype reconstruction for works presented in this thesis were 
performed using two statistical methods which consistently provide good estimates of 
haplotype frequencies from genotype data (Xu et al. 2002). All singletons, and samples with 
too many missing data (≥5%), were excluded from haplotype inference. All haplotype results 
were examined by eye for ambiguities. 
 
2.3.3.1 A Bayesian method of haplotype reconstruction 
 Phase is a program which employs a Bayesian method of haplotype reconstruction 
from population genotype data (Stephens et al. 2001). Phase calculates the probability of two 
or more polymorphic sites occurring on the same or different haplotypes, based on the 
genotype data. 
 Phase uses Gibb’s sampling, a Markov chain Monte Carlo algorithm, which aims to 
determine the posterior distribution of unknown haplotypes in a population, given the 
genotype data. Phase begins by resolving all unambiguous haplotypes in a population based 
on the genotype data. Homozygous genotype data can be resolved much more quickly than 
those from heterozygous loci. Once all unambiguous haplotypes have been resolved an initial 
probability, the prior probability, of haplotype frequencies within the sample population is 
guessed, P0 (Stephens and Donnelly 2003). Phase then attempts to resolve all ambiguous 
haplotypes within a population. Phase assumes that changes between individuals within a 
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population, and the population progenitor, are likely to be few. An individual with an 
ambiguous genotype is selected, at random, and the algorithm attempts to resolve the 
individual’s genotype data into one of the unambiguous haplotypes. This generates a new 
haplotype reconstruction P1. Each successive iteration, where ambiguous haplotypes are 
resolved, generate a new haplotype reconstruction i.e. P0, P1, P2….Pn. Each haplotype 
reconstruction is a component of the Markov chain.  
If an individual’s genotype data resolves into two or more haplotypes of the 
unambiguous pool then the program assigns an equal probability of the individual having 
each haplotype for a single chromosome. In this case it is not possible to accurately determine 
the Phase of these individuals using statistical methods alone. Where an individual’s genotype 
data cannot be resolved into any one unambiguous haplotype then the algorithm will assume 
that the individual has a rare haplotype. At the end of the algorithm, individuals are assigned 
haplotype pairs, which have been calculated to be the most probable combination given their 
genotype data. Singleton variants (a mutation observed in a single heterozygous individual) 
and individuals with data missing at least one polymorphic locus were excluded from the 
haplotype analysis and were assigned to haplotypes by eye, where possible. 
 
2.3.3.2 The Expectation-Maximisation (EM) algorithm 
 The expectation-maximisation (EM) algorithm (Excoffier and Slatkin 1995) 
reconstructs haplotypes and infers haplotype frequencies which maximise the likelihood of 
observing the known genotype frequencies in a population. The model assumes that there are 
no deviations from Hardy-Weinberg equilibrium. EM estimated haplotype frequencies can 
vary depending upon the assumed distribution of haplotypes within a population, a so called 
starting point. In practice a number of different starting points are used. Each starting point 
generates a matrix of haplotype frequencies based on the observed genotype data. The matrix 
which contains haplotype frequencies which are most consistent with the observed genotype 
data (maximum likelihood), and do not violate the assumptions of Hardy-Weinberg 
equilibrium, are assumed to be correct. 
For works presented in this thesis, the EM algorithm was employed using 
PowerMarker software (Liu and Muse 2005), which is freely available online. In order to 
improve the estimate of haplotype frequencies generated by EM, PowerMarker implements 
four starting states. The first starting point infers all possible haplotypes that could occur in a 
population, given the observed genotype data, and assumes that each haplotype has an equal 
probability of occurring. The second starting point assigns random frequencies to all possible 
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haplotypes that can occur in a population, given the observed genotyping data. The third 
starting point assumes that all haplotypes are in linkage equilibrium and the final starting 
point utilises the composite haplotype method. 
 
2.3.4 Linkage disequilibrium 
 Linkage disequilibrium refers to the non-random association between variant alleles 
at two or more loci. Linkage disequilibrium was calculated using the D´ parameter (Lewontin 
1964) using LDmax software, which is part of the GOLD software package (available freely 
online at: http://www.sph.umich.edu/csg/abecasis/GOLD/index.html) and PowerMarker 
(Liu and Muse 2005). 
D´ is a normalised parameter of the statistic D. If a haplotype is comprised of two loci, 
A and B, and each locus can have two alleles: i.e. at locus A, the alleles A and a can occur and at 
locus B, the alleles B and b can occur, then under linkage equilibrium the observed frequency 
of haplotype AB is given by the probability of the two allele frequencies of A and B i.e. PAB = PA 
x PB. D is calculated by subtracting the expected frequency of a haplotype from the observed 
frequency i.e. D = PAB – (PA x PB). The alleles at the two loci are said to be in linkage 
disequilibrium if D is significantly different from zero.  
 However D is dependent on allele frequencies at two or more loci. Due to fluctuations 
in allele frequencies D is not always comparable between loci. Instead, the normalised D´ 
parameter is used which improves comparability.  D´ is given by dividing D by its maximum 
possible value given the allele frequencies at the two loci. LDmax also employs a chi-square 
test to determine the significance of any associations between polymorphic sites at different 
loci. 
 
2.3.5 Diversity comparisons 
 All analyses of diversity required full haplotypes of the 12,237 base pair region for 
each individual. Missing data were recorded as “N” and accounted for in the analyses. Full 
12,237 base pair haplotypes, for each individual, were entered into Microsoft Excel 2007 and 
converted to FASTA format using the online programme ReadSeq 
(http://searchlauncher.bcm.tmc.edu/seq-util/readseq.html). The FASTA files were then 
copied into notepad files. Two versions of each FASTA file were created: haplotypes were 
inferred excluding singleton variants from the analysis. However for calculations of analyses 
of departures from neutrality, singleton variants for individuals were assigned randomly on 
one of their two haplotypes. 
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 All diversity analyses, and tests for departures from neutrality, were performed using 
DnaSP (version 5.0) (Librado and Rozas 2009) and MEGA (version 5.0) (Tamura et al. 2007).  
 Haplotype diversity (also called gene diversity) was measured using Nei’s h (Nei 
1987). Nei’s h represents the proportion of choosing two different haplotypes at random from 
a population. Haplotype diversity calculations were performed using the programme 
test_h_diff and implemented in the R programming environment using code that had been 
written by Dr Mike Weale (Thomas et al. 2002). The multiple alleles extension of Nei’s h was 
employed via the programme, along with sample bias correction. This gave the unbiased 
estimator of haplotype heterozygosity as: 
 
Where N is the number of individuals (note that 2N refers to the number of chromosomes and 
hence haplotypes) and  refers to a particular haplotype. 
 DNA sequence diversity was measured using the nucleotide diversity measure (Nei 
1987). represents the weighted average number of differences, per nucleotide, between two 
or more haplotype sequences within a population. It measures the probability of picking two 
different nucleotides, at random, from a population by chance. An unbiased estimator of is 
calculated using the formula: 
 
Where i and j are two different alleles,  and  are the frequencies of the ith and jth 
sequences respectively, and is the estimated nucleotide differences between the i and j. K 
refers to the number of different haplotypes and n is the number of chromosomes (Nei 1987). 
 
2.3.6 Tests of neutrality 
 Tajima’s D (Tajima 1989) compares two estimates of the expected levels of diversity 
within a population: θw; a measure of DNA sequence variation based on the observed number 
of segregating sites and the number of chromosomes in a sample and ; a measure of 
sequence variation based on the average pairwise distance between all sequences in the 
sample (Biswas and Akey 2006). Under neutral evolution the two values should be equal and 
Tajima’s D equal to 0. In addition to calculating the value of Tajima’s D, DnaSP calculates the 
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significance of deviations, of the Tajima’s D statistic, from zero. Significantly positive values 
can indicate balancing selection or population subdivision, whereas significant negative 
values can indicate positive selection or indicate population growth (Jobling et al. 2004). 
 In addition to Tajima’s D, Fu and Li’s D* and F* (Fu and Li 1993) Fu’s FS (Fu 1997) 
were calculated to test for an excess of rare variants within each of the individual populations 
and within the entire cohort. D* measures the proportion of all polymorphic sites, within a 
population, which are singletons i.e. only observed once, F* also measures the number of 
singletons and compares them to the nucleotide diversity measure, , to ascertain how many 
pairwise differences between sequences within a population are attributed to rare variants 
(Sabeti et al. 2006). The FS statistic compares nucleotide diversity ( ) with the number of 
observed haplotypes and calculates the number of haplotypes which are defined by rare 
variants (Sabeti et al. 2006). The significance of the number of rare haplotypes proportional to 
the total number observed within the population is calculated.  
 Fay and Wu’s H test was performed to test for an excess of high frequency derived 
alleles in the cohort. Tests for a significant reduction in polymorphism levels between closely 
related primates and human CYP3A5 sequences was calculated using the HKA test. A 
McDonald and Kreitman test was performed to detect an increase in the number of high 
frequency derived variants within the CYP3A5 coding region. 
 
 
2.3.7 FST and exact test of population differentiation 
 Both pairwise FST and Exact tests of population differentiation were calculated using 
Arlequin software. FST compares the total amount of genetic diversity observed within a meta-
population to that seen in sub-populations. In other words FST apportions the total amount of 
genetic diversity observed within a population to individual sub-populations. The significance 
of differences in diversity observed within each sub-population is then calculated. FST is 
calculated by the following formula: 
FST = (HT-HS)/HT 
Where HT is the total amount of variation observed in the meta-population and HS is the 
estimated variation within each sub-population. 
 An Exact test of population differentiation (Raymond and Rousset 1995) was used to 
calculate pairwise genetic differences, at the haplotype level, between populations. The tests 
are analogous to a Fisher’s Exact Test (Lee et al. 2004) in that a contingency table of 
frequencies are compared. However for Exact tests of population differentiation, the tables 
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are larger than 2x2 tables and extended to size r x k; where r is the number of populations 
being compared and k is the number of haplotypes. A Markov chain random walk is 
implemented in Arlequin to generate r x k tables based on the input data, and the probability 
of obtaining a table with equivalent values to those observed in the cohort is calculated. 
Populations are considered to be significantly different if the obtained p value is less than 
0.05. 
 
2.3.8 PCO analysis 
 Pairwise FST values were used to construct principal co-ordinates (PCO) plots to 
enable genetic distances between populations to be visualised in two dimensions. Principal 
components analysis essentially analyses a set of observations, in this case pairwise FST 
values, and arranges them in order of their similarity to each other. The data are initially 
standardised by subtracting the mean of the data; by doing this the weighted mean of the data 
is equal to zero. The first principal component, effectively a line of best fit, is calculated as the 
line that goes through the weighted mean of the data and minimises the square of the distance 
of each point to that line. The first principal component is calculated to capture as much of the 
variation between the data points as possible. The second principal component must also pass 
through the weighted mean but it must be completely uncorrelated to the first principal 
component and so pass through the data at a right angle. For the PCO plot, each axis is given 
an eigenvalue which corresponds to the proportion of total variation in the dataset that is 
captured by each PCO axis; typically the x axis should capture a higher proportion of the total 
variation. PCO plots were constructed in the R-programming environment using a code 
written by Dr Christopher Plaster. 
 
2.3.9 Bioinformatics 
 Since the publication of the human genome (Venter et al. 2001) there has been a rapid 
expansion in the availability of whole genome data which have focused analyses of whole 
genome variation as opposed to single gene approaches alone. A number of datasets, 
including the genomes of numerous species, are now available online; one of the most recent 
examples is the ongoing 1000 Genomes project (Siva 2008; Patterson 2011). This project has 
expanded since it originally started and now aims to re-sequence over 2000 individuals from 
28 global populations to capture as much genetic variation as possible. However for the 
majority of individuals that are currently re-sequenced (~1200), the depth and coverage of 
re-sequencing data available is low (~X2-X4) which is problematic for in-depth analysis of 
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rare variants (Zhang and Dolan 2010). Even analysis of coding region data, which are 
currently at higher coverage than non-coding data (~X4 versus X2), have high rates of type I 
errors (false positive results) (Tintle et al. 2011) and so the data were deemed unsuitable for 
integrative analyses with the data generated from re-sequencing in this thesis. 
 Given the rapid advances in, and increasing cost-effectiveness of, sequencing 
technology it has become increasingly necessary to find methods of interpreting the effects of 
individual sequence variants on protein and disease phenotypes. Bioinformatics analyses 
have aimed to provide a rapid way of interpreting both large and small amounts of re-
sequencing data in a bid to understand the phenotypic implications of genetic variation. 
Tangible evidence of the effects of genetic variation on phenotypes can only come from 
experimental techniques. However bioinformatics predictions at the very least identify 
genomic regions, or variants, which are candidates for affecting phenotypes and so need to be 
examined in greater detail using experimentally established techniques. Bioinformatics 
analyses were performed to identify which CYP3A5 variants are candidates for causing 
low/non protein expression. 
 
2.3.9.1 ClustalW 
 ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/) was used to perform 
alignments of human CYP3A5 with orthologous sequences in closely related primates and in 
the more distantly related cow and mouse (see chapter 5). The technique of aligning multiple 
species’ sequences has been used to identify candidate evolutionarily conserved sequences 
(Goode et al. 2010; Lomelin et al. 2010); including identifying evolutionarily conserved 
regions in the promoters of different CYP3A genes (Thompson et al. 2004; Thompson et al. 
2006). However this approach is not conclusive alone, experimental techniques will need to 
establish the true effect of polymorphisms within regulatory, coding and non-coding genic 
regions. However, it is true that functionally important regions are often conserved and so 
multiple sequence alignments were performed to identify such regions in the CYP3A5 




 The regulation of transcription has a fundamental role in controlling mRNA and 
protein expression levels within specific cells and tissues. Promoter sequences are the main 
regulatory elements of gene expression; however the regulation of gene expression is often 
more complex and involves multiple regulatory proteins (transcription factors) and 
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enhancers (Alberts 2002). Differential binding of cell-type specific transcription factors which 
aid or hinder gene transcription can lead to tissue/cell-type specific expression of particular 
genes and proteins. Multiple prediction programmes, such as MatInspector, are now available 
which aim to detect gene regulatory motifs and predict potentially functional transcription 
factor binding sites (Ladunga 2010). Given the complexity of transcription factor binding in 
vivo, and the large number of identified transcription factor binding sites and regulatory 
elements (Ghosh 2000; Kolchanov et al. 2002) computational prediction programmes need to 
be able to handle deviations from set motif sequences while still being confident that a 
particular site is a candidate for binding of regulatory proteins in particular cells or tissues.  
 Analyses of regulatory motifs in the CYP3A5 promoter were performed using 
MatInspector software (Cartharius et al. 2005); which examines and matches an input 
sequence to a library of known regulatory motifs to see if there are patterns within the input 
sequence which are characteristic of core transcription factor binding sites. MatInspector 
utilises information on real site consensus sequences, contained within the reference library, 
and looks for the same patterns of conserved, consensus sequences within the input sequence 
(of length 5-29 nucleotides). The input sequence is then scanned, and compared to a reference 
library, to see whether there are additional patterns consistent with known transcription 
factor binding motifs. The probability of the input sequence being similar to common binding 
motifs is then calculated. This is called a position weight matrix where the position of a 
particular nucleotide (of the input sequence) is compared with known regulatory motifs and 
the likelihood that it is a true transcription factor binding site is calculated (Lapidot et al. 
2008; Ladunga 2010). MatInspector provides tissue specific information and so results can be 
filtered and false positives controlled by accounting for tissue and cell type specificity. 
 It is important to note that, like all prediction programmes, MatInspector can infer the 
binding potential, but not the functionality of a binding site. Tangible evidence of an effect of a 
mutation, or motif, on transcription factor binding can only be established through the use of 
experimental techniques (see section 5.4.2) (Lapidot et al. 2008; Jones and Swallow 2011). 
 
2.3.9.3 PolyPhen2 
 Analysis of the effects of coding region variation on protein function was performed 
using PolyPhen2 software (Adzhubei et al. 2010). PolyPhen2 aligns human amino acid 
sequences against orthologous sequences to predict whether amino acid changes are likely to 
have benign, possible damaging, probably damaging, or definitely damaging effects on protein 
structure/function. PolyPhen2 also examines whether the mutation occurs in an 
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evolutionarily conserved site (as inferred from comparisons with orthologous sequences) to 
help predict functional consequences of an amino acid change (Adzhubei et al. 2010). 
 
2.3.9.4 BDGP splice predictor 
Almost all eukaryotic genes are composed of exonic (coding) and intronic (non-
coding) segments. Initial transcription of a gene from the DNA template involves transcription 
of both exons and introns into the pre-mRNA transcript, in the nucleus. Intronic regions need 
to be excised in the nucleus prior to translation of the transcript into protein which occurs in 
the cytoplasm.  
Highly conserved signals are encoded in the DNA template and recognised by nuclear 
proteins to enable splicing to occur (Shapiro and Senapathy 1987). Regions of genes that need 
to be spliced out of the transcript following transcription have two splice sites; one at the 5’ 
end of the region, called a donor site, and one at the 3’ end of the region, called an acceptor 
site. The consensus signal at donor sites in eukaryotic genes is GT (GU in the mRNA) and that 
at the acceptor site is AG (Shapiro and Senapathy 1987), additionally at the 5’ splice site; a 
sequence of 8 nucleotides is conserved at the exon-intron boundary and a 4 nucleotide 
sequence was found to be conserved at the exon-intron boundary at the 3’ splice site (Shapiro 
and Senapathy 1987). These additional signals are essential to prevent splicing of all regions 
of the genome which may have GT or AG repeats. Following correct splicing the mRNA 
transcript is ready to transport into the cytoplasm for translation (Figure 2.5). 
 Mutations which affect the identification of correct splice sites can occur and 
significantly affect protein function; certain, functionally important, variants of CYP3A5 are 
defined by mutations within splice recognition regions. 
 Berkeley Drosophila Genome Project (BDGP) splice predictor (Reese et al. 1997) is an 
online programme which calculates the probability that a given polymorphism is likely to 
affect pre-mRNA splicing. BDGP splice predictor implements Hidden Markov Models (HMMs) 
to determine the likelihood that an input sequence is characteristic of a consensus splice site. 
The programme begins by scanning an input sequence in two rounds; one scans 15 nucleotide 
windows at a time searching for motifs characteristic of donor sites, as defined by (Shapiro 
and Senapathy 1987), and the second round scans 40 nucleotides at a time searching for 
motifs characteristic of acceptor sites (Shapiro and Senapathy 1987). The sequence is then 
scanned for consensus AG and GT splice signals to assign the likelihood that the sequence is a 
consensus splice site. In order to perform the analysis an ancestral nucleotide sequence is 
input into the software and then motifs and predictions of splice sites generated. Following 
this a sequence containing the polymorphism is input and the results compared with those 
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from the ancestral sequence to see whether there has been a change in probabilities of 
generating/disrupting a consensus splice site. 
 
Figure 2.5: A diagram showing pre-mRNA processing (image has been taken from 





 BioEdit is a programme which enables editing, alignment and manipulation of 
nucleotide and protein sequences (http://www.softpedia.com/get/Science-
CAD/BioEdit.shtml). BioEdit can translate nucleotide sequences into the corresponding amino 
acid sequence. The software itself cannot perform any detailed analysis of sequences, 
however it can identify where polymorphisms can cause deviations from an ancestral amino 
acid sequence. All coding region (exonic) polymorphisms were analysed for their effect, if any, 
on amino acid sequence of CYP3A5 using BioEdit software. A comparison of the ancestral 
amino acid sequence with each mutant sequence was performed to determine whether an 
exonic polymorphism was synonymous or non-synonymous. The resulting changes were 




2.4 Web resources 
Arlequin:  http://cmpg.unibe.ch/software/arlequin35/ 
DnaSP:   http://www.ub.edu/dnasp/ 
MEGA:   http://www.megasoftware.net/ 
PowerMarker:   http://statgen.ncsu.edu/powermarker/ 
PHASE:  http://stephenslab.uchicago.edu/software.html 
LDMax:  http://www.sph.umich.edu/csg/abecasis/GOLD/docs/ldmax.html 
BioEdit:  http://www.softpedia.com/get/Science-CAD/BioEdit.shtml 
PolyPhen2:  http://genetics.bwh.harvard.edu/pph2/ 
BDGP splice:  http://www.fruitfly.org/seq_tools/splice.html 
MatInspector:  http://www.genomatix.de/cgi-bin/matinspector_prof/ 
   mat_fam.pl?s=f37a3f157a0d57ed17e9c10c727382e6 
UCSC:   http://genome.ucsc.edu/ 
NCBI:   http://genome.ucsc.edu/ 
Ethnologue:  http://www.ethnologue.com/web.asp 
Graphpad:  http://www.graphpad.com/quickcalcs/index.cfm 




3. The prevalence of clinically relevant CYP3A5 alleles in 
 Africa 
3.1 Introduction 
3.1.1 Previously reported frequencies of functionally important CYP3A5 variants 
 Four CYP3A5 alleles are the most common determinants of interethnic variability in 
CYP3A5 expression and consequently affect clinical outcomes (see section 1.2.3.1). Multiple 
studies have reported the frequencies of the CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7 
alleles in different populations. A summary of all of the currently reported frequencies, 
including data generated for this thesis, by population group are provided in Table 3.8. 
Genotype data from the 1000 Genomes genotyping databases have also been incorporated 
into the Table, but were not included for integrative analyses. 
 CYP3A5*3 is the main CYP3A5 variant that determines global CYP3A5 expression 
levels, particularly in populations outside of the African continent (Hustert et al. 2001; Lee et 
al. 2003; Saeki et al. 2003; Yamaori et al. 2005). In contrast CYP3A5*6 and CYP3A5*7 are 
observed primarily in populations with recent African ancestry (Hustert et al. 2001; Kuehl et 
al. 2001; Wojnowski et al. 2004; Roy et al. 2005; Mirghani et al. 2006; Quaranta et al. 2006). 
The prevalence of CYP3A5*6 and CYP3A5*7 in these populations may explain why CYP3A5 
expression is reported to be highly variable within these populations (55-95%), despite high 
frequencies of CYP3A5*1. The Maasai from Kinyawa in Kenya, and Ethiopians have much 
lower frequencies of CYP3A5*1 than other sub-Saharan African groups, and interestingly 
CYP3A5*7 has not been observed in any Ethiopian individual (Gebeyehu et al. 2011). 
Additionally, individuals from Zimbabwe have CYP3A5*3 allele frequencies that are 
comparable to those observed for non sub-Saharan African populations. 
 
3.1.2 Rationale of study 
While some African populations have been genotyped for common CYP3A5 variants, 
the distribution of CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7 alleles across the continent 
is still largely unknown. Africa has high levels of genetic diversity (Campbell and Tishkoff 
2008) and frequencies of clinically relevant CYP3A5 alleles across the region may be highly 
variable. Multiple CYP3A5 drug substrates are in use across Africa; an improved 
understanding of common CYP3A5 variation across diverse populations from the continent 
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may aid in improving healthcare outcomes within the region. Many populations within sub-
Saharan Africa are prone to experiencing water shortages and it will be interesting to examine 
whether a previous report of an association between latitude and CYP3A5*1 frequencies is 
also seen within a larger African cohort. 
 
3.1.3 Aims of this study 
The first aim of this study was to determine the frequencies of the four most common, 
allelic variants of CYP3A5, CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7, within 2538 
individuals from 36 geographically and ethnically distinct populations from in and around 
Africa. A second aim was to use the genotypic data to infer expression patterns of CYP3A5 
within the continent. A third aim was to examine whether there is a correlation between 
latitude and CYP3A5*1/CYP3A5*3 allele frequencies, and CYP3A5 expression phenotypes, in 
Africa. A final aim was to identify potential implications of CYP3A5 variability on medical 
treatment with CYP3A5 substrates, and disease risks within the continent. 
 
3.2 Materials and Methods 
 Detailed information about all genotyped populations and statistical analyses of the 
data are provided in chapter 2. 
 
3.2.1 Sample information 
2538 samples were genotyped for this study (see sections 2.1.1.1.1-2.2.1.3.23). The 
cohort comprises 36 different sample sets, from 19 countries which span seven geographic 
regions, and represent six of the world’s major language families. The 2538 cohort are divided 
into 36 distinct sample sets: some are grouped by self-declared ethnic identity and others 
according to where they were collected (Table 3.1).  
The entire dataset overlaps with populations who were genotyped to identify the 
distribution of a functionally important allele of the gene encoding the drug metabolising 
enzyme Flavin-containing monooxygenase 2 (FMO2) (Veeramah et al. 2008) and African 
frequencies of clinically relevant alleles of UDP-glucuronosyltransferase 1A (UGT1A) genes 
(Horsfall et al. 2011).  
1028 genotypes for 51 global populations, from the HGDP-CEPH panel, which had 
previously been published (Thompson et al. 2004), were combined with the 2538 sample 
cohort for integrative analyses (see section 2.1.1.4).  
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3.2.2 Genotyping of CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7 
 Genotyping of CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7 was performed using a 
combination of Dideoxy sequencing (Slatko et al. 2001), TaqMAN allelic discrimination 
genotyping technology (Shen et al. 2009), and KASPar genotyping methods 
(http://www.kbioscience.co.uk). To ensure that results were consistent 150 samples, from 
across the 2538 sample cohort, were genotyped at two loci using a minimum of two methods. 
 
3.2.3 Integrative data analyses 
 Distances from the equator (in kilometres) were calculated for all populations, for 
which geographic coordinate information was available, using the online programme: 
(http://www.movable-type.co.uk/scripts/latlong.html). Spearmann’s Rank correlation 
analysis was performed, to test for a correlation between latitude and CYP3A5 allele 
frequencies, in the R-programming environment and SPSS software (version 20); both gave 
identical results.  
 Given the large number of sample sets included, and statistical tests performed in this 
study a multiple testing correction was applied for HWE analysis, pairwise FST comparisons, 
exact tests of population differentiation and linkage disequilibrium analysis. The Bonferonni 
correction (Salkind 2007) adjusts a pre-defined significance threshold (often 0.05) by dividing 
it by the number of tests carried out, for example HWE analysis was carried out 36 times 
(once for each population genotyped) for the CYP3A5*3 locus, therefore the initial significance 




Table 3.1: A list of the numbers of individuals successfully genotyped for CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7 in this geographic survey. The 2538 
cohort were grouped into 36 distinct sample sets: some are labelled according to self-declared ethnic identity (a) and others according to where the samples 
were collected (b). 
Geographic region Country Sample set Major language family Latitude Longitude Number of individuals 
Europe Armenia Southern Armenians  (b) Indo-European 40.00 45.00 100 
 Turkey Anatolian Turks (a) Altaic 39.00 35.00 74 
Arabian Peninsula Yemen Yemeni from Hadramaut (b) Afro-Asiatic 14.91 48.07 82 
  Yemeni from Sena and Msila (b) Afro-Asiatic 16.08 49.67 37 
North Africa Algeria Northern Algerians (b) Afro-Asiatic 35.505 -1.045 161 
 Morocco Berbers (a) Afro-Asiatic 34.03 -6.84 86 
 Sudan Northern Sudanese (b) Afro-Asiatic 15.59 32.52 136 
  Sudanese from Kordofan (b) Afro-Asiatic 13.08 30.35 30 
Central East Africa Ethiopia Afar (a) Afro-Asiatic 11.602 41.360 73 
  Amhara (a) Afro-Asiatic 9.869 38.660 76 
  Anuak (a) Nilo-Saharan 7.953 34.412 76 
  Maale (a) Afro-Asiatic 5.715 36.643 75 




Southern Sudanese (b) 
Chagga (a) 













West Africa Ghana Asante (a) Niger-Congo A 5.82 -2.82 35 
  Bulsa (a) Niger-Congo A 10.73 -1.29 90 
  Kasena (a) Niger-Congo A 10.89 -1.09 47 
 Senegal Manjak (a) Niger-Congo A 12.986 -15.88 94 
  Wolof (a) Niger-Congo A 14.687 -17.453 94 
West Central Africa Cameroon Kotoko (a) Afro-Asiatic 13.00 14.5 40 
  Shewa Arabs (a) Afro-Asiatic 15.05 12.11 69 
  Cameroonians from Mayo Darle (b) Niger-Congo A 6.47 11.55 118 
  Mambila from Somie, in the Cameroonian Grassfields (b) Niger-Congo A 6.00 12.5 65 
 Congo Congolese from Brazzaville (b) Niger-Congo B -4.26 15.28 55 
 Nigeria Igbo (a) Niger-Congo A 4.95 8.32 88 
South East Africa Malawi Chewa (a) Niger-Congo B -13.47 34.188 92 
  Lomwe (a) Niger-Congo B -13.47 34.188 18 
  Ngoni (a) Niger-Congo B -13.47 34.188 18 
  Tumbuka (a) Niger-Congo B -13.47 34.188 62 
  Yao (a) Niger-Congo B -13.47 34.188 56 
 Mozambique Bantu speakers from Sena (b) Niger-Congo B -17.44 35.05 85 
 South Africa Bantu speakers from Pretoria (b) Niger-Congo B -25.71 28.23 41 
 Zimbabwe Lemba (a) Niger-Congo B -23.095 29.075 24 




3.3.1 The distribution of CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7 within Africa 
CYP3A5 allele frequencies are largely consistent across sub-Saharan Africa (Figure 
3.1) and frequencies of the CYP3A5*1 allele range from 33-96%. The large range reflects East 
African heterogeneity (Table 3.3); and differences between East Africans and other sub-
Saharan Africans. North African CYP3A5*3 frequencies range from 45-81%; the large range is 
influenced by high frequencies of the CYP3A5*1 allele in the two Sudanese sample sets 
compared to Algerians and Moroccan Berbers. The lowest frequencies of the CYP3A5*1 
defining allele were observed in Europe (5-9%). 
 CYP3A5*6 allele frequencies range from 12% to 33% in sub-Saharan Africa. CYP3A5*6 
was also observed at an average frequency of 11% in North Africa (although this is likely to be 
skewed due to the high frequencies observed in individuals from Kordofan in the Sudan); and 
8% in the Arabian Peninsula. CYP3A5*6 was not observed in Europe. 
CYP3A5*7 is largely restricted to sub-Saharan African populations, with frequencies 
ranging from 3-22%, from West, West Central and South East Africa. CYP3A5*7 is also 
observed at low frequencies in North Africa (~1%) and in the Yemen (average frequency of 
2%). Considerable heterogeneity in CYP3A5*7 allele frequencies was observed in East Africa; 
Ugandans and Tanzanians had CYP3A5*7 frequencies which are comparable to those in West, 
West Central and South East Africa. In contrast, CYP3A5*7 frequencies in Ethiopia (~1%) were 
characteristic of non sub-Saharan African populations. 
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Table 3.2: A summary of the genotype and allele frequencies and 2 p-values testing for deviation from HWE at each CYP3A5 locus by sample set genotyped for this thesis. 
No population deviated from Hardy-Weinberg equilibrium, following Bonferonni correction (for CYP3A5*3: adjusted p value = 0.00139; correction for 36 tests, for 
CYP3A5*6: adjusted p value=0.0015; correction for 34 tests, for CYP3A5*7: adjusted p value=0.0017; correction for 30 tests).  
Deviations from HWE cannot be calculated for monomorphic loci: labelled “N/A” on the Table. “Total” refers to the number of individuals, from a given population, 
successfully genotyped at each locus. Sample set refers to the grouping of individuals either by self-declared ethnicity or geography/place collected (Table 3.1). 
 
Region Country Sample set CYP3A5*1/CYP3A5*3 CYP3A5*6 CYP3A5*7 
   AA AG GG Total G [*3] HWE GG GA AA Total A [*6] HWE -/- -/T T/T Total T [*7] HWE 
Europe Armenia Southern Armenians 0 10 90 100 0.95 1.00 100 0 0 100 0.00 N/A 100 0 0 100 0.00 N/A 
 Turkey Anatolian Turks 2 10 62 74 0.91 0.11 74 0 0 74 0.00 N/A 74 0 0 74 0.00 N/A 
Arabian Peninsula Yemen Yemeni from Hadramaut 2 21 59 82 0.85 1.00 77 5 0 82 0.03 1.00 80 2 0 82 0.01 1.00 
  Yemeni from Sena and Msila 7 17 13 37 0.58 0.74 29 7 1 37 0.12 0.42 35 2 0 37 0.03 1.00 
North Africa Algeria Northern Algerians 9 42 108 159 0.81 0.12 146 15 0 161 0.05 1.00 159 2 0 161 0.01 1.00 
 Morocco Berbers 3 28 54 85 0.80 1.00 79 7 0 86 0.04 1.00 85 1 0 86 0.01 1.00 
 Sudan Northern Sudanese 24 58 51 133 0.60 0.29 104 28 0 132 0.11 0.36 135 1 0 136 0.00 1.00 
  Sudanese from Kordofan 11 11 8 30 0.45 0.16 19 10 1 30 0.20 1.00 29 1 0 30 0.02 N/A 
East Africa Ethiopia Afar 10 31 32 73 0.65 0.61 47 26 0 73 0.18 0.11 73 0 0 73 0.00 N/A 
  Amhara 14 22 40 76 0.67 0.004 55 19 2 76 0.15 0.67 76 0 0 76 0.00 N/A 
  Anuak 38 32 6 76 0.29 1.00 44 25 7 76 0.26 0.23 75 1 0 76 0.01 1.00 
  Maale 20 36 19 75 0.49 0.82 53 22 0 75 0.15 0.34 74 1 0 75 0.01 1.00 
  Oromo 12 28 34 74 0.65 0.20 55 19 1 75 0.14 1.00 75 0 0 75 0.00 N/A 
 Sudan Southern Sudanese 74 42 9 125 0.24 0.46 58 50 15 123 0.33 0.42 117 8 0 125 0.03 1.00 
 Tanzania Chagga 28 18 4 50 0.26 0.71 36 14 0 50 0.14 0.57 41 9 0 50 0.09 1.00 
 Uganda Bantu speakers from Ssese 36 3 0 39 0.04 1.00 22 17 0 39 0.22 0.16 23 16 0 39 0.21 0.31 
West Africa Ghana Asante 27 8 0 35 0.11 1.00 20 13 1 34 0.22 1.00 29 5 0 34 0.07 1.00 
  Bulsa 58 29 3 90 0.19 1.00 61 28 0 89 0.16 0.11 69 19 2 90 0.13 0.62 
  Kasena 28 17 2 47 0.22 1.00 31 16 0 47 0.17 0.32 35 12 0 47 0.13 1.00 
 Senegal Manjak 57 29 4 90 0.21 1.00 59 24 9 92 0.23 0.02 81 13 0 94 0.07 1.00 
  Wolof 55 31 8 94 0.25 0.27 58 31 1 90 0.18 0.29 78 15 1 94 0.09 0.55 
West Central 
Africa 
Cameroon Kotoko 18 21 0 39 0.27 
 
0.04 23 16 1 40 0.23 0.65 36 4 0 40 0.05 1.00 
  Shewa Arabs 26 31 12 69 0.40 0.62 42 24 3 69 0.22 1.00 60 9 0 69 0.07 1.00 
  Mayo Darle 66 38 13 117 0.27 0.06 71 33 13 117 0.25 0.01 102 15 0 117 0.06 1.00 
  Somie, Cameroonian Grassfields 36 28 1 65 0.23 0.16 44 19 2 65 0.18 1.00 52 13 0 65 0.10 1.00 
 Congo Congolese from Brazzaville 35 18 2 55 0.20 1.00 43 11 1 55 0.12 0.55 45 10 0 55 0.09 1.00 
 Nigeria Igbo 64 23 0 87 0.13 0.35 60 24 4 88 0.18 0.47 73 12 2 87 0.09 0.14 
South East Africa Malawi Chewa 66 25 1 92 0.15 1.00 66 23 3 92 0.16 0.69 60 31 0 91 0.17 0.06 
  Lomwe 13 4 1 18 0.17 0.39 10 8 0 18 0.22 0.53 14 4 0 18 0.11 1.00 
  Ngoni 15 2 1 18 0.11 0.17 9 6 3 18 0.33 0.31 16 2 0 18 0.06 1.00 
  Tumbuka 44 18 0 62 0.15 0.34 40 17 5 62 0.22 0.14 45 17 0 62 0.14 0.59 
  Yao 37 18 1 56 0.18 0.67 43 12 1 56 0.13 1.00 46 10 0 56 0.09 1.00 
 Mozambique Sena 58 21 3 82 0.16 0.44 51 28 5 84 0.23 0.75 59 25 1 85 0.16 0.68 
 South Africa Bantu speakers 22 17 2 41 0.26 1.00 29 9 3 41 0.18 0.10 34 4 2 40 0.10 0.03 
 Zimbabwe Lemba 17 6 0 23 0.13 1.00 13 10 1 24 0.25 1.00 17 7 0 24 0.15 1.00 
  Zimbabweans from Mposi 36 7 4 47 0.16 0.008 36 10 3 49 0.16 0.09 34 16 2 52 0.19 1.00 
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Figures 3.1 and 3.2: CYP3A5 allele frequencies by geographic region and by major language family 






Genotype data for 32 populations were used to perform pairwise FST comparisons 
(Supplementary Figure 1; on CD) and exact tests of population differentiation (Supplementary 
Figure 2; on CD). Only sample sets with 30 or more individuals were included for the analysis. 
Pairwise FST values were used to perform principal co-ordinates analysis (PCO) to visualise 
inter-population differences (Figure 3.3). 
 
Figure 3.3: A principal co-ordinates (PCO) plot showing genetic differences between populations in 
which ≥30 individuals were genotyped. Supplementary Table 1 shows the associated FST and p values. 
Axis labels show the percentage of genetic distance captured by each axis. FST values were calculated 
from allele frequencies at the i) CYP3A5*1/CYP3A5*3, ii) CYP3A5*6 and iii) CYP3A5*7 loci.  
 
2382 individuals from 32 populations were included in the analysis. Population codes correspond to the following 
populations: Southern Armenians (ARS), Anatolian Turks (AT), Algerians (ALG), Moroccan Berbers (BER), North Sudanese 
(KHN), Southern Sudanese (KHS),  Yemeni from Hadramaut (YH) and from Sena (YS), Ethiopian Afar (EAF), Amhara (EAM), 
Anuak (EAN), Maale (EML) and Oromo (EOR), Tanzanian Chagga (TAN), Ugandan Bantu speakers (UJW), Kotoko (KOT), Shewa 
Arabs (SHW), Cameroonians from Mayo Darle (MD), Cameroonians from Somie (SOM), Congolese individuals from Brazzaville 
(CON), Nigeria Igbo (IGBO), Ghanaian Asante (ASH), Bulsa (BUL) and Kasena (KAS), Senegalese Manjak (MANJ) and Wolof (WOF), 




 The results from PCO analysis show that the 32 populations broadly fall into distinct 
clusters. The majority of sub-Saharan African sample sets cluster together, although 
Ethiopians separate into two groups; the Anuak cluster with the large sub-Saharan African 
cohort, whereas the Afar, Amhara and Oromo cluster with North African and Yemeni sample 
sets. European groups are separate from all remaining populations genotyped in this study. 
The Yemeni from Sena are similar to the Ethiopian Anuak and Maale and Southern Sudanese 
individuals; which is likely to be influenced by appreciable CYP3A5*6 and CYP3A5*7 
frequencies observed in this sample set (Table 3.2). 
 The most striking result from PCO analysis is that over 95% of population 
differentiation is explained by the first principal component. This is a result of differences in 
CYP3A5*3 allele frequencies which explains the clustering of groups with similar frequencies 
of the allele. The second principal component differentiates groups on the basis of CYP3A5*6 
and CYP3A5*7 allele frequencies. 
 The results from PCO analysis (Figure 3.3) suggest that groups from East Africa, North 
Africa and the Arabian Peninsula are the most heterogeneous. These results were confirmed 
by Pearson’s chi squared tests which examined overall heterogeneity, based on data for all 
three CYP3A5 loci by geographic region (Table 3.3) and major language family (Table 3.4). 
Only Anatolian Turks were Altaic speakers and Southern Armenians Indo-European speakers 
and so these language groups were excluded from this analysis. Comparisons of sample sets 
by major language family found significant heterogeneity only between Afro-Asiatic speaking 
groups (consistent with Figure 3.2). The Afro-Asiatic speakers are distributed over a wide 
geographic area: both within and outside of sub-Saharan Africa and it is likely that differences 
observed between these groups are due to geographic distance and differences in ancestry. 
  
 89 
Table 3.3: Pearson’s chi-squared test of overall heterogeneity within the seven geographic regions 
represented by the dataset. P-values which are significant at the 5% level (p<0.05) are shown in bold 
and highlighted in green. 
 
Geographic region Total number of 
individuals 
Degrees of freedom Chi-square P-value 
Europe 174 3 1.32 0.251 
North Africa 441 9 37.61 0.0137 
Arabian Peninsula 131 3 13.16 0.0043 
East Africa 732 21 157.69 5.95 x 10
-23
 
West Africa 458 12 6.687 1 
West Central Africa 553 15 20.69 0.133 
South East Africa 588 24 13.24 0.967 
 
Table 3.4: Pearson’s chi-squared test of overall heterogeneity within the six major language families 
represented by the dataset. P-values which are significant at the 5% level (p<0.05) are shown in bold 
and highlighted in green. 
 
Language family Total number of 
individuals 
Degrees of freedom Chi-square P-value 
Afro-Asiatic 940 33 144.2 1.44 x 10
-16
 
Niger-Congo A 631 21 15.81 0.754 
Niger-Congo B 592 33 24.45 0.819 
Nilo-Saharan 201 3 1.608 0.50 
 
Both Table 3.3 and 3.4 are consistent with Figures 3.1 and 3.2 respectively. 
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3.3.2 Examining the statistical associations between CYP3A5*1, CYP3A5*3, CYP3A5*6 
 and CYP3A5*7 alleles 
3.3.2.1 Linkage disequilibrium 
The D´ measure of linkage disequilibrium (LD) between the three genotyped CYP3A5 
loci (see section 2.3.4) was calculated using LDmax and PowerMarker software programs, 
which gave identical results. D´ was calculated using genotype data from sample sets. 
Individuals with missing data at any locus were excluded from this analysis. The CYP3A5*6 
and CYP3A5*7 alleles are absent in Europe meaning that LD could not be calculated for these 
populations. CYP3A5*7 is monomorphic in a number of sample sets and LD for this locus was 
not calculated in every population. A total of 2465 individuals were included for this analysis. 
Population specific D´ values are presented in Table 3.5. 
The CYP3A5*1/CYP3A5*3 locus is located 7704 nucleotides (nt) from the CYP3A5*6 
locus and 20,145 nt from the CYP3A5*7 locus. The CYP3A5*6 locus is located 12,441 nt from 
CYP3A5*7. The D´ values for the combined cohort of 2465 individuals show that LD between 
the three loci is high; the CYP3A5*7 defining T insertion is in complete LD with the CYP3A5*1 
allele i.e. D´ = 1, p<0.0001; the CYP3A5*6 defining allele is in high LD with the CYP3A5*1 allele 
D´= 0.96, p<0.0001; LD between the CYP3A5*6 and CYP3A5*7 loci is high D´=1.00, p<0.0001. 
However, haplotype analysis (see section 3.3.2.2) found that the CYP3A5*6 and CYP3A5*7 
defining alleles was non-existent; the alleles were not observed on the same chromosome. 
Therefore the observation that D´=1.00 between these two loci is between the ancestral 
alleles; not the derived, clinically relevant mutations. D´ values for individual sample sets were 
consistent with those reported for the 2465 sample cohort. 
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Table 3.5: Pairwise D´ values for each allelic combination at the CYP3A5*1/CYP3A5*3, CYP3A5*6 and 
CYP3A5*7 loci, shown by geographic region, country and ethnic group. Statistically significant D´ values, 
following a Bonferonni correction for multiple testing are highlighted in green. Adjusted significance 
thresholds for each pairwise comparison are shown in brackets after the allelic combination. “–“ 
indicates that at least one of the two loci is monomorphic and so LD could not be calculated.  
 
Geography key: AP; Arabian Peninsula, NA; North Africa, EA; East Africa, WA; West Africa, WCA; West Central Africa; 
SEA; South East Africa 
 
   
   D´ values 
Geographic 
region 









Europe Armenia Southern Armenians - - - 
Europe Turkey Anatolian Turks - - - 
AP Yemen Hadramaut 0.73 1.00 0.47 
AP Yemen Sena and Msila 1.00 1.00 1.00 
NA Algeria Northern 1.00 1.00 1.00 
NA Morocco Berbers 1.00 1.00 1.00 
NA Sudan Northern 1.00 - - 
NA Sudan Kordofan 1.00 1.00 1.00 
EA Ethiopia Afar 1.00 - - 
EA Ethiopia Amhara 0.77 - - 
EA Ethiopia Anuak 1.00 1.00 1.00 
EA Ethiopia Maale 0.86 1.00 1.00 
EA Ethiopia Oromo 0.90 - - 
EA Sudan Southern 1.00 1.00 1.00 
EA Tanzania Chagga 1.00 1.00 1.00 
EA Uganda Bantu speakers from Ssese 0.71 1.00 1.00 
WA Ghana Asante 0.27 1.00 1.00 
WA Ghana Bulsa 1.00 0.81 1.00 
WA Ghana Kasena 1.00 1.00 0.07 
WA Senegal Manjak 0.60 1.00 1.00 
WA Senegal Wolof 1.00 1.00 0.12 
WCA Cameroon Kotoko 1.00 0.26 1.00 
WCA Cameroon Shewa Arabs 0.85 1.00 1.00 
WCA Cameroon Mayo Darle 1.00 1.00 1.00 
WCA Cameroon Mambila from Somie 1.00 1.00 1.00 
WCA Congo Brazzaville 0.85 1.00 1.00 
WCA Nigeria Igbo 1.00 0.74 1.00 
SEA Malawi Chewa 1.00 1.00 1.00 
SEA Malawi Lomwe 0.14 1.00 1.00 
SEA Malawi Ngoni 1.00 1.00 1.00 
SEA Malawi Tumbuka 1.00 0.30 1.00 
SEA Malawi Yao 0.69 0.49 1.00 
SEA Mozambique Sena 1.00 1.00 1.00 
SEA South Africa Bantu speakers 1.00 1.00 1.00 
SEA Zimbabwe Lemba 1.00 1.00 1.00 




3.3.2.2 Haplotype inference 
Haplotypes were inferred from genotype data for 2465 individuals successfully 
genotyped at each of the three CYP3A5 loci. Eight haplotypes are possible from the genotyping 
data (see Table 3.6) but only five were inferred from the cohort. 
 
Table 3.6: The eight potential haplotypes which can occur based on allelic data for the 
CYP3A5*1/CYP3A5*3, CYP3A5*6 and CYP3A5*7 loci. Allelic combinations which were inferred from the 
cohort are highlighted in green. 
 
Allelic combinations at all three CYP3A5 loci  
CYP3A5*1/*3 CYP3A5*6 CYP3A5*7 Haplotype name 
A G - *1 
A G insT *7 
A A - *6 
A A insT *6/*7 
G G - *3 
G G insT *3/*7 
G A - *3/*6 
G A insT *3/*6/*7 
 
The three low/non-expresser alleles occur on independent haplotype backgrounds 
indicating that they act independently on CYP3A5 expression. A low frequency recombinant 
CYP3A5*3/CYP3A5*6 haplotype was inferred for 10 heterozygous individuals; which explains 
why D´ between the CYP3A5*1 and CYP3A5*6 alleles is not equal to 1. CYP3A5*7 always occurs 
on the same haplotype background as CYP3A5*1; consistent with the results for LD analysis 
(section 3.3.2.1). The results show that genotyping of the CYP3A5*1/CYP3A5*3 locus alone 
does not account for additional low/non-functional alleles, in certain populations, which are 
in high LD with the CYP3A5*1 allele. 
Inter-population differences in gene diversity are presented in Figure 3.5. Gene 
diversity estimates are largely consistent across sub-Saharan Africa, although the Afar, 
Amhara and Oromo have lower estimates of gene diversity than other populations from the 
sub-continent. The highest frequencies of the AG- (CYP3A5*1) “expresser” haplotype were 
observed in sub-Saharan African populations, especially in Niger-Congo speaking groups 
(Figure 3.4 and Table 3.7). The distribution of the AA- (CYP3A5*6) haplotype was similar 
across all sub-Saharan African groups, in contrast the AGinsT (CYP3A5*7) haplotype was 
almost exclusively observed in Niger-Congo speakers. The recombinant GA- 
(CYP3A5*3/CYP3A5*6) haplotype was not restricted to a particular geographic region, 
although this may be due to its low frequency in the dataset. CYP3A5*3 and CYP3A5*1 have a 




Table 3.7: The proportion of each inferred CYP3A5 haplotype by sample set out of all haplotypes observed in each population. 
Geographic region Language family Sample set Frequencies of inferred haplotypes 
   AG- (*1) AGinsT (*7) AA- (*6) GG- (*3) GA- (*3/*6) 
Europe Indo-European Southern Armenians 0.05 - - 0.95 - 
 Altaic Anatolian Turks 0.09 - - 0.91 - 
Arabian Peninsula Afro-Asiatic Yemeni from Hadramaut 0.12 0.01 0.02 0.84 0.006 
 Afro-Asiatic Yemeni from Sena and Msila 0.27 0.03 0.12 0.58 - 
North Africa Afro-Asiatic Northern Algerians 0.14 0.01 0.05 0.81 - 
 Afro-Asiatic Berbers 0.15 0.01 0.04 0.80 - 
 Afro-Asiatic Northern Sudanese 0.27 0.003 0.11 0.62 - 
 Afro-Asiatic Sudanese from Kordofan 0.33 0.02 0.20 0.45 - 
East Africa Afro-Asiatic Afar 0.17 - 0.18 0.65 - 
 Afro-Asiatic Amhara 0.20 - 0.13 0.65 - 
 Nilo-Saharan Anuak 0.45 0.007 0.26 0.29 - 
 Afro-Asiatic Maale 0.36 0.007 0.14 0.49 0.007 
 Afro-Asiatic Oromo 0.22 - 0.13 0.64 0.007 
 Nilo-Saharan Southern Sudanese 0.40 0.03 0.33 0.24 - 
 Niger-Congo B Chagga 0.51 0.09 0.14 0.26 - 
 Niger-Congo B Bantu speakers from Ssese 0.54 0.21 0.22 0.04 - 
West Africa Niger-Congo A Asante 0.60 0.07 0.22 0.10 - 
 Niger-Congo A Bulsa 0.52 0.12 0.16 0.20 - 
 Niger-Congo A Kasena 0.48 0.13 0.17 0.22 - 
 Niger-Congo A Manjak 0.49 0.07 0.23 0.20 0.01 
 Niger-Congo A Wolof 0.47 0.09 0.18 0.25 - 
West Central Africa Afro-Asiatic Kotoko 0.46 0.05 0.22 0.27 - 
 Afro-Asiatic Shewa Arabs 0.33 0.07 0.21 0.39 0.007 
 Niger-Congo A Mayo Darle 0.40 0.07 0.25 0.28 - 
 Niger-Congo A Mambila from Somie 0.49 0.23 0.18 0.10 - 
 Niger-Congo B Congolese from Brazzaville 0.59 0.09 0.12 0.20 - 
 Niger-Congo A Igbo 0.59 0.09 0.18 0.13 - 
South East Africa Niger-Congo B Chewa 0.54 0.18 0.15 0.13 - 
 Niger-Congo B Lomwe 0.50 0.11 0.22 0.17 - 
 Niger-Congo B Ngoni 0.50 0.11 0.22 0.17 - 
 Niger-Congo B Tumbuka 0.50 0.14 0.22 0.15 - 
 Niger-Congo B Yao 0.61 0.18 0.13 0.09 - 
 Niger-Congo B Sena 0.46 0.17 0.21 0.16 0.006 
 Niger-Congo B Bantu speakers 0.45 0.10 0.19 0.26 - 
 Niger-Congo B Lemba 0.48 0.15 0.24 0.13 - 
 Niger-Congo B Zimbabweans from Mposi 0.45 0.22 0.17 0.16 - 
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Figure 3.4: A map showing the distribution of the five inferred CYP3A5 haplotypes across the 
geographic region represented by the 36 populations in the dataset. The size of each circle is 
proportional to the number of individuals sampled from a given population. The allele 
combinations listed in the key are equivalent to those discussed in section 3.3.4. 




Figure 3.5: Gene diversity (Nei’s h) for the five CYP3A5 haplotypes, inferred from genotype 
data for each of 36 populations, for the three loci defining the CYP3A5 alleles: 
CYP3A5*1/CYP3A5*3, CYP3A5*6 and CYP3A5*7. Populations are coloured to the geographic region 
to which they belong, see Table 3.1. Error bars denote standard deviation. 





































Gene diversity: Nei's h
  
 96 
3.3.3  Inferred CYP3A5 protein expression patterns across sub-Saharan Africa 
The geographic and ethnic distributions of inferred low/non-, intermediate- and high-
expression phenotypes, based on individual diplotypes, are presented in Figure 3.6. Within 
Africa populations from South East, West and West Central Africa (all Niger-Congo speakers) 
are predicted to have the highest frequencies of high/normal CYP3A5 expressers. This is 
assuming that there are no additional variants within these populations which can affect 
protein expression. Populations from Europe are predicted to have the highest frequencies of 
individuals who are low/non-CYP3A5 expressers; consistent with previous reports (Quaranta 
et al. 2006). Consistent with all previous analyses, there is considerable heterogeneity in East 
and West Central Africa; similarities in inferred expression profiles are correlated with major 
language family. 
The low/non-expresser and expresser haplotypes were considered as two alleles at an 
“expression” locus. Individuals who had two “low/non-expresser” haplotypes were assigned 
the pseudo genotype LL (low/low), individuals who were heterozygous for an expresser and a 
low/non-expresser haplotype were assigned HL (high/low) and individuals who have two 
copies of the expresser haplotype were assigned HH (high/high). These pseudo genotypes 
were used to examine whether any population deviated significantly from Hardy-Weinberg 
equilibrium (HWE) in their CYP3A5 expression phenotypes. No population deviated from 
HWE following Bonferonni correction (adjusted p≤0.00139). 
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Figure 3.6: A map showing the distribution of predicted CYP3A5 protein expression levels 
across the geographic region represented by the dataset. The size of each circle is 





3.3.4 Examining African CYP3A5 allele frequencies in a global context 
 A summary of global CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7 allele and 
genotype frequencies, including those reported in this study, are provided in Table 3.8. 
Previous reports have focused mainly on the CYP3A5*1/CYP3A5*3 locus, therefore the main 
comparisons between the data reported in this study and global populations are for 
CYP3A5*1/CYP3A5*3 data. Figure 3.7 shows the average CYP3A5 allele frequencies by 
geographic region. 
 CYP3A5*3 has been observed in all population groups that have been studied. The 
highest frequencies of CYP3A5*3 have been observed in individuals with recent European 
ancestry from North America and Europe (Table 3.8) (Dally et al. 2004; Roy et al. 2005; 
Quaranta et al. 2006). Frequencies of CYP3A5*3 in populations from Asia, Oceania and South 
America are intermediate between those in Africa and Europe (Balram et al. 2003; Quaranta 
et al. 2006; Diczfalusy et al. 2008; Sinues et al. 2008). Outside of sub-Saharan Africa, the 
largest variation in CYP3A5*3 frequencies were observed in North America; CYP3A5 allele 
frequencies vary between African-Americans and other groups from the region. Caucasian 
and Asian populations from the region are largely homogeneous in their allele frequencies. 
 Comparisons of CYP3A5*6 allele frequencies reported in this study with those from 
HapMap and NIEHS populations and published data confirm that CYP3A5*6 frequencies are 
highest in sub-Saharan Africa. CYP3A5*6 frequencies are largely consistent across populations 
from the sub-continent, unlike CYP3A5*1, CYP3A5*3 and CYP3A5*7. CYP3A5*6 is absent in all 
East Asian populations, in almost every European population (a single CYP3A5*1/CYP3A5*6 
heterozygote from Tuscany, Italy was observed), and is observed at low frequencies in North 
Africa. The largest inter-regional variation in CYP3A5*6 allele frequencies was observed in 
West Central Africa; which is almost entirely influenced by higher frequencies of CYP3A5*6 in 
populations from Lake Chad comparative to other West Central Africans. 
CYP3A5*7 has not been genotyped in HapMap populations to date. Comparisons of 
CYP3A5*7 frequencies with NIEHS populations and with published data confirm that the 
highest frequencies of CYP3A5*7 are in sub-Saharan Africa. Appreciable frequencies of this 
allele were observed in ethnic Koreans (Diczfalusy et al. 2008) and North African populations 
(own data). CYP3A5*7 is not present in Europe. North American populations have 
considerable inter-regional variation in CYP3A5*7 allele frequencies; which is almost certainly 
due to inter-ethnic differences between populations sampled from the region. 
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Table 3.8: A table summarising all known allele frequencies of CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7, in different population groups.  Information has been 
compiled from reports in the literature and online databases including The International HapMap Consortium (http://hapmap.ncbi.nlm.nih.gov/) and NIEHS SNPs 
(http://egp.gs.washington.edu/). Care has been taken to ensure that individuals have not been counted more than once. Where the same individuals have been genotyped, 
the average of each allele frequency has been reported. Data generated for this thesis has also been added into the Table. A reference list is provided beneath the Table. “-“ 
indicates missing information. 
       CYP3A5*1/CYP3A5*3 CYP3A5*6   CYP3A5*7     
       Genotypes Alleles Genotypes Alleles Genotypes Alleles   
Geographic 
region 




















Yemen Hadramaut 48.07 14.91 1658 82 2 21 59 0.15 0.85 77 5 0 0.97 0.03 80 2 0 0.99 0.01  1 
  Sena 49.67 16.08 1788 37 7 17 13 0.42 0.58 29 7 1 0.88 0.12 35 2 0 0.97 0.03  1 
East Asia Numerous East Asian - - - 24 2 11 11 0.31 0.69 0 0 23 1.00 0.00 24 0 0 1.00 0  4 
 Cambodia Khmer 12N 105E 1334 11 1 4 6 0.27 0.73 - - - - - - - - - -  2 
 China Chinese - - - 108 9 35 64 0.25 0.75 108 0 0 1.00 0.00 - - - - -  5 
  Dai 21N 100E 2335 10 1 7 2 0.45 0.55 - - - - - - - - - -  2 
  Daur 48-49N 124E 5393 10 0 3 7 0.15 0.85 - - - - - - - - - -  2 
  Han 26-39N 108-
120E 
3614 44 2 18 24 0.25 0.75 - - - - - - - - - -  2 
  Han Chinese in Beijing - - - 124 12 46 66 0.28 0.72 125 0 0 1.00 0.00 - - - - -  3 
  Southern Han Chinese - - - 100 24 46 30 0.47 0.53 100 0 0 1.00 0.00 - - - - -  18 
  Hezhen 47-48N 132-
135E 
5282 10 0 3 7 0.15 0.85 - - - - - - - - - -  2 
  Lahu 22N 100E 2446 10 0 5 5 0.25 0.75 - - - - - - - - - -  2 
  Miaozu 28N 109E 3113 10 1 5 4 0.35 0.65 - - - - - - - - - -  2 
  Mongola 48-49N 118-
120E 
5393 10 0 7 3 0.35 0.65 - - - - - - - - - -  2 
  Naxi 26N 100E 2891 9 0 5 4 0.28 0.72 - - - - - - - - - -  2 
  Orogen 48-53N 122-
131E 
5615 10 0 2 8 0.10 0.90 - - - - - - - - - -  2 
  She 27N 119E 3002 10 3 3 4 0.45 0.55 - - - - - - - - - -  2 
  Tu 36N 101E 4003 10 0 2 8 0.10 0.90 - - - - - - - - - -  2 
  Tujia 29N 109E 3225 10 2 3 5 0.35 0.65 - - - - - - - - - -  2 
  Uygur 44N 81E 4893 10 0 1 9 0.05 0.95 - - - - - - - - - -  2 
  Xibo 43-44N 81-82E 4837 9 0 4 5 0.22 0.78 - - - - - - - - - -  2 
  Yizu 28N 103E 3113 10 1 2 7 0.20 0.80 - - - - - - - - - -  2 
 Japan Japanese - - - 200 14 65 121 0.23 0.77 200 0 0 1.00 0.00 - - - - -  8 
  Japanese 38N 138E 4225 31 2 10 19 0.23 0.77 - - - - - - - - - -  2 
  Japanese in Tokyo - - - 113 5 48 60 0.26 0.74 112 1 0 0.996 0.004 - - - - -  3 
 South Korea Koreans - - - 162 - - - 0.19 0.81 - - - 1.00 0 - - - 0.97 0.03  7 
 Malaysia Malay - - - 98 10 56 32 0.39 0.61 98 0 0 1.00 0.00 - - - - -  5 
South Asia India Indians - - - 90 11 51 28 0.41 0.59 90 0 0 1.00 0.00 - - - - -  5 
 Pakistan Balochi 66-67N 30.31E 3370 25 0 10 15 0.20 0.80 - - - - - - - - - -  2 
  Brahui 66-67N 30.31E 3370 25 0 6 19 0.12 0.88 - - - - - - - - - -  2 
  Burusho 36-37N 73-75E 4059 25 3 5 17 0.22 0.78 - - - - - - - - - -  2 
  Hazara 33-34N 70E 3725 24 0 12 12 0.25 0.75 - - - - - - - - - -  2 
  Kalash 35-37N 71-71E 4003 25 1 10 14 0.24 0.76 - - - - - - - - - -  2 
  Makrani 26N 66-66E 2891 25 0 7 18 0.14 0.86 - - - - - - - - - -  2 
  Pathan 32-35N 69-72E 3725 25 0 6 19 0.12 0.88 - - - - - - - - - -  2 
  
 100 
  Sindhi 24-27N 68-70E 2835 25 1 7 17 0.18 0.82 - - - - - - - - - -  2 
Central 
America 
Mexico Maya 19N 91W 2113 24 4 6 14 0.29 0.71 - - - - - - - - - -  2 
  Pima 29N 108W 3225 25 5 17 3 0.54 0.46 - - - - - - - - - -  2 
 El Salvador and 
Nicaragua 
Mestizo - - - 232 7 96 129 0.24 0.76 - - - - - - - - - -  15 
South 
America 
Brazil Karitiana 10S 63W 1112 24 1 9 14 0.23 0.77 - - - - - - - - - -  2 
  Surui 11S 62W 1223 21 1 5 15 0.17 0.83 - - - - - - - - - -  2 
 Colombia Colombians 3N 68W 333.6 13 0 4 9 0.15 0.85 - - - - - - - - - -  2 
 Colombia Colombians from Medellian - - - 60 16 25 19 0.48 0.52 59 1 0 0.98 0.02 - - - - -  18 
 Ecuador Mestizo - - - 317 7 64 246 0.12 0.88 - - - - - - - - - -  16 
Europe Numerous European - - - 22 0 1 21 0.02 0.98 0 0 21 1.00 0.00 22 0 0 1.00 0  4 
 Armenia Southern Armenians 40 45 5004 100 0 10 90 0.05 0.95 100 0 0 1.00 0.00 100 0 0 1.00 0.00  1 
 France French 46N 2E 5115 29 1 3 25 0.09 0.91 - - - - - - - - - -  2 
  French Basque 43N 0E 4781 24 0 2 22 0.04 0.96 - - - - - - - - - -  2 
  French Caucasians - - - 51 0 8 43 0.08 0.92 51 0 0 1.00 0 51 0 0 1.00 0  13 
 Finland Finnish - - - 93 19 45 29 0.45 0.55 100 0 0 1.00 0 - - - - -  18 
 Numerous Sephardi Jews - - - 66 0 14 52 0.11 0.89 68 0 0 1.00 0.00 68 0 0 1.00 0.00  1 
 Germany German Caucasians - - - 1210 11 143 1056 0.07 0.93 - - - - - - - - - -  6 
 Israel Druze 32N 35E 3558 48 1 6 41 0.08 0.92 - - - - - - - - - -  2 
  Palestinian 32N 35E 3558 51 2 14 35 0.18 0.82 - - - - - - - - - -  2 
  Bedouin 31N 35E 3447 48 2 12 34 0.17 0.83 - - - - - - - - - -  2 
 Italy Bergamo (Northern Italian) 46N 10E 5115 14 1 3 10 0.18 0.82 - - - - - - - - - -  2 
  Sardinia 40N 9E 4448 28 0 3 25 0.05 0.95 - - - - - - - - - -  2 
  Tuscan 43N 11E 4781 8 0 1 7 0.06 0.94 - - - - - - - - - -  2 
  Tuscans - - - 102 0 11 91 0.05 0.95 101 1 0 0.995 0.005 - -  - -  3 
 Orkney Islands Orcadian 59N 3W 6561 16 1 3 12 0.16 0.84 - - - - - - - - - -  2 
 Russia Russian 61N 39-41E 6783 25 0 4 21 0.08 0.92 - - - - - - - - - -  2 
  Adygei 44N 39E 4893 17 0 4 13 0.12 0.88 - - - - - - - - - -  2 
 Siberia Yakut 62-64N 129-
139E 
7005 25 0 5 20 0.10 0.90 - - - - - - - - - -  2 
 Spain Northern Spaniard - - - 204 3 31 171 0.09 0.91 - - - - - - - - - -  10 
  Southern Spaniard - - - 177 5 22 150 0.09 0.91 - - - - - - - - - -  15 
  Iberians - - - 14 2 7 5 0.39 0.61 14 0 0 1.00 0 - - - - -  18 
 Sweden Swedes - - - 136 1 16 119 0.07 0.93 136 0 0 1.00 0 136 0 0 1.00 0  7 
 Turkey Anatolians 35.00 39.00 4337 74 2 10 62 0.09 0.91 74 0 0 1.00 0 74 0 0 1.00 0.00  1 
 United Kingdom British in England and 
Scotland 
- - - 89 13 37 39 0.35 0.65 89 0 0 1.00 0 - - - - -  18 
 Numerous Ashkenazi Jews - - - 90 0 6 84 0.03 0.97 90 0 0 1.00 0.00 91 0 0 1.00 0.00  1 
Oceania Bougainville NAN Melanesian 6S 155E 667.2 22 1 6 15 0.18 0.82 - - - - - - - - - -  2 
 New Guinea Papuan 4S 143E 444.8 17 1 5 11 0.21 0.79 - - - - - - - - - -  2 
North 
America 
Canada Canadian Caucasians - - - 77 - - - 0.07 0.93 - - - 1.00 0 - - - 1.00 0  14 
 Puerto Rico Puerto Ricans - - - 55 16 30 9 0.56 0.44 49 6 0 0.95 0.05 - - - - -  18 
 U.S.A. African Americans - - - 15 6 7 2 0.63 0.37 0 3 10 0.88 0.12 9 4 1 0.79 0.21  4 
  African ancestry in S.W. 
USA 
- - - 87 39 41 7 0.68 0.32 71 15 0 0.91 0.09 - - - - -  3 
  Chinese in Denver, 
Colorado 
- - - 109 6 42 61 0.25 0.75 - - - - - - - - - -  3 
  Gujarati Indians in Houston, 
Texas 
- - - 101 6 38 57 0.25 0.75 - - - - - - - - - -  3 
  Hispanic - - - 22 0 11 11 0.25 0.75 0 0 21 1.00 0.00 21 0 0 1.00 0  4 
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  Mexican ancestry in Los 
Angeles 
- - - 85 5 32 48 0.25 0.75 82 4 0 0.98 0.02 - - - - -  3 
  North American 
Caucasians 
- - - 437 3 74 358 0.09 0.90 - - - - - - - - - -  12 
  Northern and Western 
European ancestry (CEPH 
collection) 
- - - 143 0 11 132 0.04 0.96 67 0 0 1.00 0 - - - - -  3 
North Africa Algeria Algerians -1.045 35.505 3948 161 9 42 108 0.19 0.81 146 15 0 0.95 0.05 159 2 0 0.99 0.01  1 
  Mzab (Mozabite) 32N 3E 3558 29 0 9 20 0.16 0.84 - - - - - - - - - -  2 
 Morocco Berber -6.84 34.03 3784 85 3 28 54 0.20 0.80 79 7 0 0.96 0.04 85 1 0 0.99 0.01  1 
 Sudan Kordofan 30.35 13.08 1454 30 11 11 8 0.55 0.45 19 10 1 0.80 0.20 29 1 0 0.98 0.02  1 
  Northern 32.53 15.59 1734 133 24 58 51 0.40 0.60 104 28 0 0.89 0.11 135 1 0 1.00 0.00  1 
 Tunisia Tunisian - - - 36 0 14 22 0.19 0.81 35 1 0 0.99 0.01 36 0 0 1.00 0  13 
Central 
Africa 
Central African Republic Biaka Pygmies 4N 17E 444.8 33 28 3 2 0.89 0.11 - - - - - - - - - -  2 
 D.R. Congo Mbuti Pygmies 1N 29E 111.2 15 13 2 0 0.93 0.07 - - - - - - - - - -  2 
East Africa Ethiopia Afar 41.36039 11.60212 1290 73 10 31 32 0.35 0.65 47 26 0 0.82 0.18 73 0 0 1.00 0.00  1 
  Amhara 38.65951 9.869192 1097 76 14 22 40 0.33 0.67 55 19 2 0.85 0.15 76 0 0 1.00 0.00  1 
  Anuak 34.41219 7.953241 884.4 76 38 32 6 0.71 0.29 44 25 7 0.74 0.26 75 1 0 0.99 0.01  1 
  Ethiopians - - - 150 - - - 0.79 0.21 - - - 0.88 0.12 - - - 1.00 0  9 
  Maale 36.64333 5.714812 635.5 75 20 36 19 0.51 0.49 53 22 0 0.85 0.15 74 1 0 0.99 0.01  1 
  Oromo 37.30817 7.83736 871.5 74 12 28 34 0.35 0.65 55 19 1 0.86 0.14 75 0 0 1.00 0.00  1 
 Kenya Bantu NE 3S 37E 333.6 12 9 2 1 0.83 0.17 - - - - - - - - - -  2 
  Luhya (Webuye, Kenya) - - - 110 83 24 3 0.86 0.14 61 39 9 0.74 0.26 - - - - -  3 
  Maasai (Kinyawa, Kenya) - - - 184 45 97 42 0.51 0.49 137 43 4 0.86 0.14 - - - - -  3 
 Sudan Southern 31.77 5.18 576 125 74 42 9 0.76 0.24 58 50 15 0.67 0.33 117 8 0 0.97 0.03  1 
 Tanzania Chagga 38.05 -5.38 598.2 50 28 18 4 0.74 0.26 36 14 0 0.86 0.14 41 9 0 0.91 0.09  1 
  Tanzanians - - - 143 90 52 1 0.81 0.19 95 42 6 0.81 0.19 111 31 1 0.88 0.12  7 
 Uganda Bantu speakers 31.45 -0.57 63.38 39 36 3 0 0.96 0.04 22 17 0 0.78 0.22 23 16 0 0.79 0.21  1 
  Ugandans - - - 140 - - - 0.82 0.18 - - - 0.83 0.17 - - - 0.89 0.11  11 
South East 
Africa 
Malawi Chewa 33.78 -13.98 1555 92 66 25 1 0.85 0.15 66 23 3 0.84 0.16 60 31 0 0.83 0.17  1 
  Lomwe 33.78 -13.98 1555 18 13 4 1 0.83 0.17 10 8 0 0.78 0.22 14 4 0 0.89 0.11  1 
  Other Malawians 33.78 -13.98 1555 14 9 4 1 0.79 0.21 10 4 0 0.86 0.14 10 4 0 0.86 0.14  1 
  Ngoni 33.78 -13.98 1555 18 15 2 1 0.89 0.11 9 6 3 0.67 0.33 16 2 0 0.94 0.06  1 
  Tumbuka 33.92 -11.45 1273 62 44 18 0 0.85 0.15 40 17 5 0.78 0.22 45 17 0 0.86 0.14  1 
  Yao 33.78 -13.98 1555 56 37 18 1 0.82 0.18 43 12 1 0.88 0.13 46 10 0 0.91 0.09  1 
 Mozambique Sena 35.05 -17.44 1939 82 58 21 3 0.84 0.16 51 28 5 0.77 0.23 59 25 1 0.84 0.16  1 
 South Africa Bantu speakers 28.23 -25.71 2859 49 27 20 2 0.76 0.24 29 9 3 0.82 0.18 34 4 2 0.90 0.10  1 
 Zimbabwe Lemba 29.075 -23.095 2568 23 17 6 0 0.87 0.13 13 10 1 0.75 0.25 17 7 0 0.85 0.15  1 
  Shona - - - 100 - - - 0.22 0.78 - - - 0.78 0.22 - - - 0.90 0.10  14 
  Zimbabweans 30 -19.67 2187 47 36 7 4 0.84 0.16 36 10 3 0.84 0.16 34 16 2 0.81 0.19  1 
South West 
Africa 
Namibia San 21S 20E 2335 7 6 1 0 0.93 0.07 - - - - - - - - - -  2 
West Africa Gabon Gabonese - - - 36 21 15 0 0.79 0.21 14 7 0 0.81 0.19 14 7 0 0.81 0.19  13 
 Gambia Gambians - - - 288 183 90 15 0.79 0.21 179 100 9 0.80 0.20 222 62 4 0.88 0.12  17 
 Ghana Asante 6.17 -0.55 686.1 35 27 8 0 0.89 0.11 20 13 1 0.78 0.22 29 5 0 0.93 0.07  1 
  Bulsa 10.73 -1.29 1193 90 58 29 3 0.81 0.19 61 28 0 0.84 0.16 69 19 2 0.87 0.13  1 
  Kasena 10.89 -1.09 1211 47 28 17 2 0.78 0.22 31 16 0 0.83 0.17 35 12 0 0.87 0.13  1 
 Senegal Mandenka 12N 12W 1334 24 12 9 3 0.69 0.31 - - - - - - - - - -  2 
  Manjak -15.88 12.986 1444 90 57 29 4 0.79 0.21 59 24 9 0.77 0.23 81 13 0 0.93 0.07  1 
  Wolof -17.453 14.687 1633 94 55 31 8 0.75 0.25 58 31 1 0.82 0.18 78 15 1 0.91 0.09  1 




  Lake Chad other 14.5 13 1446 23 12 11 0 0.76 0.24 9 12 1 0.68 0.32 20 3 0 0.93 0.07  1 
  Mayo Darle 11.55 6.47 719.4 117 66 38 13 0.73 0.27 71 33 13 0.75 0.25 102 15 0 0.94 0.06  1 
  Shewa Arab 14.5 13 1446 69 26 31 12 0.60 0.40 42 24 3 0.78 0.22 60 9 0 0.93 0.07  1 
  Somie 12.5 6 667.2 65 36 28 1 0.77 0.23 44 19 2 0.82 0.18 52 13 0 0.90 0.10  1 
 Congo Congolese 15.28 -4.26 473.7 55 35 18 2 0.80 0.20 43 11 1 0.88 0.12 45 10 0 0.91 0.09  1 
 Nigeria Igbo 8.32 4.95 550.4 87 64 23 0 0.87 0.13 60 24 4 0.82 0.18 73 12 2 0.91 0.09  1 
  Yoruba - - - 198 130 60 3 0.83 0.17 134 53 6 0.83 0.17 - - - - -  3 
  Yoruba 6-10N 2-8E 889.6 25 9 3 0 0.94 0.06 - - - - - - - - 1.00 0  2 
  Yoruba - - - 12 22 3 0 0.88 0.13 1 2 5 0.25 0.75 11 0 0 - -  4 
 
List of references for Table 3.10: 
1. R Bains, unpublished data from this study, 
2. (Thompson et al. 2004), 
3. The International HapMap project (http://hapmap.ncbi.nlm.nih.gov/), 
4. NIEHS SNPs program (http://egp.gs.washington.edu/), 
5. (Balram et al. 2003), 
6. (Dally et al. 2004), 
7. (Diczfalusy et al. 2008), 
8. (Fukuen et al. 2002), 
9. (Gebeyehu et al.), 
10. (Floyd et al. 2003), 
11. (Mukonzo et al.), 
12. (Plummer et al. 2003), 
13. (Quaranta et al. 2006), 
14. (Roy et al. 2005), 
15. (Sinues et al. 2007), 
16. (Sinues et al. 2008), 
17. (Wojnowski et al. 2004) 
18. 1000 Genomes genotyping data, from the Illumina Omni platform, for populations that are not part of the HapMap database.
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Figure 3.7: A graph showing the average CYP3A5 allele frequencies by geographic region. The Figure shows the average frequencies for each geographic region listed 







































3.3.5 The association between CYP3A5 allele frequencies and latitude 
 A previous study reported that CYP3A5*3 allele frequencies are positively correlated 
with increased distance from the equator (Thompson et al. 2004). The genotype data for the 
CYP3A5*1/CYP3A5*3 locus for the 36 populations genotyped in this study were combined 
with data for 1028 individuals from 51 populations genotyped in the original paper (n=3570 
from 87 populations) to test for a global correlation between CYP3A5*1 and CYP3A5*3 allele 
frequencies and latitude (Figure 3.8 and 3.9). 
 A significant global positive correlation between increased distance from the equator 
and CYP3A5*3 allele frequencies was observed when all 87 populations were examined 
[Spearmann Rho = 0.701, p<0.0001]. Analysis of the seven geographic regions represented by 
the 87 populations, where more than ten population groups had been sampled, found a 
significant positive correlation between latitude and CYP3A5*3 allele frequencies in Asia 
[Spearmann Rho = 0.853, p <0.001] but not within Europe [Spearmann Rho = 0.002, p=0.994] 
or Africa [Spearmann Rho = 0.277, p=0.08]. Although removal of the heterogeneous Ethiopian 
populations from the analysis found a significant positive correlation in Africa [Spearmann 
Rho = 0.369, p=0.04]. The lack of an association between latitude and allele frequencies in 
Europe is due to homogeneity in allele frequencies between population groups from the 
region. 
There is a strong positive correlation between north latitude and CYP3A5*3 allele 
frequencies [Spearmann Rho = 0.781, p<0.0001] but not for south latitude [Spearmann Rho = 
-0.318, p=0.199]. Due to the overrepresentation of north latitude populations in both datasets 
(69 populations out of a total of 87), the analysis was performed using only data obtained for 
African groups. The results confirmed those for 87 populations; CYP3A5*3 frequencies are 
positively correlated with north latitude (26/40 African groups) [Spearmann Rho = 0.621, 




Figure 3.8: A map showing the distribution of the CYP3A5*1/CYP3A5*3 alleles in each of 87 populations; 51 of which were previously genotyped 





Figure 3.9: A scatter plot showing the correlation between CYP3A5*3 allele frequencies and distance from the equator in kilometres. The allele 







































There is a strong global trend towards CYP3A5*3 frequencies increasing with increased distance from the equator.
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 An examination of correlations between CYP3A5*6 and CYP3A5*7 alleles was 
performed for the 36 populations genotyped for this thesis. A significant negative correlation 
between CYP3A5*6 frequencies and geographic distance from the equator was observed 
[Spearmann Rho = -0.35, p=0.03]; although this correlation was no longer significant when 
only groups south of the equator were examined [Spearmann Rho = 0.237, p=0.163]. No 
significant correlation between CYP3A5*7 frequencies and distance from the equator was 
observed [Spearmann Rho = -0.089, p=0.603]. This is almost certainly influenced by the 
confined distribution of the CYP3A5*7 allele to Niger-Congo speaking groups; who are 
homogeneous and spread over large geographic distances. 
 
3.3.6 The correlation between CYP3A5 expression phenotype and latitude 
 A Spearmann’s Rank correlation test was performed to examine whether there is an 
association between CYP3A5 expression phenotypes inferred from diplotypes (Figure 3.10). 
Significantly negative correlations between inferred high- and intermediate- CYP3A5 
expression phenotypes and distance from the equator were observed from the data 
[Spearmann Rho = -0.404, p<0.02] and [Spearmann Rho = -0.44, p=0.007] respectively. In 
contrast to low/non- protein expression [Spearmann Rho = 0.454, p<0.006]. There was a 
strong negative correlation between the frequencies of expresser haplotypes and distance 
from the equator [Spearmann Rho = -0.490, p=0.002] and a strong positive correlation 
between the collective frequencies of low/non-expresser haplotypes and distance from the 
equator [Spearmann Rho = 0.490, p=0.002] (Figure 3.11). The results suggest that latitude is a 




Figure 3.10: A scatter plot showing the correlation between geographic distance from the 
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Figure 3.10 continued; the correlation between geographic distance from the equator (in kilometres) 
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The correlation between inferred low/non-expressers of 
CYP3A5 and distance from the equator (kilometres)
 
Figure 3.11: The correlation between CYP3A5 haplotypes (expresser and collective low/non-
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3.4.1 Intra-African CYP3A5 expression levels are likely to be highly variable 
In this chapter the distribution of CYP3A5 variants, previously reported to affect 
protein expression, were genotyped in African populations. The results from this study are 
consistent with previous reports that the highest frequencies of CYP3A5*1 are found in 
populations with recent African ancestry (Roy et al. 2005; Quaranta et al. 2006). The results 
also indicate that the CYP3A5*6 and CYP3A5*7 variants are found at high frequencies across 
Africa, suggesting that multiple variants are likely to affect CYP3A5 expression levels across 
the continent. Interestingly the three low/non expresser variants occur on independent 
haplotype backgrounds suggesting that traits causing low/non CYP3A5 expression in Africa 
have evolved more than once. 
Previous studies have estimated that between 55-95% of individuals with recent 
African ancestry have high levels of CYP3A5 expression (Hustert et al. 2001; Kuehl et al. 2001; 
Lamba et al. 2002). One explanation for the large reported range of CYP3A5 expressers is the 
choice of CYP3A5 markers used to infer protein expression in previous studies. The majority 
of previous studies have focused on the CYP3A5*1/CYP3A5*3 locus as a single determinant of 
CYP3A5 expression. Genotyping of the CYP3A5*1/CYP3A5*3 locus alone may be sufficient to 
predict CYP3A5 expression profiles in non African-American and African populations. 
However the high frequencies of CYP3A5*6 and CYP3A5*7 in Africa, reported in this chapter, 
reiterate the importance of genotyping these variants in populations with recent African 
ancestry. 
The classification of CYP3A5 alleles as expresser or non-expresser is likely to have an 
effect on the range of reported expresser frequencies in Africa. Of the three low/non-
expresser variants genotyped in this study, there is some doubt over the functional 
implications of the CYP3A5*6 variant. The effect of CYP3A5*6 on exon 7 skipping (see section 
1.2.3.1) has only been established once in 2001 (Kuehl et al. 2001) and has not been 
independently replicated. Although the authors reported that CYP3A5*6 caused skipping of 
exon 7, they observed that normally spliced mature mRNA was present in all individuals who 
carried the CYP3A5*6 variant (Kuehl et al. 2001). The study only included three individuals 
who were heterozygous for the CYP3A5*6 mutation and therefore it is not known whether 
normally spliced mature mRNA is observed in individuals who are homozygous for CYP3A5*6; 
and if so, at what concentration comparative to CYP3A5*1 homozygotes. 
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One method by which the functionality of CYP3A5*6 could be established is to examine 
clinical data on a drug substrate of CYP3A5, such as the well studied immunosuppressant 
tacrolimus. The effect of low/non-CYP3A5 expression, determined by genotypes at the 
CYP3A5*1/CYP3A5*3 locus, on tacrolimus associated adverse drug reactions is well 
established (Goto et al. 2004; Quteineh et al. 2008). Therefore patients, particularly those with 
recent African ancestry, who are not heterozygous or homozygous for CYP3A5*3 and yet 
display the same adverse clinical outcomes as CYP3A5*3 carriers should be genotyped for the 
CYP3A5*6 variant. If a significant number of patients who are CYP3A5*6 carriers have adverse 
clinical outcomes then it would provide evidence of an association between CYP3A5*6 and 
adverse clinical outcomes that are known to be associated with low/non CYP3A5 expression. 
To establish the effect of CYP3A5*6 on mRNA splicing, an in vitro splicing assay in 
which double stranded DNA known to contain the CYP3A5*6 variant could be cloned into a 
bacterial vector, transformed into bacterial culture and transfected into eukaryotic cells using 
established techniques (Webb et al. 2003). Following incubation and extraction of mRNA for 
analysis by reverse transcription, an examination and comparison of the cDNA sequence from 
the CYP3A5*6 clones alongside a control, from a homozygous non-CYP3A5*6 clone would be 
performed. If CYP3A5*6 causes exon skipping then the cDNA sequence, obtained from 
CYP3A5*6 clones, would not contain the sequence for exon 7 of CYP3A5. 
The results from either method could change the classification of CYP3A5*6, as a 
low/non-expresser variant, to a variant which can reduce protein expression or a variant 
which has no effect on protein expression and processing at all. This could alter which CYP3A5 
variants are considered to be clinically relevant. 
Another reason for the wide range of reported CYP3A5 expresser frequencies are that 
African populations have been underrepresented in previous studies on CYP3A5 variability. A 
large number of studies have estimated CYP3A5 expression levels in sub-Saharan Africa by 
extrapolating data obtained for African-American populations. The proportion of individuals 
expressing CYP3A5 protein, at high concentrations, is expected to be lower in African-
American populations comparative to sub-Saharan Africans. The rationale of expecting higher 
frequencies of CYP3A5 expressers in sub-Saharan African populations is due to Caucasian 
admixture in African-American populations (Reed 1969; Destro-Bisol et al. 1999). 
The data from this study are consistent with previous expectations that the 
frequencies of CYP3A5 expressers in Africa are higher than in other global populations. 
However, the proportion of Africans who express CYP3A5, at high concentrations, is likely to 
be much lower than the previous estimate of 95%. Additionally expression phenotypes are 
likely to be highly variable across Africa; sub-Saharan Africans have higher frequencies of 
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CYP3A5 expressers than North Africans. There are also considerable differences between East 
Africans and other sub-Saharan populations. The East African populations typed in this study 
have substantially lower levels of predicted CYP3A5 expression than in other regions of sub-
Saharan Africa, additionally there is substantial heterogeneity within Ethiopia, consistent with 
a previous study of CYP3A5 variability within the country (Gebeyehu et al. 2011). This 
demonstrates that the method of inferring African CYP3A5 expression phenotypes from 
African-American data does not account for the considerable heterogeneity observed across 
the continent. 
The data strongly suggest that language family and north latitude are stronger 
predictors of CYP3A5 expression phenotype than African ancestry or geographic region alone. 
Individuals predicted to express CYP3A5 at high concentrations are overrepresented in 
equatorial and Niger-Congo speaking populations. These findings are consistent with previous 
reports that there is a correlation between African genetic diversity and language (Wood et al. 
2005; Reed and Tishkoff 2006). Within language families, there was less diversity in CYP3A5 
allele frequencies between Niger-Congo speaking populations than for other language groups 
in Africa. The similarities between Niger-Congo speaking populations are influenced by the 
recent expansion of Bantu-speaking populations ~4000 years ago (Beleza et al. 2005). This is 
consistent with previous studies of genetic diversity in Africa; non Niger-Congo speaking 
groups have greater intra-population diversity (Wood et al. 2005) and this is also true of 
diversity at the CYP3A5 locus. 
 
3.4.2 The potential implications of CYP3A5 variability in Africans 
As outlined in section 1.1.4, sub-Saharan Africa has a high burden of diseases which 
are treated with a wide spectrum of drugs (Aspray et al. 1998; Coleman 1998). The results 
from this study show that there is variability in the expression of an important drug 
metabolising enzyme; responsible for the metabolism of a wide spectrum of clinical drugs 
(Lamba et al. 2002). CYP3A5 variability has been previously reported as having significant 
effects on treatment of many drugs (see section 1.2.4) including those used in the treatment of 
malaria, (Ferreira et al. 2008) HIV-1, (Josephson et al. 2007) cancer (Dandara et al. 2005) 
heart disease (Bochud et al. 2006) and immunosuppressants, (Quteineh et al. 2008); diseases 
which are common in populations with recent African ancestry.  
What is clear from the data reported in this chapter is that the approach of grouping 
African populations in translational medical research would overlook, potentially fatally, the 
substantial diversity within the continent; particularly between East Africans and other sub-
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Saharan Africans. Intra-African differences in the prevalence of clinically relevant alleles mean 
that standardising dosages of CYP3A5 substrates within these populations on the basis of skin 
colour would not benefit individuals in a way that methods accounting for population-specific 
variability, such as language family or geographic region of ancestry, would.  
 
3.4.3 Natural selection at the CYP3A5 locus 
One of the most striking features of the results is the large disparity in 
CYP3A5*1/CYP3A5*3 frequencies between African and non-African populations. Previous 
studies have reported that the Sahara desert acts as a major barrier to gene flow between sub-
Saharan Africans and other global populations (Cruciani et al. 2002; Salas et al. 2002). The 
substantial differences in CYP3A5 allele frequencies between North and sub-Saharan Africans 
(reported in this study) are consistent with, but not entirely explained by, the Sahara barrier. 
The results from Africa fit a correlation from a previous report (Thompson et al. 2004) 
that CYP3A5*3 frequencies are positively correlated with increased distance from the equator. 
However the correlation appears to be specific to increased north latitude. The ratio of north 
to south latitude groups in this study is ~4:1 which may have skewed the initial observation 
that latitude is correlated with CYP3A5*1/CYP3A5*3 frequencies. However when only African 
groups were considered, the ratio of north to south latitude African groups is ~1:1, there was 
a correlation between CYP3A5*1/CYP3A5*3 frequencies and north latitude. 
 One of the most interesting features of the data reported in this chapter and those 
previously published (Thompson et al. 2004) is that the distribution of CYP3A5*1/CYP3A5*3 
alleles are identical to functionally important variants of genes involved in blood pressure 
regulation (Young et al. 2005). The frequency of the non-expresser, and protective against 
elevated blood pressure, CYP3A5*3 allele is positively correlated with distance from the 
equator. The ancestral CYP3A5*1 allele has been reported to be associated with increased 
systolic blood pressure and mean arterial pressure in African-American populations (Givens 
et al. 2003). Hypertension is highly prevalent in Africa (Cooper et al. 1997; Sobngwi et al. 
2002) and populations with recent African ancestry are overrepresented in hypertension 
patient populations. Although there are environmental and dietary factors which contribute 
to the risk of developing hypertension risk, genetic factors also play a major role in disease 
pathology (Young et al. 2005).  
 CYP3A5 has been proposed to catalyse the conversion of cortisol to 6-β-
hydroxycortisol in the kidney, which leads to higher sodium reabsorption and water retention 
(Ghosh et al. 1995). This mechanism is vital for populations who experience frequent water 
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shortages; namely those closest to the equator and those who are prone to salt loss through 
excessive sweating. This potentially explains the high prevalence of CYP3A5*1 in equatorial 
populations, previously studied, and seen in this study. Conversely, as the distance from the 
equator increases, temperature and humidity decrease and there is less selective pressure to 
retain water and reabsorb sodium.  
 Comparisons of hypertension patients with recent African ancestry and other global 
populations suggest that the CYP3A5*1 allele may provide an advantage near the equator but 
is detrimental at north latitudes. In contrast, the CYP3A5*3 allele appears to be protective 
against, genetically determined, elevated blood pressure, and this is perhaps why the allele 
has risen to such high frequency in these populations.  
 What is notable however is the CYP3A5*3 allele has almost reached fixation in 
populations outside of Africa and considerably north of the equator. There may be evidence of 
selection for the low/non-functional CYP3A5*3 allele outside of Africa. Evidence for this would 
come from an examination of the haplotype backgrounds on which the non-functional variant 
occurs. Any new mutation will occur on a specific haplotype background, under neutrality we 
would expect to see the mutation associated with a subset of all haplotypes and its frequency 
would vary according to genetic drift. However if the allele becomes advantageous and is 
selected for, it will rise in frequency and all tightly linked and associated variation, on a 
particular haplotype background, will be selected for. If this is fairly recent then there will be 
an excess of rare mutations on the haplotype containing the selected mutation and the 
haplotype will have far less diversity than expected under a neutral model of mutation, a so 
called mutation-selection-balance model (Di Rienzo and Hudson 2005). The following 
chapters will examine this in greater detail by examining the full CYP3A5 gene sequence 
obtained for different global populations to examine evidence of selection in and outside of 
Africa. 
 As for the CYP3A5*6 and CYP3A5*7 variants, the geographic distribution of CYP3A5*7 
appears to be identical to a major demographic event that occurred within Africa 
approximately 4000 years ago; known as the Expansion of the Bantu Speaking Peoples 
(Tishkoff and Verrelli 2003; Beleza et al. 2005). CYP3A5*7 was observed at high frequencies 
within West, West Central and South East Africa which would be consistent with the second 
wave of the Expansion of Bantu Speaking Peoples, and this suggests an origin of CYP3A5*7 
prior to this event ~4000 years ago. It is likely that CYP3A5*7 evolved in West or West Central 
Africa and spread through Africa as a result of human migration patterns. What is interesting 
about this variant is that, whilst its distribution is restricted, it appears to have evolved in 
populations close to the equator and has a null effect on CYP3A5 expression. It is possible that 
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it may have evolved to help regulate the water retention and salt reabsorption effects of the 
CYP3A5*1 allele; which may be detrimental if unregulated, even in equatorial populations. 
 In contrast the geographic distribution of CYP3A5*6 is much more consistent across 
sub-Saharan Africa and suggests that this variant evolved before CYP3A5*7 and had increased 
time to spread across the region. This variant is observed at low frequencies in the Yemeni 
and North African sample sets, although this may be as a result of the Arab slave trade during 
the 8-19th centuries (Richards et al. 2003). It is possible that CYP3A5*6 and CYP3A5*7 evolved 
to regulate too much sodium reabsorption and water retention in equatorial populations, this 
may explain their relatively low frequencies across the continent, in contrast to the high 
frequencies of CYP3A5*3 observed outside of Africa. 
 
3.4.4 Conclusions 
 Sub-Saharan Africans have been largely underrepresented in evolutionary and 
medical studies (Campbell and Tishkoff 2008). The data from this chapter aim to correct this 
by reporting data on functionally important variants of a medically important gene, CYP3A5. 
The significant positive correlation between latitude and decreased CYP3A5 expression is 
consistent with a hypothesis of positive selection for low/non expression of CYP3A5 in 
populations who reside at large distances north of the equator. Variability in CYP3A5 
expression is likely to have important implications for the specificity of drugs and dosages 
used to treat patients with recent African ancestry, and in predicting their susceptibility to 
many diseases; such as hypertension. The following chapters aim to characterise intra-African 
CYP3A5 variability further by identifying novel, and potentially functionally important, 
CYP3A5 variants, and evaluate evidence of positive selection on the gene. 
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4. Intra-African diversity at the CYP3A5 gene 
4.1 Overview and specific aims of the chapter 
 In chapter 3, considerable intra-African differences in the frequencies of clinically 
relevant CYP3A5 alleles were identified. Principal co-ordinates (PCO) analysis found that 
differences in CYP3A5*3 allele frequencies account for over 95% of all inter-population 
variation. This chapter is a more restricted survey, than presented in chapter 3, and examines 
intra-African population structure in a 4448bp region of the CYP3A5 gene. 
 The re-sequenced region includes exons 1, 2, 3, 4, 6, 7 and 11, plus the flanking 
introns. Thirteen diverse African populations were chosen for re-sequencing (see Table 4.1 
and Figure 4.1). Details of primers, PCR and re-sequencing conditions are provided in chapter 
2. All of the sample sets were genotyped as part of the geographic survey, presented in 
chapter 3. The populations represent four major global language families and a large 
geographic region within Africa. Given time and funding constraints it was not possible to re-
sequence the entire CYP3A5 gene in all thirteen African populations. However the regions 
encompassing the CYP3A5*1/CYP3A5*3, CYP3A5*6 and CYP3A5*7 loci were re-sequenced, as 
well as part of the proximal promoter in each population. Intra-African diversity was analysed 
in a global context with re-sequencing data for the same 4006 base pair region in three, 
ethnically diverse, North American populations from the Coriell repositories (see section 
2.1.1.4.1). Ethiopian data for the entire CYP3A5 gene are analysed in detail in chapter 5; in this 
chapter part of the dataset were included to analyse intra-African diversity. 
 
4.2  CYP3A5 variation 
4.2.1  Intra-African diversity in the re-sequenced CYP3A5 region 
 20 polymorphic sites were identified within a 4448 base pair region (see Figure 4.2). 
Table 4.2 shows the full list of polymorphic sites identified in 8 non-Ethiopian African groups; 
Ethiopian re-sequencing data are presented in Table 5.6. Outside of Ethiopia all, except one 5´ 
UTR variant, occurred in the CYP3A5 coding region. 18 variants were single nucleotide 
substitutions; one was a single base insertion in exon 11 which defines the CYP3A5*7 variant 
and a novel 10 base pair deletion was observed in five heterozygous individuals. One variant 
was a singleton and only one, non-singleton, variant identified was specific to a population. 
Within an equivalent 4448 base pair region re-sequenced in five Ethiopian populations, a total 
of 26 variants were identified; 5 of which were singletons and 4 were specific to a population. 
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Table 4.1: A full list of sample sets in which CYP3A5 was re-sequenced, including details on geographic location and language family. Some have 
been named according to ethnicity (a) and others according to where, geographically (b), the samples were collected. 
 
Country Sample set Language family Sample 
size 
















Ethiopia Afar (a) Afro-Asiatic 73 11.602 41.360 1290 0.35 0.65 0.18 0.00 
 Amhara (a) Afro-Asiatic 76 9.869 38.660 1097 0.33 0.67 0.15 0.00 
 Maale (a) Afro-Asiatic 75 5.715 36.643 635.5 0.51 0.49 0.15 0.01 
 Oromo (a) Afro-Asiatic 74 7.837 37.308 871.5 0.35 0.65 0.14 0.00 
 Anuak (a) Nilo-Saharan 76 7.953 34.412 884.4 0.71 0.29 0.26 0.01 
Sudan Kordofan (b) Nilo-Saharan 30 13.08 30.35 1454 0.55 0.45 0.20 0.02 
Ghana Asante (a) Niger-Congo A 34 5.82 -2.82 686.1 0.89 0.11 0.22 0.07 
 Bulsa (a) Niger-Congo A 22 10.73 -1.29 1193 0.81 0.19 0.16 0.13 
Cameroon Shewa Arabs (a) Afro-Asiatic 65 15.05 12.11 1446 0.60 0.40 0.22 0.07 
 Somie (b) Niger-Congo A 65 6.00 12.5 667.2 0.77 0.23 0.18 0.10 
Congo Brazzaville (b) Niger-Congo B 55 -4.26 15.28 473.7 0.80 0.20 0.12 0.09 
Malawi Chewa (a) Niger- Congo B 50 -13.47 34.188 1555 0.85 0.15 0.16 0.17 
Mozambique Sena (b) Niger-Congo B 51 -17.44 35.05 1939 0.84 0.16 0.23 0.16 
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Figure 4.1: A map showing the distribution of the thirteen sub-Saharan African populations 
re-sequenced in this study. The image has been adapted from taken from 




Figure 4.2: A full list of all polymorphic sites identified across the 4448 base pair region re-sequenced in eight, non-Ethiopian, African 
populations.  
 The pink boxes represent re-sequenced CYP3A5 exons, although they are not spaced according to scale. The red box represents the proximal 
promoter region of CYP3A5. Spacer regions, represented by black lines between adjacent exons, are introns. Grey boxes represent regions that 
were not re-sequenced in these populations. 
 The exons are ordered from Exon 1-13, although they are not all numbered on the Figure.  








Table 4.2: A list of all polymorphic sites identified in a 4448 base pair region re-sequenced in 8 (non-Ethiopian) African populations. f  is the 
frequency and n is the number of chromosomes and light blue shading indicates novel mutations 




(NCBI Build 132, 
February 2009) 
CYP3A5 variant and its 
position relative to the 
translation initiation 
codon (A of ATG is +1) 
NCBI dbSNP 
database 
refSNP ID Effect f n f n f n f n f n f n f n f n 
Total re-
sequenced 
5´ UTR of exon 1 99277593 -74 C>T rs28371764  0.00 1 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 3 666 
Intron 1 99277445 74 10 base pair deletion    0.00 0 0.00 1 0.00 0 0.00 0 0.00 0 0.00 0 0.01 4 0.00 0 666 
Intron 1 99277383 136 C>T    0.00 2 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 666 
Intron 1 99277230 289 G>C    0.00 0 0.00 0 0.00 2 0.00 0 0.00 0 0.00 0 0.00 1 0.00 0 666 
Intron 2 99273701 3818 G>A    0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.00 0 668 
Intron 3 99272310 5209 C>T rs28365067  0.01 8 0.00 2 0.00 2 0.00 0 0.00 3 0.00 2 0.01 5 0.01 5 724 
Intron 3 99272290 5229 G>A rs41301652  0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.00 1 0.00 3 0.00 0 724 
Intron 3 99272009 5510 T>A rs28969392  0.00 1 0.00 0 0.00 1 0.00 2 0.00 1 0.00 1 0.00 3 0.00 2 724 
Intron 3 99271928 5591 C>T rs41301655  0.00 1 0.00 3 0.01 6 0.01 5 0.00 2 0.00 1 0.01 10 0.00 0 724 
Intron 3 99271853 5666 A>G rs41301658  0.01 10 0.02 11 0.00 3 0.01 6 0.01 9 0.02 14 0.02 13 0.00 0 724 
Intron 3 99271808 5711 A>G rs41258334  0.01 7 0.00 2 0.00 1 0.00 0 0.00 3 0.00 1 0.01 4 0.01 5 724 
Intron 3 99270539 6980 A>G rs776746 Defines CYP3A5*3 0.07 53 0.03 22 0.01 8 0.01 7 0.02 13 0.02 16 0.04 30 0.04 27 744 
Intron 3 99270318 7201 C>T rs8175345  0.02 12 0.02 12 0.00 3 0.01 7 0.01 9 0.03 21 0.02 13 0.00 1 746 
Intron 4 99270165 7354 C>T    0.00 0 0.00 0 0.00 0 0.00 0 0.01 4 0.00 0 0.00 0 0.00 2 746 
Intron 5 99264391 13128 C>G    0.00 0 0.00 2 0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.00 0 700 
Intron 6 99264149 13370 G>A rs41301670  0.00 3 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 700 
Exon 7 99262835 14684 G>A rs10264272 Defines CYP3A5*6 0.04 30 0.02 13 0.02 15 0.01 9 0.02 15 0.03 20 0.03 23 0.02 12 742 
Exon 7 99262793 14726 A>G rs28383472 Synonymous 0.00 0 0.00 2 0.01 5 0.01 4 0.00 2 0.00 0 0.01 8 0.00 0 742 
Intron 7 99262689 14830 C>T    0.00 0 0.00 0 0.00 1 0.00 0 0.00 2 0.00 0 0.00 0 0.00 0 742 
Exon 11 99250394 27125 1bp insertion rs41303343 Defines CYP3A5*7 0.01 8 0.01 10 0.01 5 0.00 1 0.03 22 0.02 15 0.02 13 0.00 1 742 
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 A cross-species alignment of the re-sequenced CYP3A5 region with other primates, 
found that 16/20 polymorphic sites were in highly conserved nucleotide positions in 
primates. Highly conserved nucleotide positions are polymorphic sites where the ancestral 
allele, as inferred from the chimpanzee sequence, is identical in all primate species 
(Thompson et al. 2004; Thompson et al. 2006).  
 3 exonic polymorphisms were identified in the non-Ethiopian African cohort, 
compared to 7 in Ethiopians. Of all identified exonic variants, 2 are non-synonymous and only 
observed in Ethiopians. 40% of all identified polymorphic sites are within intron 3, including 
the CYP3A5*3 defining polymorphism. A novel 10 base pair deletion was identified in intron 1 
in five heterozygous individuals from West Central Africa. The deletion was not predicted to 
affect pre-mRNA splicing by BDGP (http://www.fruitfly.org/seq_tools/splice.html). However 
given the close proximity of this deletion to the intron 1 splice site, experimental evidence will 
provide an indication of how this deletion may affect CYP3A5 transcription. 
 The proportion of singleton variants identified in the eight non-Ethiopian African 
populations was 0.05% (see Figure 4.3). There were more high and intermediate frequency 
variants than rare observed from the data. 
 
4.2.2 CYP3A5 diversity in sixteen populations 
 A total of 39 variants were identified within a 4006bp region of CYP3A5 in all sixteen 
populations (Figure 4.4). 10 (~25.6%) were exonic polymorphisms; 2 non-synonymous, 1 
insertion (CYP3A5*7), 3 synonymous (one of which defines the CYP3A5*6 mutation) and 4 in 
the 5´ UTR of exon 1. All identified non-synonymous polymorphisms, except one in exon 4 
identified in a single heterozygous Ethiopian (see Table 5.10), were predicted to have a 
benign effect on protein function (examined using PolyPhen2). The proportion of exonic 
polymorphisms observed is higher than neutral expectations for protein coding genes; 
although the observed number of amino acid changes relative to the number of codons 
(~0.008%) is lower than reported for protein coding genes (0.56%) (Kitano et al. 2004). No 
identified exonic polymorphism was predicted to affect mRNA splicing; and no polymorphism 




Figure 4.3: The number of times a particular variant is observed within the non-Ethiopian 
sub-Saharan African cohort (n=746 chromosomes). The frequency refers to the number of 
chromosomes on which a particular variant was identified. A “singleton” is a variant that was observed 
in a single heterozygous individual. The y-axis shows the proportion of the total amount of identified 
variation that is attributed to variants of particular frequencies; i.e. singletons account for ~0.05% of all 

















































Number of chromosomes on which a variant is observed in the cohort (n=746 chromosomes)
 
 
 Consistent with previous studies of global diversity, populations with recent African 
ancestry have more diversity (even for a small 4006bp CYP3A5 region) than observed in 
Europeans and Han Chinese (see Figure 4.4). Han Chinese individuals had the lowest number 
of polymorphic sites. Non-synonymous polymorphisms were only identified in European 
individuals and in the Anuak. Only populations with recent African ancestry had the CYP3A5*7 
defining T allele insertion in exon 11. Populations with recent African ancestry are also more 
varied in the types of variation observed; no insertion or deletion was identified in Europeans 
or Han Chinese which is consistent with comparisons of other genomic regions (Campbell and 
Tishkoff 2010). Populations with recent African ancestry appear to be homogeneous in the 
type of variation that is observed. No one population had a higher number of insertions or 
deletions in the gene region than the others. 
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Figure 4.4: A graph summarising the identified variation in a 4000bp region of CYP3A5, re-sequenced in sixteen populations. The key summarises the types of 
variation identified and the graph shows the total numbers of each type of polymorphic site identified from the re-sequenced region in each population. The 










































Summary of variation identified in a 4006bp CYP3A5 region re-sequenced in sixteen 
populations









4.2.3 Population structure at the CYP3A5 gene 
 Allelic data were used to calculate pairwise FST so that singleton variants could be 
accounted for when assessing inter-population differences. Pairwise FST values were used to 
perform PCO analysis. The results of intra-African analyses (Figure 4.5) are consistent with 
those reported in chapter 3; the Afar, Amhara and Oromo are distinct from other sub-Saharan 
African populations. However a comparison of all sixteen groups (Figure 4.6) found that 
African groups cluster together and Europeans and Asians are the outlying populations.  
 A notable feature of the PCO analyses is that the majority (over 96%) of population 
differentiation at the CYP3A5 gene is explained by the first principal component. As reported 
in chapter 3, inter-population differences in the frequency of the CYP3A5*3 allele shape 
population structure at the gene; even when variation over a larger gene region is considered. 
Few variants were identified in Europeans and Han Chinese other than CYP3A5*3 which is the 
main factor which differentiates these populations from Africans at CYP3A5. An interesting 
observation is that CYP3A5*3 frequencies also shape population structure in Africa, followed 
by CYP3A5*6, CYP3A5*7 and all additional variation identified in these populations. It is 
possible that within a larger genomic region there may be additional variation which will 
further differentiate African populations. However the data from this chapter suggest that 




Figure 4.5: A principal co-ordinates (PCO) plot showing the differences between thirteen African 
groups, based on re-sequencing data for a 4006bp region of CYP3A5. Values along either axis represent 
the total amount of variation captured by each principal-coordinate. The PCO plot was constructed 
using pairwise FST comparisons. 
 
 
Sample set codes: EAF; Afar, EAM; Amhara, EAN; Anuak, EML; Maale, EOR; Oromo, SHW; Shewa Arabs, 
CON; Congolese, GPN-ASH; Ghanaian Asante, GPN-BUL; Ghanaian Bulsa, CHW; Malawian Chewa, SENA; 
Mozambicans from Sena, SOM; Cameroonians from Somie, KOR; Sudanese individuals from Kordofan. 
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Figure 4.6: A principal co-ordinates (PCO) plot showing the differences between sixteen global 
populations, based on re-sequencing data for a 4006bp region of CYP3A5. Values along either axis 
represent the total amount of variation captured by each principal-coordinate. The PCO plot was 
constructed using pairwise FST comparisons. 
 
 
Sample set codes: EAF; Afar, EAM; Amhara, EAN; Anuak, EML; Maale, EOR; Oromo, SHW; Shewa Arabs, 
CON; Congolese, GPN-ASH; Ghanaian Asante, GPN-BUL; Ghanaian Bulsa, CHW; Malawian Chewa, SENA; 
Mozambicans from Sena, SOM; Cameroonians from Somie, KOR; Sudanese individuals from Kordofan, 
AA; African-Americans, AS; Han Chinese, CA; individuals of recent European ancestry. 
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4.2.3 Molecular diversity at the CYP3A5 locus 
 Analyses of molecular diversity were performed using DnaSP software (version 5.0) 
and are presented in Table 4.3. Nucleotide diversity estimates are low for each of the sixteen 
groups, compared to the estimate that approximately 1 in every 1000 nucleotides in the 
human genome are polymorphic (Sachidanandam et al. 2001; Jobling et al. 2004; Rotimi and 
Jorde 2010) although this may reflect the small size of the CYP3A5 region analysed. The Afar, 
Amhara and Oromo have marginally lower estimates of nucleotide diversity compared to 
other African populations. Tajima’s D values indicate that there is a skew towards rare 
variants in East Africa and in four other sub-Saharan African groups; although significant 
departures from neutrality were not observed in the Afar following Bonferonni correction for 
multiple tests (0.004<p<0.05). A skew towards rare variants in East Africa may indicate 
evidence of differential selective pressures across the African continent. Although it is 
important to note that the results reported here are for a smaller region than that analysed in 
chapter 6. Comparative analyses of the entire CYP3A5 gene region between the thirteen 
groups will identify whether there is evidence of differential selective pressures across the 
African continent.  
 A skew towards rare variants was observed in all three Coriell populations. Significant 
departures from neutrality were not observed in Han Chinese individuals; however this may 
be due to the paucity of CYP3A5 variation observed within this population. The Afar and 
Oromo have a greater skew towards rare variants than Han Chinese and African-Americans; 
although this reflects the paucity of variation observed in the latter two groups. A significant 
departure from neutrality was observed in both Europeans and African-Americans, however 




Table 4.3: Molecular diversity estimates for sixteen global sample sets. Statistically significant departures from neutrality, following Bonferonni correction are 
highlighted in green (correction for 16 tests; adjusted significance level is p≤0.003). 
 AA AS CA EAF EAM EAN EML EOR SHW CON GPN-
ASH 




9 2 5 12 12 17 14 17 12 11 12 8 14 11 14 9 
Number of 
singletons 
2 1 1 1 0 1 2 1 0 0 0 0 0 0 1 0 
Nucleotide 
diversity ( ) 
4.3 x 10
-4
 1.0 x 10
-4
 1.6 x 10
-4
 3.0 x 10
-4
 3.2 x 10
-4




 2.2 x 10
-4
 5.2 x 10
-4
 4.3 x 10
-4
 3.9 x 10
-4
 4.3 x 10
-4
 7.1 x 10
-4
 4.7 x 10
-4
 4.9 x 10
-4
 4.8 x 10
-4
 
Tajima’s D -0.918 -0.932 -1.603 -1.15 -0.967 -1.33 -0.764 -1.91 1.44 -0.701 -0.584 -0.0398 -0.680 1.04 0.552 0.168 
Fu and Li’s 
D* 
-0.812 -1.680 -1.846 -0.301 0.106 -1.59 0.778 -0.177 0.805 1.25 0.05 1.25 1.12 0.825 0.919 -0.144 
Fu and Li’s 
F* 
-0.997 -1.69 -2.075 -0.716 -0.342 -1.79 0.255 -0.992 1.18 0.69 -0.177 0.99 0.616 1.05 0.943 -0.055 
Fu’s FS -12.03 -0.218 5.18 -2.37 -7.99 -11.6 -7.85 -14.3 -0.108 -2.54 -1.50 -1.44 -1.94 0.235 0.535 -1.089 
 
Sample set codes: AA; African-Americans, AS; Han Chinese, CA; individuals of recent European ancestry, EAF; Afar, EAM; Amhara, EAN; Anuak, EML; Maale, 
EOR; Oromo, SHW; Shewa Arabs, CON; Congolese, GPN-ASH; Ghanaian Asante, GPN-BUL; Ghanaian Bulsa, CHW; Malawian Chewa, SENA; Mozambicans from 
Sena, SOM; Cameroonians from Somie, KOR; Sudanese individuals from Kordofan. 
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4.3 Statistical association of identified variation 
4.3.1 Haplotype inference 
 A total of 35 haplotypes were inferred for a 4006bp region from data for sixteen 
populations; 29 were observed in Africa. ~42.9% of all haplotypes were CYP3A5*1, ~34.3% 
were defined by the CYP3A5*3 mutation alone, ~14.3% by CYP3A5*6, ~5.7% by CYP3A5*7 and 
a single recombinant CYP3A5*3/CYP3A5*6 haplotype was observed in 9 heterozygous 
individuals; see Figures 4.7a-b. CYP3A5*1 was the most diverse haplogroup; followed by 
CYP3A5*3; CYP3A5*6; CYP3A5*7 and CYP3A5*3/*6 (Figure 4.7c).  
 Within Africa, CYP3A5*3 haplotype frequencies for Shewa Arabs and Sudanese 
individuals from Kordofan were comparable to the Ethiopian Maale. ~40% of inferred 
haplotypes for Shewa Arabs and ~43% of those for Sudanese individuals from Kordofan were 
defined by the CYP3A5*3 variant. CYP3A5*7 was observed at high frequencies in non 
Ethiopian sub-Saharan Africans; the highest frequencies of the haplotype were observed in 
the Chewa from Malawi (frequency ~22%).  
 Within Africa, variation in haplotype frequencies and distribution is highest in 
populations outside of Ethiopia, see Figure 4.7b. Consistent with Y chromosome and 
mitochondrial DNA (de Filippo et al.), Niger-Congo speakers are homogeneous in their 
CYP3A5 haplotype frequencies (Figures 4.7b). This is consistent with the observed correlation 
between major language family and CYP3A5 structure reported in chapter 3. Population 
similarities between Niger-Congo speaking groups, who are spread over large geographic 
distances, are due to recent demographic events. Haplotype patterns in the Nilo-Saharan 
speaking Sudanese and Afro-Asiatic speaking Shewa Arabs differ from Niger-Congo groups. 
Shewa Arabs and Kordofanian Sudanese also have the highest frequencies of CYP3A5*3 
haplotypes and appear to have more variation within this haplotype class than Niger-Congo 
speakers. 
 The majority of haplotypes observed in Han Chinese and European populations were 
defined by CYP3A5*3. Of the three Coriell groups, haplotype diversity was greatest in African-




Figure 4.7a: The 35 global haplotypes inferred from re-sequencing data for a 4006 base pair region of CYP3A5. Each position is an identified polymorphic site. 
Positions are numbered from the ATG start codon where base A is +1; and correspond to details provided in chapter 4. Yellow indicates the ancestral allele at 
each position (as inferred from chimpanzee sequence) and blue the derived (polymorphism). “N” refers to the total number of chromosomes of a particular 




Figure 4.7b: The frequencies of each inferred haplotype (as shown in Figure 4.5a) in each global population. Haplotype codes correspond to those listed in 













Afar Amhara Anuak Maale Oromo Shewa 
Arabs



















1 (*1) 2 (*1) 3 (*1) 4 (*1) 5 (*1) 6 (*1) 7 (*1) 8 (*1) 9 (*1) 10 (*1) 11 (*1) 12 (*1)
13 (*1) 14 (*1) 15 (*1) 16 (*3) 17 (*3) 18 (*3) 19 (*3) 20 (*3) 21 (*3) 22 (*3) 23 (*3) 24 (*3)
25 (*3) 26 (*3) 27 (*3) 28 (*6) 29 (*6) 30 (*6) 31 (*6) 32 (*6) 33 (*3/*6) 34 (*7) 35 (*7)
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CYP3A5*1 haplotype diversity in 16 global populations













CYP3A5*3 haplotype diversity in 16 global populations













CYP3A5*6 haplotype diversity in 16 global populations













CYP3A5*7 haplotype diversity in 16 global populations
34 (*7) 35 (*7)
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4.3.2 Assessing the diversity of inferred haplotypes 
 Nei’s gene diversity (h) was calculated to assess haplotype diversity; between 
populations and CYP3A5 haplotype classes. The significance of inter-population differences in 
gene diversity was assessed using an exact test of population differentiation (presented in 
Table 4.4). 
 Within Africa gene diversity was highest in groups outside of Ethiopia and North 
Africa (Kordofanians from Sudan), see Figure 4.8. This is expected given their comparatively 
higher frequencies of CYP3A5*3 haplotypes than observed in other African populations. 
CYP3A5*3 haplotypes have less diversity than those defined by the ancestral CYP3A5*1 allele 
(Figure 4.7). Although from Figure 4.9, it is also apparent that CYP3A5*3 haplotype diversity is 
highest in populations with high frequencies of the allele, and in African-Americans and 
Sudanese Kordofanians CYP3A5*3 haplotype diversity is almost equal to that seen in the 
CYP3A5*1 haplogroup. Within the sub-Saharan African cohort, the Afar, Amhara, Oromo and 
Somie have the highest frequencies of the CYP3A5*3 allele and subsequent higher levels of 
diversity in the CYP3A5*3 haplogroup. 
   
Figure 4.8: Nei’s h estimate of gene diversity, for a 4006bp CYP3A5 region, in sixteen populations. 
Error bars denote standard deviation, calculated as outlined in chapter 2, and bars are coloured 































Table 4.4: An exact test of population differentiation to measure the significance of differences in gene diversity estimates (measured by Nei’s h) in sixteen 
populations. Statistically significant differences following Bonferonni correction (for 16 tests; adjusted p-value = 0.003125) are shown in bold and highlighted 
in green. Population codes are as provided for Figures 4.3-4.4. 
 
 EAF EAM EAN EML EOR SHW CON ASH BUL CHW SENA SOM KOR AA AS CA 
EAF *                
EAM 0.42537 *               
EAN <0.0001 <0.0001 *              
EML 0.00004 0.00336 0.0001 *             
EOR 0.4755 0.65113 <0.0001 0.01571 *            
SHW <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 *           
CON <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.00055 *          
ASH <0.0001 <0.0001 0.00007 <0.0001 <0.0001 <0.0001 0.05376 *         
BUL <0.0001 <0.0001 0.00618 <0.0001 <0.0001 0.00553 0.15141 0.32365 *        
CHW <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.06596 0.04871 0.03493 *       
SENA <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.00006 0.00574 0.00001 0.02583 0.05286 *      
SOM <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.0001 0.11521 0.08024 0.60052 0.03531 0.01705 *     
KOR 0.00558 0.04739 0.02513 0.00942 0.04052 0.21083 0.00022 0.0007 0.00252 <0.0001 <0.0001 0.00021 *    
AA <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.00013 0.00097 <0.0001 <0.0001 <0.0001 0.0057 *   
AS 0.00455 0.03955 <0.0001 0.00071 0.29675 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 *  
CA <0.0001 0.00024 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.00229 * 
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Figure 4.9: Nei’s h estimates for each of five CYP3A5 haplotype classes (CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7 and CYP3A5*3/*6) in each re-sequenced 
































4.4 Testing for correlations between CYP3A5 diversity, environmental 
 and demographic factors 
 Examining population differences using FST and pairwise exact tests of population 
differentiation alone cannot differentiate between variables which influence genetic diversity 
and similarity; for example populations which are geographically close together tend to be 
much more similar than those located further away. However, sometimes populations located 
closely to each other are found to differ; perhaps due to specific environmental boundaries 
which may prevent gene flow (such as the Sahara desert between North and sub-Saharan 
Africa) (Jobling et al. 2004). In these cases the true geographic distance between populations 
is larger than first thought. These differences can be modelled using spatial autocorrelation 
analyses; however the samples used in this thesis were largely collected from multiple ethnic 
groups in one location within the specified country meaning that detailed spatial 
autocorrelation analyses cannot be performed. However in the absence of data on specific 
environmental factors, a Mantel test is often useful (Mantel 1967). Often information on 
pairwise comparisons of different aspects of the data is available as matrices; a Mantel test 
examines whether there are correlations between two or more matrices for a given 
population. Such comparisons may highlight specific differences which help to explain the 
observed genetic differences. There is a problem with Mantel tests in that each pairwise 
correlation between matrices is not strictly independent. However, Mantel tests have been 
critical in improving understanding of the origins of different populations, such as in Europe 
(Jobling et al. 2004).  
 Although the re-sequencing data examined in this chapter are for a small region of 
CYP3A5, comparisons of matrices may highlight specific environmental variables which are 
shaping the differences between the populations. The objectives of the analyses presented in 
this section are to examine whether there are correlations between geographic proximity and 
genetic similarity; and to examine whether there is a correlation between CYP3A5*3 
haplotype diversity and latitude. Of the sixteen populations geographic co-ordinates were 
available for all thirteen African populations; the Coriell datasets were excluded from these 
analyses.  
A Mantel test to compare pairwise genetic differences (measured by FST) and 
geographic proximity (in kilometres) was performed in the R-programming environment. The 
results were significant (p=0.0064); meaning that there is a correlation between geographic 
proximity and genetic similarity at the CYP3A5 locus in Africa. 
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As a strong positive correlation between CYP3A5*1/*3 allele frequencies and latitude 
was identified in chapter 3, a test for the correlation (if any) between CYP3A5*1 and CYP3A5*3 
haplotype diversity and latitude was performed by Spearmann’s Rank Correlation analyses. 
No significant correlation between gene diversity in the CYP3A5*1 haplogroup (Rho = 0.5536, 
p=0.1813) or CYP3A5*3 haplogroup (Rho = -0.1142, p=0.7102) and latitude was observed. It is 




 The results presented in this chapter are an extension of those presented in chapter 3. 
Population structure at the CYP3A5 gene is almost entirely influenced by frequencies of the 
CYP3A5*3 mutation. This is perhaps surprising given that Africans have high levels of genetic 
diversity; although additional variants do affect intra-African population structure at the gene. 
CYP3A5 haplotypes defined by the low/non-expresser CYP3A5 alleles are comparatively less 
diverse than for those defined by CYP3A5*1. This is expected as CYP3A5*1 is the ancestral 
allele. A significant reduction in diversity levels on low/non-expresser haplogroups, from 
neutral expectations, may be consistent with the alleles being recent mutations; rapid 
population expansion; or positive selection for low/non-expression. Significant departures 
from neutrality can be assessed by comparing larger genomic regions, which include the 
CYP3A5 gene, in multiple populations. 
 
4.5.1 Intra-African diversity at the CYP3A5 locus 
  Consistent with the results from the geographic survey (chapter 3) there is 
considerable heterogeneity within East Africa. Overall diversity in the gene region was low for 
all populations and the intra-African structuring seen from PCO analysis is similar to that in 
Figure 3.3. The Afar, Amhara and Oromo (all Afro-Asiatic speaking) populations differ from 
other sub-Saharan African groups. Kordofanian Sudanese (North Africans) also differ 
significantly from other sub-Saharan Africans; consistent with the Sahara desert acting as a 
major barrier to gene flow across the continent (Cruciani et al. 2002). Interestingly, no East 
African population differed from Kordofanian Sudanese. It is possible that the short 
geographic distance between these populations facilitates gene flow readily. It is also possible 
that North African admixture with East Africans, coupled with gene flow from the Arabian 
Peninsula, has influenced the patterns of CYP3A5 diversity that are observed in the region 
(Richards et al. 2003).  
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  The finding that population differentiation, as a result of CYP3A5 variation, is largely 
explained by differences in CYP3A5*3 allele frequencies is consistent with a hypothesis of 
selection on the allele in populations outside of Africa. There are two feasible explanations for 
high frequencies of CYP3A5*3, coupled with a paucity of variation on CYP3A5*3 haplotypes and 
a skew towards rare variants in three of the five Ethiopian populations. The first is that 
Ethiopian heterogeneity is a result of differential selective pressures on the gene across the 
continent. This would mean that there may be specific environmental pressures which 
influence the high levels of diversity; even between East African populations. An alternative 
explanation is that East African heterogeneity, and the clustering of the Afar, Amhara and 
Oromo (from PCO analysis) between a larger African cohort and non-African populations is 
due to admixture with North Africans and populations from the Arabian Peninsula. There is a 
known genetic contribution of Arabian populations to populations in the North and North East 
of Ethiopia (Cruciani et al. 2002; Lovell et al. 2005). A comparison with sequences from the 
Arabian Peninsula will aid in elucidating the proportion of genetic differentiation in East Africa 
that is attributable to admixture. 
  A limitation of the CYP3A5 data presented in this chapter is that the full gene has not 
been re-sequenced in all 13 African populations. Identifying and analysing variation across the 
entire gene in these groups may identify more variants which are likely to affect protein 
function and/or expression. Analyses of the frequencies of identified African CYP3A5 variants 
will provide evidence of whether intra-African diversity is a result of differences in 
demographic history or selective constraints. A comprehensive understanding of African 
CYP3A5 diversity will be essential for determining suitable drug concentrations within the 
region and in predicting disease risks; such as hypertension and hyponatremia. 
 
4.5.2 Inter-population CYP3A5 diversity 
  A comparison of African CYP3A5 re-sequencing data with Coriell populations found 
that CYP3A5 diversity was higher in populations with recent African ancestry than European 
and Han Chinese individuals. Many previous studies on CYP3A5 variation have extrapolated 
data obtained for African-American populations to predict the patterns of variation and 
frequencies of CYP3A5 expressers within Africa. However given the extensive amount of 
variation observed across the African continent, and reported for CYP3A5 in this thesis, this 
method of extrapolating data for African-Americans is unlikely to account for East African 
heterogeneity, such as differences between North and sub-Saharan Africans; or between East 
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Africans and other sub-Saharan African groups. In order to characterise intra-African CYP3A5 
diversity multiple populations from within the continent must be considered. 
  Using data from the sixteen populations core haplogroups were identified; those 
defined by one of the CYP3A5*3, CYP3A5*6 and CYP3A5*7 alleles, those defined by the 
ancestral CYP3A5*1 and a single recombinant haplotype CYP3A5*3/*6. It is possible that there 
are additional variants which define core CYP3A5 African haplotypes, outside of the re-
sequenced region. Within each haplogroup the modal haplotypes are defined by a paucity of 
variation. CYP3A5*3 haplogroup diversity was greatest in Europeans and Han Chinese; 
populations in which it is believed that a selective sweep of CYP3A5*3 has occurred 
(Thompson et al. 2004). Although the frequencies of additional low/non-expresser haplotypes 
is rare; suggesting that differentiation of the CYP3A5*3 haplogroup is rare even in populations 
where the CYP3A5*3 allele is observed at high frequencies. 
  One method of establishing whether there is strong evidence of differential selection 
in Africa is to model expectations for multiple polymorphic sites and compare the expected 
diversity, under a hypothesis of neutrality, with the observed data. Such a method is similar to 
simulating datasets under specific conditions (see chapter 7) but simpler as it is less 
computer-intensive. Additionally such a method does not generate an additional dataset but 
provide an approximate distribution of allele frequencies within a population. One way of 
doing this is through the Bayenv program (Coop et al. 2010) which uses Bayesian methods to 
simulate an expected distribution of allele frequencies, given the data, and then compares the 
data with those observed to determine the significance of differences between observed and 
expected data differences. This could be used for comparative analyses of a larger region of the 
CYP3A5 gene in African and other global populations to identify populations which may have 
undergone a selective sweep and/or differential selective pressures within a global cohort.  
 
4.5.3 Intra-African diversity at the CYP3A5 locus is likely to have implications for healthcare 
 of populations within and from the region 
  One of the most significant findings of this, and the previous, chapter is that Ethiopians 
differ from other sub-Saharan African populations in the amount of clinically relevant CYP3A5 
variation. An appreciation of how demography, evolutionary history and anthropology shape 
genetic diversity in medically important genes can help to identify subsets of individuals from 
a large geographic region who are distinct from a wider patient population. The separation of 
some East African populations from a wider African cohort will almost certainly have 
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important medical implications across the continent and challenge the practise of treating 
“Africans” as a large homogeneous group in medicine. 
  Within the 4448bp region, in Africans there is a paucity of intermediate or high 
frequency variants likely to affect CYP3A5 function, other than CYP3A5*3, CYP3A5*6 and 
CYP3A5*7. This finding complements those from the previous chapter; genotyping of common, 
clinically important variants, as opposed to re-sequencing of large regions of medically 
important genes, may be a cost-effective way to identify patients who require idiosyncratic 
health interventions. However, a novel rare ten base pair deletion immediately adjacent to the 
3´ splice site, was identified in five heterozygous individuals and may affect mRNA splicing and 
consequently protein expression. This deletion occurs on a CYP3A5*1 haplotype background. 
Therefore conclusions about an individual’s protein expression status based on CYP3A5*1 
genotype may overlook rare, clinically relevant variation. The ten base pair deletion may be an 
as yet uncharacterised clinically important African CYP3A5 mutation and suggests that an 
appreciation of the effects of rare mutations in the gene may be necessary in individuals with 
recent African ancestry to help prevent adverse clinical outcomes. Experimental techniques 
will help to establish the effect of such a large deletion in the gene sequence on protein 
expression (discussed in section 5.4.2). The 4448bp region analysed in this chapter is also 
approximately half of the gene, and it is likely that additional high-, intermediate- and low-
frequency CYP3A5 variants which are likely to affect CYP3A5 expression and inter-population 
differences in clinical outcomes were overlooked. The following chapter will examine CYP3A5 
variation in more detail. Bioinformatics analyses of CYP3A5 variation identified in a 4448bp 
region (reported in this chapter) and in the entire gene (re-sequenced in Ethiopian 
populations) will identify which, if any, variants are predicted to impact CYP3A5 expression by 
impacting the gene at the level of transcription or translation. 
  The World Health Organisation (WHO) has data on hypertension incidence and 
prevalence for multiple populations; including Africans. However, the data have not been 
standardised by age and geographic co-ordinate information is not available for each 
individual population (personal correspondence with Dr Richard Cooper3 and Dr Charles 
Rotimi4). This makes the data difficult to interpret and compare accurately. There are groups, 
such as those run by Dr Cooper and Dr Charles Rotimi, who look at incidence of hypertension 
                                                             
3
 Dr Richard Cooper is a physician epidemiologist with an interest in cardiovascular disease based in the 
Department of Preventative Medicine and Epidemiology at Loyola University Medical Centre in Chicago. 
 
4
 Dr Charles Rotimi is the director for the Centre for Research on Genomics and Global Health at the National 




within the African Diaspora however the data are still being collated and it was not possible to 
incorporate them into the analyses presented in this chapter. Data on differential prevalence 
of hypertension in individuals with recent African ancestry who reside at high latitudes, 
including diverse Ethiopian groups, may identify intra-African differences in the susceptibility 
to and incidence of hypertension. 
  Conversely if CYP3A5*3 confers a disadvantage in populations closest to the equator 
(as previously reported (Thompson et al. 2004)) then high frequencies of CYP3A5*3 and other, 
novel low/non-expresser variants observed in the Afar, Amhara and Oromo from Ethiopia (see 
chapter 6) would be expected to have a detrimental effect; given their geographic proximity to 
the equator, and mean that they have a higher predisposition to conditions such as 
hyponatremia (not enough sodium retention). Hyponatremia has, to date, not been considered 
as a consequence of CYP3A5 variability because Ethiopian populations have been largely 
underrepresented in large genotyping and CYP3A5 re-sequencing surveys. However, the data 
from this chapter, and subsequent chapters, suggests that there may be a gradient within the 
country regarding disease susceptibility.  
  Aside from hypertension and hyponatremia risk, there are additional implications for 
healthcare within the region as a result of CYP3A5 variability. CYP3A5 metabolises many 
therapeutic drugs used to treat a wide spectrum of diseases endemic in Africa (Fellay et al. 
2005; Diczfalusy et al. 2008). The African cohort analysed in this chapter are at risk of multiple 
communicable and non-communicable diseases (Mabayoje 1956; Aspray et al. 1998; Coleman 
1998; Walker et al. 1998; Wurthwein et al. 2001). Given the paucity of funding for many 
diseases, particularly communicable, within the region there has been a shift in focus towards 
mass drug administration regimens to manage infections within the continent (Hotez 2009; 
Smits 2009). However the current emphasis on mass drug administration overlooks 
population-specific differences in drug treatment responses and may bias against, and so be 
detrimental to, specific populations within/from Africa. What is unknown at present is 
whether there are incidences of adverse clinical outcomes associated with mass drug 
administration campaigns which occur in patients as a result of CYP3A5 variability (or that of 
any other drug metabolising enzymes). Critically, the distribution of drugs as part of large 
campaigns at European specific doses overlooks intra-African diversity in medically important 




5. Assessing the functional significance of CYP3A5 variation 
 in Africa 
5.1 Chapter overview and aims  
Significant intra-African diversity in the frequencies of functionally important CYP3A5 
alleles is likely to influence population differences in the susceptibility to adverse clinical 
outcomes attributed to variability in CYP3A5 expression (discussed in section 1.2.4). In 
chapters 3 and 4 it was reported that the low/non-expresser CYP3A5*3, CYP3A5*6 and 
CYP3A5*7 alleles occur largely on independent haplotype backgrounds; suggesting that traits 
causing low/non-expression of CYP3A5 have evolved more than once. It is possible that there 
are additional variants, which occur on the same or different haplotype backgrounds as 
CYP3A5*3, CYP3A5*6 or CYP3A5*7, and contribute to polymorphic enzyme expression in 
global populations. Additional CYP3A5 variation may also be responsible for adverse clinical 
outcomes in patients with recent African ancestry despite having a CYP3A5*1 genotype.  
 This chapter aims to use bioinformatics tools to analyse all variation identified in a 
12,237 base pair region of CYP3A5 in five Ethiopian populations and a 4448 base pair region 
re-sequenced in eight additional sub-Saharan African populations. Tables 2.2 and 4.1 have 
information on populations analysed in this chapter. All PCR and re-sequencing conditions are 
as outlined in section 2.2. Within the re-sequenced regions, all identified promoter, exonic, 
splice site and 3´ UTR variants were analysed for potential effects on CYP3A5 transcription 
and protein expression, using bioinformatics software (see section 2.3.9). For all analyses, the 
ancestral allele at a given nucleotide position was inferred from the NCBI chimpanzee CYP3A5 
reference sequence. 
 
5.1.1 Previously reported variation at the CYP3A5 locus  
 To date a total of 258 variants have been identified within CYP3A5 (from the 5´ UTR of 
exon one to the 3´ UTR) and 114 of these occur at a global frequency of ≥1% 
(http://www.ncbi.nlm.nih.gov/). A further 9 variants have been identified within 2500 base 
pairs upstream of the ATG start codon: 4 occur in the proximal promoter; none of which occur 
in experimentally established transcription factor binding sites and so are unlikely to affect 
the initiation of CYP3A5 transcription (Nakamura et al. 2001; Xie et al. 2004). 15 variants have 
been identified within a 2385 base pair region immediately downstream of the 3´ UTR of 
CYP3A5. Of the common variants (i.e. with a global frequency of ≥1%), the majority occur in 
non-coding regions. Figure 5.1 shows the distribution of all identified variants across the 
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CYP3A5 gene region; Table 5.1 provides details about the type of polymorphisms identified in 
the CYP3A5 gene and information about the size of each genic region, as listed on the NCBI 
database (http://www.ncbi.nlm.nih.gov/). Figure 5.2 shows the outline of the CYP3A5 gene 
with proportions of common variation (≥1% global frequency) annotated. 
 
Figure 5.1: The distribution of all identified variants across the CYP3A5 gene region. Data 


































The distribution of all identified CYP3A5 variation across the gene
 
  
 A comparison of the coding regions (ATG start codon to the 3´ UTR) of the four CYP3A 
genes: CYP3A4, CYP3A5, CYP3A7 and CYP3A43, found that CYP3A4 has the highest number of 
identified variants (284) compared to its paralogues CYP3A5 (218), CYP3A7 (181) and 
CYP3A43 (273). Although only 28% of all identified CYP3A4 variants are observed at a global 
frequency of ≥1%; in contrast to 43% for CYP3A5, 65% for CYP3A7 and 82% for CYP3A43 
(http://www.ncbi.nlm.nih.gov/). Chi-squared tests, with Yates’ correction, found that CYP3A4 
has significantly more polymorphic sites, relative to fixed sites, than the remaining CYP3A 
genes (Table 5.2). Fisher’s exact tests were performed to examine whether there are 
significant inter-CYP3A differences in the ratios of common variation (occurs at a global 
frequency of ≥1%) to rare variants (presented in Table 5.3). CYP3A4 and CYP3A5 both have 
significantly fewer common variants relative to CYP3A7 and CYP3A43. 
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Table 5.1: A summary of global variation at the CYP3A5 locus, plus 2500 base pairs either side, as reported by NCBI (http://www.ncbi.nlm.nih.gov/) 
CYP3A5 region Size of region 
(base pairs) 













5´ upstream 1700 11 8 3 0 - - - - - 
Proximal promoter 800 11 11 0 0 0 - - - - 
3´ untranslated 
region 114 3 3 0 0 0 0 - - 0 
3´ downstream 2386 15 12 2 1 - - - - - 
Exon 1 71 0 - - - - - - - - 
Exon 2 94 5 4 1 0 - - 4 0 1 
Exon 3 53 0 - - - - - - - - 
Exon 4 100 2 2 0 0 - - 2 0 0 
Exon 5 114 0 - - - - - - - - 
Exon 6 89 0 - - - - - - - - 
Exon 7 149 3 3 0 0 - - 2* 1 0 
Exon 8 128 0 - - - - - - - - 
Exon 9 67 2 2 0 0 - - 1 1 0 
Exon 10 161 1 1 0 0 - - 0 1 0 
Exon 11 227 4 2 2 0 - - 0 2 2** 
Exon 12 160 2 2 0 0 - - 0 2 0 
Exon 13 96 2 2 0 0 - - 0 2 0 
Intron 1 3617 32 26 6 0 - 0 - - - 
Intron 2 1529 11 10 1 0 - 0 - - - 
Intron 3 1853 15 14*** 1 0 - 0 - - - 
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Intron 4 5514 39 31 7 1 - 0 - - - 
Intron 5 262 5 5 0 0 - 0 - - - 
Intron 6 1286 7 6 1 0 - 0 - - - 
Intron 7 1070 7 7 0 0 - 0 - - - 
Intron 8 1085 9 9 0 0 - 0 - - - 
Intron 9 2156 14 14 0 0 - 0 - - - 
Intron 10 7719 31 23 7 1 - 0 - - - 
Intron 11 2320 12 12 0 0 - 0 - - - 
Intron 12 1672 15 12 3 0 - 0 - - - 
 
Note: 
* A synonymous substitutions in exon 7 defines the CYP3A5*6 variant, which has been reported to be associated with low/non-expression of 
CYP3A5 protein by causing skipping of exon 7 (Hustert et al. 2001; Kuehl et al. 2001). 
** A frameshift mutation in exon 11 defines the CYP3A5*7 variant, which has been reported to be associated with low/non-expression of CYP3A5 
due to the creation of a premature termination codon (Hustert et al. 2001; Xie et al. 2004) 
*** A substitution in intron 3 defines the CYP3A5*3 variant, which has been experimentally shown to reduce in vivo CYP3A5 expression, in some 
cases to undetectable levels (Lin et al. 2002; Busi and Cresteil 2005) 
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Figure 5.2: A diagram of the distribution of variants reported in the CYP3A5 gene.  
 The pink boxes represent CYP3A5 exons, although they are not spaced according to scale. The red box represents the proximal promoter region of 
CYP3A5 and the green box is the 3´ untranslated region (UTR). Spacer regions, represented by black lines between adjacent exons, are introns. 
 Xn refers to a specific exon of number n. 
 The 5´ upstream and 3´ downstream regions either side of the gene correspond to 1700 base pairs and 2386 base pairs, respectively. 
 The exons are ordered from Exon 1-13, although they are not all numbered on the Figure.  
 The numbers in the brackets correspond to the total number of variants reported, on the NCBI database (http://www.ncbi.nlm.nih.gov/), in each 
region of CYP3A5. The values preceding the “/” indicate the number of variants which occur at a global frequency of ≥1%, the numbers after the “/” 




Table 5.2: The results of chi-squared tests which compared pairwise differences in the CYP3A 
ratios of polymorphic to fixed sites. Yates’ correction was applied for each comparison. The 
data compared have been compiled from the NCBI database, build 132 
(http://www.ncbi.nlm.nih.gov/). Statistically significant differences at the 5% level are highlighted in 
green and shown in bold. 
 
 CYP3A4 CYP3A5 CYP3A7 CYP3A43 
CYP3A4 *    
CYP3A5 <0.0001 *   
CYP3A7 0.0001 0.2516 *  
CYP3A43 0.0001 0.6675 0.0970 * 
 
Table 5.3: The results of pairwise Fisher’s exact comparisons of the ratios of common 
variation (observed at a global frequency of ≥1%) to rare variation in CYP3A genes. The data 
compared have been compiled from the NCBI database, build 132 (http://www.ncbi.nlm.nih.gov/). 
Statistically significant differences at the 5% level are highlighted in green and shown in bold. 
 
 CYP3A4 CYP3A5 CYP3A7 CYP3A43 
CYP3A4 *    
CYP3A5 0.0135 *   
CYP3A7 <0.0001 0.0173 *  
CYP3A43 <0.0001 <0.0001 0.1211 * 
 
 Nine CYP3A5 variants, which include CYP3A5*3, CYP3A5*6 and CYP3A5*7, have been 
reported to be candidates for low/non enzyme expression (Xie et al. 2004). To date, in vivo 
studies have established a role for CYP3A5*3 in affecting enzyme activity and function (Givens 
et al. 2003); this is due to high frequencies of this variant observed in many populations, and a 
bias towards genotyping of this variant alone in previous medical association studies. There 
are fewer data for the effect of CYP3A5*6 and CYP3A5*7 on enzyme activity and expression, 
although CYP3A5 catalytic activity, measured by Western blot, was observed to be lower in 
CYP3A5*6 heterozygotes than in CYP3A5*1 homozygotes, see section 1.2.3.1 (Kuehl et al. 
2001). CYP3A5*7 was also observed to be associated with low/non hepatic expression of 
CYP3A5 (Hustert et al. 2001). A previous study identified an anomalous CYP3A5*1/*3 
heterozygote with undetectable levels of CYP3A5 protein. The individual had a CYP3A5*7 
mutation on the CYP3A5*1 chromosome; providing further evidence that this allele is 
associated with decreased CYP3A5 expression (Givens et al. 2003). 
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 For the remaining six candidate low/non expression alleles, in vitro data are available. 
However due to the lower global frequencies of these alleles, comparative to CYP3A5*3, 
CYP3A5*6 and CYP3A5*7, it has been difficult to elucidate the independent effects of these 
alleles in vivo (Xie et al. 2004) and they are often observed in populations with high 
frequencies of CYP3A5*3 (Table 5.4). 
 There is a general problem with examining the effect of CYP3A5 alleles on hepatic and 
intestinal drug clearance. There is considerable substrate overlap between CYP3A5, CYP3A4 
and a membrane efflux transporter protein P-glycoprotein, present in many tissues in which 
CYP3A enzymes act, encoded by the MDR1 gene (Kim et al. 1999; Kim et al. 2008). This makes 
it difficult to examine the in vivo effects of CYP3A5 protein alone; in vitro experiments can 
elucidate the effects of specific variants, on protein activity, but may not reflect what actually 
happens in vivo. There are some examples of where there is a strong association between 
CYP3A5 activity and disease pathology, such as salt-sensitive hypertension (Givens et al. 
2003; Fromm et al. 2005; Bochud et al. 2006; Bochud et al. 2009), and adverse clinical 
outcomes associated with drug therapy, such as with the immunosuppressant drug tacrolimus 
(Zhao et al. 2005), although the metabolism of tacrolimus is also influenced by the MDR1 gene 
and P-glycoprotein (Zheng et al. 2003). 
 
5.1.2 Characteristics of variation at the CYP3A5 locus  
 Linkage disequilibrium (LD) across CYP3A5 varies between populations genotyped as 
part of the HapMap consortium (http://www.hapmap.org/), see Figure 5.3. LD is high across 
Tuscans from Italy; individuals of Mexican ancestry from Los Angeles; Japanese individuals 
from Tokyo; Gujarati Indians from Houston Texas; Chinese individuals from Metropolitan 
Denver and from Beijing; and individuals with Northern and Western European ancestry in 
the United States; all non-African populations. This is consistent with previous studies 
reporting that LD is higher in populations outside of Africa (Conrad et al. 2006). 
 There is strong LD across the ~220kb CYP3A locus, see Figure 5.4. One of the most 
comprehensive studies of human variation at the CYP3A locus found that the CYP3A5*3 
mutation defined 84% of the CYP3A haplotypes observed in Han Chinese individuals and 98% 
of those in European individuals (Thompson et al. 2006). Additionally in African-Americans 
the authors observed that a number of CYP3A haplotypes were defined by high LD between 
the CYP3A5*1 allele and a CYP3A7*2 variant, which occurs in exon 11 of the CYP3A7 gene and 
causes increased enzyme expression (Rodriguez-Antona et al. 2005) and it was suggested that 
tight linkage between these two variants, and increased expression of both CYP3A5 and 
CYP3A7 enzymes, may provide a selective advantage in the foetus.   
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Table 5.4: A list of CYP3A5 alleles that have been reported to be candidates for causing low/non protein expression; “n” refers to the number of 
individuals sampled. 
Variant name Variant Region of gene Coding/non-coding Evidence for low/non expression Population and variant 
allele frequency 
Reference 
CYP3A5*2 C>A Exon 11 Coding: non-synonymous; T398N 
In vitro observation found 2/5 livers not expressing CYP3A5 
protein were homozygous for CYP3A5*2, although it is unknown 




(Jounaidi et al. 1996; 
Chou et al. 2001; Lee et 
al. 2003) 
CYP3A5*3 A>G Intron 3 
Non-coding, reported to cause part of intron 3 to 
be retained in the mature mRNA 
In vitro and in vivo data, including medical association studies 
with the immunosuppressant drug tacrolimus 
See Table 3.8 
(Hustert et al. 2001; 
Kuehl et al. 2001; Busi 
and Cresteil 2005) 
CYP3A5*4 A>G Exon 7 Coding: non-synonymous; Q200R No functional in vitro data due to the low frequency of the variant Chinese (0.36% n=110) (Chou et al. 2001) 
CYP3A5*5 T>C Intron 5 
This transition occurs in intron 5 immediately 
adjacent to the intron 5 donor splice site. 
An in vitro study found that CYP3A5*5 produced multiple 
splicing products in Caco-2 cell lines 
Chinese (0.99%; n=110) 
(Chou et al. 2001; Lamba 
et al. 2002) 
CYP3A5*6 G>A Exon 7 
Coding: synonymous; reported to create a splice 
site which causes skipping of exon 7 
cDNA extracted from CYP3A5*1/CYP3A5*6 hepatocytes did not 
have the sequence for exon 7. Heterozygotes also had lower 
catalytic activity towards midazolam (a known CYP3A substrate) 
than CYP3A5*1 homozygotes 
See Table 3.8 
(Hustert et al. 2001; 
Kuehl et al. 2001) 
CYP3A5*7 T insertion Exon 11 
Coding: non-synonymous change; creates 
premature termination codon at position 348 
CYP3A5*1/CYP3A5*7 individuals have lower catalytic activity 
towards midazolam than CYP3A5*1 homozygotes 
See Table 3.8 (Hustert et al. 2001) 
CYP3A5*8 C>T Exon 2 Coding: non-synonymous change; R28C 
In vitro studies found that CYP3A5 with the CYP3A5*8 mutation, 
purified from an Escherichia coli system, had decreased ability 
to metabolise testosterone (a known CYP3A substrate) 
Africans (4%; n=24) (Lee et al. 2003) 
CYP3A5*9 G>A Exon 10 Coding: non-synonymous change; A337T 
In vitro studies found that CYP3A5 with the CYP3A5*9 mutation, 
purified from an Escherichia coli system, had decreased ability 
to metabolise testosterone (a known CYP3A substrate) 
East Asians (2%; n=24) (Lee et al. 2003) 
CYP3A5*10 T>C Exon 12 Coding: non-synonymous change; F446S 
In vitro studies found that CYP3A5 with the CYP3A5*10 has 
almost complete loss of activity. This is because the mutation 
occurs within the heme binding site of CYP3A5, which is 
essential for P450 mediated drug metabolism. 
Caucasians (2%; n=24) (Lee et al. 2003) 
N.B. The 24 Africans genotyped in the 2003 paper by Lee et al (Lee et al. 2003) comprise 15 African-Americans and 9 African Pygmies; the 24 Asians are 4 Indo-Pakistani, 5 
native Taiwanese, 5 mainland Chinese from Beijing, 3 Cambodians, 3 Japanese and 4 Melanesian; and the 24 Caucasians are from the USA and Europe. 
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 Interestingly, across the CYP3A locus, nucleotide diversity per base pair is much lower 
for CYP3A5, than for the remaining genes, in every re-sequenced population (Table 5.5). 
Additionally comparisons of all CYP3A genes found that CYP3A5 is characterised by an excess 
of rare variants in each of the African-American, European and Han Chinese populations; and 
had the lowest amount of sequence divergence from the chimpanzee (Thompson et al. 2006). 
LD is highest across the CYP3A cluster in populations in which the CYP3A5*3 allele is observed 
at high frequencies. These populations also have lower measures of nucleotide diversity 
comparative to those in which the CYP3A5*1 allele is at higher frequencies.  
 Genome scans have identified candidates for positive selection on human 
chromosome 7 (Sabeti et al. 2006). An excess of rare variants and regions of extended 
haplotype homogeneity have been identified in a region surrounding the Kell blood antigen 
cluster (Sabeti et al. 2006) and a functional polymorphism in the gene encoding the antigen 
CD36; found at high frequency in African populations and associated with differential 
susceptibility to cerebral malaria (Aitman et al. 2000; Pain et al. 2001). CYP3A5 has also been 
proposed as a target of selection (Thompson et al. 2004; Sabeti et al. 2006); given the strong 
LD observed within the region and the excess of rare variants at the CYP3A5 locus in these 
populations (Thompson et al. 2006). However it is important to note that LD across 
chromosome 7 may extend beyond the CYP3A cluster and there may be an alternative target 
of selection, tightly linked to the CYP3A5*3 allele, which has driven it to high frequencies in 
certain populations. Additionally, it is possible that CYP3A5*3 is a young allele which has 
recently evolved on an existing haplotype background with a paucity of variation; and may 




Figure 5.3: Linkage disequilibrium at the CYP3A5 locus in 11 populations, genotyped as part of the HapMap consortium (http://www.hapmap.org/). Values in boxes 
refer to D´; where there is no number the value of D´ is equal to 1. Red and pink boxes indicate a significant D´ value; blue and white indicate non-significant. 
 
African ancestry in Southwest USA 
 
Utah residents with Northern and Western European ancestry from the 
CEPH collection 
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Figure 5.4: The extent of linkage disequilibrium across the entire CYP3A cluster of genes in three ethnically distinct global populations. The 
image has been taken from (Thompson et al. 2006). Each row is a haplotype and each column is a polymorphic site. Rows with grey shading are the 
corresponding chimpanzee sequence, which was used to infer the ancestral allele at each polymorphic position. Derived variants are show in blue and 
ancestral in yellow. Note the lack of variation in the CYP3A5 gene (far right hand side). The most common variant observed, in each of the three populations, is 





Table 5.5: Summary statistics of polymorphism data from African-American, Han Chinese and European individuals re-sequenced at the entire 
CYP3A cluster. The image has been taken from (Thompson et al. 2006). Note the low measures of nucleotide diversity for CYP3A5, in each of the three 






5.2 Variation at the CYP3A5 locus in Ethiopia 
5.2.1 Variation across the entire CYP3A5 locus 
 76 polymorphic sites were identified within a 12,237 base pair region of chromosome 
7, which includes the CYP3A5 promoter, coding region and 3´ untranslated region (UTR), re-
sequenced in five Ethiopian populations. A diagram showing the distribution of all 
polymorphic sites observed in the 12,237 base pair region is presented in Figure 5.5. 50 of all 
observed variants (~65.79%) occur in introns 3 and 9, the CYP3A5 promoter and in ≥1700 
base pairs of sequence either side of the gene. Table 5.6 shows the full list of polymorphic 
sites identified in the five Ethiopian groups and indicates which are novel and which have 
been previously identified. 69 variants were single nucleotide substitutions; 5 were deletions 
(2 single nucleotide deletions, 1 double nucleotide deletion and 2 triple nucleotide deletions); 
1 insertion (a single base in exon 11); and 1 microsatellite repeat were also observed. A total 
of 13 variants, excluding singletons, were private to specific Ethiopian populations.  
 51 polymorphic sites were identified within an 8571 base pair region comprising the 
CYP3A5 promoter, full coding region and 3´ UTR, and 16 of these were singletons. 
Interestingly, every observed exonic polymorphism was a singleton, and the highest 
frequency variants were CYP3A5*3 and CYP3A5*6. Excluding the singletons, 8 variants were 
private to specific Ethiopian groups. 
 The majority (53%) of all identified variants were observed at a frequency of <0.66% 
of chromosomes (n=758), see Figure 5.5 and 5.6. 23 of the 76 variants (~30.3%) are 
singletons, i.e. they were observed in a single heterozygous individual. The only variants 




Figure 5.5: A full list of all polymorphic sites identified across the 12,237 base pair CYP3A5 region re-sequenced in five Ethiopian populations.  
 The pink boxes represent CYP3A5 exons, although they are not spaced according to scale. The red box represents the proximal promoter region of 
CYP3A5 and the green box is the 3´ untranslated region (UTR). Spacer regions, represented by black lines between adjacent exons, are introns. 
 The 5´ upstream and 3´ downstream regions either side of the gene correspond to 1700 base pairs and 2385 base pairs, respectively. 
 The exons are ordered from Exon 1-13, although they are not all numbered on the Figure.  









Table 5.6: A list of all polymorphic sites identified in a 12,237 base pair CYP3A5 region re-sequenced in five Ethiopian populations. 
 For each Ethiopian population: n refers to the total number of chromosomes on which a particular variant was observed and f is the 
 relative frequency a variant was observed in a particular Ethiopian group and was calculated by dividing n for a population by n for the 
 Ethiopian cohort. 
 “Total re-sequenced” refers to the total number of chromosomes, in the Ethiopian cohort, successfully re-sequenced at a particular site. In 
 the “Total” columns; n refers to the total number of chromosomes on which a variant allele(s) was seen and f is the frequency within the 
 entire Ethiopian cohort. 
 light blue shading indicates novel mutations 
     Afar Amhara Anuak Maale Oromo Total  






CYP3A5 variant and its 
position relative to the 
translation initiation codon (A 
of ATG is +1) 
NCBI dbSNP 
database 
refSNP ID Effect f n f n f n f n f n f n 
Total re-
sequenced 
5' upstream region 99279710 -2191 C>T rs10270499   0.04 28 0.03 22 0.05 37 0.03 23 0.03 19 0.1702 129 758 
5' upstream region 99279307 -1788 G>A     0.00 0 0.00 0 0.00 0 0.00 2 0.00 0 0.0027 2 754 
5' upstream region 99279136 -1617 T>C rs776741   0.05 38 0.05 38 0.10 75 0.07 53 0.05 38 0.3210 242 754 
5' upstream region 99279051 -1532 T>C     0.00 0 0.00 0 0.00 0 0.01 4 0.00 0 0.0053 4 754 
5' upstream region 99278876 -1357 C>T     0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1 758 
5' upstream region 99278862 -1343 T>A     0.00 1 0.00 3 0.01 10 0.00 3 0.01 6 0.0303 23 758 
5' upstream region 99278827 -1308 C>T     0.00 1 0.00 3 0.01 10 0.00 3 0.01 6 0.0303 23 758 
5' upstream region 99278771 -1252 1 base pair deletion     0.00 0 0.00 2 0.00 0 0.00 0 0.00 0 0.0026 2 758 
5' upstream region 99278522 -1003 A>C rs36231118   0.01 4 0.00 3 0.02 15 0.01 9 0.01 4 0.0462 35 758 
Proximal promoter 99278314 -795 T>A rs3823812   0.00 3 0.00 3 0.01 4 0.01 10 0.01 5 0.0331 25 756 
Proximal promoter 99278267 -748 C>G     0.01 5 0.00 2 0.00 1 0.00 1 0.01 6 0.0198 15 756 
Proximal promoter 99278224 -705 3 base pair deletion     0.00 1 0.00 1 0.01 5 0.00 1 0.00 3 0.0146 11 756 
Proximal promoter 99278223 -704 A>G     0.00 0 0.00 0 0.00 0 0.00 1 0.00 0 0.0013 1 756 
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Proximal promoter 99278152 -633 C>A     0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.0013 1 756 
Proximal promoter 99278146 -627 G>A     0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1 756 
Proximal promoter 99278144 -625 A>G     0.00 0 0.00 0 0.00 0 0.00 1 0.00 0 0.0013 1 756 
Proximal promoter 99278070 -551 C>A rs28365079   0.01 4 0.01 5 0.02 15 0.01 8 0.01 4 0.0476 36 756 
Proximal promoter 99277988 -469 G>A     0.00 0 0.00 0 0.00 0 0.00 1 0.00 0 0.0013 1 756 
5' UTR of exon 1 99277593 -74 C>T rs28371764   0.00 2 0.01 6 0.00 0 0.00 2 0.00 2 0.0158 12 758 
5' UTR of exon 1 99277544 -25 A>C     0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.0013 1 758 
Intron 1 99277392 127 G>A     0.00 0 0.00 0 0.00 1 0.00 2 0.00 0 0.0040 3 758 
Intron 1 99277337 182 C>A     0.00 0 0.00 0 0.00 3 0.00 0 0.00 0 0.0040 3 758 
Intron 2 99272310 5209 C>T rs28365067   0.01 11 0.02 12 0.01 5 0.01 8 0.01 8 0.0580 44 758 
Intron 2 99272290 5229 G>A rs41301652   0.00 0 0.00 0 0.00 2 0.00 0 0.00 0 0.0026 2 758 
Intron 2 99272275 5244 C>T     0.00 0 0.00 0 0.00 0 0.00 0 0.00 2 0.0026 2 758 
Intron 3 99272103 5416 C>T     0.00 0 0.00 0 0.00 0 0.00 0 0.00 2 0.0026 2 758 
Intron 3 99272009 5510 T>A rs28969392   0.01 6 0.01 4 0.01 10 0.01 9 0.00 3 0.0422 32 758 
Intron 3 99271928 5591 C>T rs41301655   0.00 0 0.01 4 0.00 1 0.00 0 0.00 2 0.0092 7 758 
Intron 3 99271853 5666 A>G rs41301658   0.00 1 0.00 1 0.00 3 0.01 7 0.00 2 0.0185 14 758 
Intron 3 99271808 5711 A>G rs41258334   0.01 11 0.01 11 0.01 5 0.01 9 0.01 8 0.0580 44 758 
Intron 3 99271778 5741 A>G     0.01 6 0.00 3 0.01 4 0.01 8 0.00 3 0.0317 24 758 
Intron 3 99270539 6980 A>G rs776746 
Defines the allelic 
variant CYP3A5*3 0.13 95 0.14 102 0.06 44 0.10 75 0.13 97 0.5581 413 740 
Intron 3 99270504 7015 3 base pair deletion     0.00 0 0.00 0 0.00 0 0.00 1 0.00 0 0.0014 1 740 
Intron 3 99270318 7201 C>T rs8175345   0.00 0 0.00 1 0.01 9 0.00 0 0.00 1 0.0149 11 740 
Exon 4 99270249 7270 G>A   G77S 0.00 0 0.00 0 0.00 0 0.00 1 0.00 0 0.0014 1 740 
Intron 4 99270164 7355 C>T rs28365074   0.00 0 0.00 0 0.00 1 0.00 0 0.00 2 0.0041 3 740 
Intron 5 99264352 13167 T>C rs68178885   0.00 3 0.00 2 0.00 1 0.00 3 0.00 1 0.0132 10 758 
Intron 6 99264149 13370 G>A rs41301670   0.00 0 0.00 0 0.00 0 0.00 0 0.00 2 0.0027 2 754 
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Exon 7 99262835 14684 G>A rs10264272 
Defines the allelic 
variant CYP3A5*6 0.04 28 0.03 23 0.05 39 0.03 23 0.03 21 0.1763 134 760 
Exon 7 99262793 14726 A>G rs2838372 Synonymous 0.00 1 0.00 0 0.00 0 0.00 0 0.00 0 0.0013 1 760 
Intron 7 99262642 14877 A>G     0.00 1 0.01 5 0.02 12 0.01 9 0.00 2 0.0382 29 760 
Intron 7 99261737 15782 T>C rs28969393   0.01 5 0.01 4 0.01 9 0.01 9 0.00 3 0.0396 30 758 
Exon 8 99261651 15868 A>G   K266R 0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1 758 
Intron 8 99261583 15936 C>A     0.00 0 0.00 0 0.00 0 0.00 2 0.00 0 0.0026 2 758 
Intron 8 99260546 16973 G>A     0.00 0 0.00 1 0.00 0 0.00 0 0.00 0 0.0013 1 756 
Exon 9 99260502 17017 C>T   R268Stop 0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1 756 
Intron 9 99260407 17112 C>T rs28383478   0.00 0 0.00 2 0.00 0 0.00 0 0.00 0 0.0026 2 756 
Intron 9 99260362 17157 G>T rs4646453   0.00 3 0.00 3 0.01 4 0.01 10 0.01 5 0.0331 25 756 
Intron 9 99260282 17237 T>G     0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1 756 
Intron 9 99260170 17349 T>G     0.00 3 0.00 2 0.01 7 0.01 7 0.00 3 0.0291 22 756 
Intron 9 99258524 18995 C>T rs10247580   0.00 0 0.00 2 0.02 12 0.01 7 0.00 1 0.0291 22 756 
Intron 9 99258320 19199 G>A     0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1 756 
Intron 9 99258316 19203 T>C     0.00 0 0.00 0 0.00 0 0.00 2 0.00 0 0.0026 2 756 
Exon 10 99258124 19395 A>C   K342T 0.00 0 0.00 0 0.00 0 0.00 0 0.00 1 0.0013 1 756 
Exon 11 99250397 27125-27126 T insertion rs41303343 
Defines the allelic 
variant CYP3A5*7 0.00 0 0.00 0 0.00 1 0.00 1 0.00 0 0.0026 2 760 
Exon 11 99250381 27138 A>G   V350M  0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1 760 
Intron 12 99247647 29872 G>T     0.00 0 0.00 0 0.00 0 0.00 2 0.00 0 0.0026 2 756 
Intron 12 99247503 30016 1 base pair deletion rs28365093   0.00 3 0.01 4 0.02 15 0.01 8 0.01 4 0.0450 34 756 
Intron 12 99246026 31493 T>C rs28365069   0.01 4 0.01 11 0.01 11 0.02 18 0.01 9 0.0699 53 758 
3' UTR 99245914 31605 C>T rs15524 
None, although is 
often on the 
background of 
rs776746 0.14 105 0.14 109 0.09 69 0.11 84 0.14 107 0.6253 474 758 
3' downstream 




region 99245707 31812 G>A     0.00 0 0.00 1 0.00 0 0.00 0 0.00 0 0.0013 1 758 
3' downstream 
region 99245537 31982 2 base pair deletion     0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1 758 
3' downstream 
region 99245499 32020 C>T     0.00 2 0.00 1 0.00 0 0.00 0 0.00 0 0.0040 3 758 
3' downstream 
region 99245373 32146 G>T rs76871422   0.01 6 0.00 3 0.00 1 0.00 1 0.00 3 0.0187 14 750 
3' downstream 
region 99245364 32155 C>T rs57922842   0.03 21 0.02 17 0.03 21 0.01 7 0.02 15 0.1080 81 750 
3' downstream 
region 99245311 32208 G>T     0.01 6 0.00 3 0.01 4 0.01 8 0.00 3 0.0320 24 750 
3' downstream 
region 99245280 32239 T>G rs4646457   0.07 53 0.07 54 0.14 108 0.11 79 0.07 50 0.4587 344 750 
3' downstream 
region 99245275 32244 T>C rs4646456   0.20 147 0.18 135 0.20 148 0.19 140 0.19 143 0.9507 713 750 
3' downstream 
region 99245267 32252 C>T     0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1 750 
3' downstream 
region 99245241 32278 A>G     0.00 0 0.00 3 0.00 0 0.00 0 0.00 0 0.0040 3 750 
3' downstream 
region 99245160 32359 G>A     0.00 0 0.00 0 0.00 1 0.00 0 0.00 0 0.0013 1 758 
3' downstream 
region 99245013 32506 A>C rs4646458   0.06 42 0.05 34 0.10 76 0.07 53 0.05 38 0.3240 243 750 
3' downstream 
region 99244460 33059 GT microsatellite repeat rs10536492  - - - - - - - - - - - - 740 
3' downstream 
region 99244392 33127 T>C rs10259288   0.01 4 0.01 4 0.02 13 0.01 8 0.01 6 0.0464 35 754 
3' downstream 





Figure 5.6: The number of times a particular variant is observed within the Ethiopian cohort (n=758 chromosomes). The frequency refers to the 
number of chromosomes on which a particular variant was identified. A “singleton” is a variant that was observed in a single heterozygous individual. The y-
axis shows the proportion of the total amount of identified variation that is attributed to variants of particular frequencies; i.e. singletons account for ~30.3% 




















































5.2.2 Analysis of variation observed in the proximal promoter of CYP3A5 
 None of the variants observed in the CYP3A5 promoter occur in experimentally 
established transcription factor binding sites. There is ~95% sequence identity between the 
human CYP3A5 promoter sequence and the homologous primate sequences (see Table 5.7). A 
cross-species alignment of primate CYP3A5 promoter sequences, Figure 5.7, found that 10/11 
polymorphic sites were in highly conserved nucleotide positions in primates. A comparison of 
human CYP3A5 sequence with the mouse (Mus musculus) found 51% homology, 60% with the 
cow (Bos taurus) and 61% in the pipid frog (Xenopus tropicalis); indicating that CYP3A5 
sequence identity is highest between closely related primate species than to other distantly 
related species. 
 
Table 5.7: A summary of the sequence similarity between the human CYP3A5 promoter and the 




Human Chimpanzee Orang-utan Rhesus macaque 
Human -    
Chimpanzee 99 -   
Orang-utan 93 93 -  







Figure 5.7: An alignment of multiple primate CYP3A5 promoter sequences performed using 
ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/). Stars indicate nucleotide positions 
which are identical in all four species. Positions are numbered from the ATG start codon where base A 
is +1. All identified human CYP3A5 polymorphic sites which occur in highly conserved primate 
nucleotide positions are highlighted in red. Human variants which occur in non-conserved sites are 
highlighted in blue.  
 
Human           ----------------------TCTATTGCTATCACCACAGAGTCAGAGGGGATGAGAC- -764 
Chimp           -------------------------ATTGCTATCACCACAGAGTCAGAGGGGATGAGAC- -767 
Orangutan       TTGAGTCCCAAGCAACCATTAGTCTATTGCTATCACCACAGAGTCAGAGGGGATGAGAC- -742 
Rhesus          -----------------------CTATTGCTATCACCACAGAGTCAGAGGGGATGACACA -764 
                                         ******************************* **  
 
Human           -----GCCCAGCAATCTCACCCAAGACAACTCCACCAACATTCCTGGTTACCCACCATGT -709 
Chimp           -----GCCCAGCAATCTCACCCAAGACAACTCCACCAACATTCCTGATTACCCACCATGT -712 
Orangutan       -----GCCCAGGAATCTCACCCAAGACAACTCCACCAACACTCCTGGTTACCCACCGTGT -687 
Rhesus          CGGGGGCCCAGCAATCTCACCCAAGTCAACTCCACCAACATTCCTGGTTACCCACCGTAT -704 
                     ****** ************* ************** ***** ********* * * 
 
Human           GTACAGTACCCTGCTAGGAACCAGGGTCATGAAAGTAAATAATACCAGACTGTGCCCTTG -649 
Chimp           GTACAGTACCCTGCTAGGAACCAGGGTCATGAAAGTAA-TAATACCAGACTGTGCCCTTG -653 
Orangutan       GTACAGTACCCTGCTAGGAACCAGGGTCATGAAAGTAAATAATACCAGACTGTGCCCTTG -627 
Rhesus          GTACAGTACCCTGCTAGGGACCAGGGTCATGACAGTAAATAATACCAGACTGTGCCCTTG -644 
                ****************** ************* ***** ********************* 
 
Human           AGGAGCTCACCTCTGCTAAGGGAAACAGGCATAGAAACTTACAATGGTGGTAGAGAGAAA -589 
Chimp           AGGAGCTCACCTCTGCTAAGGGAAACAGGCACAGAAACTTACAATGGTGGTAGAGAGAAA -593 
Orangutan       AGGAGCTCACCTCTACTAAGGGAAACAGGCACAGAAACCCACAATGGTGGTAGAGAGAAA -567 
Rhesus          AGGAGCTCACCTCTGCTAAGGGAAACATGCACAGAAACCCACAATGGTGGCAGAGAGGAA -584 
                ************** ************ *** ******  ********** ****** ** 
 
Human           AGAGGACAATAGGACTGTGTGAGGGGGATAGGAGGCACCCAGAGGAGGAAATGGTTACAT -529 
Chimp           AGAGGACAATAGGACTGTGTGAGGGGGATAGGAGGCACCCAGAGGAGGAAATGGTTACAT -533 
Orangutan       AGAGGACAATAGAACTGTGTGAGGGGGATAGGAGGCACCCAGAGGAGGAAATGGTTACAT -507 
Rhesus          AGAGGACAATGGGACTGTGTGAGGGGGATAGGAGGCACCCAGAGGAGGAAATGG------ -530 
                ********** * *****************************************       
 
Human           TTGTGTGAGGAGGTTGGTAAGGAAAAATTTTAGCAGAAGGGGTCTGTCTGGCTGGGCTTG -469 
Chimp           TTGTGTGAGGAGGTTGGTAAGGAAAAATTTTAGCAGAAGGGGTCTGTCTGGCTGGGCTTG -473 
Orangutan       TTGTGTGAGGAGGTTGGTAAGGAAAAATTTTAGCAGAAGGGGTCTGTCTGGCTGGGGTTG -447 
Rhesus          ----GTGAGGAGGTTGGTAAGGAAAGATTTTAACAGAAGGGGTCTGTCTGGCTGGACATG -474 
                    ********************* ****** **********************   ** 
 
Human           GAAGGATACGTAGGAGTCATCTAGAGGGCACAGGTACACTCCAGGCAGAGGGAATTTCGT -409 
Chimp           GAAGGATACGTAGGAGTCATCTAGAGGGCACAGGTACACTCCAGGCAGAGGGAATTGCGT -413 
Orangutan       GAAGGATGTGTAGGAGTCATCTAGGGGGCACAGGTACACTCCACGGAGAGGGAATTGCGT -387 
Rhesus          GAAGGACATGTAGGAGTCATCTAGAGGGCACAGGTACACTCCAGGCAGAGGGAATTGCAT -414 
                ******   *************** ****************** * ********** * * 
 
Human           GGGTAAAGATGTGTAGGTGTGGCTTGTGAGGATGGATTTCAATTATTCTAGAATGAAGGC -349 
Chimp           GGGTAAAGATGTGTAGGTGTGGCTTGTGAGGATGGATTTCAATTATTCTAGAATGAAGGC -353 
Orangutan       GGGTAAAGATGTGTAGGTGTGGCTTGTGAGGATGGATTTCAATTATTCTAGAATGAAGGC -327 
Rhesus          GGGTAAAGATCTGTAGGTATGGCTTGTGAGGATGGATTTCAATTATTCTGGAATGAGGGC -354 
                ********** ******* ****************************** ****** *** 
 
Human           AGCCATGGAG----GGGCAGGTGAGAGGAGGGTTAATAGATTTCATGCCAATGGCTCCAC -293 
Chimp           AGCCATGGAGACAGGGGCAGGTGAGAGGAGGGTTAATAGATTTCATGCCAATGGCTCCAC -293 
Orangutan       AGCTATGGAGACAGGGGCAGGTGAGAGGAGGGTTAATAGATTTCATGCCAATGGCTCCGC -267 
Rhesus          GGCCATGGAGACAAGGGCAGGTGAAAGGAGAGTTAACAGATTTCATGCCAATGGCTCTGC -294 
                 ** ******    ********** ***** ***** ********************  * 
 
Human           TT-GAGTTTCTGATAAGAACCCAGAACCCTTGGACTCCCCGATAACACTGATTAAGCTTT -234 
Chimp           TT-GAGTTTCTGATAAGAACCCAGAACCCTTGGACTCCCCGATAACACTGATTAAGCTTT -234 
Orangutan       TT-GAGTTTCTGATAAGAACCC--------------------------TGATTAAGTTGT -234 
Rhesus          TTTGAGTTTCTGATAAGAACCCAGAACCCTTGGACTCCCCACTAACACTGATTAAGGTTT -234 




Human           TCATGATTCCTCATAGAACATGAACTCAAAAGAGGTCAGCAAAGGGGTGTGTGCGATTCT -174 
Chimp           TCATGATTCCTCATAGAACATGAACTCAAAAGAGGTCAGCAAAGGGGTGTGTGCGATTCT -174 
Orangutan       TTGTGATTCCTCATAGAACATGAACTCAAAAGAGGTCAGCAAAGGAGTGTGTGCGATTCT -174 
Rhesus          TTATGATTCCTCATAGAACATGAACTCAAAGGAGGTCAGCAAAGGGGTGTGTGTGATTCT -174 
                *  *************************** ************** ******* ****** 
 
Human           TTGCTATTGGCTGCAGCTATAGCCCTGCCTCCTTCTCCAGCACATAAATCTTTCAGCAGC -114 
Chimp           TTGCTATTGGCTGCAGCTATAGCCCTGCCTCCTTCTCCAGCACATAAATCTTTCAGCAGC -114 
Orangutan       TTGCTATTGGCTGCAGCTACAGCCCTGCCTCCTTCTCCAGCACATAAACATTTCAGCAGC -114 
Rhesus          TTGCTATTGGCTGCAGCTGCAGCCCCGCCTCCTTCTCCAGCACATAAACATTTCGGCAGC -114 
                ******************  ***** **********************  **** ***** 
 
Human           TTGGCTGAAGACTGCTGTGCAGGGCAGGGAAGCTCCAGGCAAACAGCCCAGCAAACAGCA -54 
Chimp           TTGGCTGAAGACTGCTGTGCAGGGCAGGGAAGCTCCAGGCAAACAGCCCAGCAAACAGCA -54 
Orangutan       TTGGCTGAAGACTGCTGTGCAGGGCAGGGAAGCTCCAGGCAAACAGCCCAGCAAACAGCA -54 
Rhesus          TTGGCTGCAGACTGCTGTGCAGGGCAGGGAAGCCCCAGGAACACAGTCCAGCAAACAGCA -54 
                ******* ************************* ***** * **** ************* 
 
Human           GCACTCAGCTAAAAGGAAGACTCACAGAACACAGTTGAAGAAGGAAAGTGGCG -1 
Chimp           GCACTCAGCTAAAAGGAAGACTCACAGAAGACAGTTGAAGAAGGAAAGTGGCG -1 
Orangutan       GCACGCAGCTAAAAGGAAGACTCACAGAAGACAGTTGAAGAAGGAAAGTGGCG -1 
Rhesus          GCACGCAGCTAAAAGGAAGACTCAGAGGAGACAGTTGAAGAAGGAAAGTGGCG -1 




 Given the importance of CYP3A5 in drug metabolism two previous studies have only 
characterised hepatic and intestinal transcription factor binding sites (Lin et al. 2002; Burk et 
al. 2004). CYP3A5 is the major extra-hepatic drug metabolising enzyme and predictive 
analysis was used to identify which of the CYP3A5 polymorphisms were candidates for 
affecting transcription factor binding in tissues in which the enzyme is known to be expressed 
(Lamba et al. 2002). Bioinformatics analysis predicted that 4 of the 9 identified CYP3A5 
promoter variants were candidates for affecting transcription factor binding. There are 
problems associated with predicting functionally relevant transcription factor binding sites 
given the intricacy of binding complexes in different tissues (Jones and Swallow 2011). For 
this analysis, variants were only considered to be candidates for affecting transcription factor 
binding to the CYP3A5 promoter if the identified site was predicted to bind transcription 
factors present in tissues in which CYP3A5 protein is expressed and also if the three 





Table 5.8: A summary of the MatInspector analysis of identified CYP3A5 promoter variants. A detailed outline of the criteria used to choose variants 






5.2.3 Analysis of variation observed in the CYP3A5 coding region 
 A total of 39 variants were identified in the CYP3A5 coding region (Figure 5.5). There 
is ~93% sequence homology between the human CYP3A5 coding region re-sequenced in this 
study and the corresponding regions in other primates; see Table 5.9.  An alignment of 
primate CYP3A5 coding regions found that 28/39 polymorphic sites were in highly conserved 
primate nucleotide positions. The highest frequency variants observed were the CYP3A5*3 
and CYP3A5*6 defining alleles. CYP3A5*7 was observed in two heterozygous individuals. No 
polymorphisms were identified in consensus splice sites and bioinformatics analysis of all 
intronic polymorphisms, with BDGP (http://www.fruitfly.org/seq_tools/splice.html), did not 
identify any variants which were predicted to affect pre-mRNA splicing.  
 
Table 5.9: A summary of the sequence similarity between the human, chimpanzee, Orang-utan and 




Human Chimpanzee Orangutan Rhesus 
macaque 
Human -    
Chimpanzee 99 -   
Orangutan 88 89 -  
Rhesus 
macaque 
92 92 84 - 
 
 Of the 76 polymorphic sites, 8 (10.5%) occur within exons and of these 5 (6.58%) of 
all identified exonic polymorphisms are predicted to cause changes to the amino acid 
sequence. Not all non-synonymous substitutions are damaging to the structure or function of 
a protein; there are degrees of similarity between different amino acids and the replacement 
of an amino acid with a similar one is called a conservative replacement and unlikely to have a 
major effect on the protein function or structure. Non-conservative changes (or radical 
changes) are much more likely to affect the structure or function of the protein as they may 
alter the polarity, molecular weight and chemical composition (Graur et al. 2000). 
 The effect of each non-synonymous substitution on CYP3A5 protein was analysed 
using PolyPhen2 software (http://genetics.bwh.harvard.edu/pph2/) (see section 2.3.9.3). The 
results are presented in Table 5.10. Only three of the five identified non-synonymous 
mutations were predicted to be damaging to the CYP3A5 protein. 
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variant and its 
position 















Exon 8 99261651 15868A>G K266R Benign Score: 0.009 
Sensitivity:0.97 
Specificity: 0.76 
Exon 9 99260502 17017C>T R268Stop Damaging - 









 The significance of differences in the proportion of synonymous and non-synonymous 
variation can be measured by a codon-based Z test which compares the relative abundance of 
either type of polymorphism in a gene sequence and calculates the significance of the 
differences using a Bootstrap method described by (Nei and Kumar 2000). The results were 
non-significant for these analyses; (Z=0.961 and p=0.169) indicating that the proportion of 
non-synonymous variation observed in the gene does not significantly differ from the amount 
of identified synonymous variation. 
 However a paper in 2004 examining the total number of amino acid changes within 
and between primate lineages found that within 103 protein-coding genes (26,999 codons), 
147 amino acid changes were observed (0.56%) (Kitano et al. 2004). However the results for 
CYP3A5 within Ethiopia (5/502 codons; ~1%) are double that for a fraction of the total 
number of codons analysed in the original study. This suggests that there are more non-
synonymous substitutions observed within the CYP3A5 gene than for multiple protein-coding 
genes. This suggests that variants for low/non-expression of the protein, in addition to 
CYP3A5*3, CYP3A5*6 and CYP3A5*7, may be selected for within Ethiopia (positive selection) 
and selection for removing them (purifying selection) is weak. 
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5.2.4 Analysis of variation observed in the 3´ untranslated region of CYP3A5 
 A single, high frequency, variant was identified in the 3´ UTR (rs15524); see Figure 5.5 
and Table 5.6. This variant has been previously reported to be in high linkage disequilibrium 
with the CYP3A5*3 defining G allele; although a study found that this variant alone has no 
effect on CYP3A5 protein activity (Busi and Cresteil 2005). 
 
5.2.5 Analysis of the gene flanking sequence 
 A total of 9 and 16 variants were identified in the 5´ and 3´ regions re-sequenced 
either side of the CYP3A5 gene, see Figure 5.5 and Table 5.6. This included a –GT 
microsatellite repeat. ~32.9% of all identified polymorphic sites occurred in genomic 
sequence flanking the CYP3A5 gene. The proportion of variation identified in both the 5´ (9 
variants/1691 fixed sites) and 3´ (16 variants/2370 fixed sites) gene flanking regions was 
similar to that observed in the gene sequence itself (51 variants/8100 fixed sites). No 
significant differences in the proportion of variation observed between the gene sequence and 
the 5´ gene flanking region (chi-square=0.0225, p=0.8807, 1 d.f.) or the 3´ gene flanking region 
(chi-square=0.07301, p=0.7870, 1 d.f.). A comparison of the CYP3A5 sequence with larger 
flanking regions on either side of the gene may ascertain whether the proportion of variation 
within flanking regions is greater than that for an equivalent region of the gene. 
 
5.3  Variation at the CYP3A5 locus in non Ethiopian sub-Saharan 
 Africans 
 As reported in chapter 4, a novel 10 base pair deletion, identified in intron 1, was not 
predicted to affect pre-mRNA splicing by BDGP 
(http://www.fruitfly.org/seq_tools/splice.html). However given the close proximity of this 
deletion to the intron 1 splice site, experimental evidence will provide an indication of how 
this deletion may affect CYP3A5 transcription. No other identified polymorphism in the non-
Ethiopian African cohort (see Table 4.2) was predicted to affect the initiation of CYP3A5 




5.4 Comparing intra-African CYP3A5 diversity in a global context 
 To date, the full CYP3A5 coding regions have been re-sequenced in five diverse 
populations (see Table 5.12), excluding Ethiopian groups within this study [(Thompson et al. 
2004)(http://egp.gs.washington.edu/)]. The proximal promoter has been re-sequenced in 
African-Americans, Europeans and Han Chinese individuals (Thompson et al. 2004). Some re-
sequencing data have also been generated as part of the 1000 Genomes database, however the 
coverage for the majority of individuals (~700) re-sequenced within this project is still 
relatively low at X2 (Zhang and Dolan 2010). Consequently rare variants are much more 
difficult to identify; since CYP3A5 is characterised by an excess of rare variants (Thompson et 
al. 2004), the 1000 Genomes data are not ideal to compare with those generated for this study 
at present. 
 A total of 36 polymorphic sites were identified within a 13,853 base pair region of 
chromosome 7, including the CYP3A5 promoter and coding region, re-sequenced in 24 
African-Americans, 24 Europeans and 24 Han Chinese individuals (Thompson et al. 2004). 
20/36 polymorphic sites were specific to African-American individuals. The European and 
Han Chinese individuals re-sequenced had high frequencies of the CYP3A5*3 defining allele 
and a variant present in the 3´ UTR (rs15524) but had very few additional variants.  
 A total of 81 polymorphic sites were identified within a 17,222 base pair region of 
CYP3A5 re-sequenced in 95 individuals from 5 different population groups. Populations with 
recent African ancestry had more variation at the CYP3A5 locus than European, Hispanic and 
Asian populations. 
 The African data reported in this, and the previous, chapter are consistent with 
previous observations that there is more variation at the CYP3A5 locus in populations with 
recent African ancestry than in other global populations. Sub-Saharan African groups, 
including those from Ethiopia, had more variation within a 4448 base pair region of CYP3A5 
than a 17,222 base pair region re-sequenced in East Asian and Hispanic populations from the 
NIEHS cohort. Africans also had more variation within a 4448 base pair region than was 
reported for a 13,853 base pair region re-sequenced in European and Han Chinese 
populations (Thompson et al. 2004). Across the overlapping 4448 base pair region, a total of 
17 identified variants were unique to African populations; although it is interesting to note 
that the majority were singletons and none were predicted to have an effect on pre-mRNA 
splicing or gene transcription. 
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Table 5.12: A full list of all population groups in which CYP3A5 has been re-sequenced. Information is provided on the number of variant sites identified in 




N.B. All***: some CYP3A5 intronic regions have not been re-sequenced in NIEHS SNPs populations. The flanking introns have been re-sequenced 




5.4.1 Variation in the CYP3A5 gene in diverse Ethiopian populations 
 Multiple variants were identified across the CYP3A5 locus in thirteen African 
populations (also seen in chapter 4). An interesting observation is that ~30.3% of all variants 
identified within the 12,237 base pair region, re-sequenced in five Ethiopian populations, are 
singletons. Within the gene region itself ~40% of all identified Ethiopian variants are 
singletons. Additionally the proportion of non-synonymous variants was unusually high and 
twice the frequency for a much larger protein-coding genomic region (Kitano et al. 2004). 
Normally protein-coding regions and regulatory regions have functional constraint and low 
tolerance of mutations which can cause low/non-expression. The intensity of purifying 
selection (which removes damaging mutations) is determined by the degree of intolerance of 
a particular genomic site towards deleterious mutations (Graur et al. 2000). Studies of 
multiple genes have often found that genes which have high rates of protein evolution, or are 
losing their function (such as pseudogenes), have higher levels of non-synonymous mutations 
than conserved genes (Graur et al. 2000; Bachtrog 2008). The high frequencies of CYP3A5*3 in 
the Afar, Amhara, Oromo and Maale, coupled with an excess of rare variants and high 
frequencies of non-synonymous variation are consistent with signatures of a selective sweep 
at the CYP3A5 locus in Ethiopia. A comparison of the 4448 base pair region between all 
thirteen sub-Saharan African groups (see chapter 4) found that there were more rare variants 
within the Ethiopian cohort than in other populations from the sub-continent. This may be 
evidence of different regional selective pressures within sub-Saharan Africa, or a result of 
differences in population histories. 
 
5.4.2 A number of identified novel variants are predicted to affect CYP3A5 transcription and 
 protein expression in Africans 
 An intronic novel ten base pair deletion, immediately adjacent to the 3´ splice site of 
exon 1, was identified in five heterozygous individuals from West Central Africa (see Table 
4.2) and may have implications for gene transcription and protein expression. An in vitro 
splicing assay such as the exon-trapping technique (Webb et al. 2003) can be performed to 
resolve the issue. Briefly, a double stranded DNA fragment, known to contain the ten base pair 
deletion, is cloned into a bacterial vector, transformed into bacterial culture and then isolated 
and transfected into eukaryotic cells. Following incubation and extraction of mRNA, and 
reverse transcription to cDNA, an examination and comparison of the cDNA sequence from 
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the clones containing the ten base pair deletion with a clone containing the ancestral 
sequence to see how and whether the sequences differ. 
 Four identified promoter variants were predicted to have an effect on gene 
transcription in Ethiopians. It is important to note that there are significant drawbacks to 
forming conclusions from bioinformatics analysis alone. Prediction programs generate a large 
number of results, of which the majority are false positives. Transcription factor binding sites 
vary considerably in length (~6-20 base pairs), are imprecise and can often bind many 
different transcription factors (Lapidot et al. 2008). Although transcription factor binding site 
motifs can vary, there are some bases which have a high probability of occurring within the 
motifs (Lapidot et al. 2008). Prediction programmes, such as MatInspector, compare the 
observed sequence for motifs and match them against a database of known regulatory motifs 
to see if these common bases occur within the sequence and so are characteristic of a binding 
site. The probability of the input sequence being similar to common binding site motifs is 
calculated. This is called a position weight matrix where the position of a particular nucleotide 
(of the input sequence) is compared with known regulatory motifs to calculate the likelihood 
that it is a true transcription factor binding site (Lapidot et al. 2008). However, because of the 
flexibility in binding site specificity, mutations which occur in regulatory motifs are not 
necessarily going to alter the affinity for a transcription factor to a particular site. 
Additionally, transcription factors may only influence gene transcription in particular cells 
and polymorphic sites within particular motifs may be cell-type specific (Jones and Swallow 
2011). MatInspector provides tissue information for inferred binding sites, and so the 
multiple results can be filtered to identify candidate transcription factor binding sites.  
 However, only experimental methods can provide tangible evidence of the effects of 
identified polymorphisms on transcription factor binding. Electrophoretic mobility shift 
assays (EMSAs) are a straightforward way to determine the effect of nucleotide substitutions 
on transcription factor binding. Briefly, EMSA is a technique used to characterise protein/DNA 
interactions. DNA molecules are negatively charged and will migrate rapidly towards a 
positive electrode under an electric field, protein molecules which are bound to DNA will 
cause it to migrate slower through a polyacrylamide gel; the larger the protein bound to DNA 
the slower it moves through an electric field. For this assay, a short DNA fragment, of specific 
sequence and length, is radioactively labelled and incubated with purified proteins and non-
specific DNA competitors. Following incubation the complex is analysed on a polyacrylamide 
gel, a positive interaction between the radiolabelled DNA and a protein will result in a shift in 
the mobility of the DNA fragment, as determined by a comparison with a radiolabelled free 
DNA molecule as a control (Alberts 2002).  
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 EMSAs are often performed alongside DNase footprinting assays; which identify the 
DNA sequence a protein binds to. Briefly, a radiolabelled protein-bound DNA fragment, of 
known sequence and length, is incubated with a non-specific DNA cleaving restriction 
enzyme. The protein protects the DNA motif from cleavage through strong binding to the site. 
The complex is then run on a polyacrylamide gel and a gap, or footprint, is seen where the 
restriction enzyme has not been able to cut; thus identifying the DNA motif that the protein 
binds to (Alberts 2002). 
 Both EMSA and DNA footprinting techniques will provide evidence that a DNA 
fragment is capable of binding a specific protein in vitro and will identify the sequence motif. 
However it is important to note that in vivo binding is often complicated and a particular 
protein may not preferentially bind to the identified motif in vivo. 
 An interesting observation is that three of the four promoter variants, which are 
candidates for affecting CYP3A5 transcription, occur at frequencies of ≤1%; the novel ten base 
pair deletion, likely to have an effect on pre-mRNA splicing in five West Central African 
individuals, was observed at a frequency of ~0.007%; and all identified non-synonymous 
mutations were singletons. Although the proportion of all variants identified which were 
exonic variants was high (~10.5%) and of these 6.58% were non-synonymous changes. Of the 
nine previously reported candidates for causing polymorphic CYP3A5 expression (Table 5.4); 
only CYP3A5*3, CYP3A5*6 and CYP3A5*7 were identified in the African re-sequencing data.  
This suggests that CYP3A5*3, CYP3A5*6 and CYP3A5*7 are the main determinants of 
polymorphic CYP3A5 expression in all global populations that have been re-sequenced to 
date.  
 
5.4.3 Comparing African CYP3A5 variability with other global populations 
 As expected there is more variability in the CYP3A5 gene in populations with recent 
African ancestry than in other global populations. This is consistent with previous reports that 
genetic diversity within populations with recent African ancestry is greater than in non-
African populations (Tishkoff et al. 2009). A comparison of CYP3A5 variability between sub-
Saharan African populations and African-Americans found that there was more variation in 
sub-Saharan Africa (discussed further in chapters 4 and 6). Considerable European ancestry 
within African-American populations may be influencing the amount of variation observed in 
the CYP3A5 gene in this population (Reed 1969; Destro-Bisol et al. 1999). Populations with 
high frequencies of the derived CYP3A5*3 allele had an excess of rare variants, supporting a 
hypothesis of directional selection within these populations. Interestingly, large numbers of 
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rare variants were observed in all Ethiopian groups, except the Anuak. This may be evidence 
of differential selection on CYP3A5 within parts of Africa. Considerable admixture within 
North Eastern Ethiopian populations with those from the Arabian Peninsula (De Stefano et al. 
2002; Lovell et al. 2005) may also be influencing the pattern of CYP3A5 variability observed in 
the Afar, Amhara and Oromo.  
 The results from this chapter indicate that population structure at the CYP3A5 gene in 
diverse Ethiopian populations is likely to be influenced by novel, rare variants in addition to 
CYP3A5*3, CYP3A5*6 and CYP3A5*7. The following chapter will examine intra-Ethiopian 
differences alongside re-sequencing data for Coriell populations. The recent evolutionary 




6. Analysing intra-Ethiopian diversity at the CYP3A5 gene in a 
 global context 
 A number of polymorphic sites, identified in chapter 5, are novel candidates for 
causing low/non CYP3A5 expression phenotypes in Africa. Previously (Gebeyehu et al. 2011) 
reported collective frequencies of CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7 in 
Ethiopians from multiple ethnic groups, not accounting for inter-ethnic diversity. It has been 
consistently shown in this thesis that the Ethiopian Afar, Amhara and Oromo significantly 
differ from other Africans and are characteristic of both African and non-African populations. 
This chapter aims to examine intra-Ethiopian diversity across the entire CYP3A5 gene in detail 
and examine the observed diversity alongside three ethnically diverse Coriell populations 
from North America. Statistical associations between all identified polymorphic sites will be 
analysed through haplotype and linkage disequilibrium analyses. In addition, analyses of the 
allele frequency spectrum to test for significant departures from neutrality are presented. 
 
6.1 CYP3A5 variation in Ethiopia 
6.1.1. Haplotype association of Ethiopian variants 
 Haplotypes were inferred from genotype data to examine the distribution of identified 
variants on Ethiopian chromosomes. Singleton variants, which could not be inferred onto a 
specific haplotype, were omitted from this part of the analysis. 100 haplotypes were inferred 
for a 12,237bp region, see Figures 6.1a-e, and ~81% of these occurred at a frequency of <1%. 
~55% of all inferred haplotypes were defined by the CYP3A5*3 mutation alone, ~17.7% by 
CYP3A5*6 and ~0.003% by CYP3A5*7. The remaining haplotypes were all defined by the 
ancestral CYP3A5*1 allele. CYP3A5*3 defined the majority of haplotypes observed in the Afar, 
Amhara and Oromo, and CYP3A5*1 defined the majority in the Maale, and nearly all in the 
Anuak (Figure 6.2). 
 The modal CYP3A5*3 haplotype was ~7x more frequent than the second most 
frequent within this haplogroup. There were two main CYP3A5*6 haplotypes; one ~2x more 
frequent than the other. The modal CYP3A5*3 and CYP3A5*6 haplotypes are characterised by 
high levels of polymorphisms in the CYP3A5 flanking regions and a paucity of variation within 
the coding region or promoter. This is also true for the one CYP3A5*7 haplotype. 
 All non-synonymous and promoter variants predicted to affect gene transcription and 
protein translation (reported in chapter 5), occur on CYP3A5*1 haplotype backgrounds. Each 
identified non-synonymous polymorphism was a singleton; as a result not all exonic 
polymorphisms could be inferred onto specific CYP3A5*1 haplotypes.  
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Figure 6.1a: Inferred CYP3A5*3 haplotypes for five Ethiopian populations. Positions marked in yellow are ancestral alleles at each position (as inferred from the chimpanzee 
sequence) and blue are the derived. The position defining CYP3A5*3 is shown in red. Each row corresponds to a haplotype and each column to a polymorphic site. The numbers above each 
column correspond to the position of each polymorphic site relative to the ATG start codon (NCBI, Build 132, http://www.ncbi.nlm.nih.gov/). The numbers at the end of each row correspond 




Figure 6.1b: Inferred CYP3A5*6 haplotypes for five Ethiopian populations. Positions marked in yellow are ancestral alleles at each position (as inferred from the chimpanzee 
sequence) and blue are the derived. The position defining CYP3A5*6 is shown in red. Each row corresponds to a haplotype and each column to a polymorphic site. The numbers above each 
column correspond to the position of each polymorphic site relative to the ATG start codon (NCBI, Build 132, http://www.ncbi.nlm.nih.gov/). The numbers at the end of each row correspond 






Figure 6.1c: Inferred CYP3A5*7 haplotypes for five Ethiopian populations. Positions marked in yellow are ancestral alleles at each position (as inferred from the chimpanzee 
sequence) and blue are the derived. The position defining CYP3A5*7 is shown in red. Each row corresponds to a haplotype and each column to a polymorphic site. The numbers above each 
column correspond to the position of each polymorphic site relative to the ATG start codon (NCBI, Build 132, http://www.ncbi.nlm.nih.gov/). The numbers at the end of each row correspond 







Figure 6.1d: Inferred CYP3A5*3/*6 recombinant haplotypes for five Ethiopian populations. Positions marked in yellow are ancestral alleles at each position (as inferred 
from the chimpanzee sequence) and blue are the derived. The position defining CYP3A5*3 and CYP3A5*6 are shown in red. Each row corresponds to a haplotype and each column to a 
polymorphic site. The numbers above each column correspond to the position of each polymorphic site relative to the ATG start codon (NCBI, Build 132, http://www.ncbi.nlm.nih.gov/). The 






Figure 6.1e: Inferred CYP3A5*1 haplotypes for five Ethiopian populations. Positions marked in yellow are ancestral alleles at each position (as inferred from the chimpanzee 
sequence) and blue are the derived. Each row corresponds to a haplotype and each column to a polymorphic site. The numbers above each column correspond to the position of each 
polymorphic site relative to the ATG start codon (NCBI, Build 132, http://www.ncbi.nlm.nih.gov/). The numbers at the end of each row correspond to the number of Ethiopian chromosomes 







Figure 6.2a: The frequency of CYP3A5 haplotypes (%) within each Ethiopian population. The key is numbered according to the haplotype codes assigned in Figures 6.1a-e; 




Figure 6.2b: A map showing the spatial distribution, of CYP3A5 haplotypes, across Ethiopia. The map 
image has been taken from: http://commons.wikimedia.org/wiki/File:Ethiopia_location_map.svg?uselang=fr, and 













 An interesting observation is that levels of diversity in the CYP3A5*3 haplogroup are 
highest in populations closest to the Arabian Peninsula. CYP3A5*7 haplotypes are observed at 
low frequencies in Ethiopia and are also found in the two populations located furthest from 
the Arabian Peninsula (Anuak and Maale).  
 
6.1.2 Examining linkage disequilibrium across CYP3A5 
 Pairwise linkage disequilibrium (LD), calculated using the D´ parameter, was 
measured within Ethiopia as a whole and within each of the five populations. Genotype data 
for all polymorphic loci, except singletons, were included for LD analyses. The results are 
consistent with those for haplotype inference. Within Ethiopia, the majority of loci are in 
complete LD (D´=1), see Supplementary Figure 3 on CD, consistent with previous studies 
(Thompson et al. 2004; Thompson et al. 2006) although not all associations are statistically 
significant. High levels of non-significant LD are a result of an excess of low frequency variants 
in the dataset. These variants occur on a single haplotype background but, due to their low 
frequencies, are not significantly associated. However D´=1 indicating that there is no 
recombination between specific loci, even if the association is not statistically significant. 
 There are distinct LD patterns, relating to the CYP3A5*3 and CYP3A5*6 variants, see 
Table 6.1. Across the 12,237bp region, CYP3A5*3 and CYP3A5*6 are in high LD with variants 
either side of the gene region. LD extends across a region of up to 35,318bp (bp); between 
variants located 2191bp upstream of the ATG start codon; and those located 2385bp 
downstream of exon 13.  
 D´ between CYP3A5*3 and CYP3A5*6 is equal to 1 and the association between the two 
loci is statistically significant. The CYP3A5*6 allele almost always occurs on a haplotype with a 
CYP3A5*1 allele. The high LD between CYP3A5*3 and a variant at position 31605 (rs15524) 
and another at position 32244 (rs4646456) reflects the most common CYP3A5*3 Ethiopian 
haplotype. The high LD between CYP3A5*6 and variants in the 5´ [rs10270499 and rs776741] 
and 3´ [rs57922842, rs4646456, rs4646457, and rs4646458] flanking regions also reflect the 
most common CYP3A5*6 haplotype observed in Ethiopia. CYP3A5*7 allele frequencies are low 
and therefore very little can be deduced about LD from this locus alone. The results show that 
LD across CYP3A5 is likely to extend beyond the gene region. 
 LD between CYP3A5*7 and other polymorphic sites is insignificant (Table 6.1). This is 
almost certainly because the variant is observed at low frequency within Ethiopia.
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Table 6.1: Pairwise LD between each of CYP3A5*1/CYP3A5*3 (rs776746), CYP3A5*6 (rs10264272) and 
CYP3A5*7 (rs41303343) defining loci and all identified polymorphic sites across the Ethiopian cohort. 
Statistically significant D´ values, following Bonferroni correction (adjusted p-value = 0.00096; for 52 tests), are 




 CYP3A5 region Position of 
CYP3A5 variant 
relative to ATG 
start codon 
 Pairwise D´ values 






99279710  5´ flanking 
region 
-2191  0.944 1 1 
99279308   -1789  0.992 1 1 
99279136   -1617  0.896 0.923 1 
99279051   -1532  0.999 1 1 
99278876   -1343  0.649 0.033 1 
99278862   -1308  0.649 0.033 1 
99278827   -1252  1 1 1 
99278522   -1003  1 0.737 1 
99278314  Proximal 
promoter 
-795  0.894 0.542 1 
99278267   -748  0.599 0.071 1 
99278224   -705  1 0.158 1 
99278070   -551  1 0.969 1 
99277593   -74  1 0.736 1 
99277392  Intron 1 127  1 1 1 
99277337   182  1 1 1 
99272310  Intron 2 5209  0.09 0.962 1 
99272290   5229  1 1 1 
99272275   5244  0.999 1 1 
99272103  Intron 3 5416  0.999 0.224 1 
99272009   5510  0.914 0.973 1 
99271928   5591  0.22 0.467 1 
99271853   5666  0.778 0.004 1 
99271808   5711  0.122 0.962 1 
99271778   5741  0.881 0.455 1 
99270539   6980  - 0.91 0.992 
99270504   7201  1 0.27 1 
99270164  Intron 4 7355  1 1 1 
99264352  Intron 5 13167  1 0.368 1 
99264149  Intron 6 13370  0.09 1 1 
99262835  Exon 7 14684  0.91 - 1 
99262642  Intron 7 14877  1 0.837 1 
99261737   15782  0.909 0.995 1 
99261583  Intron 8 15936  0.992 1 1 
99260407  Intron 9 17112  1 1 1 
99260362   17157  0.894 0.542 1 
99260170   17349  1 0.593 1 
99258524   18995  1 0.998 1 
99258316   19203  0.992 1 1 
99250397  Exon 11 27125-27126  0.992 1 - 
99247647  Intron 12 29872  0.992 1 1 
99247503   30016  1 0.994 1 
99246026   31493  0.938 1 1 
99245914  3´ untranslated 
region 
31605  0.902 0.956 0.999 
99245499  3´ flanking 
region 
32020  0.994 0.111 1 
99245373   32146  1 1 1 
99245364   32155  0.937 1 1 
99245311   32208  0.881 0.455 1 
99245280   32239  0.94 0.895 0.991 
99245275   32244  0.143 0.264 1 
99245241   32278  1 0.111 1 
99245013   32506  0.923 0.923 1 
99244392   33127  0.92 0.737 1 
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6.1.3 The CYP3A5 allele frequency spectrum and analyses for departures from neutrality 
 A total of 76 polymorphic sites were identified in 379 individuals from five Ethiopian 
populations (chapter 5). A summary of the number of polymorphic sites, and singleton 
variants, identified in each ethnic group is shown in Table 6.2.  
 
Table 6.2: Molecular diversity estimates for the five Ethiopian populations. Percentages expressed in 
brackets indicate the proportion of variants, identified within a specific sample set, which are 
singletons. 
 
Sample set Number of identified polymorphic 
sites 
Number of variants which occur on a 
single chromosome 
Afar 37 8 (21.6%) 
Amhara 41 6 (14.6%) 
Anuak 49 17 (34.7%) 
Maale 45 9 (20%) 
Oromo 42 23 (57.8%) 
 
 The overall nucleotide diversity within the Ethiopian cohort is 4.7 x 10-4 and Tajima’s 
D is -1.48; indicating a skew towards rare variants. Nucleotide diversity ( ) varies between all 
five sample sets; see Table 6.3. The Afar, Amhara and Oromo all have lower measures of 
nucleotide diversity than the Anuak and Maale. Nucleotide diversity, in all five Ethiopian 
populations, was comparatively lower than for a similarly sized region in African-Americans 
(see Table 6.8). 
 Nucleotide diversity was examined for departures from neutrality using Tajima’s D, Fu 
and Li’s D* and F*, and Fu’s FS statistics, see Table 6.3. These methods evaluate whether there 
is an excess of rare variants within the re-sequenced region; a pattern consistent with a 
selective sweep or directional selection. All statistics reported negative values for each 
Ethiopian population, indicating a skew towards rare variants. However only Fu’s FS reported 
a significant departure from neutrality, in all five Ethiopian populations, before and after 
Bonferonni correction (p<0.0001 for all populations).  
 The Afar, Amhara and Oromo have the largest skew towards rare variants. 
Interestingly, estimates for Tajima’s D for these three populations are comparable to those for 
Han Chinese individuals (-1.21) (Thompson et al. 2004). Although the values suggest that the 
skew towards rare variants is not as high as reported for Europeans (-2.11) but much more 
than for African-Americans (-1.13). 
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Table 6.3: Molecular diversity indices for a 12,237bp CYP3A5 region re-sequenced in five Ethiopian 
populations. All five Ethiopian groups showed a significant departure from neutrality, following 
Bonferonni correction (correction for 5 tests; p≤0.01), based on the Fu’s FS p-value. 
 
 Ethiopian sample set 
 Afar Amhara Anuak Maale Oromo 
Nucleotide 
diversity ( ) 
3.91 x 10
-4
 3.8 x 10
-4
 5.14 x 10
-4
 4.82 x 10
-4
 3.55 x 10
-4
 
Tajima’s D -1.22 -1.57 -0.95 -0.75 -1.35 
Fu and Li’s D* -1.14 0.35 -2.09 0.65 0.25 
Fu and Li’s F* -1.41 -0.34 -1.93 0.08 -0.50 




6.1.4 CYP3A5 haplotype diversity 
 The entire Ethiopian cohort (379 individuals; 758 chromosomes) was used to analyse 
haplotype diversity between inferred CYP3A5 expressers and low/non-expressers; and 
between the five CYP3A5 haplotype classes: CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*3/*6 
and CYP3A5*7. The highest levels of gene diversity were observed in the Anuak (0.914 ± 
0.012) and the lowest in the Afar (0.742 ± 0.036). Exact tests of population differentiation 
were performed to assess the significance of pairwise inter-population differences in gene 
diversity (Table 6.4). Consistent with the results from the geographic survey (chapter 3), the 
Afar, Amhara and Oromo do not significantly differ from each other, i.e. haplotype diversity 
estimates are similar in all three groups. The Anuak differ from all other Ethiopian sample 
sets; as do the Maale.  
 Within Ethiopia, gene diversity is highest in the Anuak, Maale and Amhara. The Anuak 
and Maale have the highest frequencies of CYP3A5*1 haplotypes; which are the most diverse 
haplogroup (Table 6.5, Figure 6.1). This is likely to explain the high levels of gene diversity 




Figure 6.3: Haplotype diversity, calculated using Nei’s h, for each of the five Ethiopian sample sets. 
Nei’s h was calculated using Arlequin and the test_h_diff program written by Mike Weale (Thomas et al. 
2002); results from both programmes were identical. Error bars denote standard deviation. Values 






























Table 6.4: Nei’s h of the 12,237bp CYP3A5 region across populations. Significance of pairwise 
differences, in diversity estimates, was measured using an exact test of population differentiation 
(executed in Arlequin software). P-Values, shown in the bottom left corner of the grid, which are 
significant after Bonferroni correction (for 5 tests; adjusted p-value = 0.01) are highlighted in green. 
 
Nei’s h 0.742 0.833 0.914 0.897 0.781 
 Afar Amhara Anuak Maale Oromo 
Afar *     
Amhara 0.04  *    
Anuak <0.001  <0.001  *   
Maale <0.001  <0.001  0.003  *  






Table 6.5: A comparison of heterozygosity in each of the five CYP3A5 haplogroups: CYP3A5*1, 
CYP3A5*3, CYP3A5*6, CYP3A5*3/CYP3A5*6 and CYP3A5*7. Significance was measured using the h-diff 
test (Thomas et al. 2002). Values which were significant after Bonferroni correction (for 5 tests; 
adjusted p-value = 0.01) are highlighted in green. 
 
Nei’s h 0.952 0.545 0.571 0.000 0.000 
 CYP3A5*1 CYP3A5*3 CYP3A5*6 CYP3A5*7 CYP3A5*3/*6 
CYP3A5*1 *     
CYP3A5*3 <0.0001 *    
CYP3A5*6 <0.0001 0.59 *   
CYP3A5*7 <0.0001 <0.0001 <0.0001 *  
CYP3A5*3/*6 <0.0001 <0.0001 <0.0001 <0.0001 * 
 
  
 The low/non-expresser haplogroups (CYP3A5*3, CYP3A5*6, CYP3A5*3/*6 and 
CYP3A5*7) have significantly less diversity than CYP3A5*1 haplotypes. One possible 
explanation is the CYP3A5*3, CYP3A5*6 and CYP3A5*7 defining alleles are younger than the 
ancestral CYP3A5*1. New, and neutral, haplotypes generally fluctuate in their frequencies and 
have not had an equivalent amount of time to acquire additional mutations, compared to 
ancestral lineages.  
 The most common low/non-expresser CYP3A5*3 and CYP3A5*6 haplotypes, observed 
in Ethiopia, have very little variation over a large genomic region, i.e. they are characterised 
by extended haplotype homogeneity (Figures 6.1a-b). This may be a result of directional 
selection on particular CYP3A5 variants (Sabeti et al. 2002). CYP3A5*7 is at low frequency in 
Ethiopia and so not much can be inferred about selection on this allele; hence the low Nei’s h 
calculated score. A recombinant CYP3A5*3/CYP3A5*6 haplotype is observed in Ethiopia, 
although its low frequency suggests that CYP3A5*3 and CYP3A5*6 are subject to independent 
selective pressures and events. 
 A comparison of diversity in each CYP3A5 haplotype class, by Ethiopian group, is 
shown in Figure 6.4. CYP3A5*7 and CYP3A5*3/*6 recombinant haplotypes are observed at low 
frequencies within the dataset; and that there is a large variance around the estimates of Nei’s 
h. CYP3A5*1 haplotypes are the most diverse of all haplotype classes in all Ethiopian sample 
sets. CYP3A5*3 and CYP3A5*6 are considerably less diverse than CYP3A5*1 haplotypes across 




Figure 6.4: A comparison of diversity in each of the five CYP3A5 haplotype classes (CYP3A5*1, 
CYP3A5*3, CYP3A5*6, CYP3A5*3/*6 and CYP3A5*7) by Ethiopian sample set. Nei’s h was calculated 
using the h-diff sets of function and executed in the R-programming environment (Thomas et al. 2002). 






























 Nei’s h was used to compare diversity between CYP3A5 expresser and low/non-
expresser haplotypes within each of the five populations, see Figure 6.5. Of the novel 
mutations predicted to affect CYP3A5 gene transcription and/or protein translation only one 
could be inferred onto a particular (CYP3A5*1) haplotype. However, as outlined in section 
5.4.2, bioinformatics software can only predict whether a polymorphism may have an effect 
on gene transcription, mRNA processing or protein translation; no variant can be conclusively 
classed as either expresser or low/non-expresser based on bioinformatics analysis alone. 
Therefore individuals carrying this variant were excluded from these analyses. Only variants 
which have been shown to affect CYP3A5 expression in vitro/in vivo were classified as 
low/non-expresser variants. This meant that, of all identified CYP3A5 variants, only CYP3A5*3, 
CYP3A5*6 and CYP3A5*7 were considered low/non-expresser and the remaining 





Figure 6.5: A comparison of heterozygosity between CYP3A5 expresser and low/non-expresser 
haplotypes in each Ethiopian sample set. Nei’s h and the significance of differences were measured 
using the h-diff test (Thomas et al. 2002). All comparisons were significant following Bonferonni 
































 Within each population, significantly higher levels of diversity were observed on 
expresser haplotypes than on low/non-expresser haplotype backgrounds in all five Ethiopian 
sample sets; consistent with the results for nucleotide diversity. 
 
6.1.5 Examining population differentiation at the CYP3A5 locus in Ethiopia 
 Inter-ethnic differentiation at the CYP3A5 locus in Ethiopia was measured by 
calculating pairwise FST values and performing an exact test of population differentiation 
(both executed in Arlequin). Pairwise FST values were calculated using allele frequencies 
instead of haplotype information. This allowed for all polymorphic information, including 
singleton variants, to be accounted for when evaluating pairwise population differences. 
Pairwise FST values are shown in Table 6.6 and p-values from the exact test of population 





Table 6.6: Pairwise FST values, based on CYP3A5 genotypic data for five Ethiopian populations. Pairwise 
FST values are shown in the bottom left side of the Table, the corresponding p-values are shown in the 
top right of the Table. P-values which are significant after Bonferroni correction (adjusted p-value = 
0.0125; correction for 4 tests) are highlighted in green and the corresponding FST values are shown in 
red bold. 
 
  Afar Amhara Anuak Maale Oromo 


















Maale 0.01931 0.0212 0.02614 * 0.00743 ± 
0.0009 




Table 6.7: The resultant p-values from an exact test of population differentiation, based on Ethiopian 
genotypic data. Values shown in the Table correspond to p-values from pairwise population 
comparisons. P-values which are significant after Bonferroni correction (adjusted p-value = 0.0125; 
correction for 4 tests) are highlighted in green. 
 
 Afar Amhara Anuak Maale Oromo 
Afar *     
Amhara 0.75305 *    
Anuak 0.00000  0.00368  *   
Maale 0.00000  0.21842  0.01469  *  
Oromo 0.60824  0.95138  0.00126 0.00241 * 
 
 A principal co-ordinates (PCO) plot was constructed, using pairwise FST values, to 
visualise population sub-structuring, see Figure 6.6. The Anuak significantly differ from the 
Afar, Amhara and Oromo; whereas the Maale are midway between Afro-Asiatic speakers and 
the Nilo-Saharan speaking Anuak. 
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Figure 6.6: A Principal Co-ordinates (PCO) plot based on pairwise FST values between the five 
Ethiopian populations. Pairwise FST values were calculated using Ethiopian CYP3A5 genotype 
data for the 12,237bp re-sequenced region. Axis labels show the percentage of genetic 






6.2 Examining Ethiopian data in a global context 
6.2.1 The global CYP3A5 allele frequency spectrum 
 The African CYP3A5 data were analysed in a global context by integrating the results 
with those previously published for datasets from the Coriell repositories (see chapter 2). A 
total of 8063bp of re-sequencing data, including the CYP3A5 promoter and coding region, 
overlapped between the Ethiopian and Coriell datasets.  
 Nucleotide diversity is highest in African-Americans, the Anuak and Maale (Table 6.8). 
Nucleotide diversity levels are higher across the Ethiopian cohort than in Europeans and Han 
Chinese. Sliding windows analyses (using DnaSP software) were performed to analyse how 
nucleotide diversity varies across the re-sequenced 8063bp region in each population. A 
“diversity window” is a specific sized region, of the total data, for which  is calculated. The 
8063bp fragment was divided up into overlapping windows (each 1000bp in length) which 
were generated every 100bp of sequence;  was then calculated for each window. This 
generated a series of  values which were plotted to show a “continuous” change in diversity, 
see Figure 6.7 (executed in the R-programming environment using a code written by Mr 
Pawel Zmarz).  
 African-Americans appear to have more diversity across the region than all other 
global populations. Within each population, there were sharp rises in diversity within a region 
at position ~2200-2300 (corresponding to the CYP3A5*1/CYP3A5*3 locus). Within all 
populations of recent African ancestry there was also a peak at position 4000, corresponding 
to the CYP3A5*6 locus. CYP3A5*7 was observed at low frequency in the global cohort (2 
heterozygous individuals) and so did not affect diversity scores. Every population also had a 
peak at position at ~7700, corresponding to the position of the variant rs15524. This variant 
is often in high LD with the CYP3A5*3 variant; although has no effect on gene transcription, 
mRNA processing or protein translation (Busi and Cresteil 2005). 
  
 195 
Figure 6.7: Sliding window analysis of diversity across an 8063bp CYP3A5 region in 8 populations. Increases in pi ( ) at position 2000 and 4000 correspond to CYP3A5*1/CYP3A5*3 and CYP3A5*6 











6.2.2 Tests for departures from neutrality 
 Molecular diversity indices and tests of departures from neutrality are shown in 
(Table 6.8). A comparison of the ratio of synonymous to non-synonymous variation within 
human populations and between species (chimpanzee and human comparisons), by a 
McDonald-Kreitman test, was not significant. The results of the HKA test, comparing intra- 
and inter-species CYP3A5 diversity were not significant (p=0.6346). A non-significant result 
suggests that the observed intra- and inter-species diversity do not significantly differ from 
neutral expectations (Kimura 1979). A non-significant p-value obtained here may be due to 
the paucity of variation, and excess of rare variants, identified in the global cohort. 
 The results of Tajima’s D, Fu and Li’s D* and F*, Fu and Li’s F and D (comparison with 
the chimpanzee), and Fu’s FS analyses indicated a global skew towards rare variants (Table 
6.8). Fu and Li’s D* and F* analyses reported a significant departure from neutrality for both 
Europeans and the Anuak; although the results were only significant for individuals of recent 
European ancestry following Bonferonni correction for multiple testing. Fu and Li’s FS 
reported a significant departure from neutrality for 7 of the 8 populations after Bonferonni 
correction. Strobeck’s S calculates the probability of obtaining an equal number, or fewer, 
haplotypes than observed based on the gene frequency distribution. The results for all 8 
populations were significant (p<0.0001 for every comparison); indicating that the CYP3A5 
haplotype structures observed in the global cohort, given the gene frequency data are atypical 
from neutral expectations. That is the distribution of all identified variants on haplotypes is 
not consistent with neutral expectations. The results from Strobeck’s S are consistent with 
Fu’s FS which found that the number of haplotypes defined by rare mutations significantly 
differs from neutral expectations. 
 An excess of high frequency derived alleles may be seen soon after a selective sweep 
has completed or during an ongoing selective sweep. This can be assessed using the H test 
(Fay and Wu 2000). The results of the H test for CYP3A5 were not statistically significant 
within any population (p>0.05), however nucleotide diversity is low at this locus and this may 
be affecting the calculation, as reported previously (Thompson et al. 2004). 
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Table 6.8: A summary of the tests for departures from neutrality for the 8063bp overlapping region of CYP3A5. Statistically significant departures from 
neutrality, following Bonferonni correction (correction for 8 tests; adjusted p≤0.00625) are shown in bold and highlighted in green. 
 
 Global populations Ethiopian populations 
 African-
Americans 
Europeans Han Chinese Afar Amhara Anuak Maale Oromo 
Sample size 23 24 23 75 76 76 76 76 
Nucleotide 
diversity ( ) 
5.4 x 10
-4
 9 x 10
-5
 1.1 x 10
-4
 2.1 x 10
-4
 2.5 x 10
-4
 3.6 x 10
-4
 3.5 x 10
-4





0.475 0.50 0.777 0.462 0.475 0.576 1.00 0.777 
Tajima’s D -1.04 -1.92 -1.21 -1.46 -1.13 -1.26 -0.96 -1.79 
Fu and Li’s D* -0.97 -2.86 -1.82 -1.19 0.12 -2.72 -0.11 -1.05 
Fu and Li’s F* -1.17 -3.00 -1.91 -1.54 -0.43 -2.57 -0.53 -1.58 
Fu and Li’s D  -0.64 -1.37 -1.45 -1.56 -0.08 -1.93 0.73 -0.96 
Fu and Li’s F  -0.92 -1.81 -1.55 -1.79 -0.52 -1.96 0.13 -1.48 
Fu’s FS -31.06 -5.71 -1.54 -9.48 -11.74 -18.44 -11.08 -22.84 
Strobeck’s S 1.00 0.999 0.929 1.00 1.00 1.00 1.00 1.00 
Fay and Wu’s H 
statistic 
-0.13140 -3.25532 -1.89372 0.10774 -0.23998 -0.47177 -0.87086 -1.75514 
 
N.B: Statistics highlighted in blue were performed using overlapping sequence from the chimpanzee genome as an out-group. For the McDonald-
Kreitman test (based on coding region variation only) and Strobeck’s S values are shown. 
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6.2.3 Haplotype associations of CYP3A5 alleles 
 Figures 6.8a-e show inferred haplotypes, for the 8063bp region, within each of the 8 
populations. The inferred haplotypes confirm the results from sliding windows analyses; 
there are four main haplogroups, each defined by one of CYP3A5*1, CYP3A5*3, CYP3A5*6, 
CYP3A5*7, although three low frequency CYP3A5*3/*6 haplotypes were observed.  
 CYP3A5*3, CYP3A5*6 and CYP3A5*7 haplotypes are characterised by a paucity of 
additional variation. Fewer CYP3A5*3 haplotypes were observed in Ethiopia than in the 
Coriell datasets; although CYP3A5*3 haplotype diversity is higher in the Oromo and Amhara 
than in other Ethiopian groups. CYP3A5*6 haplotypes are largely homogeneous between all 
populations in which they were observed. CYP3A5*7 was only observed, at low frequency, in 
Ethiopia. Diversity was highest in the CYP3A5*1 haplogroup. 
 Approximately 98% of European and 83% of Han Chinese haplotypes are defined by 
the CYP3A5*3 mutation as are the majority of Ethiopian Afar (~64%), Amhara (~67%) and 
Oromo (~67%) chromosomes (Figure 5.8). Notably, the haplotypes observed in these three 
Ethiopian groups are typical of those observed in non-Africans. Within an 8063bp region of 
CYP3A5, fewer CYP3A5*3 and CYP3A5*6 haplotypes have been inferred from the genotype 
data than for a 12,237bp region in the same individuals. A comparison of inferred haplotypes 
for the two re-sequenced regions suggests there are more high frequency derived variants in 
CYP3A5 flanking regions, as little as ≤2000bp in size, than across the actual gene region itself 
(see section 5.2.5). These can define additional CYP3A5*3 and CYP3A5*6 haplotypes, although 
are unlikely to affect CYP3A5 transcription or translation.  
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Figure 6.8a: Inferred CYP3A5*3 haplotypes for 8 populations. Haplotype information for African-American, European and Han Chinese populations has been adapted 
from (Thompson et al. 2004), so that only data for the overlapping genomic region are shown. Positions marked in yellow are ancestral alleles at each position (as inferred from 
the chimpanzee sequence) and blue are the derived. Each row corresponds to a haplotype and each column to a polymorphic site. The numbers above each column correspond 
to the position of each polymorphic site relative to the ATG start codon (NCBI, Build 132, http://www.ncbi.nlm.nih.gov/). The locus which defines the CYP3A5*1/CYP3A5*3 




Figure 6.8b: Inferred CYP3A5*6 haplotypes for 8 populations. Haplotype information for African-American, European and Han Chinese populations has been 
adapted from (Thompson et al. 2004), so that only data for the overlapping genomic region are shown. Positions marked in yellow are ancestral alleles at each 
position (as inferred from the chimpanzee sequence) and blue are the derived. Each row corresponds to a haplotype and each column to a polymorphic site. The numbers above 
each column correspond to the position of each polymorphic site relative to the ATG start codon (NCBI, Build 132, http://www.ncbi.nlm.nih.gov/). The locus which defines the 
CYP3A5*6 allele is highlighted in green. “N” refers to the number of chromosomes that are of a particular haplotype.  
 
 









Figure 6.8c: Inferred CYP3A5*7 haplotypes for 8 populations. Haplotype information for African-American, European and Han Chinese populations has been 
adapted from (Thompson et al. 2004), so that only data for the overlapping genomic region are shown. Positions marked in yellow are ancestral alleles at each 
position (as inferred from the chimpanzee sequence) and blue are the derived. Each row corresponds to a haplotype and each column to a polymorphic site. The numbers above 
each column correspond to the position of each polymorphic site relative to the ATG start codon (NCBI, Build 132, http://www.ncbi.nlm.nih.gov/). The locus which defines the 
CYP3A5*7 allele is highlighted in green. “N” refers to the number of chromosomes that are of a particular haplotype.  
 
 









Figure 6.8d: Inferred recombinant CYP3A5*3/*6 haplotypes for 8 populations. Haplotype information for African-American, European and Han Chinese 
populations has been adapted from (Thompson et al. 2004), so that only data for the overlapping genomic region are shown. Positions marked in yellow are 
ancestral alleles at each position (as inferred from the chimpanzee sequence) and blue are the derived. Each row corresponds to a haplotype and each column to a polymorphic 
site. The numbers above each column correspond to the position of each polymorphic site relative to the ATG start codon (NCBI, Build 132, http://www.ncbi.nlm.nih.gov/). The 
two loci which define the CYP3A5*3 and CYP3A5*6 alleles are highlighted in green. “N” refers to the number of chromosomes that are of a particular haplotype.  
 






Figure 6.8e: Inferred CYP3A5*1 haplotypes for 8 populations. Haplotype information for African-American, European and Han Chinese populations has been adapted from (Thompson et al. 2004), 
so that only data for the overlapping genomic region are shown. Positions marked in yellow are ancestral alleles at each position (as inferred from the chimpanzee sequence) and blue are the derived. The numbers 
above each polymorphic site correspond to the position of each polymorphic site relative to the ATG start codon (NCBI, Build 132, http://www.ncbi.nlm.nih.gov/). “N” refers to the number of chromosomes that are of a 
particular haplotype.  
 




Figure 6.9a: The proportion of inferred CYP3A5 haplotypes, for an 8063bp region, in each of 8 populations. Each haplotype has been numbered from 1-72 and 













African-American Asian Caucasian Afar Amhara Anuak Maale Oromo
The proportion of CYP3A5 haplotypes within 8 global populations
1 (*3) 2 (*3) 3 (*3) 4 (*3) 5 (*3) 6 (*3) 7 (*3) 8 (*3) 9 (*3) 10 (*3) 11 (*3) 12 (*3)
13 (*3) 14 (*3) 15 (*3) 16 (*3) 17 (*3) 18 (*3) 19 (*3) 20 (*3) 21 (*3) 22 (*3) 23 (*3) 24 (*3)
25 (*3) 26 (*3) 27 (*3) 28 (*3) 29 (*3) 30 (*6) 31 (*6) 32 (*6) 33 (*6) 34 (*6) 35 (*6) 36 (*6)
37 (*7) 38 (*3/*6) 39 (*3/*6) 40 (*1) 41 (*1) 42 (*1) 43 (*1) 44 (*1) 45 (*1) 46 (*1) 47 (*1) 48 (*1)
49 (*1) 50 (*1) 51 (*1) 52 (*1) 53 (*1) 54 (*1) 55 (*1) 56 (*1) 57 (*1) 58 (*1) 59 (*1) 60 (*1)
61 (*1) 62 (*1) 63 (*1) 64 (*1) 65 (*1) 66 (*1) 67 (*1) 68 (*1) 69 (*1) 70 (*1) 71 (*1) 72 (*1)
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CYP3A5*1 haplotype diversity in 8 global populations
40 (*1) 41 (*1) 42 (*1) 43 (*1) 44 (*1) 45 (*1) 46 (*1) 47 (*1) 48 (*1) 49 (*1) 50 (*1)
51 (*1) 52 (*1) 53 (*1) 54 (*1) 55 (*1) 56 (*1) 57 (*1) 58 (*1) 59 (*1) 60 (*1) 61 (*1)

















African-Americans Han Chinese European 
Caucasians
Afar Amhara Anuak Maale Oromo
CYP3A5*3 haplotype diversity within 8 global populations
1 (*3) 2 (*3) 3 (*3) 4 (*3) 5 (*3) 6 (*3) 7 (*3) 8 (*3) 9 (*3) 10 (*3)
11 (*3) 12 (*3) 13 (*3) 14 (*3) 15 (*3) 16 (*3) 17 (*3) 18 (*3) 19 (*3) 20 (*3)
21 (*3) 22 (*3) 23 (*3) 24 (*3) 25 (*3) 26 (*3) 27 (*3) 28 (*3) 29 (*3)
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African-Americans Han Chinese European 
Caucasians
Afar Amhara Anuak Maale Oromo
CYP3A5*6 haplotype diversity within 8 global populations
30 (*6) 31 (*6) 32 (*6) 33 (*6) 34 (*6) 35 (*6) 36 (*6)
 
 





























CYP3A5*3/*6 haplotype diversity in 8 global populations
38 (*3/*6) 39 (*3/*6)
 
 
Note that CYP3A5*6, CYP3A5*7 and CYP3A5*3/*6 haplotypes are not observed in every global 
population (see Figures 5.9d-f). 
 
6.2.4 Analysing Ethiopian haplotype diversity in a global context  
 Gene diversity appears to be highest in African-Americans and lowest in Europeans 
and Han Chinese (Figure 6.9a). The CYP3A5*1 haplogroup is most diverse in the Anuak and 
Maale (Figure 6.9b), but the Anuak have the lowest levels of CYP3A5*3 haplogroup diversity in 
Ethiopia (Figure 6.9c); the Amhara and the Oromo have the highest. African-Americans also 
have high levels of haplotype diversity; which appears to be higher than the Ethiopian groups 
(Figures 6.9a-d). 
 A global comparison of haplotype diversity, see Table 6.9, found that all five Ethiopian 
groups significantly differ from other global populations. Inter-Ethiopian comparisons were 
consistent with all results reported throughout this thesis; the Afar, Amhara and Oromo 
cluster together whereas the Anuak differ from every Ethiopian population. The Maale are 
intermediate between the Afar, Amhara and Oromo cluster and the Anuak. Similarities 
between the Maale, Amhara and Oromo may be due to their similar frequencies and 
compositions of CYP3A5*3 haplotypes. African-Americans differ from all other global 
populations, as do Europeans and Han Chinese. 
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Table 6.9: Nei’s h to compare heterozygosity in an 8063bp CYP3A5 in 8 populations. Nei’s h was calculated using the h-diff test (Thomas et al. 2002) and 
implemented in the R-programming environment. Significant pairwise differences were assessed using an exact test of population differentiation (executed in 
Arlequin software). Pairwise comparisons which were significant after Bonferroni correction are highlighted in green [adjusted p-value = 0.00625; correction 
for 8 tests]. 
 
Nei’s h 0.963 0.514 0.589 0.623 0.770 0.865 0.850 0.744 
 African-Americans Han Chinese Europeans Afar Amhara Anuak Maale Oromo 
African-Americans *        
Han Chinese <0.00001  *       
Europeans <0.00001  0.00046  *      
Afar <0.00001 <0.00001 0.00007  *     
Amhara <0.00001 <0.00001 0.00056  0.002  *    
Anuak <0.00001  <0.00001  <0.00001  <0.00001 <0.00001  *   
Maale <0.00001  <0.00001  <0.00001  <0.00001  0.032  0.00026 *  
Oromo <0.00001 0.00181  0.00040  0.129 0.791  <0.00001 0.011 * 
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Table 6.10: Nei’s h to compare heterozygosity in each of five major CYP3A5 haplotypes classes in eight 
populations. Nei’s h was calculated using the h-diff test (Thomas et al. 2002) and implemented in the R-
programming environment. Pairwise comparisons which were significant after Bonferroni correction 
are highlighted in green [adjusted p-value = 0.01; correction for 5 tests]. 
 
Nei’s h 0.921 0.481 0.146 0.000 0.6 
 CYP3A5*1 CYP3A5*3 CYP3A5*6 CYP3A5*7 CYP3A5*3/CYP3A5*6 
CYP3A5*1 *     
CYP3A5*3 <0.000001 *    
CYP3A5*6 <0.000001 <0.000001 *   
CYP3A5*7 <0.000001 <0.000001 0.0005 *  
CYP3A5*3/CYP3A5*6 0.068 0.849 0.172 0.179 * 
 
 
Figure 6.10: Pairwise intra-populations comparisons of expresser and low/non-expresser CYP3A5 
haplotype heterozygosity. Nei’s h and significance of differences were measured using h-diff (Thomas et 
al. 2002). *** indicates comparisons which were significant following Bonferroni correction (for 8 tests; 
adjusted p-value=0.00625), ** indicates a comparison was significant before, but not after, Bonferonni 





 A comparison of expresser and low/non-expresser haplotypes found that expresser 
haplotypes are significantly more diverse in every population except African-Americans and 
the Afar. 
 The CYP3A5*1 haplogroup is significantly more diverse than the other haplotype 
classes (p<0.0001 for every comparison), and had over twice as much diversity than the 
CYP3A5*3 haplogroup (Figure 5.11). CYP3A5*3 haplotypes are significantly more diverse than 
CYP3A5*6 and CYP3A5*7; although the latter are observed at a lower global frequency.  
 
Figure 6.11: Comparisons of gene diversity in each haplotype class by global population. Nei’s h was 






























 A comparison of diversity within expresser and within low/non-expresser haplotypes 
between populations found that African-Americans significantly differed from all other 
populations; and Han Chinese from three of the five Ethiopian groups. Interestingly, no 
significant differences, in diversity levels of low/non-expresser haplotypes, were observed 
between Europeans and Ethiopian populations. Levels of gene diversity in low/non-expresser 
haplotypes were highest in the Maale. Within the remaining populations gene diversity was 




Table 6.11a: Pairwise comparisons of heterozygosity in expresser haplogroups by an exact test of 
population differentiation. P values which are significant after Bonferroni correction are highlighted in 
green [adjusted p-value = 0.00625; correction for 8 tests]. 
 





European Afar Amhara Anuak Maale Oromo 
African-
Americans 
*        
Han Chinese <0.0000001 *       
European <0.0000001 1.000000 *      
Afar 0.297 <0.0000001 <0.0000001 *     
Amhara 0.966 <0.0000001 <0.0000001 0.248 *    
Anuak 0.888 <0.0000001 <0.0000001 0.252 0.882 *   
Maale 0.713 <0.0000001 <0.0000001 0.447 0.680 0.357 *  
Oromo 0.848 <0.0000001 <0.0000001 0.175 0.728 0.985 0.359 * 
 
 
Table 6.11b: Pairwise comparisons of heterozygosity in low/non-expresser haplogroups, by an exact 
test of population differentiation. P values which are significant after Bonferroni correction are 
highlighted in green [adjusted p-value = 0.00625; correction for 8 tests]. 
 





European Afar Amhara Anuak Maale Oromo 
African-
Americans 
*        
Han 
Chinese 4.97 x 10
-9
 
*       
European 2 x 10
-4
 0.05 *      
Afar 1.38 x 10
-12
 0.06 0.658 *     
Amhara 8 x 10
-4
 0.001 0.294 0.02 *    
Anuak 2 x 10
-4
 0.002 0.373 0.02 0.712 *   
Maale 0.0018 0.0003 0.136 0.003 0.531 0.234 *  
Oromo 4.17 x 10
-8
 0.01 0.71 0.225 0.344 0.5 0.114 * 
 
 
6.2.5 Population differentiation between Ethiopians and other global populations 
 Population differentiation at the CYP3A5 locus was measured by pairwise FST 
comparisons and by an exact test of population differentiation. Allelic data were used to 
evaluate population differentiation, allowing for all polymorphic information, including 
singleton variants, to be accounted for. Pairwise FST results are shown in Table 6.12 and the 
results from the exact test of population differentiation are shown in Table 6.13. Pairwise FST 
results were used to produce principal co-ordinates (PCO) plots to visually represent genetic 
similarities and differences, see Figure 6.12. 
 The results from all three analyses found that the Ethiopian groups split into two 
distinct clusters (as seen in Figure 6.6). The Afar, Amhara and Oromo are intermediate 
between the Han Chinese individuals and other Ethiopian groups. African-Americans are 
much more similar to the Anuak than to other populations with recent African ancestry 
(Figure 6.12). These results are an extension of those presented in chapters 3 and 4, in which 
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the Afar, Amhara and Oromo are characteristic of non-African populations at the CYP3A5 
locus. 
 
Table 6.12: Pairwise FST values based on overlapping CYP3A5 genotypic data for five Ethiopian 
populations and three other global populations. Pairwise FST values are shown in the bottom left side of 
the Table, the corresponding p-values are shown in the top right of the Table. P-values which are 
significant after Bonferroni correction (adjusted p-value = 0.00625; correction for 8 tests) are 
highlighted in green. 
 
  Afar Amhara Anuak Maale Oromo African-
Americans 
Europeans Han Chinese 
Afar 
* 0.74597 <0.00001 0.00436 0.76537 <0.00001 <0.00001 <0.00001 
Amhara -0.00248 
* <0.00001 0.00347 0.93525 <0.00001 <0.00001 <0.00001 
Anuak 
0.04566 0.05138 * 0.00257 <0.00001 <0.00001 <0.00001 <0.00001 
Maale 
0.01951 0.01736 0.01061 * 0.00267 <0.00001 <0.00001 <0.00001 
Oromo 
-0.00255 -0.0036 0.04981 0.01547 * <0.00001 <0.00001 <0.00001 
African-Americans 
0.08997 0.09366 0.01558 0.03432 0.08803 * <0.00001 <0.00001 
Europeans 
0.04873 0.03807 0.15448 0.08716 0.03371 0.19028 * 0.00257 
Han Chinese 0.10812 0.0893 0.23763 0.16215 0.09715 0.29154 0.0677 
* 
 
Table 6.13: The results of pairwise exact tests of population differentiation, based on genotype 
frequencies at the CYP3A5 locus. The values shown in the Table reflect p-values evaluating whether 
populations differ from each other based on their genotype frequencies. Statistically significant p-
values following Bonferroni correction are highlighted in pink [adjusted p-value = 0.00625; correction 
for 8 tests]. 
 




Afar *        
Amhara 0.40984  *       
Anuak 0.00000  0.00002  *      
Maale 0.00000  0.06138 0.00238  *     
Oromo 0.24611  0.84995  0.00106  0.00697  *    
African-
Americans 
0.00000  0.00000  0.00000  0.00000  0.00000  *   
Europeans 0.00000  0.00000  0.00000  0.00000  0.00000  0.00021  *  
Han 
Chinese 
0.00000  0.00000  0.00000 0.00000  0.00000  0.00000  0.00014 * 
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Figure 6.12:  A Principal Co-ordinates (PCO) plot based on pairwise FST values between eight 
populations. Pairwise FST vales were calculated based on genotype data for an 8063bp CYP3A5 region. 
Axis labels show the percentage of genetic distance captured by each axis. 
 
Population codes: AA: African-Americans; AS: Han Chinese; CA: individuals of recent 




6.3.1 CYP3A5 variation in Ethiopia is characteristic of sub-Saharan African and non sub-
 Saharan African populations  
 A consistent finding of all analyses presented in this thesis is that Ethiopian CYP3A5 
data are characteristic of African and non-African populations. The Ethiopian cohort split into 
two distinct clusters; with the Afro-Asiatic speaking Afar, Amhara and Oromo clustering 
closely with non-African populations. Measures of nucleotide diversity for these three 
Ethiopian groups indicated a skew towards rare variants on a par with the values reported for 
European and Han Chinese individuals. Principal-components analysis (PCA) found that they 
cluster closely with Han Chinese individuals. In contrast the remaining populations with 
recent African ancestry are separate from the Han Chinese and European individuals. There is 
a well known European contribution to African-American genetic diversity (Reed 1969; 
Destro-Bisol et al. 1999) and it is interesting that these individuals are furthest away from the 
individuals of recent European ancestry in the PCO plot (Figure 6.11). Consistent with the 
previous chapters, population structure across the entire CYP3A5 gene region in eight 
populations is explained predominantly by the first principal component and by differences in 
frequencies of the CYP3A5*3 allele. Re-sequencing of a larger CYP3A5 region within diverse 
Ethiopian populations found that over 30% of all identified variants were singletons; although 
there were a large number which occurred at high frequency. The allele frequency spectrum 
in Ethiopians is atypical of what is found for neutral gene regions as there are an excess of 
variants at either end of the frequency spectrum (see Figure 5.6) as opposed to a steady 
decline of the number of variants observed at high frequency in the dataset (Jobling et al. 
2004). 
 Gene diversity is lowest in the low/non-expresser haplogroups: CYP3A5*3 and 
CYP3A5*6. Low measures of gene diversity in Europeans, Han Chinese, the Afar, Amhara and 
Oromo are a results of high population frequencies of CYP3A5*3 haplotypes. Ancestral 
haplotypes are expected to have more diversity than derived. A particularly interesting 
observation is that the haplotype composition reported here is consistent with that seen in 
chapters 4; there is a paucity of variation in the gene region on derived haplotypes. Haplotype 
differentiation is largely defined by variants observed in the gene flanking regions, again 
demonstrating the paucity of variation observed in the gene sequence. Haplotypes were also 
defined by high LD between polymorphic sites and suggests that LD across the gene region, 
and across the CYP3A cluster, is high in all eight populations. 
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 Sub-Saharan African populations have been reported to have more diversity than 
other global populations (Tishkoff and Verrelli 2003) and therefore it is striking that the five 
Ethiopian populations should be less diverse than African-Americans; and that three of the 
four Afro-Asiatic speaking groups, are much more characteristic of European and Han Chinese 
populations, than other Ethiopian populations located ≤900km away. It is possible that Arab 
migrations into the continent, via the horn of Africa, in the 19th Century (Richards et al. 2003; 
Kivisild et al. 2004; Lovell et al. 2005) have influenced CYP3A5 haplotypic structure in the 
three populations located closest to the Arabian Peninsula (Afar, Amhara and Oromo). Gene 
flow may also explain the appreciable frequencies of largely African variants CYP3A5*6 and 
CYP3A5*7 in populations from the Arabian Peninsula (reported in chapter 3).  
 The work presented in this thesis also extends previous work on CYP3A5 diversity 
within Ethiopia (Gebeyehu et al.) as it examines CYP3A5 diversity within Ethiopia according to 
ethnicity and population sub-structure. The previous study by Gebenyehu et al pooled CYP3A5 
data from multiple Ethiopian ethnic groups and so overlooked the substantial inter-ethnic 
genetic diversity within the region which, as the data presented in this chapter show, is also 
reflected at the CYP3A5 locus  (Henze 2000; Lovell et al. 2005). Considerable inter-ethnic 
variability observed in Ethiopia confirms that the criterion for grouping, and analysing 
individuals, of recent African ancestry by ethnic group and language family in this thesis was 
correct. The data show that an appreciation of individual Ethiopian population histories will 
help in the identification of medically relevant genetic variation and identify groups which are 
likely to be separate from a wider patient cohort. 
 
6.3.2 The potential implications of CYP3A5 variability on clinical outcomes in Ethiopians 
 The potential medical implications of intra-African diversity in the CYP3A5 gene were 
discussed in chapters 3 and 4. The results presented in this chapter focused on intra-
Ethiopian diversity and suggest that there are likely to be differences in disease susceptibility 
and treatment outcomes in diverse groups from the country.  
 Variability in CYP3A5 expression has been previously shown to affect disease risk 
(Givens et al. 2003; Dandara et al. 2005; Zhenhua et al. 2005; Bochud et al. 2009) and adverse 
clinical outcomes associated with drug therapies (Goto et al. 2004). The most significant 
finding from the work presented in this chapter is that additional variants, which are likely to 
affect CYP3A5 transcription and protein expression (see chapter 5), occur almost exclusively 
on CYP3A5*1 haplotype backgrounds. A lot of these variants occur at low frequencies but their 
potential effect on protein expression and consequent medical phenotypes reiterate the 
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importance of characterising rare, and novel, variation in medically important genes. This is 
particularly necessary in populations with recent African ancestry (see section 4.5.3) who 
have been largely underrepresented in medical research, yet are some of the most vulnerable 
populations to multiple diseases. The haplotype background of these variants suggests that 
the presence of a CYP3A5*1 genotype, alone, may not predict CYP3A5 expression profiles. 
 The results for the entire CYP3A5 gene also reiterate the importance of not combining 
Ethiopian populations as a single uniform population; as it is overlooks inter-ethnic diversity, 
and may exacerbate disease and/or adverse clinical outcomes in specific groups. Furthermore 
the Afar, Amhara and Oromo are not overly characteristic of sub-Saharan African populations. 
Throughout this thesis it has been shown that these three populations are characteristic of 
non sub-Saharan African groups: namely Europeans and Han Chinese individuals. Therefore 
these three groups cannot be regarded as being typically “African” from a medical perspective 
and consequently it may not be appropriate to administer drugs, to individuals within these 
populations, at African-specific dosages. From a medical perspective, these three Ethiopian 
groups should be considered separately when administering drugs or when calculating 
disease risk. This will almost certainly change our perspective of population-stratified 
medicine; by altering our classification of populations as African and non-African, as our 
understanding of medically important genes, in some of the world’s most vulnerable 
populations, increases. 
 
6.3.3 There are signatures of directional selection at the CYP3A5 locus in Ethiopia 
 It has previously been reported that there is strong evidence of directional selection, 
on the CYP3A5*3 allele, in non sub-Saharan African populations (Thompson et al. 2004; 
Thompson et al. 2006; Chen et al. 2009). In populations outside of sub-Saharan Africa the 
CYP3A5 locus is characterised by an excess of rare variants, high frequencies of the CYP3A5*3 
allele and a paucity of variation on low/non-expresser haplotype backgrounds. An interesting 
observation is that these characteristics are also true of the Ethiopian CYP3A5 re-sequencing 
data.  
 Tests for departures from neutrality relied on detecting an excess of rare variants. 
Tajima’s D, and Fu and Li’s F* and D* and Fu’s FS, all indicated a skew towards rare variants in 
the Ethiopian cohort; although only Fu’s FS detected a significant departure from neutrality. 
The power of the Tajima’s D has been shown to be weak when the number of segregating sites 
is small (Simonsen et al. 1995) and this may explain why a significant departure from 
neutrality was not observed in the Ethiopian data.  Additionally, Fu and Li’s F* and D* assume 
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that a single allele has undergone a selective sweep; this is almost certainly true of 
populations outside of sub-Saharan Africa. However within Ethiopia, given the high 
frequencies of CYP3A5*6 and CYP3A5*7, it is possible that there are alternative or additional 
targets of selection within these populations. As previously reported, there was no evidence of 
a selective sweep, in Ethiopian populations, based on Fay and Wu’s H test: although this may 
be due to the low frequency of derived variants identified from Ethiopian re-sequencing data.  
 The Ethiopian data are consistent with a hypothesis of positive selection for the 
CYP3A5*3 allele in the Afar, Amhara and Oromo. An excess of rare variants is often observed 
when an allele has been selected for and risen rapidly to high frequency (Sabeti et al. 2006). 
Signatures of selection are often seen around fixed advantageous alleles; notably a reduction 
in variation around the selected allele and the creation of an extended region of haplotype 
homogeneity (Sabeti et al. 2002). The most common low/non-expresser haplotypes from the 
CYP3A5*3 and CYP3A5*6 classes, and the single CYP3A5*7 haplotype, observed in Ethiopia are 
all characterised by extended regions of haplotype homogeneity and low levels of variation. 
This suggests that the CYP3A5*3 and CYP3A5*6 alleles may have risen to high frequency 
rapidly in parts of Ethiopia, perhaps as part of a selective sweep. However, a sweep was not 
detected from Fay and Wu’s H test. It is also feasible that CYP3A5*3 and CYP3A5*6 were 
initially neutral variants which then became advantageous in certain Ethiopian groups and so 
rose rapidly to high frequencies. This phenomenon refers to when a selective sweep occurs on 
standing neutral variation. Neutral traits will often fluctuate in frequency unlike those which 
are selected for. Once an allele becomes advantageous, it may rise in frequency and there may 
be more variation on multiple haplotype backgrounds carrying this variant than seen on non-
neutral, highly positive variants.  
 However it is important to note that analysis of linkage disequilibrium (LD) across the 
12,237bp region found that the region extends beyond the CYP3A5 gene. Therefore it is 
possible that the CYP3A5*3 and CYP3A5*6 alleles are in high LD with an additional or 
alternative target of selection further up or downstream of the CYP3A5 gene region itself. 
Strongly selected alleles will often rise in frequency rapidly along with all tightly linked 
genetic variation. This often leaves “signatures” of a selective sweep; with high levels of LD 
across large genomic regions and a paucity of variation (Sabeti et al. 2002). An additional or 
alternative selection target, which is in high LD with CYP3A5*3 and/or CYP3A5*6, and has 
risen to high frequency could explain high frequencies of either the CYP3A5*3 and/or 
CYP3A5*6 alleles in Ethiopia. “Allelic surfing” refers to a phenomenon whereby neutral 
variation tightly linked to a genomic region under selection also rises to high frequency as a 
long extended haplotype (Hofer et al. 2009). 
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 The following chapter aims to elucidate the evolutionary mechanisms which have 
shaped diversity in the CYP3A5 gene; by examining evolutionary relationships between all 
haplotypes inferred from the Ethiopian and wider African cohorts; estimating the age of 
low/non-expresser CYP3A5 alleles to establish whether they are recent mutations; and 




7. The recent evolutionary history of CYP3A5 
7.1 Overview of chapter 
7.1.1 Examining the evolutionary relationships between CYP3A5 haplotypes and haplogroups 
 All inferred CYP3A5 haplotypes broadly fall into five core haplogroups; each defined 
by CYP3A5*1, CYP3A5*3, CYP3A5*6 and CYP3A5*7 alleles alone or by both CYP3A5*3 and 
CYP3A5*6. Diversity levels differ between haplogroups which could be the result of different, 
or multiple, events such as mutation, recombination or selection. CYP3A5 low/non-expresser 
haplotypes have a paucity of variation, other than the low/non-expression defining alleles. 
The mechanism(s) by which haplogroup diversity arose are unclear from the CYP3A5 
haplotype data alone. Haplotype information can be used to infer evolutionary relationships; 
particularly between individuals within a species (Salzburger et al. 2011).  
 Differences in population frequencies of CYP3A5*3, coupled with extended haplotype 
homogeneity, has been cited as evidence for positive selection for the low/non-expresser 
allele in populations furthest from the equator (Thompson et al. 2004). Whilst there are 
signatures of positive selection for low/non-expresser alleles in populations outside of Africa, 
the data presented in this thesis suggest that this may also be true for at least three of the five 
Ethiopian populations; Afar, Amhara and Oromo. However, it is important to differentiate true 
targets of positive selection, from new, low/non-expresser alleles which have arisen on 
haplotype backgrounds with little/no variation, and so mimic selection signatures (Nielsen et 
al. 2009). 
 The age of an allele is the time since it was created by mutation (Slatkin and Rannala 
2000; Rannala and Bertorelle 2001). There are multiple methods by which the age of a 
specific allele can be estimated. These can be broadly split into phylogenetic and population 
genetics approaches (Rannala and Bertorelle 2001). A phylogenetic approach aims to 
estimate the age of an allele by coalescing the time to its most recent common ancestor 
(MRCA). A representation of inferred evolutionary relationships (in the form of a tree or a 
network) between each data-point, and the gradual differentiation of all identified 
chromosomes from an MRCA is created, and the age of the allele is then estimated. A rooted 
haplotype network, such as one which shows differentiation of the human CYP3A5 lineage 
from closely related species such as the chimpanzee (Pan troglodytes), Orang-utan (Pongo 
pygmaeus) and the more distant rhesus macaque (Macaca mulatta) can provide a relative 
chronology; changes close to an ancestral taxon occurred prior to those furthest away (Jobling 
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et al. 2004). Haplotypes are useful as they incorporate information on markers linked to the 
allele of interest. However tree-like phylogenies are often unable to account for 
recombination in lineages; unlike networks which are representations of all possible trees 
inferred from a given dataset (Jobling et al. 2004).  
 Microsatellite data are also very useful in estimating allele age; due to their high 
mutation rates (Wilson and Balding 1998). The stepwise mutation model, frequently used to 
model microsatellite evolution, assumes that microsatellites mutate at a fixed rate, 
independent of repeat length, and with the same probability of the number of repeats 
increasing and decreasing (Kimura and Ohta 1978). However the processes by which 
microsatellites mutate are often complex and the methods which enable the accurate 
incorporation of such data into phylogenies; such as stepwise mutation models, are often over 
simplified (Rannala and Bertorelle 2001). Microsatellite mutation rates differ depending on 
repeat length and where they are located in the genome (Whittaker et al. 2003; Xu et al. 
2005). In the absence of data on the strength of selection at particular loci or the likelihood of 
mutations occurring at particular microsatellite loci, models such as the stepwise mutation 
model are useful. The high mutation rate of microsatellites can help to coalesce dates to 
common ancestors within particular clades and in estimating the mutation rate(s) on 
particular chromosomes (Wilson and Balding 1998). 
 Population genetics based approaches incorporate information on recombination and 
variation linked to a specific mutation of interest to estimate a value of the number of 
generations, prior to the present, at which a specific mutation is likely to have arisen on a 
particular haplotype. Initially the underlying population demography is modelled i.e. all 
possible evolutionary relationships are inferred from the dataset and are modelled in the 
form of phylogenetic trees/networks. The allele age is inferred from the decay of linkage 
disequilibrium with nearby markers; either by recombination or mutation, and from the 
distribution of mutations among descendants from a common ancestor (Rannala and 
Bertorelle 2001). Both phylogenetics and population-genetics methods aim to establish the 
underlying causative factors of observed diversity; such as mutation and recombination. 
 
7.1.2 Examining evidence of positive selection at the CYP3A5 locus 
 In addition to examining how CYP3A5 haplotype diversity arose in the eight global 
populations, this chapter aims to evaluate the evidence for positive selection on the CYP3A5*3 
allele in populations from the HapMap phase II and HGDP-CEPH datasets using data extracted 
from the Haplotter website (http://haplotter.uchicago.edu/) (Voight et al. 2006).  
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 The majority of tests designed to detect positive selection measure the degree of decay 
of linkage disequilibrium (LD) within the genome using one of two basic statistics; Extended 
Haplotype Homozygosity (EHH) and Fraction of Recombinant Chromosomes (FRC) (Wang et 
al. 2006; Huff et al. 2010). Over time LD breaks down over large genomic distances as a result 
of mutation and recombination. The retention of LD over large distances is a signature of 
recent positive selection; which results after a selective sweep has driven a selected allele 
(and all tightly linked variation) to high frequency (Sabeti et al. 2002; Sabeti et al. 2006; Huff 
et al. 2010). An examination of the decay of LD over large distances in the genome has been 
applied to whole genome scans to identify large genomic regions which may have been the 
target of positive selection; although some tests also have sufficient power to detect 
signatures of selection at single gene loci (Huff et al. 2010). 
 The LRH test, and EHH statistic, was first described in 2002 by Sabeti (Sabeti et al. 
2002). EHH is defined as the probability that two randomly chosen chromosomes, carrying a 
core haplotype of interest, are identical by descent; i.e. they have the same SNP based 
haplotype over a pre-defined region. EHH detects the transmission of an extended haplotype 
that has not undergone recombination (Sabeti et al. 2002; Huff et al. 2010). The LRH test 
examines the relationship between allele frequencies and the extent of linkage disequilibrium 
(LD); a selected allele will rise in frequency at a rate that is quicker than recombination is able 
to break down (Sabeti et al. 2002; Biswas and Akey 2006).  The result is a long haplotype 
characterised by high LD between all markers relative to neutral expectations (Sabeti et al. 
2002). The LRH test begins by defining a “core” haplotype; often one associated with a 
particular SNP. The test then calculates EHH; i.e. the probability that two chromosomes carry 
the same “core” SNP or haplotype. Positive selection is inferred by identifying core haplotypes 
which have elevated EHH relative to other haplotypes at the same locus.  
 An alternative to EHH is the Cross Population Extended Haplotype Homozygosity (XP-
EHH) statistic (Sabeti et al. 2007), which has been calculated for populations from the Human 
Genome Diversity Panel (HGDP). XP-EHH is designed to detect sweeps in which the selected 
allele has reached fixation in one or more population but remains polymorphic in the global 
human population (Sabeti et al. 2007). Whereas LRH and iHS detect partial selective sweeps, 
XP-EHH detects selected alleles that have risen to, or near, fixation in one but not all global 
populations and as a result is more powerful than LRH or iHS alone (Sabeti et al. 2007). 
 The iHS statistic was proposed by (Voight et al. 2006) and is also based on the EHH 
statistic. The iHS test applies to individual SNPs and the test initially calculates a statistic 
called the integrated EHH (iEHH). If EHH estimates against distance from a core allele are 
plotted graphically then iEHH is the area under the curve (Voight et al. 2006). The estimates 
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of iEHH are then standardized by log transformation so that iEHH values have a mean of 0 and 
a variance of 1. Large negative iHS values (-2.5) indicate unusually long haplotypes carrying 
the derived allele; whereas large positive values indicate long haplotypes carrying the 
ancestral allele (Voight et al. 2006). iHS is a standardized statistic which provides a measure 
of how unusual haplotypes around a core SNP are, relative to the genome as a whole, as is not 
itself a formal significance test. 
 A previous study which examined the relative power of multiple statistics used to 
infer positive selection found that iHS is more powerful in a single-gene candidate test than 
LRH (Huff et al. 2010). As this thesis is concerned with selection on CYP3A5, only iHS data for 
HapMap phase II and HGDP-CEPH populations are presented in this chapter. 
  
 
7.2 Specific chapter aims 
 There are three specific aims of this chapter; the primary aim is to examine the 
evolutionary relationships between CYP3A5 haplotypes to infer the mechanism(s) by which 
low/non-expresser alleles arose on separate chromosomes, from an MRCA. This will be 
achieved by constructing haplotype networks for each population and haplogroup; an 
additional aim is to use microsatellite data, for five ethnically diverse Ethiopian populations, 
to estimate the ages of the most frequent low/non-expresser CYP3A5 alleles under a stepwise 
mutation model; the final aim is to examine whether there is evidence of positive selection on 
the CYP3A5 gene within populations from HapMap phase II, the Human Genome Diversity 
Panel (HGDP) and Ethiopia (re-sequenced for this thesis), by differentiating between 





7.3.1 Haplotype networks 
 Haplotype networks were constructed using Network, version 4.6.1.0 (freely available 
from http://www.fluxus-engineering.com/netwinfo.htm). The software can construct 
networks using two different algorithms; median-joining (Bandelt et al. 1999) and reduced 
median joining (Bandelt et al. 1995). The latter is useful for binary data but median-joining 
networks are useful for all types of data, for constructing rooted phylogenies/networks and in 
reducing reticulations. Both algorithms produce networks which represent all shortest 
possible trees; however this can sometimes produce unnecessary cross links (reticulations). 
The median-joining algorithm is useful for reducing the number of unnecessary links in a 
network and was used to infer evolutionary relationships for this thesis. Data on haplotype 
composition and frequency information were input into the programme and all networks 
were manually rooted with an ancestral haplotype. The ancestral haplotype was inferred 
using information, extracted from NCBI (http://www.ncbi.nlm.nih.gov/) on the chimpanzee 
allele at each polymorphic site. The ancestral haplotype was identical to a CYP3A5*1 
haplotype observed in humans (labelled ROOT in the networks; see section 7.4.1). Networks 
were created using Network software and then exported to Adobe Photoshop CS4 software 
for re-colouring. 
 
7.3.2 Estimating the age of common low/non-expresser CYP3A5 alleles 
 The ages of the CYP3A5*3, CYP3A5*6 and rs15524 mutations were estimated using 
microsatellite data obtained for Ethiopians. Microsatellites are highly informative genetic 
markers due to their high mutation rates which vary depending on the length and size of the 
repeat (Payseur et al. 2002; Whittaker et al. 2003; Xu et al. 2005) and where they are in the 
genome. A study examining differences in microsatellite repeat numbers between parents and 
their offspring (Whittaker et al. 2003) found that the average mutation rate of dinucleotide 
microsatellite repeats, across the entire genome, is ~4.5x10-4. This mutation rate was used in 
the analyses to date CYP3A5 alleles and is consistent with independent estimates (Farrall and 
Weeks 1998). However, a mutation rate of ~4.5x10-4 does not necessarily accurately define 
the microsatellite mutation rate for the region of the genome which has been genotyped for 
this chapter. In the absence of the known mutation rate for this region, the use of an average 
dinucleotide mutation rate may provide an indication of the approximate age of the CYP3A5 
variants genotyped for this thesis. 
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 The gametic phase of CYP3A5 mutations and the –GT microsatellite (rs72492208) was 
not determined empirically; therefore the age of each CYP3A5 mutation was estimated using 
data for homozygotes for particular variants. As no Ethiopian individual was identified to be a 
CYP3A5*7 homozygote, this variant could not be dated. The distribution of microsatellite 
repeats associated with each of the CYP3A5*1, CYP3A5*3 and CYP3A5*6 alleles was plotted. 
Allele ages were estimated using data for individuals homozygous for particular haplotypes. 
Under the stepwise mutation model the variance (ASD) in the microsatellite repeat length, 
from the most recent common ancestor, is a linear function of the mutation rate (μ) and 
coalescence time in generations (t); ASD=μt (Goldstein et al. 1995; Slatkin 1995). 
 ASD and t were calculated using Ytime software (Behar et al. 2003). Ytime is a set of 
Matlab/Octave functions, written by Dr Mike Weale and available at 













where the term within the large brackets defines, for a given microsatellite locus i, the average 
difference (over a sample of n chromosomes) in the repeat size between each sampled 
chromosome ( ijL ) and the repeat size of the MRCA (
0
iL ).  The complete formula, therefore, 
gives the average of this average over all microsatellite loci sampled. 
 Ytime estimates the Time to the Most Recent Common Ancestor (TMRCA) in a clade 
for which microsatellite data are available. The microsatellite length of the ancestral MRCA is 
assumed to be known. For this study the length of the microsatellite on the ancestral 
haplotype was assumed to be 35; as the majority of CYP3A5*1 haplotypes had 35 repeats. 
Confidence intervals for the age estimates were obtained from calculating the distances 
between the ancestral and derived chromosomes under a star-genealogy model; based on the 
results of network analysis of CYP3A5 haplotypes (see section 7.4.1). A generation was 
assumed to be 32 years, based on the average estimate for females (~29 years) and males 
(~35 years) (Tremblay and Vezina 2000). 
 
7.3.3 Testing for selection at the CYP3A5 locus 
 There are a number of different methods which aim to identify genomic regions which 
are likely to have been targets of positive selection (see section 7.1.2). In addition to those 
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used to examine departures from neutrality in chapter 4 and 6, this thesis utilises iHS data for 
the CYP3A5 gene available online for HapMap phase II and HGDP-CEPH populations. 
 Data extracted from Haplotter provided a visual comparison of iHS estimates for 
genomic regions surrounding the CYP3A5 gene and around the CYP3A5*3 allele in different 
populations. The data were then compared with those for other genes for which positive 
selection is known to have acted. 
 iHS estimates could not be accurately obtained for the Ethiopian data due to the 
smaller size of the re-sequenced region (~13kb) and the method of re-sequencing meant that 
large intronic regions, that are part of CYP3A5, could not be assessed and this may influence 
the iHS estimates. 
 
7.4 Results 
7.4.1 Network analysis of CYP3A5 whole gene haplotypes 
 Networks were constructed for CYP3A5 haplotypes inferred for an 8063bp region in 8 
populations (see Figure 7.1 and the corresponding key in Table 7.1). CYP3A5 haplotypes are 
the taxa and are connected by branches. The size of each taxon corresponds to its global 
frequency. Taxa are coloured coded according to which haplogroup they belong. CYP3A5*1 
haplotypes are coloured in yellow; CYP3A5*3 in red, CYP3A5*6 in blue; CYP3A5*7 in green and 
CYP3A5*3/*6 recombinants in purple. The haplotype named “ROOT” was used to manually 
root the network and corresponds to the CYP3A5 haplotype with no mutations identified 
across the gene region (Table 7.1). This haplotype is also identical to that observed in the 
closely related chimpanzee sequence. 
 A star like network phylogeny was inferred from the CYP3A5 haplotype data. Star 
phylogenies are consistent with rapid growth and differentiation of haplotypes from an 
MRCA, or with a selective sweep. Many expresser haplotypes were rare in the global dataset 
and the modal haplotypes were low/non-expresser; each 1-2 point mutations away from the 
MRCA. The expresser haplotype is the ancestral state and high frequencies of low/non-
expresser haplotypes, coupled with an inferred star phylogeny, is consistent with a hypothesis 
that there has been a rapid increase in CYP3A5*3 and CYP3A5*6 allele and haplotype 
frequencies. The network confirms the results of gene diversity analyses (see chapter 5); 
diversity is higher in the CYP3A5*1 haplogroup than in the low/non-expresser haplogroups. 
Of the low/non-expresser haplogroups; diversity is highest in the CYP3A5*3 cluster. 
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Figure 7.1: A haplotype network of all inferred CYP3A5 haplotypes from an 8063bp region in 8 populations (Ethiopians and Coriell populations). Networks 
assume single mutational steps. Haplotypes are coloured according to the haplogroup to which they belong; CYP3A5*3 haplotypes are shown in red; CYP3A5*1 
in yellow; CYP3A5*7 in green; CYP3A5*6 in blue and CYP3A5*3/*6 recombinant haplotypes are shown in purple. The size of each haplotype is proportional to 




Table 7.1: A table showing the composition of haplotypes analysed in Figure 7.1. The positions of polymorphic sites (numbered from the ATG start codon 
where base A is +1) are shown along the top. The codes correspond to those used in Figure 7.1 and n is the frequency of each haplotype in the global dataset. 
Haplogroup refers to whether each haplotype belongs to the CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7 or CYP3A5*3/*6 cluster of haplotypes. Ancestral alleles 

















































































































































































































36a 3 T C T C C G C A G C C G C C G C T T G A A A T C G C C C G C G T G A - A C G A T T C G *3/*6  
36b 3 T C T C C G C A G C C G C C G C T T G A A A T C G C C C G C G T G A - A C G A T T T G *3/*6  
1a 32 T C T C C G C A G C C G C C A C T T G G A A T C G C C C G C G T G A - A C G A T T C G *1  
1aa 4 T C T C A G C A G C C G C C A C T T G G A G T C G C C C G C G T G A - A C G A T T T G *1  
1b 25 T C T C C G C A G C C G C C A C T T G G A A T C G C C C G C G T G A - A C G A T T T G *1  
1bb 15 T C T C A G C A G C C G C C A C T T G G A G T C G C C C G C G T G A - A C G - T T T G *1  
1c 2 T C T C C G C A G C C G C C A C T T G G A A T C G C C C G C G T G A - A C G - T T C G *1  
1cc 6 T C T C A G C A G C C G C C A T T T G G A G T C G C C C G C G T G A - A C G - T T T G *1  
1d 2 T C T C C G C A G C C G C C A C T T G G A A T C G C C C G C G T G A - A T G A T T C G *1  
1dd 1 T C T C A G C A A C C G C C A C T T G G A G T C G C C C G C G T G A - A C G - T T T G *1  
1e 1 T C T C C G C A G C C G C C A C T T G G A A T C G C C C G C G T G A - A T G - T T C G *1  
1ee 1 T C T C A G C A G C C G C C A T T T G G A A T C G C C C G C G T G A - A C G - T T T G *1  
1f 1 T C T C C G C A G C C G C C A C T T G G A A T C G C C C G C G T G A - A T G - T T T G *1  
1ff 1 T C T C A G C A G C C G C C A C T T G G A G T C G C C C G C G T G A - A C G - T T C G *1  
1g 22 T C T C C G C A G C C G C C A C T T G G A A T C G C C C G T G T G A - A C G A T T C G *1  
1gg 11 T C T - C G C A G C C G C C A C T T G G A A T C G C C C G C G T G A - A C G A T T C G *1  
1h 1 T C T C C G C A G C C G C C A C T T G G A A T C G C C C G T G T G A - A T G A T T C G *1  
1hh 1 T C C C C G C A G C C G C C A C T T G G A A T C G C C C G C G T G A - A C G A T T C G *1  
1i 1 T C T C C G C A G C C G C C A C T T G G A A T C G C C C T C G T G A - A C G A T T C G *1  
1ii 13 T G T C C G C A G C C G C C A C T T G G A A T C G C C C G C G T G A - A C G A T T C G *1  
1j 2 T C T C C G C A G C C G C C A C T T G G A A T C A C C C G C G T G A - A C G - T T C G *1  
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1jj 20 A C T C C G C A G C C G C C A C T T G G A A T C G C C C T C G T G A - A C G A T T C G *1  
1k 26 T C T C C G C A G C C G C C A C T T G G A A C C G C C C G C G T G A - A C G A T T C G *1  
1kk 2 A C T C C G C A G C C G C C A T T T G G A A T C G C C C T C G T G A - A C G A C T C G *1  
1l 2 T C T C C G C A G C C G C C A C T T G G A G T C G C C C G C G T G A - A C G - T T T G *1  
1m 1 T C T C C G C A G C C G C C A C T T G G G A T C G C C C G C G T G A - A C G - T T C G *1  
1n 1 T C T C C G C A G C C G C C A C T T A G A A T C G C C C G C G T G A - A C G A T T C G *1  
1o 10 T C T C C G C A G C C G C C A C T C G G A A T C G C C C G C G T G A - A C G A T T T G *1  
1p 1 T C T C C G C A G C C G C C A T T T G G G A T C G C C C G C G T G A - A C G A T T C G *1  
1q 1 T C T C C G C A G C C G C C A T T T G G A A T C G C C C G C G T G A - A C G A T T C G *1  
1r 2 T C T C C G C A G C C A C C A C T T G G A A T C G C C C G T G T G A - A C G A T T C G *1  
1s 22 T C T C C G C A G C T G C C A C T T G G A A T C G C C C G C G T G A - A C G A T T C G *1  
1t 1 T C T C C G C A G A C G C C A C T T G G A A C C G C C C G C G T G A - A C G A T T C G *1  
1u 1 T C T C C G C A G A C G C C A C T T G G A A T C G C C C G C G T G A - A C G A T T C G *1  
1v 2 T C T C C G C A A C C G C C A C T T G G A A T A G C C C G C G T G A - A C T A T T C G *1  
1w 1 T C T C C G C C G C C G C C A C T T G G A A T C G C C C G C G T G A - A C G - T T T G *1  
1x 2 T C T C A G C A G C C G C C A C T T G G A A T C G C C C G C G T G A - A C G A T T C G *1  
1y 1 T C T C A G C A G C C G C C A C C T G G A A T C G C C C G C G T G A - A C G A T T C G *1  
1z 7 T C T C A G C A G C C G C C A C T T G G A A T C G C C C G C G T G A - A C G - T T T G *1  
3a 1 T C T C C G C A G C C G C C G C T T G G A A T C A C C C G C G T G A - A C G A T T T G *3  
3aa 2 A C T C C G C A G C C G C C G C T T G G A A T C G C C C T C G T G A - A C G A T T C G *3  
3b 377 T C T C C G C A G C C G C C G C T T G G A A T C G C C C G C G T G A - A C G A T T T G *3  
3bb 2 T C T C C G C A G C C G C C G C T T G G A A C C G C C C G C G T G A - A C G A T T C G *3  
3c 2 T C T C C G C A G C C G C C G C T T G G A A T C G C C C G C G T G A - A T G A T T T G *3  
3d 1 T C T C C G C A G C C G C C G C T T G G A A T C G C C C G C G T A A - A C G A C T T G *3  
3e 15 T C T C C G T A G C C G C C G C T T G G A A T C G C C C G C G T G A - A C G A T T T G *3  
3f 1 T C T C C G C A G C C G C C G C T T G G A A T C G C C C G T G T G G - A C G - T T T G *3  
3g 3 T C T C C G C A G C C G C C G C T T G G A A T C G C C C G C G T G A - A C G - T T T G *3  
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3h 1 T C T C C G C A G C C G C C G C T T G G A A T C G C C C G T G T G A - A C G - T T T G *3  
3i 4 T C T C C G C A G C C G C C G C T T G G A A T C G C C C G C G T G G - A C G A T T T G *3  
3j 1 T C T C C G C A G C C G C C G C T T G G A A T C G C C C G C G T G A - A C G - T C T G *3  
3k 1 T C T C C G C A G C T G C C G C T T G G A A T C G C T C G C G T G A - A T G A T T T G *3  
3l 1 T C T C C G C A G C C G C C G C T T G G A A T C G C C C G C G T G A - A C G A T C T G *3  
3m 1 T C T C C G C A G C C G C C G C T T G G A A T C G C C C G C A T G A - A C G A T T T G *3  
3n 23 T C T C C G C A G C T G C C G C T T G G A A T C G C C C G C G T G A - A C G A T T T G *3  
3o 1 T C T C C A C A G C C G C C G C T T G G A A T C G C C C G C G T G A - A C G A T T T G *3  
3p 1 T C T C C G T A G C C G C C G C T T G G A A T C G C C C G C G T G A - G C G A T T T G *3  
3q 1 T C T C C G C A G C T G C C G C T T G G A A T C G C C C G C G T G A - A T G A T T T G *3  
3r 51 T C T C C G C A G C C G C C G C T T G G A A T C G C C C G C G T G A - A C G A C T T G *3  
3s 1 T C T C C G C A G C C G C C G C T T G G A A T C G C C C G C G T G A - A C G A T T T A *3  
3t 2 T C T C C G C A G C T G C C G C T T G G A A T C G C C T G C G T G A - A C G A T T T G *3  
3u 2 T C T C C G C A G C C G C T G C T T G G A A T C G C C C G C G T G A - A C G A T T T G *3  
3v 2 T C T C C G C A G C C G T C G C T T G G A A T C G C C C G C G T G A - A C G A T T T G *3  
3w 1 A C T C C G C A G C T G C C G C T T G G A A T C G C C C G C G T G A - A C G A T T T G *3  
3x 1 T G T C C G C A G C C G C C G C T T G G A A T C G C C C G C G T G A - A C G A T T T G *3  
3y 9 T C T C C G C A G C C G C C G C T T G G A A T C G C C C G C G T G A - A C G A T T C G *3  
3z 1 T G T C C G C A G C C G C C G C T T G G A A T C G C C C G C G T G A - A C G A T T C G *3  
6a 122 T C T C C G C A G C C G C C A C T T G A A A T C G C C C G C G T G A - A C G A T T C G *6  
6b 1 T C T C C G C A G C C G C C A C T T G A A A T C G C C C G C G T G A - A T G A T T C G *6  
6c 2 T C T C C G C A G C C G C C A C T T G A A A T C G C C C G C G T G A - A C G - T T C G *6  
6d 3 T C T C C G C A G C C G C C A C T T G A A A T C G C C C G C G C G A - A C G A T T C G *6  
6e 1 T C T C C G C A G C C G C C A C T T G A A A T C G T C C G C G T G A - A C G A T T C G *6  
6f 2 T C T C C G C A G C C G C C A T T T G A A A T C G C C C G C G T G A - A C G A T T C G *6  
6g 1 T C T C A G C A G C C G C C A C T T G A A A T C G C C C G C G T G A - A C G - T T T G *6  
7a 2 T C T C C G C A G C C G C C A C T T G G A A T C G C C C G C G T G A T A C G A T T C G *7  
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 There is evidence of recombination which is seen as reticulations in the network. 
Recombination has occurred mostly between expresser (CYP3A5*1) and low/non-expresser 
haplotypes from the CYP3A5*3 and CYP3A5*6 haplogroups; which manifested itself in 
haplotypes 3AA, 3BB, 3Z, 6B, 6F and 6G. There is also evidence of recombination between the 
high frequency CYP3A5*3 and CYP3A5*6 haplotypes, resulting in haplotypes 36A and 36B. The 
majority of recombination events have occurred in Ethiopian and African-American 
populations (see Figure 7.2). CYP3A5*6 appears to have arisen on three different CYP3A5*1 
haplotypes. The two recombinant CYP3A5*3/CYP3A5*6 haplotypes are separated by a single 
point mutation; it appears that CYP3A5*6 evolved twice on two separate CYP3A5*3 
backgrounds generating two recombinant haplotypes. CYP3A5*7 is a point mutation away 
from the root haplotype. 
 
7.4.2. Network analysis of entire gene haplotypes by population 
 Nearly all haplotypes observed in Europeans and Han Chinese individuals are defined 
by the CYP3A5*3 mutation. A number of private CYP3A5*3 haplotypes were observed in each 
population (see Figure 7.2); although they were observed at low frequencies. Consistent with 
the results presented in chapter 6, all populations with recent African ancestry had more 
differentiation of CYP3A5 haplogroups; although surprisingly the Anuak had low levels of 
diversity in the CYP3A5*3 haplogroup. Recombination was observed in all populations with 
recent African ancestry and in Han Chinese individuals; suggesting that CYP3A5 haplotype 
diversity within these populations is a result of both mutation and recombination events. In 
contrast, European haplotypes arose exclusively by mutation alone. 
 No one individual, from the global cohort, was homozygous for the ancestral “ROOT” 
haplotype. The modal haplotype in every population was the derived CYP3A5*3 (3B) 
haplotype. Within populations with recent African ancestry, a number of rare CYP3A5*6 
haplotypes were only observed in the Anuak and Maale. A comparison of a larger genomic 
region in all populations may lead to further differentiation of haplotypes. When the Coriell 
populations were re-sequenced across the CYP3A cluster; diversity was lowest in the CYP3A5 
gene; and CYP3A haplotypes which are defined by the CYP3A5*3 mutation are characterised 
by distinctive LD patterns (Thompson et al. 2006). Little differentiation of CYP3A5 haplotypes 
is seen; consistent with the low nucleotide diversity estimates. 
  
 231 
Figure 7.2: Networks of inferred CYP3A5 haplotypes from an 8063 base pair region within 8 populations. Networks assume single mutational steps. 
Haplotypes are coloured according to the haplogroup to which they belong; CYP3A5*3 haplotypes are shown in red; CYP3A5*1 in yellow; CYP3A5*7 in green; 
CYP3A5*6 in blue and CYP3A5*3/*6 recombinant haplotypes are shown in purple. The size of each haplotype is proportional to its frequency in the global 
database. Table 7.1 contains information on the exact composition of each coded haplotype in accordance with Figure 7.1. The haplotype named “ROOT” was 
used to root each network and is equivalent to the chimpanzee CYP3A5 sequence and to haplotype 1 (Table 7.1). 
 African-Americans 
 




















7.4.3 Examining the evolutionary relationships between CYP3A5 haplotypes inferred for a 
 ~4kb region in sixteen populations 
 A network of all haplotypes, inferred for a 4448bp region, in thirteen African 
populations is presented in Figure 7.3; all haplotypes inferred for a 4006bp region in sixteen 
populations (see chapter 4) in Figure 7.4; and by geographic region in Figure 7.5. The 
corresponding key for all haplotypes in each network is presented in Table 7.2. 
 The modal CYP3A5*3, CYP3A5*6 and CYP3A5*7 haplotypes are defined by a paucity of 
variation. It is possible that there are additional variants, found on CYP3A5*3, CYP3A5*6 and 
CYP3A5*7 haplotype backgrounds, within a larger gene region in these populations. A single, 
synonymous, exonic variant (observed in sub-Saharan Africa) was inferred on a CYP3A5*1 
haplotype background. The five individuals (four Afro-Asiatic speakers and one Niger-Congo 
B speaker) identified as having a novel intronic ten base pair deletion (see chapter 4) were all 
CYP3A5*3 homozygotes. This suggests that a novel variant, likely to affect CYP3A5 
transcription, has evolved onto an existing low/non expresser haplotype background in West 
Central Africa (haplotype 18). It is possible that CYP3A5*3 haplotypes are more diverse, over a 
larger genomic region, in Niger-Congo populations than in Europeans and Han Chinese 
analysed for this thesis. 
  As for a larger CYP3A5 region, see sections 7.4.1-7.4.2, star-phylogenies were inferred 
from the haplotype data; consistent with rapid population growth or of a selective sweep 
(Martins and Housworth 2002; Jobling et al. 2004). Single point mutations separate each 
haplotype and there was evidence of recombination which manifested itself in haplotypes 3, 9, 
18, 21, 24, 25, 27 and 29. 
 Across geographic regions (Figure 7.5) diversity was highest in East Africa and West 
Central Africa. Overall African populations were more diverse than populations from the 
Coriell Repositories (diverse populations sampled from North America). CYP3A5*3 haplotype 
diversity is higher in Coriell populations than in Africa (with the exception of East Africa). 
CYP3A5*6 haplogroup differentiation is greatest in West Central Africa; whereas CYP3A5*7 is 
consistent across regions in which it was observed, perhaps due to this allele having arisen 
from a recent mutation. West Central African diversity is likely to be influenced by the 
presence of both Afro-Asiatic and Niger-Congo speaking groups, sampled from the region; 
groups which differ from each other in terms of CYP3A5 variation (see chapters 3 and 4). 
Across Niger-Congo speaking groups are homogeneous in terms of haplotype diversity and 
structure is similar; which is due to shared recent ancestry as a result of the Bantu expansion 
(Beleza et al. 2005; Berniell-Lee et al. 2009). 
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Figure 7.3: A network of all haplotypes inferred for a 4448 base pair CYP3A5 region, in thirteen African populations. Networks assume single mutational steps. 
The size of each haplotype (pies) is proportional to its frequency in the African cohort. Haplotype codes refer to those listed in Table 7.2. “Root” refers to the 
ancestral sequence for the polymorphic sites; inferred from the closely related chimpanzee sequence; and identical to haplotype 1. Haplotypes defined by the 




Figure 7.4: A network of all haplotypes inferred for a 4006 base pair CYP3A5 region in sixteen populations. Networks assume single mutational steps. The size 
of each haplotypes (pies) is proportional its frequency in the global cohort. Haplotype codes refer to those listed in Table 7.2. “Root” refers to the ancestral 
sequence for the polymorphic sites; inferred from the closely related chimpanzee sequence; and identical to haplotype 1. Haplotypes defined by the CYP3A5*3 




Figure 7.5: Networks of haplotypes within each geographic region. Population-specific haplotype frequencies are presented in Figures 7.1b-g. The size of each 
haplotypes (pies) is proportional its frequency in the global cohort. Haplotype codes refer to those listed in Table 7.2. “Root” refers to the ancestral sequence for the 
polymorphic sites; inferred from the closely related chimpanzee sequence; and identical to haplotype 1. Haplotypes defined by the CYP3A5*3 mutation are coloured 
in red; those defined by CYP3A5*6 in blue; CYP3A5*1 in yellow; CYP3A5*7 in green; and CYP3A5*3/*6 recombinant in purple. “n” is the number of chromosomes. 
 
a) North Africa (n=56) 
 
b) East Africa (n=761) 
 
c) West Africa (n=107) 
 
 
d) West Central Africa (n=357) 
 
e) South East Africa (n=192) 
 
f) North American Coriell samples (n=138) 
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Table 7.2: A table showing the composition of haplotypes analysed in Figures 7.3-7.5. The positions of polymorphic sites (numbered from the ATG start codon 
where base A is +1) are shown along the top. The codes correspond to those used in Figures 7.3-7.5 and n is the frequency of each haplotype in the global 
dataset. Haplogroup refers to whether each haplotype belongs to the CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7 or CYP3A5*3/*6 cluster of haplotypes. 




7.4.4. Network analysis of CYP3A5 haplogroups 
 Network analysis of CYP3A5 haplogroups is presented in Figures 7.6-7.7. Overall, for 
both the entire CYP3A5 gene, and a 4kb region, the greatest differentiation of haplotypes was 
observed in the CYP3A5*1 and CYP3A5*3 haplogroups. Recombination was observed in the 
CYP3A5*1 and CYP3A5*3 haplogroups suggesting that diversity, within both haplogroups, 
arose by mutation and recombination events. Star phylogenies were inferred for the 
CYP3A5*1 and CYP3A5*3 haplogroups also, and the CYP3A5*3 network was characterised by 
multiple, low-frequency (often singleton) haplotypes. The CYP3A5*3 haplogroup has 
differentiated into more haplotypes than the remaining low/non-expresser haplogroups; 
although diversity is highest in the ancestral CYP3A5*1 (expresser) haplogroup overall. 
 
7.4.5. The distribution of microsatellite counts associated with low/non-expresser CYP3A5 
 alleles 
 A –GT microsatellite was genotyped in each of 379 Ethiopian individuals, in addition 
to re-sequencing of the entire CYP3A5 coding region, exon-flanking introns and proximal 
promoter. CYP3A5 haplotypes were not inferred using microsatellite data due to the wide 
variation in the number of repeats and the inability to accurately infer microsatellite counts 
onto the chromosomes of heterozygous individuals. The microsatellite repeat distribution 
associated with homozygotes for particular CYP3A5 alleles is presented in Figure 7.8. The 
differences in the collective number of chromosomes defined by a specific variant in Figure 
7.8 reflect the different number of chromosomes used for analysis of each variant. No 
individual was homozygous for CYP3A5*7 and so the associated distribution of variation in –
GT repeats could not be plotted for this allele. 
 The range of microsatellite repeats associated with CYP3A5*3 (28-39 GT repeats) is 
higher than that for CYP3A5*1 (33-41) and CYP3A5*6 (32-38); although the distribution of 
microsatellite variation associated with the CYP3A5*1 and CYP3A5*6 alleles is more spread 
out than for CYP3A5*3. A striking observation about the distribution of -GT repeats in 
CYP3A5*3 homozygotes is that the spread is narrow and almost all CYP3A5*3 chromosomes 
have 35-36 GT repeats. Given that microsatellites normally have a high mutation rate the 
narrow spread of data in CYP3A5*3 carriers is consistent with the idea that the CYP3A5*3 
allele has risen to high frequency rapidly. 
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Figure 7.6: Networks of a) CYP3A5*1 haplotypes; b) CYP3A5*3 haplotypes; c) CYP3A5*6 haplotypes; and d) CYP3A5*7 haplotypes inferred for a ~4kb region. 
Networks assume single mutational steps. The size of each circle is proportional to haplotype frequency. Haplotype codes refer to those listed in Table 7.2. 
“Root” refers to the ancestral sequence for the polymorphic sites; inferred from the closely related chimpanzee sequence; and identical to haplotype 1. 












Figure 7.7: Haplotype networks of three CYP3A5 haplogroups, inferred for an 8063bp region. 
Haplotypes are coloured according to the haplogroup to which they belong; CYP3A5*3 haplotypes are 
shown in red; CYP3A5*1 in yellow; CYP3A5*7 in green; CYP3A5*6 in blue and CYP3A5*3/*6 recombinant 
haplotypes are shown in purple. The size of each haplotype is proportional to its frequency in the global 
database. Table 7.1 contains information on the exact composition of each coded haplotype in 
accordance with Figure 7.1. The haplotype named “ROOT” was used to root each network and is 
equivalent to the chimpanzee CYP3A5 sequence and to haplotype 1 (Table 7.1). 
 CYP3A5*1 haplogroup 
 
 
 CYP3A5*3 haplogroup 
 
 
 CYP3A5*6 haplogroup 
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Figure 7.8: The variation in the number of –GT microsatellite repeats in individuals homozygous for one of CYP3A5*1, CYP3A5*3, CYP3A5*6 and rs15524 
alleles. The Figure shows the amount of variation in the –GT microsatellite repeats associated with each allele. Heterozygotes for one or more of the alleles 







7.4.6. Estimating the ages of common low/non-expresser CYP3A5 alleles 
 The age of the CYP3A5*3, CYP3A5*6 and rs15524 variants were estimated using Ytime 
software (executed in Matlab, see Table 7.3). Interestingly the CYP3A5*3 allele (~76,000 
years) was estimated to be younger than CYP3A5*6 (~200,000 years). The distribution of –GT 
microsatellite repeats associated with the rs15524 mutation almost completely overlaps with 
the CYP3A5*3 allele (see Figure 7.8), which reflects the modal CYP3A5 haplotype (see Table 
7.1). rs15524 was estimated to be older than CYP3A5*3, consistent with the analysis of 
haplotype networks (see Figure 7.1), and suggests that the modal CYP3A5*3 haplotype (3B) 
arose as a result of the CYP3A5*3 mutation appearing on an existing haplotype with the 
rs15524 mutation.  
 An interesting finding is that the estimated age of the CYP3A5*3 variant does not 
predate the approximate date for the first wave of human migration out of Africa ~100,000 
years ago (Reed and Tishkoff 2006). The consensus model of human migration out of Africa 
estimates that ~70-80,000 years ago modern humans were in the Arabian Peninsula (Figure 
7.9a) and had also migrated from East to West Africa (Figure 7.9b). The estimated age of the 
CYP3A5*3 allele is consistent with its distribution in Africa (based on data generated for this 
thesis) and globally. An estimated young age (~76,000 years) coupled with global differences 
in the frequency of the allele (see chapter 3) is consistent with a hypothesis of recent spread 
of CYP3A5*3 as a result of positive selection in non-African populations. However it is possible 
that the CYP3A5*3 mutation is older than 76,000 years, and that selection has influenced the 
age estimates as a result of recent positive selection.  
 The distribution of the CYP3A5*6 allele (chapter 3) is similar to that of another variant 
in the gene encoding the drug metabolising enzyme Flavin-containing monooxygenase 2 
(FMO2); FMO2*1, previously genotyped in the majority of the cohort genotyped for chapter 3 
(Veeramah et al. 2008). This variant is found at high frequencies throughout sub-Saharan 
Africa, the authors estimated the age of the FMO2*1 variant to be 502,404 years (95% 
confidence intervals: 154,790 years – 1,041,243 years) based on a coalescent-based method 
described in (Griffiths and Marjoram 1996). The age estimates of both the CYP3A5*6 and 
FMO2*1 alleles predate the exodus of modern humans out of Africa. It is possible that the 
CYP3A5*6 mutation was lost in a population bottleneck out of Africa; which would explain its 
African distribution and why the age estimates of this allele are older than for CYP3A5*3.
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Table 7.3: Estimating the age of CYP3A5 variants which define the most common haplogroups in Ethiopia. Allele ages were estimated using a mutation rate of 
0.00045 (Whittaker et al. 2003) and a generation time of 32 years (Tremblay and Vezina 2000). The confidence intervals for the estimated age of the CYP3A5*6 
are large; most likely a reflection of the small sample size. 


















Time to most recent 
common ancestor 
95% confidence intervals of allele age estimate 
based on a star phylogeny 
      Estimate of allele age Lower Upper 
      Generations Years Generations Years Generations Years 
CYP3A5*3 99270539 Intron 3 G 134 1.0746 2388 76,416 1797 57,504 3211 102,752 
CYP3A5*6 99262835 Exon 7 A 18 3.0714 6825 218,400 3086 98.752 11975 383,200 
rs15524 99245914 3´ UTR T 324 1.8426 4095 131,040 3157 101,024 5413 173,216 
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Figure 7.9a: Human migratory patterns out of Africa. The dates shown are conservative estimates of 




Figure 7.9b: Human migratory routes out of Africa. The dates shown are conservative estimates of 
when modern humans first appeared in specific geographic regions. The image has been taken from: 
http://datamining.typepad.com/data_mining/2009/08/the-human-journey.html 
 
Image is only available in the 
print version of this thesis 
Image is only available in the 
print version of this thesis 
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 A recent study of CYP1A2 variation in the same five Ethiopian groups re-sequenced in 
this thesis (Browning et al. 2010) identified a number of novel and known variants in the 
gene. The authors dated a number of variants from the study using microsatellite data for the 
populations. All variants which were observed at similar frequencies to the CYP3A5*6 allele in 
Ethiopia (~20%) were estimated to be over 100,000 years old. There are reports of different 
selection pressures on CYP1A2 (reported to be a target of purifying selection) (Browning et al. 
2010) and CYP3A5 (reported to be a target of positive selection for low/non-expression) 
(Chen et al. 2009). However the similarity in variant allele frequencies in the two genes 
enables a comparison of age estimates. The estimated age of CYP3A5*6 is higher than for 
CYP1A2 alleles of similar frequencies and predates the exodus of modern humans out of 
Africa; suggesting that the estimate for CYP3A5*6 as being older than CYP3A5*3 is correct. 
 
7.4.7. Examining the CYP3A5 locus for evidence of positive selection 
 The estimated age of CYP3A5*3 (~76,000 years) suggests that it may have undergone 
a recent selective sweep, and rapid spread, in non-African populations. Its presence and global 
inter-population differences suggest that there are distinct environmental, or alternative, 
pressures, which are more pronounced as distance from the equator increases, and provide a 
selective advantage to having the low/non-expresser allele. Environmental pressures 
associated with increased distance from the equator would explain the significant positive 
correlation between CYP3A5*3 allele frequencies and latitude (reported in chapter 3). This 
section examines evidence of positive selection on the CYP3A5 gene in populations from 
HapMap phase II and the HGD panel. 
 
7.4.7.1. Evidence from haplotype structure 
 Haplotypes for SNPs genotyped over a ~2Mb region of chromosome 7, including the 
CYP3A5*3 mutation (rs776746), in HGDP samples were extracted from Haplotter. This 
allowed for an examination of a larger genomic region surrounding the CYP3A5 gene, 
comparative to the Ethiopian data. The position of the CYP3A5*3 mutation is annotated in 
Figure 7.10. Haplotypes were coloured according to their similarity in a method outlined by 
Conrad et al (Conrad et al. 2006). Briefly the modal, or core, haplotypes in each geographic 
region are identified and coloured. Each subsequent haplotype, in order of decreasing 
frequency, is compared against the core haplotype and coloured according to where it is 
similar to, and differs from, the modal. The colouring enables similarities and differences 
between haplotypes to be visualised (Conrad et al. 2006). 
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Figure 7.10: Inferred haplotypes for a 2Mb region of chromosome 7, surrounding the CYP3A5*3 locus (rs776746), for 52 global populations from the HGDP 
database extracted from (http://hgdp.uchicago.edu/cgi-bin/gbrowse/HGDP/). Data are shown by geographic region. The region boxed in yellow shows a 





 A comparison of haplotype structures by geographic region found that there is more 
evidence of recombination and variation on African haplotypes than those observed in other 
global populations (Figure 7.10). This is consistent with network analysis of haplotypes in 
section 7.4.3 which found more recombinant haplotypes in a ~4kb region (n=9) than an 
8063bp region (n=8); and with previous reports that haplotype diversity is highest in 
populations with recent African ancestry (Conrad et al. 2006; Li et al. 2008; DeGiorgio et al. 
2009). Haplotypes defined CYP3A5*1 are more variable than those defined by the CYP3A5*3 
mutation; these haplotypes are also defined by more recombination events, particularly in 
Africans where CYP3A5*1 is observed at high frequencies. Interestingly, there were multiple 
long CYP3A5*3 haplotypes observed in global populations; suggesting that haplotypes 
carrying the mutation have extended homozygosity which may have arisen due to a selective 
sweep on CYP3A5*3, or another mutation in high LD with the allele. A ~500,000bp of 
haplotype homozygosity is annotated on Figure 7.10. The genomic sequence surrounding the 
annotated region is characterised by high levels of recombination and diversity in all 
geographic regions. 
 The modal CYP3A5*3 haplotypes inferred from Ethiopian re-sequencing data (see 
chapter 6) are characterised by a paucity of variation, high LD between polymorphic markers 
and homogeneity over a ~12kb region. Additionally, there is more variation in CYP3A5 
flanking regions than in the gene itself, consistent with HGDP data. The genomic region re-
sequenced in Ethiopians is much smaller than that represented by SNPs genotyped in the HGD 
panel and it is possible that over a large genomic region there would be more differentiation 
of CYP3A5*3 haplotypes in Ethiopia than in non-African HGDP populations. Given the 
considerable intra-Ethiopian diversity characterised in this thesis, it is also likely that 
haplotypes in an equivalent region to that shown in Figure 7.10 in the Afar, Amhara and 
Oromo are likely to be similar to those from the Middle East; in contrast to the Anuak who are 
likely to have haplotypes much more similar to those observed in Africa. It is also possible 
that intra-African diversity within the eight non-Ethiopian African sample sets re-sequenced 
for this thesis (see chapter 4) will be high and further differentiate African variation at the 
CYP3A5 gene. 
 
7.4.7.2. Evidence from HapMap II and HGDP populations 
 As outlined in section 7.1.2 a number of different tests aim to detect signatures of 
positive selection in the genome. iHS scores for each HapMap II population were negative 
indicating that the degree of decay on derived haplotypes, carrying the CYP3A5*3 allele, is 
lower (i.e. derived haplotypes are longer) than ancestral haplotypes. The greatest skew to 
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negative values was observed in Europeans (iHS = -1.354 for a 2Mb region surrounding the 
CYP3A5*3 mutation), followed by East Asians (iHS = -0.724), and the lowest in the Yoruba (iHS 
= -0.589); although no estimate was at the extreme end of iHS estimates [(iHS = -2) (Voight et 
al. 2006)]. 
 The extent of LD decay in a 2Mb region surrounding the CYP3A5*3 mutation in each of 
three HapMap II populations is shown in Figure 7.11. Dark blue and red down the centre 
column of each Figure corresponds to the ancestral CYP3A5*1 and derived CYP3A5*3 alleles 
respectively. Core haplotypes defined by either allele are also coloured either dark blue or 
red. Genomic regions where haplotype homogeneity breaks down, for example due to 
recombination, are then coloured differently from the core regions. All CYP3A5*3 haplotypes, 
those annotated in each of the Figures, are characterised by high LD which extends over a 
region of at least 0.25Mb; consistent with the haplotypes extracted for HGDP populations 
(Figure 7.10).  
 Data on the degree of haplotype decay surrounding the CYP3A5*6 allele (rs10264272) 
were extracted for Yoruba individuals from the HapMap cohort (data not shown). The 
CYP3A5*6 locus is monomorphic in Europeans and East Asian populations and iHS scores for 
the region surrounding the CYP3A5*6 allele could not be obtained for these populations. The 
iHS score for the region immediately surrounding CYP3A5*6 (iHS = -1.351) suggests that 
haplotype homozygosity surrounding the CYP3A5*6 mutation is higher than that surrounding 
CYP3A5*3 in the Yoruba. 
 Integrated haplotype scores (iHS), which were calculated by (Li et al. 2008), for a 2Mb 
region surrounding the CYP3A5*3 mutation were extracted from Haplotter (see Figure 7.12). 
Differences in iHS estimates between geographic regions were observed. Across the 2Mb 
region iHS estimates were highest in populations from Europe, Central Asia, East Asia and the 
Middle East. iHS values that are ≥2 are considered to provide evidence of positive selection 
(Voight et al. 2006). iHS scores indicative of positive selection were identified in populations 
from the same geographic regions as those reported in which there is strong evidence that the 
CYP3A5*3 allele has undergone a selective sweep (Li et al. 2011). The iHS scores, coupled with 
the haplotype structure observed in Figure 7.10 is consistent with the hypothesis of a 
selective sweep having acted on the CYP3A5*3 outside of Africa (Thompson et al. 2004), and 




Figure 7.11: The decay of haplotypes over a 2Mb (2,000,000bp) region surrounding the CYP3A5*3 
allele compared to the ancestral CYP3A5*1 allele. Core haplotypes defined by either the CYP3A5*1 or 
CYP3A5*3 allele are coloured dark blue and red respectively. Genomic regions where haplotype 
homogeneity breaks down, for example due to recombination, are then coloured differently from the 
core regions. Horizontal lines are haplotypes; SNP positions are shown below each haplotype plot. The 
regions within dark blue boxes in each Figure highlight the CYP3A5*3 haplotypes in each population. 
Plots are shown for 60 individuals of northern and western European ancestry (CEU); 89 Japanese and 
Han Chinese individuals from Tokyo and Beijing respectively (ASN); and 60 Yoruba from Ibadan, 







Figure 7.12: integrated haplotype score (iHS) for populations from seven geographic regions from the HGD panel. Log transformed data are presented for a 
2Mb region of chromosome 7 which incorporates the CYP3A5 gene region. Data have been extracted from the Haplotter website 
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7.4.7.3. Examining signatures of selection at the CYP3A5 locus in the context of other known 
 targets of selection 
 Genomic scans for positive selection have identified additional genes on chromosome 
7 which are believed to have undergone positive selection; such as CD36 (Sabeti et al. 2006). 
CD36 encodes a cell surface receptor protein which is involved in multiple physiological 
processes including angiogenesis, thrombosis and atherogenesis (Martin et al. 2011). 
Mutations in CD36 are protective against cerebral malaria caused by the parasitic isoform 
Plasmodium falciparum (Aitman et al. 2000; Pain et al. 2001). Erythrocytes infected with red 
blood cells often aggregate and can cause some of the more severe pathological effects of 
malaria such as vasocclusion (the restriction of blood flow through the vessels). CD36 
proteins mediate adhesion of infected erythrocytes (Cserti-Gazdewich et al. 2011), similarly 
to the ABO blood group; where the A sugar mediates adhesion of infected red blood cells but 
the O group does not; and is found at high frequencies in malaria endemic regions (Cserti-
Gazdewich et al. 2011). Mutations in the CD36 gene are highly prevalent in Plasmodium 
falciparum endemic regions and are associated with reduced adhesion of infected red blood 
cells; so reducing malaria-associated pathological effects (Aitman et al. 2000). 
 Given that CD36 is known to have been the target of positive selection in populations 
exposed to Plasmodium falciparum malaria (predominantly in Africa); iHS estimates for a 2Mb 
region immediately surrounding the CD36 gene were extracted for African populations from 
HapMap (Figure 7.13) and the HGD panel (Figure 7.14). African populations from both 
datasets had significantly higher iHS scores than non-African populations (p≤0.001). The iHS 
scores reported for CD36 are similar to those reported for CYP3A5 in non-African populations. 
A comparison of CYP3A5 iHS estimates with those for the gene encoding the enzyme lactase, 
which has been shown to have undergone positive selection in Europe, (Tishkoff et al. 2007; 
Ingram et al. 2009; Gerbault et al. 2011), were similar (data not shown). The data that are 
available for HapMap and HGDP-CEPH populations provide support for a hypothesis of 




Figure 7.13: comparisons of iHS estimates for CD36 in populations from the HapMap II panel. Note the 
large iHS values obtained for the Yoruba comparative to the European and East Asian populations. Data 
have been extracted from the Haplotter website (http://haplotter.uchicago.edu/) (Voight et al. 2006). 




Figure 7.14: iHS scores for a 2Mb region of chromosome 7 surrounding the CD36 gene (annotated on 
the Figure). There is a significant increase in the iHS score in the region surrounding CD36. Data are 
presented for the African populations which are part of the HGD panel, and have been extracted from 





7.5.1. The evolutionary relationships between CYP3A5 haplotypes are characteristic of 
 rapid growth 
 Haplotype networks were constructed to show the most parsimonious relationships 
between CYP3A5 haplotypes inferred from the re-sequencing data. A star phylogeny was 
inferred from all global haplotypes; characteristic of rapid population growth or a selective 
sweep (Martins and Housworth 2002). Differentiation within CYP3A5 haplogroups is 
predominantly a result of novel mutations arising on a single modal haplotype within each 
haplogroup. Although there is evidence of recombination across the haplotype networks; 
particularly in populations with recent African ancestry.  
 Despite the lower age estimate of the CYP3A5*3 allele (~76,000 years), comparative to 
CYP3A5*6 (~200,000 years), greater differentiation of CYP3A5*3 haplotypes was observed. 
There is strong evidence of positive selection acting on the CYP3A5*3 allele in populations 
outside of sub-Saharan Africa (discussed further in section 7.5.3). Rapid growth and a global 
prevalence of the allele are consistent with the inferred star-like phylogenies. Selection and 
rapid growth would explain one modal CYP3A5*3 haplotype with multiple, low frequency 
haplotypes in the haplogroup. This is seen in all populations with high frequencies of the 
CYP3A5*3 allele. 
 The ancestral haplotype, named “ROOT”, which is observed at low frequency in the re-
sequenced cohort and is identical to the chimpanzee sequence for the identified polymorphic 
sites, was manually used to the root the haplotype networks. Interestingly in Ethiopia no 
individual was observed to be homozygous for this haplotype; not even in the Anuak who 
have the highest frequencies of the CYP3A5*1 allele (see chapter 3). From re-sequencing data 
for the entire gene, all individuals in every population have at least one haplotype with a 
derived allele; and the modal haplotype was defined by the CYP3A5*3 mutation. As discussed 
in chapter 6, conserved genes tend to have low tolerance for damaging mutations, which are 
removed by purifying selection, unlike pseudogenes or those which are targets of positive 
selection (Graur et al. 2000). This is consistent with directional, or positive, selection for 




7.5.2. The CYP3A5*3 mutation is estimated to have arisen after the exodus of modern humans 
 from Africa ~100,000 years ago 
 Fossil and genetic diversity data support an African origin of modern humans 
~200,000 years ago (White et al. 2003; McDougall et al. 2005; Campbell and Tishkoff 2008). 
The recent African origin model of human evolution estimates that the first exodus of modern 
humans out of the continent, via East Africa, occurred ~100,000 years ago (Tishkoff and 
Verrelli 2003) initially into the Middle East and West Africa 70-80,000 years ago; followed by 
subsequent expansions into other geographic regions (see Figures 7.9a-b). 
 The CYP3A5*3 mutation is estimated to have arisen ~76,000 years ago, based on data 
within this chapter. The age of the mutation is consistent with its presence within Africa as 
well as in other global populations. It is possible that the allele is older than the estimates 
within this thesis; the microsatellite mutation rate within the genomic region may differ from 
the genome average for dinucleotide repeats (4.5x10-4) used in this chapter, and this may 
have influenced estimates generated from the stepwise mutation model. If selection has 
played a role in driving the allele to high frequency in populations outside of Africa then this 
would also influence the allele age estimates and predict them to be younger than they really 
are. Positive selection would drive CYP3A5*3 and all tightly variation, including microsatellite 
markers, to high frequency at a rate that mutation would be unable to generate diversity in 
the number of repeats. Decreased diversity in microsatellite repeat numbers would influence 
estimates of the allele age. 
 The estimated age of CYP3A5*3, coupled with a significant increase in its frequency in 
populations outside of Africa suggest that the allele may be advantageous outside of the 
continent. The frequencies of CYP3A5*3 are high in non-African populations; almost to 
fixation in some European groups. The estimated age of CYP3A5*3 show that it is not a recent 
mutation onto a haplotype background with a paucity of additional variation, which means 
that it is a plausible candidate on which positive selection could have acted (see section 7.5.3). 
An age of ~76,000 years is consistent with its presence within and outside of Africa. The shift 
in allele frequencies, coupled with other selection signatures on haplotypes defined by this 
allele, in non-Africans suggest that the allele may have undergone selection when modern 
humans first appeared in the Middle East due to an environmental change causing it to be 
advantageous outside of Africa. This hypothesis would be consistent with the observed 
positive correlations between CYP3A5*3 frequencies and increased latitude (reported in 
chapter 3). It is plausible that an increase in latitude of ~20° (difference between the Middle 
East and Ethiopia; the likely exit point for modern humans out of Africa) is coupled with 
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specific environmental changes in temperature and precipitation which provided an initial 
selective pressure which was then further exacerbated as humans migrated to higher 
latitudes; in Europe and East Asia. For example across populations from the HGDP-CEPH 
panel, (Young et al. 2005) observed that 74% of all variants observed in populations within 
10° of the equator were a result of heat adaptation. This provides support for the hypothesis 
of strong selective pressure for low/non expression of CYP3A5 at latitudes ≥20°. There are 
latitudinal correlations observed within Africa as well; and frequencies of the CYP3A5*3 allele 
are higher within Southern Africa than elsewhere; although an examination with 
heterogeneous Southern African groups will reveal whether there are selective pressures on 
the allele within the continent as well. 
 The age of the rs15524 mutation was estimated as it is found on the modal CYP3A5*3 
haplotype background in Ethiopia (see Table 7.1).  The age of this allele (~131,000 years) is 
estimated to be older than CYP3A5*3 which is consistent with network analysis of haplotypes 
and suggest that CYP3A5*3 evolved onto an existing haplotype background with the rs15524 
mutation. 
 The estimated age of the CYP3A5*6 mutation (~214,000 years) predates estimates of 
the exodus of modern humans from Africa. Despite a paucity of variation observed on 
CYP3A5*6 haplotype backgrounds (see chapter 6), the allele age is estimated to be quite old. 
The global distribution of the allele is almost entirely restricted to sub-Saharan Africa; with 
the exception of low frequencies observed in North Africa and in the Arabian Peninsula. These 
observed frequencies are almost certainly a result of population admixture with East African 
populations. The age, and restricted geographic distribution, of the allele suggest that it was 
lost in a population bottleneck when modern humans first left Africa. The allele frequency 
across sub-Saharan African populations is very similar (18-20%); consistent with its spread 
being related to intra-African migrations. Additionally, an examination of inferred Ethiopian 
CYP3A5*6 haplotypes for a 12,237 base pair CYP3A5 region (see chapter 6) found that 
CYP3A5*6 is in high LD with other derived variants. The results of Fay and Wu’s H test of high 
frequency derived variants were not significant; although this is likely to be due to a paucity of 
variation observed within the CYP3A5 gene. However high frequency derived variants, on 
existing CYP3A5*6 haplotype backgrounds and a paucity of variation on haplotypes suggest 
that the allele may have been a target of selection, although not necessarily recent selection 
(i.e. not within the last ~30,000 years and detected by the LRH test), within Africa (Sabeti et 
al. 2006).  
 The age of the CYP3A5*7 mutation could not be estimated as there were no observed 
homozygotes, for this allele, within the Ethiopian cohort. However, the distribution of the 
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allele is almost exclusively in Niger-Congo speaking population (chapter 3). This suggests that 
it has an origin that is much more recent than either CYP3A5*3 or CYP3A5*6, and that its 
distribution within sub-Saharan Africa can be explained by recent migrations across the 
continent ~4000 years ago. 
 
7.5.3. There is evidence of positive selection acting on the CYP3A5*3 allele in  populations 
 outside of Africa 
 In chapter 6, it was reported that there is a skew towards rare variants in all 8 
populations from the Coriell Repositories and Ethiopia. The estimated ages of common 
low/non-expresser CYP3A5 alleles (reported in this chapter) were consistent with them being 
old enough to have been true targets of selection. These findings are consistent with a 
hypothesis of positive selection having acted on the CYP3A5 gene in non-African populations. 
This chapter aimed to examine these selection signatures further in populations from HapMap 
phase II and HGDP-CEPH. 
 Data extracted from online resources were consistent with a hypothesis of positive 
selection driving the CYP3A5*3 allele to high frequency; iHS estimates found that the 
haplotypes surrounding the CYP3A5*3 mutation extend ~500kb around the allele in non-
African or Oceanian populations. Haplotypes extracted from online databases found that those 
carrying the derived CYP3A5*3 allele have extended regions of homozygosity than those 
carrying the ancestral CYP3A5*1 allele. Crucially, the observed iHS scores for CYP3A5*3 
haplotypes were similar to those for genomic regions believed to have undergone positive 
selection. Additionally, iHS scores which are considered evidence of positive selection were 
observed in populations from geographic regions where the CYP3A5*3 allele is believed to 
have been the target of a selective sweep (Li et al. 2011). The results from (Li et al. 2011) 
were consistent with those reported previously (Thompson et al. 2004; Thompson et al. 
2006); the allele frequency spectrum for CYP3A5 shows strong evidence of a selective sweep. 
The data presented here for HapMap phase II and HGDP populations extend the findings by 
examining haplotypes around a large genomic region surrounding the CYP3A5*3 mutation. 
The data provide further evidence of positive selection on the low/non-expresser variant; and 
that the allele is advantageous outside of Africa. 
 Although there were not enough Ethiopian data to obtain iHS estimates, a comparison 
of the haplotype structure within these populations with groups from the HGDP cohort found 
that there were similarities in haplotype structure and recombination patterns between 
Ethiopians and populations from the Middle East. It has been previously mentioned, that low 
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frequencies of the CYP3A5*6 allele observed in the Middle East are likely to be due to gene 
flow between Ethiopia and populations from the Arabian Peninsula. Additionally, there is a 
known Arabian contribution to Ethiopian ancestry (Kivisild et al. 2004; Lovell et al. 2005) 
which is a likely contributor to the observed diversity seen in CYP3A5 haplotypes in the Afar, 
Amhara and Oromo.  
 If a specific environmental variable(s) associated with increased latitude was a 
selective factor which originally drove the CYP3A5*3 allele to high frequency then its 
frequency in the Afar, Amhara and Oromo is anomalous; given that these groups are on almost 
the same latitudinal plane as West and West Central African groups (which have lower 
CYP3A5*3 allele frequencies, see chapter 3). It is unlikely that selection would have caused 
high frequencies of CYP3A5*3 within Ethiopia. The effect that such high CYP3A5*3 allelic 
frequencies may have on Ethiopian healthcare is discussed in more detail in chapters 4 and 6. 
 An LRH test, with larger genomic regions re-sequenced or genotyped in Ethiopian 
populations, would aid in elucidating how far haplotype homogeneity extends within these 
populations. It is possible that over longer genomic regions; haplotype homogeneity would 
break down. It is also possible that, as LD extends across large genomic regions of 
chromosome 7; in all global populations that have been genotyped and re-sequenced, that 
CYP3A5*3 is not itself a target of selection but instead in high LD with a selection target 
located further along chromosome 7. Given the paucity of Ethiopian data generated for this 
thesis this cannot be ruled out. 
 A strong positive latitudinal correlation is observed for genes that are involved in the 
regulation of hypertension (Young et al. 2005). If CYP3A5 is involved in the regulation of and 
differential susceptibilities to salt-sensitive hypertension, as is suggested by a strong positive 
correlation between the CYP3A5*3 allele and latitude, then this could be an explanation for 
why the allele is likely to have undergone a selective sweep. A correlation between CYP3A5*3 
allele frequencies and latitude was detected using Spearmann’s Rank Correlation analysis 
(chapter 3). An alternative to see how latitude affects CYP3A5*3 allele frequencies could be 
modelled using genetic boundary analysis, as described by (Barbujani et al. 1989); whereby 
the effect of an increase in latitude of e.g. 0.5° is used to estimate the corresponding allele 
frequencies based on the observed data. This would map the effect of latitude on CYP3A5*3 
allele frequencies at a fine scale and elucidate how much of an effect this environmental factor 




7.5.4. Potential further analyses of positive selection at the CYP3A5 locus using simulated 
 datasets 
 Phylogenetic trees/networks enable the processes by which haplotype diversity arose 
to be mapped; dating of specific alleles allows old and new alleles to be differentiated; and 
tests such as LRH, iHS and ALnLH (which measures FRC) analyse patterns in particular 
datasets and examine whether they are characteristic of positive selection signals. 
 Another method to detect evidence of selection is to compare real and simulated 
datasets to see whether haplotype composition and diversity observed is indicative of 
particular selective patterns and constraints. In silico simulations enable population 
geneticists to generate datasets, which are as close to the real data as possible. Simulated 
datasets are useful tools in population genetics as all factors which have lead to a particular 
patterns within the dataset are known (Ritchie and Bush 2010). For example, for each 
individual analysed within this thesis information on the number of polymorphic sites, the 
statistical associations of each polymorphic locus (haplotypes and LD) and the diversity of the 
population from which each individual has been sampled, is known. It is therefore possible to 
model patterns of diversity and haplotype structure at the CYP3A5 locus as a result of 
selection, genetic drift and population bottlenecks; and compare what is seen in silico to what 
is observed in the African datasets.  
 In silico analysis would aid in differentiating between true and mimicked selection 
signatures by controlling for environmental and demographic factors which can shape 
diversity in a particular gene. They would be useful here for the Ethiopian data in particular to 
ascertain whether haplotype patterns and diversity observed within certain populations from 




8. General Discussion 
8.1. A review of the main findings of this thesis 
 The overall aims of this thesis were to characterise human genetic variation in the 
CYP3A5 gene in geographically, linguistically and ethnically distinct African populations; to 
identify the potential healthcare implications of CYP3A5 variability; and to examine evidence 
of positive selection acting on the gene. In summary the main findings were: 
1. There is considerable inter-population variation in the CYP3A5 gene within Africa; 
recent demographic history is likely to have shaped African differences at the CYP3A5 
locus. 
2. The low/non-expresser CYP3A5*3 allele (rs776746) has a global distribution; and is 
found at high frequencies in some East African groups. The low/non-expresser 
CYP3A5*6 (rs10264272) and CYP3A5*7 (rs41303343) alleles are also found at 
appreciable frequencies within Africa; indicating that multiple variants may be 
affecting protein expression levels within the region. 
3. There is a strong positive correlation between latitude and CYP3A5*3 allele 
frequencies; consistent with a hypothesis that this variant is protective against salt-
sensitive hypertension. 
4. There are additional, previously unidentified, variants which may be affecting 
expression of CYP3A5 protein within Africa. 
5. The estimated age of the CYP3A5*3 allele (~76,000 years old) and its global 
distribution suggests that the allele has increased in frequency recently, and rapidly 
outside of Africa. The age of the CYP3A5*6 allele (~200,000 years), and its restricted 
geographic distribution to the African continent, suggest that the allele was lost in a 
population bottleneck when modern humans first left Africa ~100,000 years ago. 
 This chapter discusses the implications of the main results of this thesis by placing the 






8.2. CYP3A5 variability in Africa 
 The out of Africa model of modern human origins estimates that modern humans 
evolved in Africa ~200,000 years ago and first left the continent ~100,000 years ago. Genetic 
diversity is comparatively higher in African populations than in other global groups; 
consistent with a recent African origin of modern humans (Tishkoff et al. 2009; Campbell and 
Tishkoff 2010). Consistent with other genomic studies, including those on genes which encode 
important drug metabolising enzymes (Browning et al. 2010), CYP3A5 variability is highest in 
populations with recent African ancestry.  
 Considerable heterogeneity was observed in East Africa and differences between 
Ethiopian groups and others from the continent were observed. A previous study on CYP3A5 
in Ethiopia did not account for inter-ethnic variability in the individuals that were sampled 
(Gebeyehu et al. 2011). This thesis found considerable inter-population differences within 
Ethiopia. This is consistent with previous studies on Ethiopian populations which have 
examined genetic differences by ethnicity (Browning et al. 2010), (CYP3A4 unpublished data, 
Creemer O. et. al) and Ethiopian Y-chromosome data (Plaster C., et. al, unpublished data).  
 CYP3A5 haplotype structure and allele frequencies in the Afar, Amhara and Oromo, all 
Afro-Asiatic speaking groups, are characteristic of non sub-Saharan African populations and of 
what would be observed after recent positive selection (Biswas and Akey 2006; Sabeti et al. 
2007). There is an excess of rare variants and low/non-expresser haplotypes have a paucity of 
variation in addition to low/non-expresser mutations. The Afar, Amhara and Oromo ethnic 
groups are found in the North East of Ethiopia and of all five groups re-sequenced for this 
thesis are geographically closest to the Arabian Peninsula (Henze 2000). There is a known 
Arabian contribution to Ethiopian ancestry as a result of back migration of Semitic speaking 
groups into the region ~5000 years ago (Cruciani et al. 2002; Kivisild et al. 2004) and as a 
result Ethiopian genetic diversity is intermediate between sub-Saharan African and Eurasian 
groups (Lovell et al. 2005). The back migration of Semitic speakers into Ethiopia occurred at 
approximately the same time as the first long range migration of Bantu-speaking 
agriculturalists across Africa (~4000 years ago). These migrations occurred relatively 
recently, in the context of human evolutionary history. It has been proposed that the positive 
correlation between increased latitude and CYP3A5*3 allele frequencies are beneficial in 
populations closest to the equator. From this explanation the high CYP3A5*3 frequencies in 
three of the Ethiopian groups are anomalous. It is possible that there has been an alternative 
selective pressure on the CYP3A5 gene in Ethiopia. However the most likely explanation for 
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the patterns of CYP3A5 diversity observed within Ethiopia is due to extensive Arabian 
admixture in the three North Eastern groups compared to the Anuak and the Maale. 
 
8.3. There are potential medical implications for African populations due to CYP3A5 
 variability 
 CYP3A5 is involved in the metabolism of many clinically used drugs which are in 
widespread use for diseases prevalent in sub-Saharan Africa (Lamba et al. 2002; Wojnowski 
2004). Variability in protein expression is associated with differential efficacy of drug 
treatment and susceptibility to diseases including hypertension (Givens et al. 2003; Bochud et 
al. 2009) and numerous cancers (Dandara et al. 2005; Zhenhua et al. 2005).  
 The data generated for this thesis, particularly in chapters 3 and 4, show that there is 
likely to be high levels of intra-African variability in protein expression. The study of intra-
African variability in medically important genes would be of benefit for the world’s most 
vulnerable populations, and for the African Diaspora. The quantity and quality of re-
sequencing data that are available on public databases is expanding rapidly with the 
availability of new and cheaper sequencing technologies; in a so-called “genomics revolution” 
(Butler 2001; Friedrich 2001; Chung 2010). Until recently, few African genomic data were 
available on public databases. However a number of African populations have been included 
for re-sequencing as part of the 1000 Genomes project (Kaiser 2008). Although the 1000 
Genomes data are currently low coverage, inclusion of multiple African groups presents a way 
forward for genomics and medical research. Additionally, as re-sequencing technologies 
become cheaper, with the progression towards the $1000 genome (Bennett et al. 2005; 
Mardis 2006; Service 2006; Wade 2006; Defrancesco 2012), it is possible to sequence more 
genomes of the world’s most diverse, unique and vulnerable populations to aid in disease 
research and the tailoring of medical treatments worldwide. 
 Advances in genomics are improving the availability of re-sequencing technologies 
and data. Currently these approaches are not yet widely available and instead approaches 
focusing on population based variability and diversity in medically important genes are good 
strategies. Over 90% of the global disease burden is found in developing countries and a 
substantial number of developing countries are within Africa (Aspray et al. 1998). The 
inclusion of ethnically and geographically diverse African populations in large scale re-
sequencing efforts would aid in focusing population-specific medical intervention efforts 
across the continent; as mass drug administration administers drugs at dosages that were 
optimised for patients with recent European ancestry. It is possible that re-sequencing 
technologies may be unattainable, even at $1000 for whole genome re-sequencing, in many 
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developing countries. Therefore population genetics based approaches whereby dosages are 
optimised based on population-specific genetic variability are ideal. At present there are not 
enough data on the associated adverse clinical outcomes with mass drug intervention within 
Africa and therefore it is not known how European centric dosages are influencing 
therapeutic outcomes within the region. 
 So what approaches are there to study or tailor medical treatment based on specific 
population variability? One strategy is that described within chapter 3, where clinically 
relevant variants, of a medically important gene, are genotyped in multiple populations from 
across continental regions. This would provide an overview of genetic diversity levels within a 
particular geographic region and aid in understanding where specific drug regimens are likely 
to need adjusting. The data presented in chapter 3 suggest that for CYP3A5 substrates, East 
Africans are likely to be split into those populations who require non-African dosages of 
CYP3A5 drug substrates, and those which do. Further analysis of unique populations by re-
sequencing of medically important genes will also provide an overview of whether there are 
novel and rare variants, in addition to well characterised ones, which may also influence 
protein expression and therapeutic outcomes. Of course drug metabolism is often complex 
with multiple enzymes influencing the metabolism of a specific drug. An example is the well 
studied immunosuppressant tacrolimus; CYP3A5 is one of multiple enzymes involved in its 
metabolism (Hesselink et al. 2003; Zheng et al. 2003). However variability in CYP3A5 
expression has been shown to directly affect therapeutic outcomes associated with tacrolimus 
treatment. Ideally analyses of genetic variability in multiple medically important genes in 
specific populations will be a progression in medicine; however single gene studies are also 
useful in predicting clinical outcomes. 
 Genotyping of medically important variants is not only useful for predicting the 
likelihood of adverse reactions as a result of treatment with specific drugs, but also in 
predicting disease risks. For CYP3A5 variability, inter-ethnic differences in the risk of 
developing salt-sensitive hypertension are well established (Givens et al. 2003; Brown 2006; 
Bochud et al. 2009). Adequate salt and water retention is beneficial in populations which are 
found close to the equator. The high frequencies of CYP3A5*3 in Ethiopia may be causing 
conditions such as hyponatremia (abnormally low levels of sodium in the blood which is 
associated with dehydration). The Ethiopian data re-sequenced as part of this study suggest 
that there may be differential susceptibilities to hyponatremia within the country. An 
interesting study could be to examine differences in the prevalence of hyponatremia between 
the five Ethiopian groups and examine whether the condition is a) frequent within Ethiopia, 
b) observed at different frequencies in Ethiopia and c) associated with the CYP3A5*3 allele. An 
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additional study which would be interesting is to examine whether there are misdiagnoses of 
prevalent infectious and tropical diseases, such as malaria, which are actually hyponatremia. 
Common phenotypic effects of hyponatremia include nausea, vomiting, headaches, confusion, 
lethargy, fatigue and appetite loss; all symptoms; which are also associated with malaria 
infection (Cook et al. 2003). Malaria is highly prevalent within Ethiopia (Karunamoorthi and 
Bekele 2009). During diagnosis of infection, if a patient presents with malaria-like symptoms, 
but has a negative smear for parasites, they are often treated with anti-malarials. It would be 
interesting to see whether a large number of these cases are actually hyponatremia. 
 
8.4. There is strong evidence of positive selection for low/non CYP3A5 expression 
 The “genomics” revolution will undoubtedly aid studies which look for genomic 
targets of positive selection. Whole genome scans and studies of individual genes can identify 
genomic regions which are likely to have undergone positive selection. Signatures of positive 
selection are often seen following a selective sweep and can be detected by a number of 
different statistics (see Figure 8.1).  
 
Figure 8.1: Signatures of positive selection. Neutral polymorphisms (shown in blue) are driven to high 
frequency as a result of being in high LD with a selected, advantageous allele (shown in red). The 
resulting selective sweep leads to a reduction in polymorphism levels in haplotypes surrounding the 
selected region. Reduction in polymorphism levels are detected by statistics which include nucleotide 
polymorphism levels (θw), nucleotide diversity ( ) and the HKA test. Additional statistics detect an 
excess of rare variants (Tajima’s D and Fu and Li’s D and F), high frequency derived variants (Fay and 
Wu’s H). Finally, extended regions of linkage disequilibrium, relative to neutral expectations are also 




 The data generated for this thesis complement the results of previous publications 
which reported evidence of geographically restricted positive selection on the CYP3A5 gene; 
specifically on the CYP3A5*3 low/non-expresser allele (Thompson et al. 2004; Biswas and 
Akey 2006; Li et al. 2011). Few signatures of positive selection were observed in the African 
populations re-sequenced for this thesis, outside of East Africa. Of course examination of the 
entire CYP3A5 region in different African groups will enable accurate comparisons with non-
African populations regarding selection. 
 Prior to work presented in this thesis the age of the CYP3A5*3 allele had not been 
estimated. This thesis estimated that the CYP3A5*3 mutation first arose ~76,000 years ago 
(chapter 6). This date is consistent with its presence in and outside of Africa. These data 
provide strong evidence of differential selection on the CYP3A5*3 allele. An examination of the 
different frequencies within and outside of Africa, and the significant positive correlation 
between latitude and CYP3A5*3 allele frequencies, strongly support a hypothesis that the 
allele is advantageous outside of the African continent. The paucity of variation observed on 
CYP3A5*3 haplotype backgrounds in non-African populations suggest that the allele swept to 
high frequency rapidly outside of Africa; perhaps soon after it first arose. The age of the allele 
is consistent with the estimates of when modern humans first appeared in West Africa and in 
the Arabian Peninsula (see chapter 7). The stark contrast in CYP3A5*3 frequencies between 
these two geographic regions suggest that some differential environmental pressures have 
selected for CYP3A5*3 and driven it to high frequency. Of course, single gene approaches to 
detecting evidence for positive selection do not have the same power as scans of large 
genomic regions where the extent of LD decay can be visualised. It is possible that the 
CYP3A5*3 allele is one of multiple targets of selection on chromosome 7 and has hitchhiked to 
high frequency on the back of advantageous mutations (Hofer et al. 2009). 
 The data presented in this thesis highlight the importance of appreciating population 
history and of utilising evolutionary approaches in clinical research in order to elucidate 
mechanisms which a) cause differentiation of patient populations and b) identify patient 
populations which are likely to be distinct from a wider cohort because of differences in 
human evolutionary history. For example it has been well established that hypertension 
incidence and prevalence is highest in populations with recent African ancestry (Cooper et al. 
1997; Rotimi and Jorde 2010). Evolutionary approaches to understanding hypertension have 
identified that inter-ethnic differences in the risk of developing the disease are linked to 
important events in human evolutionary, and migratory, history (Young et al. 2005). This in 
turn can aid in identifying groups which are at risk of elevated hypertension. Often medical 
studies have focused on the clinical implications of particular genes and overlooked 
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evolutionary aspects which can lead to population differentiation. Evolutionary based 
approaches to genes, such as CYP3A5, will identify populations where alternative drug 
regimens, to those in current widespread use, are likely to be required. Stratified, or 
personalised, medicine is a key goal of the genomics revolution (Samani et al. 2010) and 





9. Future work 
 All lab work and analyses presented in this thesis have been performed within the 
time frame for completing a Ph.D. thesis and using the funds and resources available. However 
the work also highlighted a number of areas for additional research, to understand intra-
African diversity at the CYP3A5 locus and to examine the work in the context of medical and 
evolutionary research. The main areas for future research are discussed below. 
 
9.1. African re-sequencing 
 This thesis could not elucidate intra-African diversity for the entire CYP3A5 gene, due 
to funding constraints with re-sequencing of non-Ethiopian groups. A comparison of the full 
gene sequence may identify more African populations which have CYP3A5 haplotype 
structures similar to those seen in Ethiopia or other non-African populations. This would 
enable a comprehensive comparison of intra-African diversity over the entire CYP3A5 gene. 
Additionally re-sequencing of a larger CYP3A5 region may identify novel variants, at 
appreciable frequencies, likely to affect CYP3A5 expression, and thus disease susceptibility 
and risk of adverse drug reactions, in Africa. 
 
9.2. Assessing the functional implications of CYP3A5 variants 
 Bioinformatics analysis in chapter 5 identified a number of variants which may 
potentially affect CYP3A5 protein expression levels within Africa. Bioinformatic predictions 
alone do not provide tangible evidence of what occurs in vivo, unlike in vitro splicing assays 
(discussed in 5.4.1 and 5.4.2). Of all identified variants, a novel intronic 10bp deletion, 
identified in five individuals from West Central Africa, is an immediate candidate for 
functional studies. Although bioinformatics analysis did not predict that this polymorphism 
would affect intron 1 splicing, its proximity to the intron acceptor splice site makes it an ideal 
candidate for functional analysis. 
 
9.3. Further population comparisons and simulations 
 There has been a rapid increase in the amount of genomic data available online. The 
1000 Genomes data are likely to provide one of the most comprehensive datasets of human 
genetic variation. High coverage data from the project will be invaluable for assessing global 
population differences from re-sequencing data. A comparison of the African data generated 
for this thesis with soon-to-be released high coverage data from the 1000 Genomes Project 
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will enable analysis of African diversity in a wider global context than the current data 
available online. 
 Demographic and environmental factors such as migration, population admixture and 
latitude could be modelled within simulated datasets (Ritchie and Bush 2010). Comparisons 
of simulated datasets which closely represent the observed data can infer the likely 
demographic and environmental factors which have lead to particular genomic patterns. 
Simulations of population histories could be performed to examine African CYP3A5 diversity 
in greater detail. This would also help to elucidate how CYP3A5 haplotype patterns observed 
in Ethiopia are likely to have arisen. 
 
9.4. Examining medical associations of CYP3A5 variability 
 As outlined in the Introduction to this thesis variability in CYP3A5 expression is 
associated with differential susceptibility to disease and adverse clinical outcomes. This study 
has characterised variation within the entire CYP3A5 gene. A study of variation in a medically 
important gene is useful when it is also considered for its implications on clinical outcomes. 
There is potential to perform case-control studies comparing clinical outcomes, associated 
with specific drug substrates, in different populations to see how the identified variants may 
affect clinical outcomes. This thesis has highlighted differences between East Africans and 
other sub-Saharan African groups which are likely to affect treatment outcomes. Case-control 
studies comparing inter-population differences, for example between North-Eastern 
Ethiopian groups, such as the Amhara, with the Anuak and Bantu-speaking populations, 
separately, in their ability to metabolise well-characterised CYP3A substrates such as 
midazolam; and drugs used to treat HIV-1 and malaria, as well those used in mass drug 
administration campaigns (one of the major ways in which African populations have access to 
medical treatment) would identify individuals at risk of adverse clinical outcomes within 
specific populations. Additional studies of the association between CYP3A5*3 and 
hyponatremia in equatorial Ethiopia would also be of medical benefit (see section 8.3). 
 
9.5. Re-sequencing of other CYP450 genes 
 There are multiple CYP450 genes which are responsible for the metabolism of a wide 
range of drugs in clinical use. Re-sequencing of further CYP450 genes, and others involved in 
drug metabolism could potentially characterise medically important variation. Additionally, 
characterising variation in genes which are also involved in the metabolism of many CYP3A5 
substrates may also provide further information on how multiple drug metabolising enzymes 
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interact and how variation in one gene, encoding an important enzyme, can affect a drug 
metabolising pathway. 
 
9.6. Re-sequencing of a larger region of chromosome 7 surrounding the CYP3A5 gene  
 One of the very interesting areas of research that follow on from this thesis is to 
examine a larger region of chromosome 7 within global populations, and also in Africa, to 
elucidate whether CYP3A5 is likely to have been a target of selection within the region. Within 
Africa this would be useful for haplotypes defined by the CYP3A5*6 variant. The LRH test is 
designed to detect recent selective sweeps (within the past ~30,000 years). Therefore, from 
data presented in this thesis, it cannot be ruled out that this allele had been the target of 
selection prior to this time frame. Additionally, the design of composite likelihood models to 
examine statistically significant similarities and differences in iHS and XP-EHH estimates 
would provide better indications of how likely selection signatures are indicative of true 
selection events. 
 
9.7. Concluding remarks 
 This thesis has characterised novel and known variation in a medically important gene 
which could have important clinical implications for healthcare intervention strategies. The 
African data provide an example of the importance of including diverse populations in 
genomics, medical and evolutionary research. Additionally, the work presented on CYP3A5 
has come at a time where the genomics revolution is generating huge amounts of data on 
multiple global populations; including those in Africa. This will inevitably improve the design 
of studies which look for medically important variation, and may improve the provision of 
healthcare for patients with recent African ancestry.  The UK and EU are slowly integrating 
personalised medicine into standard healthcare practices (Coggi 2011; Fricker 2011). It is 
possible that studies, such as those conducted for this thesis, will assist in genotype or 
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